"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02086838","Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy",,"Completed","No Results Available","Treatment of Iron Deficiency Anemia in Pregnancy","Drug: Theragran Hematinic|Drug: low molecular weight iron dextran","The proportion of patients who have been successfully treated|Number of participants with adverse effects","Ain Shams University","Female","20 Years to 35 Years   (Adult)","Phase 4","212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9020058","July 2013","December 2014","December 2014","March 13, 2014",,"March 19, 2015","Maternity Hospital, Faculty of Madicine, AinShams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02086838"
2,"NCT03448432","Prevalence Study of the Etiology of Pregnancy Anemia","PREGAN","Unknown status","No Results Available","Pregnancy Anemia",,"Prevalence of the etiologies of anemias occured during pregnancy|Study of obstetrical complications in women with anemia|Study of the evolution of anemia during pregnancy and postpartum|Describe the etiological and therapeutic management of pregnancy anemias","University Hospital, Brest","Female","18 Years and older   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PREGAN (29BRC17.0155)","February 27, 2018","October 27, 2019","December 27, 2019","February 28, 2018",,"March 5, 2018","CHRU de Brest, Brest, France",,"https://ClinicalTrials.gov/show/NCT03448432"
3,"NCT03202615","Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy",,"Unknown status","No Results Available","Anemia During Pregnancy","Dietary Supplement: L (lactoferrin)|Drug: F (ferrous sulphate)","change in Hemoglobin concentration|Serum ferritin|mean cell volume (MCV)|mean corpuscular hemoglobin (MCH)|mean cell hemoglobin concentration (MCHC)|cost|percentage of women who agree to take each of the two drugs for a future whole pregnancy.|Side effects:","Abdelwahed, Mai Mahmoud Mohamed, M.D.","Female","20 Years to 30 Years   (Adult)","Phase 4","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AbdelwahedM|AshoushS|IbrahimK|ElhawariG","September 2015","August 2018","October 2018","June 28, 2017",,"July 9, 2018","Mai Mahmoud Mohamed, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT03202615"
4,"NCT03657433","Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy",,"Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Dietary Supplement: Ferrous sulfate 325mg|Drug: Ferumoxytol","Change in hemoglobin|Change in other laboratory values|Blood loss at delivery|Hemoglobin change after delivery|Blood transfusion|Iron infusion|Concentration of substances in cord blood (iron studies)|Preterm delivery|Indication for delivery|Birth weight","University of Arizona|AMAG Pharmaceuticals, Inc.","Female","18 Years to 50 Years   (Adult)","Phase 3","124","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1807765944","December 17, 2018","August 27, 2021","April 1, 2022","September 5, 2018",,"September 7, 2022","University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03657433"
5,"NCT02839096","Once Versus Twice Daily Iron Supplementation in Pregnant Women",,"Unknown status","No Results Available","Anemia in Pregnancy","Drug: Placebo|Drug: Ferrous Sulfate","Hemoglobin|Incidence of gastrointestinal side effects (i.e. constipation, upset stomach) as measured by a validated questionaire|Incidence of blood transfusion at delivery","University of Missouri-Columbia","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2004638","June 2016","June 2019","December 2019","July 20, 2016",,"April 18, 2019","University of Missouri, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02839096"
6,"NCT04708665","Iron Deficiency Anemia and Non-iron Deficiency Anemia in Pregnancy in India","IDA & NIDA","Unknown status","No Results Available","Anemia|Anemia, Iron Deficiency|Anemia of Pregnancy",,"Birthweight|gestational age at birth|weight-for-gestational-age z-score|infant hemoglobin at 6 weeks","Boston University Charles River Campus|Lata Medical Research Foundation","Female","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","55207436","November 23, 2020","January 31, 2022","January 31, 2022","January 14, 2021",,"January 14, 2021","Lata Medical Research Foundation, Nagpur, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT04708665"
7,"NCT03438227","Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial","IVIDA","Completed","No Results Available","Iron Deficiency Anemia of Pregnancy|Iron Malabsorption","Drug: Iron dextran|Drug: Ferrous sulfate 325mg","Maternal outcome: hemoglobin on admission to inpatient obstetrics unit for delivery of infant|Incidence of Medication Adverse events [Safety and Tolerability]|Maternal outcome: hemoglobin on postpartum day #1|Maternal outcome: incidence of blood transfusion|Maternal outcome: mode of delivery|Neonatal outcomes: gestational age at delivery|Neonatal outcomes: birth weight|Neonatal outcomes: umblical cord gases|Neonatal outcomes: APGAR scores|Neonatal outcomes: neonatal hemoglobin|Neonatal outcomes: neonatal morbidity composite","Indiana University","Female","Child, Adult, Older Adult","Phase 4","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1809251633","April 15, 2018","December 31, 2019","December 31, 2019","February 19, 2018",,"August 18, 2020","Indiana University School of Medicine, Indianapolis, Indiana, United States|Center for Outpatient Health, Washington University in St. Louis, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03438227"
8,"NCT01193192","A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy",,"Terminated","No Results Available","Anemia in Pregnancy|Pre-eclampsia","Other: Neevo®|Other: Prenatal vitamins","Mean Hemoglobin (Hgb) Levels|Mean Change in Hemoglobin (Hgb) Levels|Incidence of Anemia|Incidence of Pre-eclampsia|Mean Infant Birth Rate","Pamlab, L.L.C.|Baylor Health Care System|Norman Regional Health System|Five Oaks Medical Group|Pamlab, Inc.","Female","21 Years to 39 Years   (Adult)",,"30","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","N-002","July 2010","November 2010","November 2010","September 1, 2010",,"November 23, 2011","Five Oaks Medical Group, Chickasha, Oklahoma, United States|Norman Regional Health System, Norman, Oklahoma, United States|Norman Regional Health System, Norman, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01193192"
9,"NCT01062958","A Retrospective Analysis of Neevo®/Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy",,"Completed","No Results Available","Anemia in Pregnancy|Preeclampsia","Other: Neevo® (a medical food)|Other: Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)","To determine the effect of Neevo®/Neevo®DHA (with higher folate and B12) versus standard prenatal vitamins on hemoglobin levels in pregnant women throughout the course of pregnancy.|To determine the effect of Neevo®/Neevo®DHA versus standard prenatal vitamins on red blood cell (RBC) levels in pregnant women.|To determine if Neevo®/Neevo®DHA administration during pregnancy results in fewer anemias than with standard prenatal vitamins.","Pamlab, Inc.|Baylor Health Care System|Women's Clinic Shoals|Gainesville Obstetrics & Gynecology|Womens Health Associates","Female","21 Years to 39 Years   (Adult)",,"100","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","N-001","December 2009","February 2010","February 2010","February 4, 2010",,"April 16, 2013","Women's Clinic Shoals, Sheffield, Alabama, United States|Women's Health Associates, Flowood, Mississippi, United States|Gainesville Obstetrics & Gynecology, Gainesville, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01062958"
10,"NCT05804071","Analysis of the Effect of Iron Supplements on Iron Deficiency Anemia in Pregnancy",,"Recruiting","No Results Available","Iron Deficiency Anemia of Pregnancy|Iron Storage Disease","Drug: Niferex","Ferritin|Elevated hemoglobin value|Hemoglobin|ferritin|serum iron|transferrin saturation|total iron binding force|reticulocyte count|Correction rate of iron deficiency anemia during pregnancy|Adverse reaction rate|Correction rate of ferritin deficiency","Qianfoshan Hospital","Female","18 Years to 45 Years   (Adult)","Phase 4","452","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","YXL-KY-2023（006）","March 28, 2023","January 2024","January 2025","April 7, 2023",,"April 7, 2023","Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT05804071"
11,"NCT05358509","Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial","RAPIDIRON","Active, not recruiting","No Results Available","Iron Deficiency Anemia|Infant, Low Birth Weight|Anemia of Pregnancy","Drug: Ferric carboxymaltose|Drug: Iron isomaltoside|Drug: Ferric Sulfate","Return to non-anemic status in the last trimester of pregnancy|Low birth weight (<2500 grams) deliveries|Changes in hemoglobin concentration by moderate anemia subgroups|Changes in transferrin saturation|Changes in ferritin|Changes in offspring hemoglobin measured from cord blood|Offspring transferrin saturation from cord blood|Offspring ferritin from cord blood|Weight gain|Mode of delivery/incidence of c-section|Incidence of hemorrhage|Incidence of hypertensive disorders|Incidence of maternal infections|Incidence of neonatal infections|Incidence of maternal mortality|Incidence of neonatal mortality|Incidence of pregnancy loss and stillbirth|Newborn length|Newborn weight|Incidence of neonatal resuscitation|Incidence of neonatal admissions to an intensive care unit|Time from delivery to cord clamping|Incidence of unscheduled healthcare visits|Incidence of breastfeeding|Well-being/quality of life|Incidence of need for 'rescue therapy'|Referral for evaluation due to little improvement|Incidence of preterm and small for gestational age births","Thomas Jefferson University|Children's Investment Fund Foundation|Jawaharlal Nehru Medical College|S. Nijalingappa Medical College|Raichur Institute of Medical Sciences|Sawai Mansingh Medical College","Female","18 Years to 40 Years   (Adult)","Phase 4","4368","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1811-03347","March 15, 2021","January 31, 2024","June 30, 2024","May 3, 2022",,"November 29, 2023","S. Nijalingappa Medical College, Bagalkot, Karnataka, India|Jawaharlal Nehru Medical College, Belgaum, Karnataka, India|Raichur Institute of Medical Sciences, Raichur, Karnataka, India|Sawai Man Singh Medical College, Jaipur, Rajasthan, India","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/09/NCT05358509/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05358509"
12,"NCT04594070","Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy",,"Terminated","No Results Available","Pregnancy Related|Iron Deficiency Anemia of Pregnancy","Drug: Ferrous sulfate","Difference in hemoglobin levels from enrollment to end of study|Change in hematocrit in the third trimester after treatment|Gastrointestinal side effects after 2-4 weeks of treatment|Complete blood count in the third trimester|Serum ferritin at time of enrollment|Total iron binding capacity at time of enrollment|Transferrin at time of enrollment|Number of participants who receive intravenous (IV) iron supplementation|Number of participants who receive a blood transfusion|Postpartum hemoglobin|Postpartum hematocrit|Neonatal weight at delivery|Level of neonatal bilirubin at birth|Neonatal Apgar scores|Number of newborns who are admitted to the Neonatal Intensive Care Unit (NICU).|Weight class at time of enrollment","The University of Texas Medical Branch, Galveston","Female","18 Years to 50 Years   (Adult)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-0068","October 27, 2020","January 12, 2024","January 12, 2024","October 20, 2020",,"January 19, 2024","University of Texas Medical Branch, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04594070"
13,"NCT03484845","Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy",,"Unknown status","No Results Available","Iron Deficiency Anemia of Pregnancy","Drug: Lactoferrin and ferrous fumarate","Increase in blood hemoglobin.","Assiut University","Female","16 Years to 45 Years   (Child, Adult)","Phase 1|Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","u1111-1210-1436","November 1, 2018","December 1, 2019","December 1, 2019","April 2, 2018",,"July 3, 2018",,,"https://ClinicalTrials.gov/show/NCT03484845"
14,"NCT03456258","Lactoferrin Versus Ferrous Sulphate for the Treatment of Iron Deficiency Anemia During Pregnancy","Lactoferrin","Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Diagnostic Test: Complete blood count","hemoglobin level|Serum ferritin","Ain Shams University","Female","20 Years to 40 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ainshams maternity hospital","September 5, 2017","December 10, 2017","January 15, 2018","March 7, 2018",,"March 7, 2018","Ainshams maternity hospital, Cairo, Abbasia, Egypt",,"https://ClinicalTrials.gov/show/NCT03456258"
15,"NCT04976179","Iron Infusion Into a Vein Compared to Iron Tablet Taken by Mouth for Treating Iron Deficiency Anemia in Pregnancy (IVON)","IVON","Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Drug: Ferric carboxymaltose|Drug: Ferrous sulfate","Prevalence of maternal anemia at 36 weeks' gestation|Incidence of preterm delivery|Proportion of patients with side effects or intolerance to medication in FCM vs. FS group, including incidence of hypophosphatemia and severe maternal adverse effects at Day 1 and 4 weeks post enrolment, at 36 weeks gestation and 6 weeks post delivery|Proportion of patients with severe maternal events, specifically, haemorrhage, sepsis, shock and the need for blood transfusion measured using data source at delivery|The incidence of low infant birthweight, prematurity, stillbirth and neonatal mortality, proportion of infants being breastfed at 1, 2 and 4 weeks of life, and receiving BCG, oral polio and hepatitis vaccination in same time period|The incidence of depression linked to emotional well-being of mothers using the validated Edinburgh Postnatal Depression Scale measured at enrolment, 36 weeks gestational age and 7 days post delivery|Maternal hemoglobin levels at 4 weeks post-initiation of treatment|Prevalence of maternal iron deficiency at 36 weeks' gestation","University of Lagos, Nigeria|Aminu Kano Teaching Hospital","Female","15 Years to 49 Years   (Child, Adult)","Phase 3","1056","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PACTR202012843695208|ISRCTN63484804|Investment ID INV-017271|2021-002867-23","August 9, 2021","April 5, 2023","June 15, 2023","July 26, 2021",,"July 21, 2023","Kabuga Comprehensive Primary Health Centre, Gwarzo, Kano, Nigeria|Kumbotso Comprehensive Health Centre, Kumbotso, Kano, Nigeria|Aminu Kano Teaching Hospital, Tarauni, Kano, Nigeria|Simpson Primary Health Centre, Ebute-Metta, Lagos, Nigeria|Lagos University Teaching Hospital, Idi Araba, Lagos, Nigeria|Iwaya Primary Health Centre, Iwaya, Lagos, Nigeria|Sheikh Jidda General Hospital, Kano, Nigeria|Nuhu Bammali Maternity Hospital, Kano, Nigeria|Sharada Primary Health Centre, Kano, Nigeria|Mother and Child Centre, Amuwo-Odofin, Lagos, Lagos, Nigeria|Lagos Island Maternity Hospital, Lagos, Lagos, Nigeria",,"https://ClinicalTrials.gov/show/NCT04976179"
16,"NCT03481790","Lactoferrin Versus Ferrous Sulphate for Treatment of Iron Deficiency Anaemia During Pregnancy",,"Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Drug: Lactoferrin|Drug: ferrous sulphate + folic acid (vitamin B9)","Hemoglobin (Hb) level.|serum ferritin level.","Ain Shams Maternity Hospital","Female","20 Years to 35 Years   (Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AinShams Maternity Hospital","September 1, 2017","March 5, 2018","March 5, 2018","March 29, 2018",,"March 29, 2018","Ain Shams Maternity Hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03481790"
17,"NCT03564756","Effect of Ascorbic Acid Supplementation in Pregnancy on Anemia (AAA)","AAA","Withdrawn","No Results Available","Anemia in Pregnancy","Dietary Supplement: Vitamin C","Change in serum hemoglobin","Fetal Medicine Foundation|Wright State University|Five Rivers Health Centers","Female","18 Years to 50 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AAA-001","August 1, 2019","March 30, 2022","March 30, 2022","June 21, 2018",,"September 22, 2022","Five Rivers Health Centers, Dayton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03564756"
18,"NCT04045002","'MyPinkMom' Educational Intervention for Pregnant Women With Anaemia",,"Unknown status","No Results Available","Anaemia in Pregnancy","Other: 'MyPinkMom' educational intervention","haemoglobin level changes|knowledge score changes|Amount of dietary iron changes|Theory of Planned Behavior construct score changes","Universiti Kebangsaan Malaysia Medical Centre","Female","20 Years to 40 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","UKM PPI/111/8/JEP-2018-674","April 1, 2020","June 30, 2020","August 31, 2020","August 5, 2019",,"February 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04045002"
19,"NCT03174652","Anemia Pregnancy Outcome on the Thai-Myanmar Border","AnPREG","Completed","No Results Available","Anemia Pregnancy",,"Hematology|Serum ferritin|The risk of maternal morbidities","University of Oxford","Female","Child, Adult, Older Adult",,"13520","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SMRU1703","July 20, 2017","July 20, 2017","July 20, 2018","June 2, 2017",,"August 31, 2018","Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand",,"https://ClinicalTrials.gov/show/NCT03174652"
20,"NCT03175042","Non-invasive Spot Hemoglobin Measurement in the Outpatient Obstetric Clinic",,"Completed","No Results Available","Anemia in Pregnancy","Device: Masimo spot hemoglobin non-invasive monitor","Hemoglobin values","The University of Texas Medical Branch, Galveston","Female","18 Years to 50 Years   (Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-0095","June 13, 2017","December 31, 2017","December 31, 2017","June 5, 2017",,"June 3, 2019","University of Texas Medical Branch, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03175042"
21,"NCT06366698","Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia","IDA","Recruiting","No Results Available","Iron Deficiency Anemia of Pregnancy","Drug: Venofer 200 MG Per 10 ML Injection|Drug: Ferrous sulfate","Hemoglobin difference|Ferritin difference|Delivery Hemoglobin|Rates of blood transfusion|Symptoms|Preterm delivery|Depression|Birthweight","Arrowhead Regional Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 3","900","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","23-55","November 21, 2023","December 30, 2025","December 30, 2025","April 16, 2024",,"April 16, 2024","Arrowhead Regional Medical Center, Colton, California, United States","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/98/NCT06366698/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT06366698"
22,"NCT05462704","Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy","IVIDA2","Recruiting","No Results Available","Iron Deficiency Anemia|Pregnancy","Drug: Ferric derisomaltose|Drug: Ferrous sulfate","Rate of peripartum blood transfusion|Concentration of maternal hemoglobin at delivery|Rate of maternal anemia presence at delivery|Concentration of maternal ferritin at delivery|Concentration of maternal hemoglobin postpartum day 1|Rate of cesarean delivery|Rate of severe infusion adverse events|Rate of mild medication adverse events|Edinburgh Perinatal Depression Scale score|Maternal EuroQol Group Quality-of-Life Questionnaire score|Rate of Maternal infection|Rate of Composite Maternal Complications|Gestational age at delivery|Rate of preterm birth at less then 37 weeks|Rate of Neonatal Intensive Care Unit Admission|Neonatal birth weight|Concentration of umbilical artery pH|Concentration of umbilical artery bicarbonate|Concentration of umbilical artery base excess|Concentration of umbilical artery lactate|Concentration of neonatal hemoglobin|Concentration of neonatal ferritin|Neonatal Apgar scores|Rate of composite neonatal complication|Concentration of child brain myelin|Child Mullen Scale of Early Learning Score","Women and Infants Hospital of Rhode Island|Hasbro Children's Hospital|University of Michigan|Washington University School of Medicine","Female","18 Years to 45 Years   (Adult)","Phase 3","746","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pro00060930","January 17, 2023","March 30, 2027","March 30, 2027","July 18, 2022",,"December 21, 2023","Michigan University Medical Center, Ann Arbor, Michigan, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Hasbro Children's Hospital, Providence, Rhode Island, United States|Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT05462704"
23,"NCT03565198","Ferritin as a Predictor for Anemia in Pregnancy",,"Unknown status","No Results Available","Anemia, Iron Deficiency",,"clinical anemia","CAMC Health System","Female","15 Years to 45 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-366","August 15, 2019","August 15, 2020","October 15, 2020","June 21, 2018",,"December 3, 2019","Charleston Area Medical Center, Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03565198"
24,"NCT03725150","Treatment of Iron Deficiency Anaemia in Pregnancy Study","TIAP","Completed","No Results Available","Anemia, Iron Deficiency",,"An increase in haemoglobin of at least 10g/L","The Royal Wolverhampton Hospitals NHS Trust","Female","18 Years to 45 Years   (Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018OBS100","June 19, 2018","December 17, 2019","December 17, 2019","October 30, 2018",,"August 10, 2022","New Cross Hospital, Wolverhampton, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03725150"
25,"NCT02441439","To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy",,"Withdrawn","No Results Available","Pregnancy","Dietary Supplement: Iron sucrose 200 mg|Dietary Supplement: Iron sucrose 500 mg","The change between the hemoglobin level at randomization and the hemoglobin level at the time of delivery|Women's satisfaction from the protocol treatment according to the VAS (visual analog scale)|Type and rate of adverse events|The rate of patients who discontinued treatment|The weekly change in hemoglobin level, ferritin, serum iron, transferrin, MCV, iron saturation and reticolocyte count from randomization|The change in hemoglobin level, ferritin, serum iron, transferrin, MCV, iron saturation and reticolocyte count from the last dose of iron sucrose to delivery in 3 weeks intervals|The need for blood transfusion post partum|The need for iron sucrose administration post partum|The rate of anemia associated symptoms|The levels of neonatal hemoglobin, ferritin and bilirubin|The rate of neonatal polycythemia and need for phototherapy","HaEmek Medical Center, Israel","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0036-15","January 1, 2022","November 7, 2022","November 7, 2022","May 12, 2015",,"November 8, 2022",,,"https://ClinicalTrials.gov/show/NCT02441439"
26,"NCT03279536","Lactoferrin Versus Total Dose Infusion (TDI) For Treating Iron Deficiency Anemia in Pregnancy: Role of Nursing","TDI","Completed","No Results Available","Iron Deficiency Anemia","Combination Product: Oral lactoferrin|Combination Product: TDI of LMW iron dextran","the change in Hb concentration|measure the change in serum iron, serum ferritin","Woman's Health University Hospital, Egypt","Female","18 Years to 40 Years   (Adult)","Phase 1|Phase 2","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","WHH","November 1, 2017","December 30, 2018","December 30, 2018","September 12, 2017",,"October 27, 2020","Women Health Hospital, Asyut, Egypt",,"https://ClinicalTrials.gov/show/NCT03279536"
27,"NCT04278651","Early Antenatal Support for Iron Deficiency Anemia","EASI-A","Unknown status","No Results Available","Pregnancy Related|Anemia, Iron Deficiency|Anemia of Pregnancy","Drug: Ferumoxytol|Drug: Ferrous Sulfate","Change in Hemoglobin|Anemia resolution|Anemia at Delivery|Need for additional therapy|Quality of life scale|Adherence|Need for post partum transfusion|Neonatal outcomes: cord blood iron indices|Neonatal outcomes: birth weight|Neonatal outcomes gestational age of delivery (weeks)","Thomas Jefferson University|Auerbach Hematology and Oncology","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19G.929","September 29, 2021","August 30, 2023","December 30, 2023","February 20, 2020",,"February 8, 2022","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04278651"
28,"NCT05479799","Prevalence and Determinants of Anemia During the Third Trimester of Pregnancy",,"Completed","No Results Available","Anemia of Pregnancy",,"Number of participants with the prevalence of anemia in the third trimester of pregnancy","Beni-Suef University","Female","18 Years to 42 Years   (Adult)",,"383","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","anemia in pregnancy: Beni-Suef","January 4, 2019","June 30, 2019","June 30, 2019","July 29, 2022",,"July 29, 2022","Beni-Suef University, Banī Suwayf, Egypt",,"https://ClinicalTrials.gov/show/NCT05479799"
29,"NCT04101461","The Oral Iron on the Prevention of Iron Deficiency Anemia in Obese Pregnant",,"Completed","No Results Available","Anemia of Pregnancy","Drug: Iron|Diagnostic Test: Complete blood count|Diagnostic Test: Serum ferritin|Diagnostic Test: Serum hepcidin|Diagnostic Test: Serum Iron|Diagnostic Test: Serum total iron binding capacity","The number of anemic women at time of delivery|The mean level of maternal Hemoglobin at 37-38 weeks .|The incidence of patients' reported side effect|The difference in serum ferritin|The difference in serum hepcidin","Assiut University","Female","20 Years to 35 Years   (Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IDA-Obese","October 1, 2019","April 1, 2022","April 1, 2022","September 24, 2019",,"May 4, 2022","Woman's Health Hospital - Assiut university, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04101461"
30,"NCT03522428","Vitamin B12 Pregnancy Supplementation",,"Completed","No Results Available","Pregnancy Anemia","Dietary Supplement: vitamin b12","Change of Red blood cells (RBC) count in first and second trimester|Change of Hemoglobin (Hgb) concentration in first and second trimester|Change of Hematocrit in first and second trimester|Change of Mean corpuscular volume (MCV) in first and second trimester|Change of Mean corpuscular hemoglobin concentration (MCHC) in first and second trimester|Change of Mean corpuscular hemoglobin (MCH) in first and second trimester|Change of Iron (Fe) in first and second trimester|Change of Haptoglobin in first and second trimester|Change of Ferritin in first and second trimester|Change of Total Iron Binding Capacity (TIBC) in first and second trimester|Change of Unsaturated Iron Binding Capacity (UIBC) in first and second trimester|Change of White Blood Cells (WBC) in first and second trimester|Change of Platelet Count in first and second trimester|Change of Transferrin in first and second trimester|Change of Neutrophils in first and second trimester|Change of Lymphocytes in first and second trimester|Change of Monocytes in first and second trimester|Change of Eosinophils in first and second trimester|Change of Basophils in first and second trimester","Mirela Zec|University of Split, School of Medicine","Female","18 Years to 40 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention","dupin","September 15, 2011","December 23, 2012","December 23, 2012","May 11, 2018",,"May 11, 2018",,,"https://ClinicalTrials.gov/show/NCT03522428"
31,"NCT04812821","Statement of Care of Anemia in Delivering Patients at Nord Franche-Comte Hospital","ANEMIA","Completed","No Results Available","Pregnancy Anemia","Other: questionnaire","Estimation of the proportion of patients presenting anemia during delivery|Risk factors underlying anemia during delivery with a large questionnaire","Hopital Nord Franche-Comte","Female","18 Years and older   (Adult, Older Adult)",,"1177","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","2019-02","April 12, 2021","October 12, 2021","March 15, 2022","March 24, 2021",,"March 16, 2022","Hôpital Nord Franche-Comté, Trévenans, France",,"https://ClinicalTrials.gov/show/NCT04812821"
32,"NCT05737862","Effect of Moringa Oleifera Leaf on Hemoglobin Levels in Anemia",,"Completed","No Results Available","Anemia of Pregnancy","Dietary Supplement: Moringa oleifera capsules|Dietary Supplement: iron and folic acid supplements","Changes in Haemoglobin (Hb) level","Universitas Padjadjaran","Female","15 Years to 50 Years   (Child, Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MAGPH-202210.01","April 1, 2022","June 30, 2022","July 30, 2022","February 21, 2023",,"March 9, 2023","University Padjajaran, Bandung, West Java, Indonesia","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/62/NCT05737862/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05737862"
33,"NCT06252103","Lactoferrin With Ferrous Gluconate Versus Ferrous Gluconate in Treatment of Iron Deficiency Anemia During Pregnancy",,"Completed","No Results Available","Lactoferrin With Ferrous Gluconate More Superior Than Ferrous Gluconate Alone in Treatment of Iron Deficiency Anemia","Drug: Ferrous Gluconate 300 MG|Drug: ferrous gluconate with lactoferrin","• Hemoglobin (Hb) level|serum ferritin|gastrointestinal side effects","Ain Shams University","Female","20 Years to 40 Years   (Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU MS298/2023","May 30, 2023","November 30, 2023","December 30, 2023","February 9, 2024",,"February 9, 2024","Ain shams university maternity hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT06252103"
34,"NCT04391998","Parasitic Infection in Anemic Pregnant Women",,"Unknown status","No Results Available","Anemia of Pregnancy","Drug: Iron Supplement|Drug: Metronidazole Oral|Drug: Albendazole","correction of naemia","Cairo University","Female","18 Years to 45 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","175","May 13, 2020","August 2021","September 2021","May 18, 2020",,"February 9, 2021","Kasr Alainy medical school, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04391998"
35,"NCT05657821","The Effect Of Pumpkin Seed Extract Capsules On Nutritional Status and Haemoglobin Level in Pregnant Women.",,"Recruiting","No Results Available","Anemia During Pregnancy","Dietary Supplement: Pumpkin seeds extract capsules","Nutritional status|hemoglobin levels","Dr. Rosdiana Syakur|Hasanuddin University|Indonesia Timur University","Female","17 Years to 39 Years   (Child, Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Indonesia TimurU","October 25, 2022","January 25, 2023","August 25, 2023","December 20, 2022",,"December 20, 2022","Stunting Locus Village, Bone, South Sulawesi, Indonesia",,"https://ClinicalTrials.gov/show/NCT05657821"
36,"NCT05151679","Chelated Oral Iron Versus Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia Late in Pregnancy",,"Available","No Results Available","Iron Deficiency Anemia of Pregnancy","Drug: Chelated Iron|Drug: Iron sucrose",,"Assiut University","Female","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Individual Patients",,"oral iron versus I.V iron",,,,"December 9, 2021",,"December 9, 2021",,,"https://ClinicalTrials.gov/show/NCT05151679"
37,"NCT05157828","Iron Deficiency Anaemia in Pregnant Patients Presenting for Antenatal Care",,"Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Other: No intervention","Prevalence of anaemia among all women presenting for antenatal care at a secondary level institution in the Western Cape, Mowbray Maternity Hospital, during a one-week period.","University of Cape Town","Female","18 Years and older   (Adult, Older Adult)",,"132","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","UCape Town","January 31, 2022","February 4, 2022","February 4, 2022","December 15, 2021",,"May 18, 2022","Mowbray maternity hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT05157828"
38,"NCT03961074","Iron Deficiency Anemia Among Chinese Pregnant Women: a Multi-center Prospective Cohort Study","IRONWOMEN","Unknown status","No Results Available","Iron Deficiency Anemia of Pregnancy","Other: Iron deficiency anemia in Chinese pregnant women","adverse maternal outcomes|adverse neonatal outcomes","West China Hospital|West China Second University Hospital","Female","Child, Adult, Older Adult",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IDA_2019","May 10, 2019","December 30, 2020","December 30, 2020","May 23, 2019",,"October 1, 2019","Peking University People's Hospital, Beijing, Beijing, China|Chongqing Health center for women and Children, Chongqing, Chongqing, China|Xiamen Maternal and Child Care Hospital, Xiamen, Fujian, China|Hubei Maternal and Child Care Hospital, Wuhan, Hubei, China|Yanan University Affiliated Hospital, Yanan, Shanxi, China|The West China Second University Hospital, Chengdu, Sichuan, China|Women'S Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03961074"
39,"NCT03378791","Efficacy of Iron Bisglycinate in Treatment of Iron Deficiency Anemia in Pregnant Women",,"Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Drug: Iron bisglycinate Oral Tablet|Drug: Ferrous Fumarate Oral Tablet","Hemoglobin level","Hatem AbuHashim|Mansoura University","Female","20 Years to 40 Years   (Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MS/15.10.05","December 31, 2015","October 31, 2017","October 31, 2017","December 20, 2017",,"December 20, 2017","Mansoura University Hospitals, Mansourah, Dakahlia Governorate, Egypt",,"https://ClinicalTrials.gov/show/NCT03378791"
40,"NCT02005588","Treatment of Iron Deficiency Anemia With Pregnancy",,"Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Drug: amino acid chelated iron|Drug: iron salt (ferrous fumarate)","change in hemoglobin level|the occurence of side effects (abdominal colics, constipation, or metallic taste)|change in serum ferritin level","Cairo University","Female","20 Years to 40 Years   (Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ferrot2013|nerhado pharmaceutical company","December 2013","June 2015","July 2015","December 9, 2013",,"July 28, 2015","faculty of medicine, Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02005588"
41,"NCT03706638","Daily vs Intermittent Iron Therapy in Pregnancy",,"Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Dietary Supplement: Ferrous Sulfate","Hematologic values assessed for anemia|Scores on self report survey of gastrointestinal adverse side effects after oral iron supplementation","UConn Health","Female","18 Years to 50 Years   (Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-181-1","October 25, 2018","March 23, 2020","March 23, 2020","October 16, 2018",,"April 21, 2020","UConn Health, Farmington, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03706638"
42,"NCT04074707","Defining a Dosing Regimen With Maximal Absorption for Oral Iron Supplementation During Pregnancy",,"Unknown status","No Results Available","Iron Deficiency Anemia of Pregnancy","Dietary Supplement: Labeled iron solution (60mg and 120mg Ferrous Sulfate)","Fractional iron absorption in %|Total iron absorption in %|Serum Hepcidin|Serum Ferritin (SF)|Hemoglobin (Hb)|Soluble transferrin receptor (sTfR)|C-reactive protein (CRP)|Alpha-1-acid glycoprotein (AGP)","Swiss Federal Institute of Technology|Mahidol University","Female","18 Years to 45 Years   (Adult)","Not Applicable","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TIPS","September 2019","December 2019","December 2019","August 30, 2019",,"August 30, 2019","Mahidol University, Salaya, Nakhon Pathom, Thailand",,"https://ClinicalTrials.gov/show/NCT04074707"
43,"NCT03188445","Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.",,"Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Drug: Iron Isomaltoside 1000|Drug: ferrous fumarate with ascorbic acid","The primary outcome measure is the achievement of an hemoglobin equal or above 11 g/dL|Achievement of an hemoglobin equal to or above 11 g/dL|Change in iron biomarkers","Pharmacosmos A/S","Female","18 Years and older   (Adult, Older Adult)","Phase 4","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-Monofer-PREG-01","July 11, 2017","June 26, 2020","August 18, 2020","June 15, 2017",,"November 13, 2020","Phamacosmos Investigational site, Hvidovre, Sjaeland, Denmark",,"https://ClinicalTrials.gov/show/NCT03188445"
44,"NCT02590224","The Effect of Iron Deficiency Anemia During Pregnancy",,"Completed","No Results Available","Iron Deficiency Anemia","Drug: Ferrous bis-glycinate|Drug: Ferrous glycine sulphate","the rate of increase of Hemoglobin level","Assiut University","Female","20 Years to 40 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IDA","January 1, 2016","July 2017","December 2017","October 28, 2015",,"March 20, 2018","Assiut university, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT02590224"
45,"NCT03392298","Study on the Mechanism of Colla Corri Asini in the Treatment of Thalassemia Patients With Pregnancy Anemia",,"Unknown status","No Results Available","Thalassemia|Pregnancy","Drug: Colla corii asini","Hemoglobin(Hb)|the level of α-、β-、γ- and δ-globin mRNA|target gene signaling pathway molecules","The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine|National Natural Science Foundation of China","Female","20 Years to 50 Years   (Adult)","Phase 4","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TH-3","December 1, 2017","December 31, 2018","February 28, 2019","January 5, 2018",,"January 16, 2018","the first affiliated hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03392298"
46,"NCT05644964","The Effect of Anemia in Adolescent and Advanced Age Pregnancies",,"Completed","No Results Available","Anemia Pregnancy|Placenta Diseases",,"%22,2 Patients's placenta with Anemia in Adolescent ( ≤18)Pregnancy and %26,7 Patients's Placenta with from Anemia in Advanced Age (≥35) Pregnancy. Placenta Tissues Staining Measured by immunohistochemistry tecnique.","Celal Bayar University","Female","18 Years to 35 Years   (Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MCBU_anemia","February 17, 2021","February 1, 2023","June 1, 2023","December 9, 2022",,"March 6, 2024","Manisa Celal Bayar University, Yunusemre, Mani̇sa, Turkey|Manisa Celal Bayar University, Yunusemre, Mani̇sa, Turkey",,"https://ClinicalTrials.gov/show/NCT05644964"
47,"NCT05975125","The Effect of Vitamin C for Iron Supplementation During Pregnancy With Risk of Anemia",,"Recruiting","No Results Available","Vitamin C Anemia|Pregnancy Anemia","Drug: Vitamin C 500 MG Oral Tablet","To compare hemoglobin and hematocrit levels|maternal and fetal pregnancy outcomes|ratio of vitamin C|side effects after receiving vitamin C","Rajavithi Hospital","Female","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","118/2566","June 28, 2023","June 27, 2024","June 27, 2024","August 3, 2023",,"August 3, 2023","Rajavithi, Phaya Thai, Ratchathewi, Thailand",,"https://ClinicalTrials.gov/show/NCT05975125"
48,"NCT06061393","Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia",,"Not yet recruiting","No Results Available","Anemia, Iron Deficiency|Pregnancy Anemia","Drug: Venofer 200 MG Per 10 ML Injection|Drug: Ferinject","ratio of women with Hb level >11 at delivery|postpartum Hb level","Western Galilee Hospital-Nahariya","Female","18 Years to 50 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0120-23-NHR","October 30, 2023","September 20, 2025","September 20, 2025","September 29, 2023",,"October 6, 2023",,,"https://ClinicalTrials.gov/show/NCT06061393"
49,"NCT04517734","Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis",,"Completed","No Results Available","Pregnancy Anemia|Newborn; Anemia",,"Maternal Erythroferrone During Pregnancy|Maternal Erythroferrone at Delivery|Neonatal Erythroferrone at Birth|Placental Erythroferrone mRNA and Ferroportin protein Expression","Cornell University|University of California, Los Angeles","Female","11 Years to 45 Years   (Child, Adult)",,"338","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0911001050","April 2006","December 2017","December 2017","August 18, 2020",,"March 22, 2022","Rochester Adolescent Maternity Program, Rochester, New York, United States|Strong Memorial Hospital, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT04517734"
50,"NCT05977686","Hemoglobin Testing in Pregnant Patients","Prosp Anemia","Not yet recruiting","No Results Available","Post Partum Hemorrhage|Anemia of Pregnancy","Device: Masimo Root Radical 7 Pulse CO-Oximeter|Device: HemoCue Hb 801","Accuracy of the devices in all obstetric patients|Ability of point-of-care hemoglobin testing devices to detect anemia (Hemoglobin less than 11 mg/dL) or severe anemia (Hemoglobin less than 9 mg/dL).|Subgroup analysis: by gestational age categories presence or absence of anemia as defined by the gold standard venipuncture|Patient perception of testing methods","George Washington University","Female","18 Years to 50 Years   (Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NCR234874","April 2024","September 2025","September 2025","August 4, 2023",,"February 20, 2024",,,"https://ClinicalTrials.gov/show/NCT05977686"
51,"NCT03317210","Intravenous Treatment of Anemia in Pregnancy",,"Completed","No Results Available","Anemia","Drug: iron sucrose (200 mg VENOFER®)|Drug: recombinant human erythropoietin (10,000 U EPREX®)","Efficacy of Treatment: hemoglobin increase after therapy","University of Zurich","Female","Child, Adult, Older Adult","Phase 4","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","34130203","September 1, 2002","July 31, 2006","July 31, 2006","October 23, 2017",,"November 6, 2017",,"""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/10/NCT03317210/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03317210"
52,"NCT03689218","Evidence Generation Related to Stunting Prevention in Balochistan",,"Completed","No Results Available","Stunting|Low Birth Weight|Anemia in Pregnancy","Dietary Supplement: Maamta (Nutritious Food Supplement)|Dietary Supplement: Wawamum (Lipid-Based Nutrient Supplement)","Reduction in stunting in children at 24 months of age|Improvement in anemia during pregnancy|Improvement in anemia in children|Reduction in low birth weight","Aga Khan University|Trust for Vaccines & Immunization (TVI)|Department of Health, Government of Balochistan|World Food Program (WFP)|Nutrition Cell, Government of Balochistan|Youth Organization, Balochistan","All","6 Months to 24 Months   (Child)","Not Applicable","2180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Stunting Study Balochistan","August 15, 2018","November 30, 2020","November 30, 2020","September 28, 2018",,"July 23, 2021","District Pishin & Quetta, Quetta, Balochistan, Pakistan|Aga Khan University, Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT03689218"
53,"NCT02487719","Different Iron Supplements for Prevention of Anemia in Pregnancy","EDISA","Unknown status","No Results Available","Iron-Deficiency Anemia|Pregnancy","Drug: Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia","Hemoglobin before delivery|Birthweight|Gestatonal age at birth|Discontinuation of iron or mulimineral supplementation|Ferritin before delivery","University of Zurich","Female","18 Years to 55 Years   (Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0475","June 2015","June 2016","August 2016","July 1, 2015",,"July 1, 2015","University Hospital Zurich, Dept of Obstetrics, Zurich, ZH, Switzerland",,"https://ClinicalTrials.gov/show/NCT02487719"
54,"NCT05921968","Effect of Lactoferrin Versus Intravenous Iron Sucrose in Treatment of Anemia",,"Not yet recruiting","No Results Available","Iron Deficiency Anemia","Drug: Intravenous iron sucrose|Drug: Lactoferrin","evaluate the effect of oral lactoferrin as compared to intravenous iron sucrose on the serum level of ferritin|evaluate the effect of oral lactoferrin as compared to intravenous iron sucrose on the serum level of hemoglobin|evaluation of lactoferrin side effect|the incidence rate of constipation","Ain Shams University","Female","20 Years to 40 Years   (Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Lactoferrin in Anemia","July 30, 2023","January 1, 2024","April 1, 2024","June 27, 2023",,"July 19, 2023",,,"https://ClinicalTrials.gov/show/NCT05921968"
55,"NCT02191527","Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services in Mozambique",,"Completed","No Results Available","HIV|Syphilis|Anemia During Pregnancy","Device: PIMA® for quantitative analysis of CD4-count|Device: Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|Device: SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis","The proportion of HIV positive pregnant women initiating antiretroviral therapy among eligible women.|Proportion of women at first ANC visit tested and treated for syphilis|The proportion of pregnant women tested and treated for anemia|Number of HIV infections in infants averted","Elizabeth Glaser Pediatric AIDS Foundation|Ministry of Health, Mozambique","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1673","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EGPAF-004","September 2013","October 2014","February 2015","July 16, 2014",,"July 23, 2020",,,"https://ClinicalTrials.gov/show/NCT02191527"
56,"NCT04810546","Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy",,"Enrolling by invitation","No Results Available","Iron-deficiency|Pregnancy Anemia|Obesity","Dietary Supplement: Jarrow Formulas Oral Bovine Lactoferrin Supplement","Understand feasibility via recruitment and retention rates|Measure participant adherence|Determine preliminary efficacy on maternal inflammation|Determine preliminary efficacy on maternal iron and hematological markers.|Determine preliminary efficacy on maternal hematological markers.|Determine preliminary efficacy on neonatal iron and hematological markers.","University of Illinois at Chicago|National Heart, Lung, and Blood Institute (NHLBI)","Female","18 Years to 45 Years   (Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","2020-1297|R34HL155481","February 1, 2022","June 30, 2024","June 30, 2024","March 23, 2021",,"February 16, 2024","University of Illinois at Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04810546"
57,"NCT03873571","Adherence of Iron Succinylate Therapy in Pregnancy","ARTEMIS","Withdrawn","No Results Available","Pregnancy Related|Pregnancy Anemia|Iron Deficiency Anemia",,"Medication Adherence","Elpen Pharmaceutical Co. Inc.","Female","18 Years to 50 Years   (Adult)",,"0","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","2019-IRPS-EL-96","December 30, 2022","December 30, 2023","December 30, 2023","March 13, 2019",,"February 15, 2023","Iaso Hospital, Athens, Greece",,"https://ClinicalTrials.gov/show/NCT03873571"
58,"NCT02038023","Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women",,"Completed","Has Results","Pregnancy","Drug: Intravaneous iron(low molecular weight iron dextran)","Percentage of Women Who Achieve Anemia Correction After a Single Dose of 1000mg of Low Molecular Weight Iron Dextran(INfeD).|Serum Ferritin|Percent Transferrin Saturation|Safety as Measured by Number of Adverse Events","Auerbach Hematology Oncology Associates P C|Pharmacosmos A/S","Female","18 Years to 45 Years   (Adult)","Phase 2","74","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intravaneous Iron in Pregnancy|Infed","July 2013","July 2015","August 2015","January 16, 2014","June 28, 2018","June 28, 2018","Auerbach Hematology Oncology Assoc, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02038023"
59,"NCT04008147","Hepcidin and Glucose Metabolism",,"Recruiting","No Results Available","Iron Deficiency Anemia of Pregnancy|Iron Metabolism Disorders|Glucose Intolerance|Gestational Diabetes","Dietary Supplement: 100mg iron fumarate|Dietary Supplement: Burgerstein Schwangerschaft & Stillzeit","Serum hepcidin|Serum iron|glucose|insulin|Serum ferritin|soluble transferrin receptor|c-reactive protein|alpha glycoprotein","Swiss Federal Institute of Technology|University Hospital, Zürich","Female","18 Years to 45 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","INDIA","July 3, 2019","December 31, 2023","December 31, 2023","July 5, 2019",,"November 1, 2023","Human Nutrition Laboratory ETH Zurich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04008147"
60,"NCT05725278","Impact Evaluation of Triggerise's Tiko Platform",,"Completed","No Results Available","Contraception|Iron Deficiency Anemia of Pregnancy|Antenatal Care|Postnatal Care","Behavioral: Tiko Platform Behavioural cum mHealth Intervention|Other: Standard of Care / Business as Usual","Proportion of women currently using any contraceptives|Proportion of women currently using modern short-term contraceptives|Proportion of women who consumed 100 or more Iron Folic Acid (IFA) tablets during last pregnancy|Proportion of women who received 4 or more antenatal check-ups during last pregnancy|Proportion of women who received a postnatal check-up within 6 week of the delivery from a healthcare provider|Out of pocket expenditure on antenatal care, iron folic acid tablets, delivery, and postnatal check-ups|Out of pocket expenditure on Family planning services and products|Proportion of women receiving Antenatal check-ups at (a) Tiko franchisee doctors, (b) other private doctors, or (c) government healthcare provider|Proportion of women receiving postnatal check-ups at (a) Tiko franchisee doctors, (b) other private doctors, or (c) government healthcare provider","Network for Engineering and Economics Research and Management","Female","18 Years to 50 Years   (Adult)","Not Applicable","1708","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Triggerise Protocol V2","February 15, 2021","May 17, 2021","March 20, 2022","February 13, 2023",,"February 13, 2023","NEERMAN, Mumbai, Maharashtra, India","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/78/NCT05725278/Prot_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/78/NCT05725278/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05725278"
61,"NCT04486456","Epidemiological Study on Anemia and Iron Deficiency in Pregnancy in Medical Institutions in Some Areas of China",,"Unknown status","No Results Available","Prevalence",,"Hb|SF","Peking University First Hospital","Female","18 Years and older   (Adult, Older Adult)",,"20000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ERIC STUDY","August 2020","August 2022","December 2022","July 24, 2020",,"July 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04486456"
62,"NCT03922087","No-worry Baby Project",,"Completed","No Results Available","Gestational Diabetes Mellitus in Pregnancy|Gestational Hypertension|Thyroid Disease Pregnancy|Obesity|Anemia in Pregnancy|Complications, Pregnancy|Depression|Obstetric Labor Complications|Asthma|Allergic Disorder|Immune System Diseases|Neurodevelopmental Disorders|Reproductive Disorder","Other: No intervention","Number of adverse birth outcomes.|Children weight changes.|Children height changes.|Number of participant with gestational complications.|Maternal weight changes(kg).|Number of participant with postnatal depression.","Sun Yat-sen University|Huizhou No.1 Maternal and Child Care Service Cencer","Female","18 Years to 49 Years   (Adult)",,"5216","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HZT2018","November 20, 2018","April 1, 2022","September 30, 2023","April 19, 2019",,"November 28, 2023","School of Public Health of Sun Yat-sen University (North Campus), Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03922087"
63,"NCT05752955","SMART Health Pregnancy 2 - Intervention to Reduce Anaemia and Cardiometabolic Risk During Pregnancy and in the First Year Following Birth",,"Recruiting","No Results Available","Anemia of Pregnancy|Gestational Diabetes|Gestational Hypertension|Pre-Eclampsia|Anemia|Type 2 Diabetes|Hypertension","Other: SMARThealth Pregnancy","Decrease anaemia prevalence in women|Decrease the proportion of women with moderate and severe anaemia|Postnatal screening for type 2 diabetes after GDM|Postnatal screening for hypertension after hypertensive disorder of pregnancy|Compliance with iron-folic acid supplements during pregnancy and breastfeeding|De-worming treatment|Point of care Haemoglobin (Hb) testing|Referral of high risk conditions|Hypertension after hypertensive disorder of pregnancy|Dysglycaemia after a pregnancy affected by GDM","The George Institute|University of Oxford","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","3240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","27-21","June 6, 2022","June 2024","December 2024","March 3, 2023",,"March 3, 2023","The George Institute for Global Health, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT05752955"
64,"NCT03738995","Retrospective Survey of Obstetric Red Cell Transfusion in a Tertiary Women's Hospital",,"Completed","No Results Available","Transfusion; Maternofetal","Biological: Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum","Number of transfused parturients per 1000 maternities for the period 2014-2015|Nature and frequency of indications for obstetric red cell transfusion|Median haemoglobin concentration pre- and post-transfusion","KK Women's and Children's Hospital","Female","17 Years to 50 Years   (Child, Adult)",,"760","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ver2072016","August 1, 2016","March 30, 2018","March 30, 2018","November 13, 2018",,"November 13, 2018",,,"https://ClinicalTrials.gov/show/NCT03738995"
65,"NCT06125860","BEP Targeting Strategies in Ethiopia","BEP","Recruiting","No Results Available","Small for Gestational Age at Delivery|Gestational Weight Gain|Stillbirth|Preterm Birth|Birth Weight|Maternal Anemia in Pregnancy, Before Birth|Neonatal Death|Perinatal Death","Dietary Supplement: Targeted BEP based on baseline nutritional status|Dietary Supplement: Targeted BEP based on baseline nutritional status and monthly GWG monitoring|Dietary Supplement: Universal BEP","Small-for-gestational-age births|Inadequate gestational weight gain|Excessive gestational weight gain|Stillbirth|Preterm birth|Low birthweight|Macrosomia|Large-for-gestational-age births|Third-trimester anemia|Neonatal death|Perinatal death|Pre-eclampsia","Harvard School of Public Health (HSPH)|Addis Continental Institute of Public Health|George Mason University","Female","18 Years to 49 Years   (Adult)","Not Applicable","5400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB22-1245","August 7, 2023","August 31, 2025","November 30, 2025","November 9, 2023",,"November 9, 2023","Addis Continental Institute of Public Health (ACIPH), Addis Ababa, Ethiopia",,"https://ClinicalTrials.gov/show/NCT06125860"
66,"NCT05545527","Neuroimaging Ancillary Study",,"Active, not recruiting","No Results Available","Iron Deficiency Anemia|Iron Deficiency Anemia of Pregnancy|Neurodevelopmental Disorder of Foetus|Iron Deficiency Anemia Treatment|Fetal Neurodevelopmental Disorder|Child Development","Drug: Ferric carboxymaltose|Drug: Iron isomaltoside|Drug: Ferric Sulfate","Fetal hippocampal volume|Fetal diffusion parameters: fractional anisotropy (FA)|Fetal diffusion parameters: mean diffusivity|Fetal sub-cortical gray matter structures|Fetal white matter microstructure measures|Child hippocampal volume|Child white matter volume|Child white matter microstructure|Child white matter connectivity|Child functional connectivity|Child cerebral metabolism","Thomas Jefferson University|Jawaharlal Nehru Medical College","Female","18 Years to 40 Years   (Adult)",,"184","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","U32401","February 21, 2023","December 2023","February 2025","September 19, 2022",,"November 29, 2023","Jawaharlal Nehru Medical College, Belgaum, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT05545527"
67,"NCT05739097","Prospective Study on Feto-maternal outcoMe In aNemIc womEn","MINNIE","Active, not recruiting","No Results Available","Anemia|Pregnancy Anemia|Pregnancy Bleeding|Transfusion-dependent Anemia|Transfusion; Embolism, Thrombus|Bleeding|Placenta Diseases","Diagnostic Test: iron deficiency, coagulation abnormalities","number of maternal deaths or venous thromboembolisms, hemorrhages|number of fetal deaths or intrauterine growth restriction","Casa Sollievo della Sofferenza IRCCS|University of Foggia|University of Bari","Female","18 Years to 45 Years   (Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MINNIE, version 12/06/2021","January 1, 2022","December 31, 2024","February 28, 2025","February 22, 2023",,"February 22, 2023","Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy|Gabriella Cicerone, Foggia, Italy","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/97/NCT05739097/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05739097"
68,"NCT05576207","BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR)","Target-BEP","Recruiting","No Results Available","Fetal Growth Retardation|Low Birth Weight|Preterm Birth|Gestational Weight Gain|Anemia of Pregnancy|Stunting|Pregnancy Complications","Dietary Supplement: Balanced energy and protein supplement for pregnant women|Dietary Supplement: Multiple Micronutrient Supplement for pregnant women","Birth weight|Low birth weight (weight < 2500 g) at birth|Small-for-gestational age|Birth length|Gestational weight change|Proportion of inadequate gestational weight gain|Head circumference at birth|Chest circumference at birth|Large for gestational age at birth","Johns Hopkins Bloomberg School of Public Health|Bill and Melinda Gates Foundation|BRAC James P Grant School of Public Health, BRAC University","Female","15 Years to 35 Years   (Child, Adult)","Not Applicable","2120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","INV-033381","October 15, 2022","June 30, 2024","March 31, 2025","October 12, 2022",,"August 15, 2023","JiVitA Project, Rangpur, Bangladesh",,"https://ClinicalTrials.gov/show/NCT05576207"
69,"NCT05262634","Pregnancy Outcome in Women With an Iron Deficiency in the First Trimester",,"Completed","No Results Available","Iron Deficiency","Other: Data collection (laboratory and obstetric results)","Proportion of anemia|Proportion of hemorrhage|Proportion of growth retardation","University Hospital, Basel, Switzerland","Female","Child, Adult, Older Adult",,"713","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-02033; bb22Hoesli2","September 1, 2021","January 31, 2022","January 31, 2022","March 2, 2022",,"March 2, 2022","Women's Clinic, University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT05262634"
70,"NCT05832840","Survey Tool for Screening of Anemia in Women Before Pregnancy","PREPSA","Completed","No Results Available","Anemia Complicating Pregnancy|Anemia Complicating Childbirth|Anemia Complicating the Puerperium",,"Validation of survey instrument","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Thomas Jefferson University|Jawaharlal Nehru Medical College|RTI International","Female","18 Years to 25 Years   (Adult)",,"503","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","GN08 PREPSA","April 17, 2023","June 13, 2023","July 4, 2023","April 27, 2023",,"November 18, 2023","Jawaharlal Nehru Medical College, Belgaum, India",,"https://ClinicalTrials.gov/show/NCT05832840"
71,"NCT00746551","Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment","EIVF","Completed","Has Results","Anemia|Pregnancy Complications","Drug: Ferli-6® (Continental Pharm co., ltd.)|Drug: Venofer® (Vifor AG, St. Gallen, Switzerland)","Serum Ferritin Level|Haemoglobin Level","Mahidol University|Vifor Pharma","Female","18 Years to 45 Years   (Adult)","Phase 4","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","296/2551(EC3)","September 2008","March 2010","April 2010","September 4, 2008","February 16, 2015","February 16, 2015","Siriraj Hospital, Mahidol University, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00746551"
72,"NCT01221844","Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies",,"Completed","No Results Available","Pregnancy|Iron Deficiency|Iron Deficiency Anemia","Dietary Supplement: Lattoglobina (Grunenthal) containing bLf|Drug: FerroGrad by Abbott","Hematological parameters|Side effects","Clinica Fabia Mater","Female","20 Years to 45 Years   (Adult)","Phase 4","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RP2010","February 2010","March 2011","May 2011","October 15, 2010",,"June 27, 2011","Clinica Fabia Mater, Rome, Rm, Italy",,"https://ClinicalTrials.gov/show/NCT01221844"
73,"NCT03347513","Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy?",,"Unknown status","No Results Available","Pregnancy Complications|Anemia, Iron Deficiency|H Pylori Infection","Drug: triple attack therapy|Drug: Ferrous(II)-glycine-sulphate complex 567.7 mg capsules","hemoglobin levels","Kasr El Aini Hospital","Female","up to 40 Years   (Child, Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A15112017","November 25, 2017","March 2019","May 2019","November 20, 2017",,"December 4, 2018","obstetrics and gynecology department, Kasr Alainy hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03347513"
74,"NCT06079918","Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania","MMS-MAP","Not yet recruiting","No Results Available","Pregnancy Related","Dietary Supplement: Multiple Micronutrient Supplements with 30 mg of elemental iron|Dietary Supplement: Multiple Micronutrient Supplements with 45 mg of elemental iron|Dietary Supplement: Multiple Micronutrient Supplements with 60 mg of elemental iron","Proportion of pregnant women with third-trimester moderate or severe anemia|Maternal hemoglobin concentration|Proportion of pregnant women with anemia|Proportion of postpartum women with anemia|Maternal serum ferritin|Proportion of pregnant women with iron deficiency|Proportion of pregnant women with iron deficiency anemia|Proportion of women with preeclampsia|Proportion of women with antepartum bleeding|Proportion of women with postpartum hemorrhage|Proportion of women with peripartum infection|Proportion of women with pregnancy-related death|Proportion of women with symptoms consistent with depression|Proportion of women with symptoms consistent with fatigue|Proportion of women with malaria infection|Proportion of fetal deaths|Proportion of stillbirths|Birthweight|Proportion of live births with low birthweight|Gestational age at birth|Proportion of preterm live births|Birthweight for gestational age|Proportion of small-for-gestational age live births (<10th percentile)|Proportion of small-for-gestational age live births (<3rd percentile)|Infant hemoglobin concentration|Infant serum ferritin|Proportion of infants with iron deficiency|Proportion of neonatal deaths|Proportion of infant deaths < 42 days","George Washington University|Ifakara Health Institute|Harvard School of Public Health (HSPH)|Muhimbili University of Health and Allied Sciences|Africa Academy for Public Health|Columbia University","Female","18 Years and older   (Adult, Older Adult)","Phase 3","6381","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MMS-MAP","September 2024","June 2025","September 2025","October 12, 2023",,"March 15, 2024",,,"https://ClinicalTrials.gov/show/NCT06079918"
75,"NCT04661865","Effect of Health Information Package Program on Knowledge and Compliance Among Pregnant Women With Anemia",,"Completed","No Results Available","Knowledge|Anemia|Pregnant Women","Other: Health Information Package Program (HIP program )","Haemoglobin|knowledge|compliance with iron supplementation","Jouf University","Female","18 Years to 45 Years   (Adult)","Not Applicable","196","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","DSR2020-04-3655","January 1, 2021","April 30, 2021","May 31, 2021","December 10, 2020",,"August 4, 2021","Primary Health Care centers, Jouf- Saudi Arabia, Jouf, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04661865"
76,"NCT04975074","Iron Deficiency Anemia in Twin Pregnancies",,"Unknown status","No Results Available","Anemia, Iron-Deficiency","Drug: Iron","Routine blood|serum ferritin","Shengjing Hospital","Female","16 Years to 50 Years   (Child, Adult)","Phase 4","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IDA in TP","July 15, 2021","December 2021","July 2022","July 23, 2021",,"July 23, 2021",,,"https://ClinicalTrials.gov/show/NCT04975074"
77,"NCT05062044","A Study to Gather Information About the Progress and Outcomes of Pregnancy in Women Using Various Vitamin Support Plans Before and During Pregnancy",,"Active, not recruiting","No Results Available","Prevention of Vitamin Deficiency During and/or Before Pregnancy","Dietary Supplement: Multivitamins (Elevit, BAY987808)|Dietary Supplement: Multivitamins (Elevit, BAY2906300)|Drug: Multivitamins (Elevit, BAY987386)|Dietary Supplement: Folic acid","Number of participants with normally completed pregnancies|Number of participants with maternal anemia of any severity in third trimester (hemoglobin [Hb] <110 g/L)|Number of participants with preeclampsia of any severity|Number of participants with small-for-gestational newborns|Number of participants having low and very low birth weight newborns|Mean and change in score of quality of life gravidarum (QoL-Grav) in first to third trimester|Number and severity of anemia at any trimesters|Number of usage of iron medications for the purposes of anemia|Change of anemia severity from first to third trimester|Number of participants with preterm birth|Number of participants with fetal growth restriction during third trimester|Number of participants with post-term birth|Number of participants with gestational diabetes|Number of participants with confirmed glucose intolerance during third trimester|Number of participants with congenital malformations|Number of participants with fetal macrosomia|Number of participants with excessive vomiting in pregnant women|Number of pregnancy within 6 months of periconceptional supplementation in women with different levels of fertile function|Number of participants with spontaneous abortion/miscarriage|Normal weight gain in newborns in the first month of life in accordance with WHO child growth standards|Number of participants with exclusive breastfeeding, mixed and artificial feeding in the first month after delivery","Bayer","Female","18 Years to 45 Years   (Adult)",,"1500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","21967","December 2, 2021","June 30, 2025","June 30, 2025","September 30, 2021",,"April 2, 2024","Many Locations, Multiple Locations, Kazakhstan|Many Locations, Multiple Locations, Russian Federation|Many Locations, Multiple Locations, Uzbekistan",,"https://ClinicalTrials.gov/show/NCT05062044"
78,"NCT03176147","Iron Metabolism Parameters At First Trimester and preGnancy outcomE","IMAGE","Unknown status","No Results Available","Iron Deficiency Anemia","Other: Iron deficiency anemia","Hemoglobin value|Rate of clinical and biological factors per patient|Rate of demographics and clinical factors per patient|Rate of biological factors per patient","University Hospital, Clermont-Ferrand","Female","15 Years to 50 Years   (Child, Adult)",,"865","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHU-336|2015-A00454-45","November 12, 2015","June 2017","January 2018","June 5, 2017",,"June 5, 2017","CHU de Clermont-Ferrand, Clermont-Ferrand, Auvergne, France",,"https://ClinicalTrials.gov/show/NCT03176147"
79,"NCT01358552","Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)",,"Terminated","No Results Available","Pregnancy","Other: Néevo®/ NéevoDHA®","To determine the safety and tolerability of Néevo®/NéevoDHA® as measured by side effects and compliance|To determine overall patient satisfaction with Néevo®/NéevoDHA® using a 9-point satisfaction scale","Pamlab, Inc.|InfoMedics, Inc.","Female","18 Years to 39 Years   (Adult)",,"53","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","N-003","January 2011","March 2012","March 2012","May 23, 2011",,"May 1, 2013","Noe Lira, M.D., Corpus Christi, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01358552"
80,"NCT01245777","Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy",,"Completed","No Results Available","Restless Leg Syndrome|Iron Deficiency Anemia","Drug: ferric carboxymaltose","Primary endpoint: = 50% reduction of RLS symptoms as measured by International Restless Legs Study Group (IRLSS)|Reduction of Periodic Limb Movements in Sleep (PLMS) ≥50% as measured with actimetry|Improvement of sleep according to the Pittsburgh Sleep Quality Questionnaire (PSQI)|Improvement of sleepiness using Epworth Sleepiness Scale (ESS)|Improvement of fatigue using Fatigue Severity Scale (FSS)|Safety of ferric carboxymaltose during pregnancy in the 3rd trimester|Parameters of the newborn baby (apgar, umbilical artery pH, weight, mode of delivery)","University of Zurich|Vifor Pharma","Female","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ITiRiP-1","October 2009","December 2012","December 2012","November 22, 2010",,"December 5, 2014","Neurocenter of Southern Switzerland, Ospedale Civico, Lugano, Ticino, Switzerland|University Hospital Zurich, Neurology, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01245777"
81,"NCT03830034","Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial",,"Unknown status","No Results Available","Iron Deficiency Anemia","Drug: Amino Acid chelated iron tab 15 mg|Drug: Ferrous Fumarate tab 350 mg( 115 mg elemental iron)","Hemoglobine (Hb) Rise|Adverse effects of the medication given","Ain Shams University","Female","18 Years to 40 Years   (Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IDA","February 2, 2019","October 15, 2019","December 1, 2019","February 5, 2019",,"February 5, 2019","Ain shams university maternity hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03830034"
82,"NCT02190565","Safety and Efficacy Study of a Food Supplement for Pregnant and Lactating Women",,"Withdrawn","No Results Available","Anaemia","Dietary Supplement: Food supplement","Prevalence of anaemia in active and placebo groups|Levels of nutritional biomarkers in maternal blood and breast milk","Oriflame Cosmetics AB|Karolinska Institutet","Female","18 Years to 40 Years   (Adult)","Not Applicable","0","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2014/815-31/4","April 7, 2018","April 7, 2018","April 7, 2018","July 15, 2014",,"December 5, 2018","Department of Woman and Child Health, Division of Obstetrics and Gynecology, Karolinska Institutet, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02190565"
83,"NCT05278793","The Efficacy of Intermittent Versus Daily Oral Iron Supplementation in Anaemic Pregnant Women.","FER-IDIP","Unknown status","No Results Available","Iron Deficiency Anemia|Pregnancy Related","Drug: Ferrous fumarate","Haemoglobin level|Side effects|Therapy compliance|Haemoglobin level at time of delivery|Term of delivery|Birth weight|Parenteral iron ante- or postpartum|Blood transfusion postpartum","Martini Hospital Groningen|dr. J.M. Munster, gynaecologist, principal investigator","Female","18 Years and older   (Adult, Older Adult)","Phase 4","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL77578.000.21|2021-005393-26","January 7, 2022","December 2022","December 2022","March 14, 2022",,"March 14, 2022","Martini Hospital Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT05278793"
84,"NCT01795131","Vitamin B12 Supplementation During Pregnancy",,"Completed","No Results Available","Nutritional Anemia in Mothers.|Nutritional Anemia in Infants.","Dietary Supplement: Vitamin B12|Dietary Supplement: Placebo","a) Percent reduction in nutritional anemia among mothers (based on measurement of Hb, ferritin, sTfR, folate, B12 levels in plasma; urinary MMA and tHcy; B12 levels in breast milk.)|Increase in influenza vaccine specific cellular and humoral responses among mothers (blastogenesis and T cell phenotyping,serum IgA, and IgG).|Increase in influenza vaccine specific immunity in infants by passive transfer (vaccine specific IgG in cord blood and breast milk and IgA in children at 3 mo).|Percent reduction in nutritional anemia in infants (based on measurement of Hb, ferritin, B12 levels in plasma;|Effect of B12 status on DNA methylation and one-carbon metabolism in mother-child pairs.|Reduce depression scores","International Centre for Diarrhoeal Disease Research, Bangladesh","All","22 Years to 35 Years   (Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Health Services Research","PR-09033","February 2010","June 2012","December 2013","February 20, 2013",,"April 3, 2014","Maternal and Child Health Training Institute, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT01795131"
85,"NCT04228627","Ferritin Screening And IRon Treatment for Maternal Anemia and FGR Prevention Trial","FAIR","Active, not recruiting","No Results Available","Iron Deficiency (Without Anemia)|Pregnancy Related","Drug: Parentral Iron","Maternal anaemia|Fetal growth restriction","Services Institute of Medical Sciences, Pakistan|Allama Iqbal Medical College|Universidad de Granada|Fatima Jinnah Medical University","Female","18 Years to 45 Years   (Adult)","Phase 4","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB/2019/599/SIMS","August 1, 2020","January 30, 2024","February 28, 2024","January 14, 2020",,"December 21, 2023","Fatima Jinnah Medical University, Lahore, Punjab, Pakistan|TAYYIBA Wasim, Lahore, Punjab, Pakistan|Allama Iqbal Medical College, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04228627"
86,"NCT04253626","Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia",,"Active, not recruiting","No Results Available","Pregnancy Related|Anemia, Iron Deficiency","Drug: Ferumoxytol Injection [Feraheme]|Drug: Ferrous Sulfate","Mean Change in Hemoglobin value before and after intervention","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years and older   (Adult, Older Adult)","Phase 3","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","54788|K12HD103084","January 21, 2021","June 2024","June 2024","February 5, 2020",,"March 8, 2024","Stanford University School of Medicine/Lucile Packard Childrens Hospital, Stanford, California, United States","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/26/NCT04253626/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04253626"
87,"NCT03836703","Doubling the Iron Dose to Prevent IDA in Twin Pregnant Women","IDA","Completed","No Results Available","Hematologic Pregnancy Complications","Drug: Feroglobin single daily use|Drug: Feroglobin twice daily dose","Hemoglobin level below 11 g/dl|blood product administration|GIT side effects|Preterm Birth|neonatal Birth weidht","Ain Shams University","Female","18 Years to 35 Years   (Adult)","Phase 4","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","3201","February 1, 2019","July 1, 2020","August 1, 2020","February 11, 2019",,"January 20, 2021","Ahmed Abass, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03836703"
88,"NCT03562143","Daily vs Alternate Day Iron Supplementation for Pregnant Women With Iron Deficiency Anemia",,"Completed","No Results Available","Iron Deficiency Anemia","Dietary Supplement: Ferrous Sulfate","Change in Hemoglobin Level|Change in Ferritin Level|Change in Fasting Hepcidin Level|Side effects from Iron Supplementation Questionnaire","Icahn School of Medicine at Mount Sinai","Female","18 Years to 64 Years   (Adult)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 18-1781","August 31, 2018","February 20, 2020","February 20, 2020","June 19, 2018",,"March 18, 2020","Mount Sinai West, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03562143"
89,"NCT02887963","Epidemiological Study of Iron Deficiency and Iron Deficiency Anemia in Chinese Pregnant Women","EIDACPW","Completed","No Results Available","Anemia, Iron-Deficiency",,"Iron Deficiency (ID)|Iron Deficiency Anemia (IDA)|Use of iron supplements","West China Hospital|West China Second University Hospital|Sichuan Provincial Hospital for Women and Children|Panzhihua Central Hospital|Chongqing Medical Center for Women and Children|Obstetrics and Gynecology Hospital of Zhejiang University|Xiamen Medical Center for Women and Children|Wenzhou People's Hospital|Suzhou Municipal Hospital|Wuhan Union Hospital, China|Maternal and Child Health Hospital of Hubei Province|The First Affiliated Hospital of Zhengzhou University|First Affiliated Hospital of Guangxi Medical University|Shanxi Provincial Maternity and Children's Hospital|The Second Affiliated Hospital of Shanxi University of Traditional Chinese Medicine|Yan'an University Affiliated Hospital|Xinjiang Provincial Hospital for Women and Children|Shengjing Hospital|Dalian Maternity and Child Care Hospital|Changchun Obstetrics and Gynecology Hospital|The Fourth Affiliated Hospital of Harbin Medical University|Beijing Obstetrics and Gynecology Hospital|Tianjin Central Hospital of Gynecology Obstetrics|Fourth Hospital of Shijiazhuang City|Beijing Friendship Hospital","Female","Child, Adult, Older Adult",,"12000","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","IDA-China-2016","September 2016","November 2016","January 2017","September 2, 2016",,"March 27, 2017","Chinese Evidence-based Medicine Centre, West China Hospital, Sichuan University, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT02887963"
90,"NCT01136850","Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea","IPTp in PNG","Completed","No Results Available","Malaria in Pregnancy|Sexually Transmitted Infections|Anaemia","Drug: chloroquine, sulphadoxine pyrimethamine, LLIN|Drug: azithromycin, sulphadoxine pyrimethamine, LLIN","Proportion of women delivering low birth weight babies, <2500 g|Prevalence of P falciparum at delivery in peripheral, placental and cord blood films and on placental histology|Mean maternal hemoglobin concentration at delivery, and proportion of women anaemic (Hb < 11 g/dl).|Prevalence (at enrolment, second treatment, and delivery) and consequences (maternal haemoglobin, birth weight and placental pathology) of P. vivax infection in pregnancy|Incidence of symptomatic malaria during pregnancy|Proportion of women carrying azithromycin-sensitive sexually transmitted infections at second treatment visit (28-34 weeks).|Incidence of Adverse Events, including severe adverse events (SAEs), and AEs possibly or probably associated with study medications|Prevalence of drug resistance markers in parasites infecting women in late pregnancy, particularly in the P falciparum and P vivax dihydrofolate reductase and dihydropteroate synthase enzymes, associated with SP resistance|Prevalence and antibiotic sensitivity patterns of S. pneumoniae in nasopharyngeal swabs collected at delivery|Maternal, perinatal and infant mortality rates|Impact of IPTp on development of immunity to malaria in pregnancy|Characteristics of parasites infecting pregnant women","University of Melbourne|Papua New Guinea Institute of Medical Research|The University of Western Australia|Walter and Eliza Hall Institute of Medical Research|University of Barcelona","Female","16 Years to 49 Years   (Child, Adult)","Phase 3","2793","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","70270","November 2009","December 2012","January 2013","June 4, 2010",,"April 23, 2013","Papua New Guinea Institute of Medical Research, Madang, Madang Province, Papua New Guinea",,"https://ClinicalTrials.gov/show/NCT01136850"
91,"NCT05251493","Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy",,"Recruiting","No Results Available","Iron Deficiency Anaemia in Childbirth","Drug: Iron Isomaltoside 1000, ferric derisomaltose|Drug: Iron sucrose","Correction of anemia|Participant's tolerance to IV iron infusion|Comparison of participant's pregnancy related symptoms- subjective measure|Convenience/barriers of IV iron appointment(s)- subjective measure|Changes in Participant's Mental Health and Physical Well-Being|Reported bonding with baby-subjective","Saskatchewan Health Authority - Regina Area|Saskatchewan Centre for Patient-Oriented Research","Female","18 Years to 50 Years   (Adult)","Phase 3","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HC6-024-c260086 SHA REB-21-64","June 6, 2022","December 31, 2024","February 28, 2025","February 22, 2022",,"November 22, 2023","Regina General Hospital, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT05251493"
92,"NCT03212781","Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women",,"Completed","No Results Available","Anemia","Drug: Iron dextran|Drug: Ferrous Fumarate","The change in Hemoglobin concentration from baseline to 8 weeks therapy","Assiut University","Female","18 Years to 45 Years   (Adult)","Phase 3","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDAO","June 2016","September 2016","October 2016","July 11, 2017",,"July 11, 2017","Assiut Faculty of Medicine, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT03212781"
93,"NCT02221752","Impact of Iron/Folic Acid vs Folic Acid Supplements During Pregnancy on Maternal and Child Health",,"Completed","No Results Available","Iron Deficiency|Iron Deficiency Anemia","Dietary Supplement: Ferrous Sulfate + folic acid|Dietary Supplement: Folic acid","Maternal iron status at follow-up prenatal visit|Cord-blood iron status|Infant gestational age|Infant birth weight","Zhao gengli|Vifor Pharma|Peking University First Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","2367","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Vifor/PFH supplement trial","June 2009","December 2011","December 2011","August 20, 2014",,"August 20, 2014","Peking University First Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02221752"
94,"NCT03759353","Lactoferrin Versus Ferrous Sulfate in Iron-deficiency During Pregnancy",,"Completed","No Results Available","Iron Deficiency Anemia","Diagnostic Test: Baseline ferritin level|Drug: Lactoferrin|Drug: Ferrous Sulfate|Diagnostic Test: Follow up ferritin level","Change in serum ferritin level|Nausea and/or vomiting|Dyspepsia|Compliance to treatment","Ain Shams University","Female","18 Years to 38 Years   (Adult)","Phase 2","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LactvsFerr","January 15, 2018","October 30, 2018","November 20, 2018","November 30, 2018",,"November 30, 2018","Ain SHams Maternity Hospital, Cairo, Abbaseya, Egypt",,"https://ClinicalTrials.gov/show/NCT03759353"
95,"NCT01131624","Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women","ASAP","Completed","No Results Available","Anaemia","Drug: ferrous sulphate|Drug: Ferinject","Average Hb increase after 3 weeks in FCM compared to oral iron treated subjects (superiority).|Change in Hb from baseline at Week 6|Change in Hb from baseline at Week 9|Change in Hb from baseline at Week 12","Vifor Pharma|Pierrel Research Europe GmbH","Female","18 Years and older   (Adult, Older Adult)","Phase 3","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FER-ASAP-2009-01","May 2010","May 2014","April 2015","May 27, 2010",,"May 29, 2015","The Northern Hospital, Epping, Victoria, Australia|Vivantes Klinikum Neukölln, Klinikum für Geburtsmedizin, Berlin, Germany|Klinik Für Frauenheilkunde und Geburtshilfe Universitätsklinikum Marburg, Marburg, Germany|Perinatalzentrum, Klinikum Innenstadt LMU, München, Germany|Kvinnokliniken, Falu lasarett, Falun, Sweden|Kvinnokliniken, University Hospital, Lund, Sweden|Kvinnokliniken, Karolinska University Hospital, Stockholm, Sweden|Karolinska Universitetssjukhuset Huddinge, Centrum för fostermedicin KK, Stockholm, Sweden|University Hospital, Dept of obstetrics and gynecology Uppsala, Uppsala, Sweden|Universitätsspital Basel, Geburtshilfe und Schwangerschaftsmedizin Frauenklinik, Basel, Switzerland|Inselspital, Department of Obstetrics and Gynecology, Bern, Switzerland|Humboldtstrasse, Bern, Switzerland|HUG, Département de Gynécologie-Obstétrique, Genève, Switzerland|CHUV, Département de Gynécologie-Obstétrique, Lausanne, Switzerland|OR Lugano, sede Ospedale Civico, Clinica ginecologia ostetricia, Lugano, Switzerland|Universitätsspital Zürich, Departement Frauenheilkunde, Zürich, Switzerland|Cukurova University Hospital, Adana, Turkey|Istanbul Uni. Ist. Med. Faculty, Istanbul, Turkey|Zeynep Kamil Hospital, Arakiyeci Haci Mehmet Mahallesi., Istanbul, Turkey|Dr. Kutfi Kirdar Kartal Research and Education Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT01131624"
96,"NCT03670537","Iron Parameters in Non-anemic First Trimester Gravidas",,"Completed","Has Results","Iron Deficiency (Without Anemia)|Pregnancy","Diagnostic Test: Iron parameters","Percent of Non-anemic Patients With Iron Deficiency Stratified by Gravidity","Auerbach Hematology Oncology Associates P C|MedStar Women's Care at Honeygo","Female","Child, Adult, Older Adult",,"102","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Protocol 3","February 7, 2018","August 24, 2018","August 24, 2018","September 13, 2018","October 15, 2018","June 26, 2019","Auerbach Hematology and Oncology, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/37/NCT03670537/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03670537"
97,"NCT03251664","Food Groups Associated With Anaemia in Pregnant Women",,"Completed","No Results Available","Anemia|Dietary Habits|Food Habits","Dietary Supplement: Food groups consumed","Food items/groups association with anemia|Reproductive factors associated with anemia|Sociodemographic and economic factors association with anemia","Tehran University of Medical Sciences","Female","18 Years to 45 Years   (Adult)",,"592","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","AAHB-217/15","October 1, 2015","February 20, 2016","February 20, 2016","August 16, 2017",,"August 22, 2017","Addis Ababa Health Bureau, Addis Ababa, Ethiopia",,"https://ClinicalTrials.gov/show/NCT03251664"
98,"NCT04093986","Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation","HELPFUL","Recruiting","No Results Available","Sickle Cell Disease|Sickle Cell Anemia","Other: Chart Review|Other: Survey","How long pregnant women with Sickle Cell Disease (SCD) were exposed to Hydroxyurea.|Dose of hydroxyurea taken during pregnancy.|How long infants were exposed to Hydroxyurea.|Dose of hydroxyurea exposure in infants.|Health outcomes of infants exposed to Hydroxyurea.|Pregnancy in Sickle Cell Disease (SCD).|Comparative analysis of congenital malformations or medical conditions in infants","Children's Hospital Medical Center, Cincinnati|University of Connecticut|University of Colorado, Denver|Guy's and St Thomas' NHS Foundation Trust|Duke University|Children's Hospital of Philadelphia","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","HELPFUL","December 22, 2019","December 2025","December 2026","September 18, 2019",,"March 13, 2023","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04093986"
99,"NCT03196882","Effectiveness of Adaptation of the Dose of Iron Supplementation in Pregnancy on Maternal-child Health. (ECLIPSES)","(ECLIPSES)","Completed","No Results Available","Anemia Ferropenic|Risk of Hemoconcentration (Iron Levels >130g/L)","Drug: 40mg/day of iron|Drug: 20mg/day of iron|Drug: 80mg/day of iron","Anemia|ferropenic anemia|Risk of hemoconcentration|C282Y polymorphisms of HFE gene|Anthropometric parameters of newborn.|Neurorconductual development of newborn (Bayley Scales)|H63D polymorphisms of HFE gene","Victoria Arija Val|University Rovira i Virgili|Catalan Institute of Health|Hospital Universitari Joan XXIII de Tarragona.|Carlos III Health Institute|Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","Female","18 Years and older   (Adult, Older Adult)","Phase 4","704","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IJG-FER-2012|2012-005480-28|PI12/02777","July 10, 2013","January 30, 2017","January 30, 2017","June 23, 2017",,"June 23, 2017","Atención a la Salud Sexual y Reproductiva (ASSIR)- REUS- Altebrat, Reus, Tarragona, Spain|Atención a la Salud Sexual y Reproductiva (ASSIR)- Tarragona Valls, Tarragona, Spain",,"https://ClinicalTrials.gov/show/NCT03196882"
100,"NCT00148629","Treatment and Prevention of Severe Anemia in Pregnant Zanzibari Women",,"Unknown status","No Results Available","Anemia|Low Birth Weight|Neonatal Mortality","Drug: multivitamin, mebendazole","Incidence of severe anemia (Hb < 7 g/dL)|Cure of severe anemia|Infant birth weight|Neonatal mortality|Neonatal morbidity|Blood loss during delivery","Cornell University|Bill and Melinda Gates Foundation|UNICEF|Johns Hopkins Bloomberg School of Public Health","Female","Child, Adult, Older Adult","Phase 3","2500","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","UCHS 02-10-030","April 2004",,,"September 8, 2005",,"February 8, 2022","Public Health Laboratory ""Ivo de Carneri"", Wawi, Zanzibar, Tanzania",,"https://ClinicalTrials.gov/show/NCT00148629"
101,"NCT01183572","Trial of Pre-Pregnancy Supplements","TOPPS","Completed","No Results Available","Anemia","Dietary Supplement: Multivitamins, Folic Acid, and Iron|Dietary Supplement: Folic Acid and Iron|Dietary Supplement: Folic Acid","Anemia|Weight Gain during intervention|Mid Upper Arm Circumference|Peripheral malaria parasitemia","Harvard School of Public Health (HSPH)|Ifakara Health Institute","Female","15 Years to 29 Years   (Child, Adult)","Not Applicable","802","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","0055/07","August 2010","January 2012","January 2012","August 17, 2010",,"September 11, 2012","Ifakara Health Institute, Rufiji, Tanzania",,"https://ClinicalTrials.gov/show/NCT01183572"
102,"NCT03122938","Lactoferrin Supplementation and Iron Metabolism in Healthy Pregnant Women",,"Unknown status","No Results Available","Iron-deficiency Anemia","Dietary Supplement: lactoferrin-supplemented formula|Dietary Supplement: formula without lactoferrin supplementation","iron-deficiency anemia morbility of pregnant women|iron metabolism of pregnant women|fetal growth|fetal growth and development|fetal development","Beingmate Baby & Child Food Co Ltd .|Sir Run Run Shaw Hospital","Female","20 Years to 34 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RD02914009A","April 2016","April 2017","May 2017","April 21, 2017",,"April 21, 2017","Sir Run Run Hospital, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03122938"
103,"NCT02191683","Foetal Exposure and Epidemiological Transition: Role of Anaemia in Early Life for Non-communicable Diseases Later","FOETALforNCD","Completed","No Results Available","Anemia and Pregnancy|Metabolism and Foetal Growth|Epigenetics",,"Outcome parameter for the pre-pregnancy study (i.):|Outcome parameter for the pregnancy study (ii.):|Incidence of conception among non-pregnant Tanzanian women.","University of Copenhagen|Copenhagen University Hospital, Denmark|Aarhus University Hospital|Lund University|National Institute for Medical Research, Tanzania|Department of Clinical Pathology Naestved Hospital Denmark","Female","18 Years to 40 Years   (Adult)",,"1748","Other","Observational","Observational Model: Other|Time Perspective: Prospective","1309-00003B|Strategiske Forskningsråd","July 2014","December 2017","October 2018","July 16, 2014",,"September 30, 2019","National Institute for Medical research, Korogwe, Tanga Region, Tanzania",,"https://ClinicalTrials.gov/show/NCT02191683"
104,"NCT01071759","Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes",,"Unknown status","No Results Available","Pregnancy|Helicobacter Pylori Infection|Iron-Deficiency Anemia",,,"E-DA Hospital","Female","Child, Adult, Older Adult",,"140","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","EDAH-D-97(P)014A|EMRP-097-123","February 2009",,,"February 19, 2010",,"February 19, 2010","E-DA Hospital, Kaohsiung County, Taiwan",,"https://ClinicalTrials.gov/show/NCT01071759"
105,"NCT01543477","Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia","PASCO II","Completed","No Results Available","Renal Anemia|Pregnancy|Lactation",,"Incidence Rate of Adverse Events of Special Interest|Adverse drug reactions|Information on treatment with Retacrit during pregnancy and lactation|Data on long term use","Pfizer|Hospira, now a wholly owned subsidiary of Pfizer","All","0 Years and older   (Child, Adult, Older Adult)",,"4501","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPOE-09-11|C1111006|PASCO II","July 7, 2010","April 29, 2020","April 29, 2020","March 5, 2012",,"October 1, 2020","MHAT ""Dr. Tota Venkova""AD, Gabrovo, Bulgaria|MHAT ""Dr. Stamen Iliev""AD, Montana, Bulgaria|UMHAT ""Georgi Stranski"" EAD, Pleven, Bulgaria|Dutchmed Dialysis Clinic (in the building of 5 DCC), Plovdiv, Bulgaria|MHAT Plodiv AD, Plovdiv, Bulgaria|MHAT ""Dr. Bratan Shukerov"" AD, Smolian, Bulgaria|Fifth MHAT EAD, Sofia, Bulgaria|Acibadem City Clinic Tokuda Hospital EAD MHAT ""Tokuda Hospital Sofia"", Sofia, Bulgaria|University Hospital Lozenets, Sofia, Bulgaria|UMHAT ""Alexandrovska"" EAD, Sofia, Bulgaria|SHATPD ""Prof. Ivan Mitev""EAD, Sofia, Bulgaria|DCC ""Sveta Anna"" Sofia, Sofia, Bulgaria|Kidney center - Medical center EOOD, Varna, Bulgaria|UMHAT ""Sveta Marina""EAD, Varna, Bulgaria|County Hospital Cakovec, Cakovec, Croatia|General Hospital Dubrovnik, Dubrovnik, Croatia|General Hospital Karlovac, Karlovac, Croatia|Health Center Labin, Labin, Croatia|University Hospital Centre Osijek, Osijek, Croatia|General Hospital Sibenik, Sibenik, Croatia|Health Center Umag, Umag, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital Merkur, Zagreb, Croatia|Department of Renal Medicine Medicinerhuset 3 sal Aalborg University Hospital, Aalborg, Denmark|Div. of Nephrology, Helsinki University HospitalHUS Kirurginen sairaala, Helsinki, Finland|Pietarsaari Hospital Medical clinic, Jakobstad, Finland|Kainuu Hospital, Kajaani, Finland|CHU Amiens-Picardie Site Sud,, service de Nefrologie, Amiens (Salouel) Cedex 1, France|CHU Amiens-Picardie Site Sud, Amiens (Salouel) Cedex 1, France|Centre Hospitalier de Cahors, Cahors Cedex 9, France|Aura Auvergne Chamalières, Chamalieres, France|Hospital Gabriel Montpied, Centre de Dialyse, Clermont Ferrand, France|35 Nephrologie Centre Medico Chirurgical de l'Europe, Le Port Marly, France|Polyclinique de la Louvière, Service Hemodialyse Nephrologie CHSA Maubeuge, Lille, France|Aura Notre Dame de Bon Secours, Paris Cedex 14, France|Aura Paris Plaisance, Paris, France|Hopital de Rangueil, service de nephrologie, Toulouse Cedex 9, France|Nephrologische Gemeinschaftspraxis, Alsfeld, Germany|PHV Dialysezentrum Alsfeld, Alsfeld, Germany|MVZ DaVita Alzey GmbH, Alzey, Germany|Gemeinschaftspraxis Dr. Gööck & Dr. Anger, Arnstadt, Germany|MVZ Bad Bevensen, Bad Bevensen, Germany|Nephrologische Gemeinschaftspraxis, Bad Homburg, Germany|Nephrologsiche Praxis, Bad König, Germany|Internistische Praxis und Nephrologie, Bad Nauheim, Germany|Nieren-und Hochdruckzentrum, Bad Wildungen, Germany|Praxis F. Nierenkrankheiten/Tagesklinik, Berlin, Germany|Gesundheitszentrum HSH, Berlin, Germany|Alwall-Haus Dialysezentrum Berlin, Berlin, Germany|Dialyse am Kurfürstendamm, Berlin, Germany|Dialyse Centrum Darmstadt, Darmstadt, Germany|MVZ DaVita Dormagen GmbH, Dormagen, Germany|KfH Nierenzentrum, Essen, Germany|Praxis für Nephrologie, Frankenthal, Germany|Nierenzentrum Heppenheim, Heppenheim, Germany|Praxisklinik-Dialysezentrum Herne DOKUSAN Gesellschaft für medizinische Studien mbH & Co. KG, Herne, Germany|DaVita Elsterland, Herzberg, Germany|Dialyse T. Menzer Homberg-Efze, Homberg/Efze, Germany|Nephrologische Gemeinschaftspraxis und Dialysezentrum, Hoyerswerda, Germany|Gemeinschaftspraxis Grahl und Johnen, Hürth-Hermülheim, Germany|Westpfalz-Klinikum Kaiserslautern, Kaiserslautern, Germany|Nieren- und Hochdruckzentrum Kiel, Kiel, Germany|Medizinisches Versorgungszentrum MVZ Diaverum Kleve GmbH, Kleve, Germany|Praxis Marsen, Köln, Germany|Praxis Dres. Schoenwald und Beck, Langenfeld, Germany|Nephrologische Praxis, Langenselbold, Germany|Nierenzentrum Leverkusen, Leverkusen, Germany|Dialysezentrum Ludwigslust, Ludwigslust, Germany|Nephrologische Gemeinschaftspraxis, Luebeck, Germany|Märkische Kliniken GmbH Klinikum Lüdenscheid, Lüdenscheid, Germany|Dialysezentrum Stadtfeld, Magdeburg, Germany|Nephrologische Praxis, Mayen, Germany|Nephrologisches Zentrum, Mettmann, Germany|Nephrologische Gemeinschaftspraxis, Mühlhausen, Germany|MVZ DaVita Viersen GmbH, Nettetal, Germany|ze:ro Dialysezentren und Gemeinschaftspraxis, Neustadt, Germany|Nephrologisches- und Dialysezentrum Niebüll, Niebüll, Germany|Klinikum Ernst von Bergmann, Potsdam, Germany|Dialysezentrum, Quedlinburg, Germany|Gemeinschaftspraxis Schuerfeld Moeller Henrich, Saarlouis, Germany|Städtisches Klinikum Solingen Abt. Nephrologie - Innere Medizin, Solingen, Germany|Dialysezentrum Tangermünde, Tangermünde, Germany|Deutsche Klinik fuer Diagnostik Department of Nephrology, Wiesbaden, Germany|General Hospital ""Asklipeiio Voulas"", Voula, Attiki, Greece|General Hospital of Rhodes, Agioi Apostoloi, Greece|General Hospital of Agios Nikolaos, Agios Nikolaos, Crete, Greece|Private Physician, Agrinio, Greece|Office of Eleni Stefanopoulou/Private Physician, Aigaleo, Greece|University General Hospital of Alexandroupoli, Alexandroupoli, Greece|Polikliniki Athinon, Athens, Greece|Therapeutical Department ""ATTIKO"", Athens, Greece|General Hospital Gennimata, Athens, Greece|General Hospital ""Alexandra"", Athens, Greece|Errikos Ntinan Hospital, Athens, Greece|Kyanos Stavros, Athens, Greece|Aretaiion Hospital, Athens, Greece|General University Hospital ""ATTIKO"", Athens, Greece|General Hospital of Athens ""A.Fleming"", Athens, Greece|Private Physician, Athens, Greece|General Hospital of Chania, Chania, Crete, Greece|Didimoticho General Hospital, Didimoticho, Greece|Drama General Hospital, Drama, Greece|Edessa General Hospital, Edessa, Greece|General Hospital of Filiates, Filiates, Greece|General Hospital of Grevena, Grevena, Greece|Kavala General Hospital, Kavala, Greece|General Hospital of Komotini Sismanogleio, Komotini, Greece|Private Physician, Kozani, Greece|General Hospital of Kyparissia, Kyparissia, Greece|Private Physician, Lamia, Greece|General University Hospital of Larisa, Larisa, Greece|General Clinic Eftichios Patsidis, Larisa, Greece|General Hospital of Mesologgi, Mesologgi, Greece|Private Physician, Nea Raidestos, Thessaloniki, Greece|General Hospital Agios Andreas, Patra, Greece|General Hospital of Prolemaida, Ptolemaida, Greece|Serres general Hospital, Serres, Greece|AHEPA University Hospital, Thessaloniki, Greece|Ippokrateion General Hospital, Thessaloniki, Greece|Private Physician, Thessaloniki, Greece|Private Physician, Thessaloniki, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Private Physician, Thessaloniki, Greece|""Diavalkaniko"" Therareutical Center, Thessaloniki, Greece|Therapeutical Department of Thermi, Thessaloniki, Greece|Papanikolaou General Hospital, Thessaloniki, Greece|Private Physician, Veria, Greece|Thessaliki Nosileutiki EPE, Volos, Greece|Private Physician, Voula, Greece|Private Physician, Voula, Greece|Merlin Park Dialysis Unit, Galway, Ireland|Presidio ospesdaliero G.CRISCUOLI - UO DIALISI, Sant'Angelo dei Lombardi, Avellino, Italy|Policlinico S. Marco di Istituti Ospedalieri Bergamaschi, U.O. Nefrologia e Dialisi, Zingonia- Osio Sotto, Bergamo, Italy|""Presidio Ospedaliero"" di Soverato - Servizio Dialisi, Soverato, Catanzaro, Italy|Presidio Ospedaliero S. GIUSEPPE e MELORIO AUSL CE/2 S. - U.O. Nefrologia e Dialisi, Santa Maria Capua Vetere, CE, Italy|Azienda Ospedaliera S. Anna, Cona-Ferrara, Ferrara, Italy|U.O.C. Nefrologia e Dialisi Ospedale degli Infermi-S.Miniato-USL 11 Empoli, San Miniato, Pisa, Italy|U.O. Nefrologia e Dialisi, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy|Ospedali Riuniti Anzio-Nettuno, Nefrologia e Dialisi ASL RMH, Anzio (RM), Italy|Centro Dialisi Nefrologia - Ospedale S. Donato Arezzo, Arezzo, Italy|Dipartimento di Nefrologia- Ospedale Mazzoni, Ascoli Piceno, Italy|P.O. S.G. Moscati, Aversa (NA), Italy|OSPEDALE MAGGIORE DI CHIERI - ASL TO 5 - S.C. Nefrologia e Dialisi, Chieri (TO), Italy|AOU Careggi Hospital Firenze, Firenze, Italy|Ospedale della Misericordia USL9, Grosseto, Italy|Dipartimento di Nefrologia Ospedale Versilia-Viareggio (Lucca), Lido Di Camaiore (Lucca), Italy|U.O. Nefrologia Lucca, Lucca, Italy|U.O. Nefrologia e Dialisi ULSS12, Mestre, Italy|Ospedale Niguarda Cà Granda - U.O. Nefrologia e Dialisi e Terapia Medica del Trapianto Renale, Milano, Italy|Universita degli Studi di Napoli Federico II - Dipartimento di Patologia Sistematica, Naples, Italy|A.O. MONALDI- Dept nephrology and Dialysis, Napoli, Italy|Azienda Ospedaliera di Rilievo Nazionale ""Antonio Cardarelli"" - U.O. S. C. Nefrologia ed Emodialisi, Napoli, Italy|Azienda Ospedaliera Universitaria della Università degli Studi della Campania ""Luigi Vanvitelli"", Napoli, Italy|ASL SA 1 P.O. Umberto I - U.O.C. di NEFROLOGIA E DIALISI, Nocera Inferiore (SA), Italy|Ospedale SANTA MARIA DELLA PIETA - U.O.C. di NEFROLOGIA E DIALISI, Nola (NA), Italy|Dipartimento di Medicina -DIMED- Policlinico Padova, Padova, Italy|Fondazione S. Maugeri - IRCCS Clinica del Lavoro e della Riabilitazione,, Pavia, Italy|UO Nefrologia, trapianti e dialisi SSN EDIFICIO 30A Azienda Ospedaliera Universitaria Pisa, PISA (Cisanello), Italy|U.O.C. Nefrologia e Dialisi - Ospedale ""Del Ceppo"", Pistoia, Italy|U.O.C. Nefrologia e Dialisi Azienda Ospedaliera, San Sebastiano, Italy|U.O.C. Nefrologia, Dialisi e Trapianto - Azienda Ospedaliera Universitaria Senese, Siena, Italy|A.O.U. San Giovanni Battista di Torino - S.C. di Nefrologia, Dialisi e Trapianto, Torino, Italy|Ospedale Martini - S.C. Nefrologia E Dialisi, Torino, Italy|Ospedale San Giovanni Bosco - Struttura Complessa Nefrologia e Dialisi, Torino, Italy|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Xanit Hospital Internacional, Benalmadena, Málaga, Spain|Hospital Lluis Alcanyis, Xativa, Valencia, Spain|Fundació Puigvert, Barcelona, Spain|Hospital de Barcelona, Barcelona, Spain|Hospital Universitario de Leon, Leon, Spain|Hospital central della Cruz Roja, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Virgen de la Concha, Zamora, Spain|Karlskoga Lasarett, Karlskoga, Sweden|Linköpings Universitetssjukhus, Linköping, Sweden|Karolinska University Hospital, Stockholm, Sweden|Njurmedicinska kliniken, Danderyds sjukhus, Stockholm, Sweden|Kings College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01543477"
106,"NCT06201910","Evaluation of Peripartum Blood Loss and Postpartum Anaemia in Macrosomia & Gemini",,"Recruiting","No Results Available","Bloodloss in Pregnancy","Other: Observation of Blood loss","Bloodloss","Goethe University","Female","18 Years to 60 Years   (Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2023-1405","October 1, 2023","May 1, 2024","August 1, 2024","January 11, 2024",,"March 6, 2024","University Hospital Frankfurt, Frankfurt, Hessen, Germany|Goethe University, Frankfurt, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT06201910"
107,"NCT00118027","A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda",,"Completed","No Results Available","Malaria|Pregnancy|Anemia","Drug: sulphadoxine-pyrimethamine intermittent preventive treatment","Timing of the first dose of SP.|Proportion of women who complete two doses of SP.|Birth weight of babies.|Proportion of low birth-weight babies.|Maternal haemoglobin and malaria parasite counts.|Proportion of adolescent pregnancies participating in the study.|Proportion of pregnant women who agree to take part in the study.|Proportion of scheduled visits completed by each delivery approach.|The costs per low birth weight of babies avoided.|The costs per anaemic pregnant woman avoided.|Mothers' perceptions on the four different SP delivery outlets","London School of Hygiene and Tropical Medicine|DBL -Institute for Health Research and Development|Ministry of Health, Uganda","Female","Child, Adult, Older Adult","Not Applicable","2150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MV-713-624-02-0033","May 2003",,"June 2007","July 11, 2005",,"January 12, 2017","Mukono District, Mukono, Central Uganda, Uganda",,"https://ClinicalTrials.gov/show/NCT00118027"
108,"NCT03374111","Colla Corii Asini Treating Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency)",,"Unknown status","No Results Available","Thalassemia","Drug: Colla corii asini|Drug: a Simulate Agent of Colla corii asini granule","Hemoglobin(Hb)|reticulocyte (RET)|immature reticulocyte fraction（IRF）|adverse event|indirect bilirubin(IBIL)|total bilirubin(TBIL)|lactic dehydrogenase(LDH)|anaemia cure rates|The curative effect of TCM Syndrome","The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine","Female","20 Years to 50 Years   (Adult)","Phase 4","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TH-2","March 1, 2018","October 1, 2019","December 30, 2019","December 15, 2017",,"December 27, 2018","The third people's Hospital of Dongguan, Dongguan, Guangdong, China|Intranet of Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China|the first affiliated hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China|Department of Gynaecology and Obstetrics,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Dongguan Guangji Hospital, Guangzhou, Guangdong, China|Shenzhen maternity and child health care hospital, Shenzhen, Guangdong, China|Liuzhou Municipal Matemal and Child Health Hospital, Liuzhou, Guangxi, China|The Guangxi Zhuang Autonomous Region National Hospital, Nanning, Guangxi, China|Ruikang Hospital of Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi, China|The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, China",,"https://ClinicalTrials.gov/show/NCT03374111"
109,"NCT00258024","Control of Pregnancy Associated Malaria With Intermittent Preventive Treatment",,"Completed","No Results Available","Anaemia|Malaria","Drug: IPT-sulphadoxinepyrimethamine","Birth weight|anaemia|parasitaemia|fever episodes","DBL -Institute for Health Research and Development","Female","14 Years to 45 Years   (Child, Adult)","Not Applicable","420","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ghana5.2.malaria","November 2005","September 2007","October 2007","November 24, 2005",,"February 21, 2008","Afiya Sekyere district, Kumasi, Ashanti region, Ghana",,"https://ClinicalTrials.gov/show/NCT00258024"
110,"NCT06176105","Mortality After Transfusion of Ever-pregnant Donor Red Blood Cells","MATER","Completed","No Results Available","Anemia",,"Mortality","Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research","All","Child, Adult, Older Adult",,"101000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PPOC 18-03","October 1, 2019","October 1, 2020","October 1, 2020","December 19, 2023",,"December 19, 2023","Sanquin blood bank, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT06176105"
111,"NCT03792464","Serum Hepcidin in Pregnant Women and the Association With Pregnancy Outcome",,"Completed","No Results Available","Anemia",,"Serum hepcidin at 11-14 weeks of gestation|Serum hepcidin at 24-28, 32-36 weeks of gestation and at labor;|serum ferritin (µg/l),|HRC (%),|hemoglobin (g/l),|red blood cells (x1012/l),|hematocrit (l/l),|MCV (fl),|MCH (pg),|MCHC (g/l),|red blood cell distribution width (%)|soluble transferrin receptors (mg/l)","University Hospital, Basel, Switzerland","Female","18 Years to 50 Years   (Adult)",,"188","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017-02322","April 30, 2019","October 31, 2021","October 31, 2021","January 3, 2019",,"November 11, 2021","University Hospital Basel, Basel, Basel Stadt, Switzerland",,"https://ClinicalTrials.gov/show/NCT03792464"
112,"NCT01084213","Intermittent Preventive Treatment Versus Scheduled Screening and Treatment of Malaria in Pregnancy","IPTp_IST","Completed","No Results Available","Malaria|Pregnancy|Anaemia","Drug: Intermittent screening and treatment of malaria in pregnancy (IST)|Drug: SP-IPTp","Prevalence of low birth weight|Prevalence of third trimester anaemia|Prevalence of placenta malaria|Prevalence of anaemia at the time of delivery or shortly afterwards.|Prevalence of peripheral blood parasitaemia|Episodes of clinical malaria during the course of the pregnancy.|Serious adverse events in the mother.|Adverse outcome of pregnancy - abortions, still births and neonatal deaths.|Occurrence of congenital abnormalities.|Feasibility and costs of each approach to the control of malaria in pregnancy.|Cost per cases of maternal anaemia (severe and non-severe) and peripheral malaria averted.|Acceptability of each approach by pregnant women and antenatal clinic staff.","London School of Hygiene and Tropical Medicine|Medical Research and Training Centre, Mali|University of Ouagadougou, Burkina Faso|Medical Research Council Unit, The Gambia|Navrongo Health Research Centre, Ghana|Liverpool School of Tropical Medicine","Female","16 Years to 45 Years   (Child, Adult)","Phase 4","5354","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","MiPcMA05","June 2010","July 2012","October 2012","March 10, 2010",,"April 11, 2014","Université de Ouagadougou, Ouagadougou, Burkina Faso|Medical Research Council Laboratories, Basse, Gambia|Navrongo Health Research Centre, Navrongo, Ghana|Medical Research and Training Centre, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT01084213"
113,"NCT01055431","A Functional Food for the Prevention of Iron-deficiency Anemia",,"Completed","No Results Available","Anemia","Other: Control bread|Other: Teff Bread","To develop Teff bread that is rich in iron (per slice).|To establish whether iron from Teff is bioavailable.|To conclude whether daily Teff consumption prevents iron-deficiency anemia in pregnancy.|To use a range of different biomarkers to determine iron status.|To compare dietary intakes of iron and iron status between the Teff/control group.","Manchester Metropolitan University","Female","18 Years to 40 Years   (Adult)","Phase 1","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","09/H1013/69","October 2009","July 2011","July 2011","January 25, 2010",,"July 30, 2014","Manchester Food Research Centre, Manchester Metropolitan University, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01055431"
114,"NCT03071666","Vitamin B12 Supplementation During Pregnancy on Cognitive Development","VitaPreg","Active, not recruiting","No Results Available","Pregnancy Related|Vitamin B 12 Deficiency|Anemia","Dietary Supplement: cobalamin|Dietary Supplement: placebo","Length|Neurodevelopment|Child hemoglobin concentration|Child development ASQ|Child development Bayley|Heart rate variability|Sleep and activity|The Infant Motor Performance|Still births|Maternal hemoglobin concentration|Number of complicated births|Children born at small for gestational age|Birth weight|Low birth weight|Very low birth weight|High birth weight","Centre For International Health|Tribhuvan University Teaching Hospital, Institute Of Medicine.|NORCE Norwegian Research Centre AS|Sykehuset Innlandet HF","Female","20 Years to 40 Years   (Adult)","Phase 2|Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CISMAC-B12|Universal Trial Number","March 27, 2017","June 28, 2022","December 31, 2029","March 7, 2017",,"April 16, 2024","Manjeswori Ulak, Bhaktapur, Nepal","""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/66/NCT03071666/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03071666"
115,"NCT02959125","NutFish and Nutrient Supplementation in Pregnancy Class to Improve Maternal and Birth Outcomes",,"Unknown status","No Results Available","Pregnancy|Protein-Energy Malnutrition|Anemia","Other: NutFish Based Food Supplementation|Dietary Supplement: Multiple micronutrients|Behavioral: Health Education in Pregnancy Class|Other: Government Food Supplementation|Dietary Supplement: Fe Supplementation","Birth weight|APGAR score|Preterm birth|Birth length|Mid upper arm circumference|Gestational weight gain|Dietary intake|Problems experience","Semarang Health Polytechnic","Female","Child, Adult, Older Adult","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","SemarangHP","December 12, 2016","October 30, 2017","December 20, 2017","November 8, 2016",,"October 24, 2017","Demak District Health Office, Demak, Central Java, Indonesia|Public Health Center of Karangawen 2, Demak, Jawa Tengah, Indonesia",,"https://ClinicalTrials.gov/show/NCT02959125"
116,"NCT00140517","Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance",,"Completed","No Results Available","Malaria in Pregnancy|Birth Weight|Anaemia","Drug: sulphadoxine-pyrimethamine|Drug: chloroquine","See detailed description|see detailed description","London School of Hygiene and Tropical Medicine|DBL -Institute for Health Research and Development","Female","15 Years to 49 Years   (Child, Adult)","Not Applicable","700","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","HSR/DD/677-01/DG-CM/624-02","October 2002","June 2007","March 2008","September 1, 2005",,"January 12, 2017","Centre Medicale Paul VI, Ouagadougou, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT00140517"
117,"NCT00432367","Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy",,"Completed","No Results Available","Malaria|Anaemia|Pregnancy","Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine","Prevalence of severe maternal anaemia (Hb < 8g/dl) at 34 to 36 weeks of gestation.|Prevalence of low birth weight (BW < 2500g) at delivery or within 72 hours of delivery.|Prevalence of maternal anaemia (Hb < 11g/dl) at 34 to 36 weeks of gestation.|Prevalence of placenta parasitaemia.|Incidence of post-intervention malaria cases|Proportions of congenital anomalies in live births among the intervention groups stratified by gestation, gravidity, parity and age.|Proportions of spontaneous abortions, intrauterine death, stillbirths, neonatal and maternal mortality and pre-term deliveries.|Cost per severe maternal anaemia averted.|Cost per (non-severe) maternal anaemia averted.|Cost per peripheral malaria case averted.|Cost per placental malaria averted.","London School of Hygiene and Tropical Medicine|Kwame Nkrumah University of Science and Technology","Female","Child, Adult, Older Adult","Phase 3","3333","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMP_REG04|HKT-GMP","February 2007","February 2009","September 2009","February 7, 2007",,"October 20, 2016","Juaben Government Hospital, Juaben, Ashanti, Ghana",,"https://ClinicalTrials.gov/show/NCT00432367"
118,"NCT00439595","A Trial of 2 'Point of Care' Diagnostic Methods to Improve Detection and Treatment of Anaemia in African Children","EARS","Completed","No Results Available","Anaemia","Device: Hemocue 210 meter|Device: Copack HBCS","The proportion of clinic attenders under the age of 5 years who are diagnosed with anaemia (adjusted for anaemia in the community)|Proportion of anaemic children and pregnant women treated for anaemia|Prevalence of anaemia in study communities by age and season|Proportion of clinic attenders referred to the district hospital with Hb> and <8g/dl.|Effectiveness of current MOH anaemia treatment regimens.|Acceptability of HBCS and Hemocue and attitudes to anaemia diagnosis among caretakers and healthworkers|Cost effectiveness of HBC or Hemocue compared to current practice in increasing anaemia diagnosis.","London School of Hygiene and Tropical Medicine|National Institute for Medical Research, Tanzania","All","up to 5 Years   (Child)","Not Applicable","450","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EARS-Handeni","February 2007","April 2008","May 2008","February 23, 2007",,"May 27, 2010","Handeni District Health Facilities, Tanga, Tanzania",,"https://ClinicalTrials.gov/show/NCT00439595"
119,"NCT00802139","Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin",,"Completed","No Results Available","Iron Deficiency Anemia","Drug: venoferrum(iron sucrose)|Drug: Bolgre (Iron acetyl-transferase)","Change of plasma hemoglobin level|Target Hb achievement rate(11g/dL), Transferrin saturation(%), Ferritin(ng/mL), TIBC(ug/dL), MCV(fl), MCH(pg) and change in reticulocyte counts","JW Pharmaceutical","Female","18 Years and older   (Adult, Older Adult)","Phase 4","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CWP-VNF-402","February 2008","June 2009","October 2010","December 4, 2008",,"March 30, 2012","Chonnam National Universitiy Hospital, KwangJu, Korea, Republic of|Asan Hospital, Seoul, Korea, Republic of|Catholic University of Korea Kangnam St. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00802139"
120,"NCT00116493","Severe Anemia Treatment Trials, Pakistan",,"Completed","No Results Available","Anemia","Dietary Supplement: Iron-folic acid and mebendazole|Drug: Mebendazole|Dietary Supplement: Multivitamins|Drug: Mebendazole + Multivitamin","Severe Anemia","Johns Hopkins Bloomberg School of Public Health|Aga Khan University","All","6 Months to 45 Years   (Child, Adult)","Phase 3","1009","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H.22.03.04.22.A2|Thrasher Research Fund 02817-9","April 2004","May 2007","May 2007","June 30, 2005",,"April 9, 2012","Aga Khan University, Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT00116493"
121,"NCT02858505","Impact of One Versus Two Amino Acid Chelated Iron Capsules on Prevention of Iron Deficiency Anemia in Non-anemic Women With Twin Gestations",,"Completed","No Results Available","Anemia","Drug: 27 mg elemental iron|Drug: 54 mg elemental iron","Hemoglobin level","Assiut University","Female","20 Years to 40 Years   (Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IDAT","August 2015","July 2016","July 2016","August 8, 2016",,"August 8, 2016","Women Health Hospital - Assiut university, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT02858505"
122,"NCT03975894","TAPS2 Transfusion Antenatally in Pregnant Women With SCD","TAPS2","Unknown status","No Results Available","Sickle Cell Disease|Pregnancy, High Risk|Blood Transfusion Complication","Biological: Serial prophylactic exchange blood transfusion (SPEBT).","Recruitment rate|Feasibility endpoints|Maternal hospital admissions|Frequency and severity of painful crisis|Mode of birth|SCD-related complications|Fetal demise/stillbirth|Infant birthweight|Gestation at birth|Fetal condition at birth|Neonatal intensive care unit/critical care admission|Safety outcome 1: transfusion reaction|Safety outcome 2: Alloimmunisation|Safety outcome 3: Delayed haemolytic transfusion reaction","Guy's and St Thomas' NHS Foundation Trust|King's College Hospital NHS Trust|Barts & The London NHS Trust|The Whittington Hospital NHS Trust|St Mary's NHS Trust|University College London Hospitals|St George's University Hospitals NHS Foundation Trust|London School of Hygiene and Tropical Medicine|King's College London|University of Southampton","Female","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAPS2version3","May 2, 2019","December 1, 2020","May 1, 2021","June 5, 2019",,"August 2, 2019","Barts Health NHS Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|King's College Hospital, London, United Kingdom|St George's University Hospitals NHS Foundation Trust, London, United Kingdom|Whittington Health NHS Trust, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03975894"
123,"NCT03700034","mHealth Integrated Model of Hypertension, Diabetes and Antenatal Care in India and Nepal",,"Not yet recruiting","No Results Available","Gestational Diabetes Mellitus (GDM)|Pregnancy Induced Hypertension (PIH)|Anemia","Other: mHealth Integrated Model of Antenatal Care","Mean number of four selected ANC components delivered by the healthcare providers per visit, observed over two visits- the trial enrolment visit and the next routine ANC appointment.|Mean number of the four selected ANC components delivered by the healthcare provider observed at the trial enrolment visit|Mean number of the current pregnancy symptoms discussed with participants (either by the provider asking or the woman mentioning), observed over the two visits.|Proportion of providers who took the appropriate action (as defined by the EDSS) in response to aforementioned current pregnancy symptoms or who were told that they had hypertension in pregnancy, GDM or anemia|Mean number of the danger signs mentioned to each participant by the healthcare provider for which she is advised to return for help|Proportion of participants with clinical parameters indicative of PIH, GDM or severe anemia|Proportion of participants who were told by the provider that they had PIH, GDM or severe anemia|Mean number of quality antenatal care components delivered in the enrolment visit","Public Health Foundation of India|London School of Hygiene and Tropical Medicine|Kathmandu University School of Medical Sciences","Female","18 Years to 49 Years   (Adult)","Not Applicable","1320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CTRI/2019/01/016857","December 2023","January 2024","March 2024","October 9, 2018",,"November 18, 2023","Primary Health Centres (PHCs), Medak, Telangana, India|Primary Health Centres (PHCs), Rangareddy, Telangana, India|Primary Health Centres, Siddipet, Telangana, India|Primary Health Centres (PHCs), Vikarabad, Telangana, India|Primary Health Centres (PHCs), Yadadri Bhuvnagiri, Telangana, India|Health posts, Dhulikhel, Nepal",,"https://ClinicalTrials.gov/show/NCT03700034"
124,"NCT03968952","SMARThealth Pregnancy: Feasibility & Acceptability of a Complex Intervention for High-risk Pregnant Women in Rural India.",,"Completed","No Results Available","Pre-Eclampsia|Gestational Diabetes|Anemia","Other: SMARThealth Pregnancy","Recruitment rate|Retention rate|Number of home visits completed by Community Health Worker|Number of pregnant women diagnosed with gestational diabetes.|Postpartum follow-up of pregnant women with gestational diabetes|Number of pregnant women diagnosed with a hypertensive disorder of pregnancy.|Number of pregnant women diagnosed with severe anaemia.|Mean postpartum haemoglobin|Mean postpartum Systolic Blood Pressure|Mean postpartum Diastolic Blood Pressure","University of Oxford|The George Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","258","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","22-19","October 1, 2019","September 14, 2020","November 1, 2020","May 30, 2019",,"November 4, 2020","The George Institute for Global Health, Hyderabad, Telengana, India",,"https://ClinicalTrials.gov/show/NCT03968952"
125,"NCT02957643","Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement",,"Completed","No Results Available","Prevention of Anemia","Drug: Iron","Measured and reported effectiveness of iron in the treatment of iron deficiency in pregnant 2nd and 3rd quarter with questionnaire|adverse reactions","Hippocration General Hospital","Female","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HippokratioGH","November 2016","September 2017","September 1, 2017","November 8, 2016",,"July 29, 2020",,,"https://ClinicalTrials.gov/show/NCT02957643"
126,"NCT00463632","Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control",,"Completed","No Results Available","Schistosomiasis|Anaemia|Pregnancy",,,"DBL -Institute for Health Research and Development|Centre Muraz","Female","15 Years to 45 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SRP-BF-ST-06","January 2007","January 2009","January 2009","April 20, 2007",,"January 12, 2010","Dori Health Centre, Dori, Burkina Faso|National Schistosomiasis Control Program, Ouagadougou, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT00463632"
127,"NCT04310059","Effect of Folic Acid Supplementation in Pregnant Women Having Thalassaemia Trait",,"Not yet recruiting","No Results Available","Thalassemia|Folic Acid Deficiency Anemia","Dietary Supplement: Folic acid|Dietary Supplement: Materna","Haemoglobin level|Maternal RBC folate concentration|Maternal serum folate concentration|Cord blood RBC|Cord blood serum folate concentration|Ferritin level|Maternal Vitamin B12|Cord blood vitamin B12","The University of Hong Kong|Queen Mary Hospital, Hong Kong","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UW 20-084","July 1, 2024","July 31, 2025","July 31, 2026","March 17, 2020",,"November 29, 2023",,,"https://ClinicalTrials.gov/show/NCT04310059"
128,"NCT02813850","Oxygen Therapy and Pregnancy in Sickle Cell Disease","DRO2G","Completed","No Results Available","Sickle Cell Disease","Device: oxygen therapy","Occurrence of at least one vaso-occlusive complication which last more than 24h|Occurrence of pregnancy-induced hypertension, pre-eclampsia, eclampsia|Occurence of hospitalisation because of premature delivery risk|Occurence of late miscarriage|Occurence of Preterm (<35SA) and very preterm ( from 26 to 32SA)|Type of delivery (vaginal, active, caesarean)|Number of days hospitalisation postpartum|Occurence of Neonatal complications ( respiratory distress, analgesics withdrawal symptom)|Number of days of hospitalisation for the newborn|Number of days of hospitalisation in resuscitation unit for the newborn|Newborn weight|Newborn size|Newborn head circumference|Apgar score assess 1 min after birth|Apgar score assess 5 min after birth|Apgar score assess 10 min after birth|Perinatal and neonatal death|pH of of the newborn|Lactate of of the newborn|Number of days using painkiller (level II and III) during pregnancy|Number of urgent consultation|Number of days of hospitalisation and hospitalisation in intensive care during pregnancy|Stage of pregnancy at the first transfusion|Total volume of transfusion during pregnancy|Way of transfusion: simple, bleeding-transfusion, erythrocytapheresis|Maternal, fetal and newborn tolerability of home-based oxygen therapy during pregnancy","Assistance Publique - Hôpitaux de Paris","Female","18 Years to 50 Years   (Adult)","Phase 3","178","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","P140030|2015-A01276-43","October 5, 2016","December 3, 2021","August 12, 2022","June 27, 2016",,"November 7, 2022","Hôpital Necker Enfants-Malades (Public Hospitals of Paris), Paris, France",,"https://ClinicalTrials.gov/show/NCT02813850"
129,"NCT01232387","Identification of Early Predictors of Fetomaternal Hemorrhage",,"Completed","No Results Available","Fetomaternal Hemorrhage|Neonatal Anemia",,"Neonatal hematocrit|Sign of fetomaternal hemorrhage in maternal blood","Icahn School of Medicine at Mount Sinai|National Center for Research Resources (NCRR)|New York Blood Center","All","up to 60 Years   (Child, Adult)",,"39","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","10-0920|KL2RR029885","May 2011","June 2012","September 2013","November 2, 2010",,"September 20, 2013","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01232387"
130,"NCT04076969","Integrated Educational Session and Enhancing Compliance Behavior",,"Completed","No Results Available","Anemia|Iron-deficiency","Behavioral: Integrated educational session","The degree of the adherence to the medication|Laboratory investigation for hemoglobin & ferrtin level|IRON Intake Calculation-Food Frequency Questionnaire (IRONIC-FFQ)|4) Dietary record diary (DRD).","Cairo University","Female","18 Years to 35 Years   (Adult)","Not Applicable","151","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","00004025","January 1, 2019","August 1, 2019","August 1, 2019","September 4, 2019",,"September 1, 2020","Rania Mahmoud Abdel Ghani, Faisal, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT04076969"
131,"NCT01115478","Malaria in Pregnancy: Nutrition and Immunologic Effects","MAL2","Completed","No Results Available","Malaria|Low Birth Weight|Anemia|Perinatal Mortality","Dietary Supplement: Vitamin A|Dietary Supplement: Zinc|Other: Placebo","Incidence of placental malaria|Low birth weight|Maternal anemia|Perinatal death|Maternal malaria","Harvard School of Public Health (HSPH)|Muhimbili University of Health and Allied Sciences","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","2500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HD57941-01A2","July 2010","June 2014","June 2014","May 4, 2010",,"April 24, 2015","Muhimbili University of Health And Allied Sciences, Dar es Salaam, Tanzania",,"https://ClinicalTrials.gov/show/NCT01115478"
132,"NCT05143021","Sickle Cell Disease Obstetric Multi-Disciplinary Care Programme","SCOB-II","Recruiting","No Results Available","Sickle Cell Disease|Pregnancy Related","Other: Multidisciplinary Sickle Cell Disease- Obstetric Team","Maternal and Perinatal Mortality Rates|The Fidelity to the Evidence-Based Guidelines|Participants with Acute Chest Syndrome|The Fidelity to the Standardized Ultrasound Protocol|Maternal Nutrition Supply Association to Fetus","Vanderbilt University Medical Center","Female","18 Years to 45 Years   (Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","211778","February 14, 2022","January 1, 2026","January 1, 2026","December 3, 2021",,"April 18, 2023","Greater Accra Regional Hospital, Accra, Ghana|Korle Bu Teaching Hospital, Accra, Ghana|Tamale Teaching Hospital, Tamale, Ghana",,"https://ClinicalTrials.gov/show/NCT05143021"
133,"NCT05423249","Treatment of Non-Anemic Iron Deficiency in Pregnancy",,"Recruiting","No Results Available","Non-anemic Iron Deficiency","Drug: Ferrous sulfate|Drug: Prenatal|Drug: Docusate Sodium|Drug: Ascorbic Acid 500Mg Tab|Drug: Placebo","Delivery admission hemoglobin|Third trimester hemoglobin|Maternal anemia|Incidence of preterm delivery|Incidence of maternal hemorrhage|Incidence of treatment of anemia|Incidence of infection|Maternal hospital stay|Infant weight|Incidence of neonatal intensive care unit admission|Rate of poor perinatal outcome","Stony Brook University","Female","18 Years to 55 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IRB2022-00121","August 12, 2022","June 15, 2024","June 15, 2024","June 21, 2022",,"April 17, 2024","University Associates in Obstetrics & Gynecology, Bohemia, New York, United States|University Associates in Obstetrics & Gynecology, Commack, New York, United States|University Associates in Obstetrics & Gynecology, East Setauket, New York, United States",,"https://ClinicalTrials.gov/show/NCT05423249"
134,"NCT00494416","Different Approaches for Delivery of IPT in Pregnancy in Burkina Faso",,"Completed","No Results Available","Malaria Parasitaemia|Birth Weight|Anaemia","Other: delivery approaches of malaria intermittent preventive treatment in pregnancy","compliance|coverage","London School of Hygiene and Tropical Medicine|DBL -Institute for Health Research and Development","Female","15 Years to 45 Years   (Child, Adult)","Not Applicable","11523","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PD 010607|REG-10","June 2007","November 2009","November 2009","June 29, 2007",,"January 26, 2017","Pissy Health District, Ouagadougou, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT00494416"
135,"NCT05253781","Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE)","PIPSICKLE","Recruiting","No Results Available","Intrauterine Growth Restriction|Preeclampsia|Sickle Cell Disease|Pregnancy Complications","Drug: Low-dose aspirin|Other: Placebo","Number of babies with birth weight below 10th centile for gestational age on the WHO INTERGROWTH-21st birthweight charts, stillbirth or fetal death or miscarriages divided by the total number of babies delivered.|Number of participants who will develop preeclampsia defined as hypertension and significant proteinuria after 20 weeks gestational age divided by the total number of participants.|Number of women that die at any gestational age during pregnancy or within 42 days after delivery from any cause arising from the pregnancy or its management but not from incidental or accidental causes, divided by the total number of participants.|Number of women delivered before 37 weeks gestational age divided by the total number of participants randomized.|Number of participants who will develop thromboembolism divided by the total number of participants.","University of Lagos, Nigeria","Female","18 Years and older   (Adult, Older Adult)","Phase 3","476","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PACTR202001787519553|2021-002867-23","July 1, 2020","June 30, 2024","June 30, 2024","February 24, 2022",,"May 24, 2023","Ajeromi General Hospital, Ajegunle, Lagos State, Ajegunle, Lagos, Nigeria|Federal Medical Centre, Ebute Metta, Lagos State, Ebute-Metta, Lagos, Nigeria|Lagos University Teaching Hospital, Idi Araba, Lagos, Nigeria|Alimosho General Hospital, Igando, Lagos State, Igando, Lagos, Nigeria|Lagos State University Teaching Hospital (LASUTH, Ikeja, Lagos, Nigeria|General Hospital, Ikorodu, Lagos State, Ikorodu, Lagos, Nigeria|General Hospital, Isolo, Lagos State, Isolo, Lagos, Nigeria|General Hospital, Somolu, Lagos State, Somolu, Lagos, Nigeria|Randle General Hospital, Surulere, Lagos State, Suru Lere, Lagos, Nigeria|Obafemi Awolowo University Teaching Hospital OAUTH), Ife, Osun State, Ife, Osun, Nigeria|Lagos Island Maternity Hospital, Lagos, Lagos, Nigeria|General Hospital, Gbagada, Lagos State, Lagos, Nigeria|General Hospital, Ibeju-Lekki, Lagos State, Lagos, Nigeria|General Hospital, Ifako Ijaiye, Lagos State, Lagos, Nigeria|General Hospital, Orile-Agege, Lagos State, Lagos, Nigeria|Mother and Child Centre, Amuwo-Odofin, Lagos, Lagos, Nigeria",,"https://ClinicalTrials.gov/show/NCT05253781"
136,"NCT01665378","Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes",,"Completed","No Results Available","Anemia|Intrauterine Growth Retardation|Preterm Delivery|Iron Deficiency","Dietary Supplement: Multiple Micronutrient|Dietary Supplement: Iron and Folic Acid|Dietary Supplement: Folic Acid","Birth Size|Gestational Age|Child growth|Child development|Weight-for-age Z score (WAZ)|Height-for-age Z score (HAZ)|Weight -for-Height Z (WHZ) or Body Mass Index Z score (BMIZ)|Body composition (Lean mass/fat free mass index)|Mothers' iron status|Infants' iron status|Maternal depression","Emory University|Micronutrient Initiative|The Mathile Institute for the Advancement of Human Nutrition","Female","18 Years to 35 Years   (Adult)","Not Applicable","5011","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00051384|10-1196-UEMORY-01","October 2011","September 2014","December 2019","August 15, 2012",,"July 8, 2021","Thainguyen University of Medicine and Pharmacy, Hành Phố Thái Nguyên, Thái Nguyên, Vietnam",,"https://ClinicalTrials.gov/show/NCT01665378"
137,"NCT05504863","RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study","RAPIDIRON-KIDS","Active, not recruiting","No Results Available","Iron Deficiency Anemia|Neurodevelopmental Abnormality|Autism Spectrum Disorder","Drug: Ferric carboxymaltose|Drug: Iron isomaltoside|Drug: Ferric Sulfate","Offspring hemoglobin|Offspring ferritin|Cognitive Domain of Bayley Scales of Infant Development (BSID)|Preferential Looking Time|Motor and language domains of the Bayley Scales of Infant Development (BSID)|Bayley Scales of Infant Development (BSID)|Behavior Rating Scale|Ages & Stages Questionnaire 3|Child Behavior Checklist for Ages 1.5-5|India Scale of Assessment for Autism|Offspring weight|Offspring height|Offspring head circumference|Infant and Young Child Feeding Practices|Maternal hemoglobin concentration|Maternal ferritin|Maternal well-being/quality of life","Thomas Jefferson University|Jawaharlal Nehru Medical College|S. Nijalingappa Medical College|Raichur Institute of Medical Sciences","Female","18 Years to 40 Years   (Adult)",,"538","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","R-2111-07169","October 11, 2022","January 2025","January 2026","August 17, 2022",,"November 29, 2023","S. Nijalingappa Medical College, Bagalkot, Karnataka, India|Jawaharlal Nehru Medical College, Belgaum, Karnataka, India|Raichur Institute of Medical Sciences, Raichur, Karnataka, India","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/63/NCT05504863/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05504863"
138,"NCT00970866","Efficacy of Lipid-Based Nutrient Supplements (LNS) for Pregnant and Lactating Women and Their Infants",,"Completed","No Results Available","Anemia|Malnutrition|Stunting","Dietary Supplement: Iron and Folic Acid (IFA)|Dietary Supplement: Multiple Micronutrient (MMN) group|Dietary Supplement: Lipid-based Nutrient Supplements (LNS) group","Maternal primary outcome is child length at birth|Child primary outcome is child length-for-age Z-score (LAZ, based on WHO 2006 growth standards) at 18 months of age","University of California, Davis","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","3499","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","223623","November 2009","December 15, 2017","December 15, 2017","September 3, 2009",,"February 24, 2022","St. Martin de Porre's Hospital, Agomanya, Ghana|Atua Government Hospital, Atua, Ghana|Kpong Reproductive and Child Health (RCH) Center, Kpong, Ghana|Somanya Polyclinic, Somanya, Ghana",,"https://ClinicalTrials.gov/show/NCT00970866"
139,"NCT04694235","Egg Intervention During Pregnancy in Indonesia","PRECODE","Unknown status","No Results Available","Weight Gain|Anemia, Iron Deficiency|Birth Weight|Birth Length|Child Development|Zinc Deficiency|Folate Deficiency|B12 Deficiency Vitamin|Amino Acid Deficiency|Mineral Deficiency|Vitamin A Deficiency|Fatty Acid Deficiency|Parasite Infestation|E. Coli Infection|Salmonella Infections|Shigella Infection|Protozoan Infections","Dietary Supplement: Egg intervention","Prevalence of stunting|Proportion of children 10-14 months with impaired fine and gross motor skills|Proportion of children 10-14 months with impaired expressive and receptive language|Proportion of children 10-14 months with impaired behavior|Proportion of children 10-14 months with impaired executive function|Proportion of children 10-14 months with impaired empathy|Proportion of children 10-14 months with impaired problem solving|Proportion of children 10-14 months with impaired attention|Proportion of children 10-14 months with impaired social-emotional reactivity|Proportion of children 20-24 months with impaired motor development|Proportion of children 20-24 months with impaired cognition|Proportion of children 20-24 months with impaired language|Proportion of children 20-24 months with impaired social-emotional development|Scores of CDI vocabulary comprehension scale in children 10-12 months|Scores of CDI vocabulary production scale in children 10-12 months|Epigenetic state of genes associated with stunting|Epigenetic markers of birth anthropometry, adult stature, metabolic state, and cognitive ability|Weight gain during pregnancy|Birth weight|Birth length|Hemoglobin concentration|Serum ferritin concentration|Serum transferrin receptor concentration|Serum zinc concentration|Serum retinol concentration|RBC folate concentration|Serum vitamin B12 concentration|RBC fatty acids concentration|Serum essential amino acids concentration|Serum methylmalonic acid concentration|Serum choline concentration|Serum betaine concentration|Serum vitamin B2 concentration|Serum vitamin B6 concentration|Serum vitamin D concentration|Serum CRP concentration|Serum AGP concentration|Serum RBP concentration|Serum hepcidine concentration|Serum homocysteine concentration|Serum HbA1C concentration|Fecal myeloperoxidase (MPO)|Fecal α1-antitrypsin (AAT)|Soil-transmitted helminths infection|Bacteria infection|Gut microbiota|Gut microbiome|Intestinal fatty acid binding protein","SEAMEO Regional Centre for Food and Nutrition|London School of Hygiene and Tropical Medicine|University of Aberdeen|University of Brighton|University College, London|Royal Veterinary College|Birkbeck, University of London|The International Livestock Research Institute (ILRI)|Cheikh Anta Diop University, Senegal|National Institute of Nutrition, India|International Centre for Research in Agroforestry|Science Made Simple|Liverpool School of Tropical Medicine|International Initiative for Impact Evaluation|Digital Green Foundation|SOAS, University of London|University of Sheffield","Female","18 Years to 40 Years   (Adult)","Not Applicable","653","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AASH Egg intervention","February 12, 2021","December 2023","March 2024","January 5, 2021",,"March 19, 2021","Aikmel, Sakra, and Sikur Subdistrict, Mataram, West Nusa Tenggara, Indonesia",,"https://ClinicalTrials.gov/show/NCT04694235"
140,"NCT00953134","Periconceptional Iron Supplementation in Rural Bangladesh",,"Completed","No Results Available","Anemia","Dietary Supplement: Ferrous fumarate (iron)|Dietary Supplement: folic acid","Hemoglobin|Plasma ferritin","The Hospital for Sick Children","Female","up to 40 Years   (Child, Adult)","Early Phase 1","273","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Periconceptional_Fe","February 2007","February 2008","March 2008","August 6, 2009",,"April 19, 2021","Brac, Dhaka, Dhaka Division, Bangladesh",,"https://ClinicalTrials.gov/show/NCT00953134"
141,"NCT02341300","Use of Cast Iron Pots to Improve Maternal Anemia",,"Terminated","No Results Available","Iron-deficiency Anemia","Device: Cast Iron Pot|Device: Alumnium Pot","Increased hematocrit in second and third trimesters of pregnancy|Compliance assessment|Incidence of adverse effects|Satisfaction|Maternal anemia postpartum|Neonatal outcomes","Weill Medical College of Cornell University","Female","18 Years to 50 Years   (Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1310014372","July 15, 2020","July 15, 2020","July 15, 2020","January 19, 2015",,"July 30, 2020","New York Prebyterian Hospital Weill Cornell, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02341300"
142,"NCT02762773","Effect of Non-Dissection of the Inferior Rectus Sheath on Intraoperative Blood Loss",,"Terminated","No Results Available","Acute Blood Loss Anemia|Postoperative Pain|Pregnancy","Procedure: non-dissection of inferior rectus sheath|Procedure: control","post-operative hemoglobin|assessment of Visual Analog Scale (VAS) scores in first 72 hours|Assessment of total narcotic use, expressed as morphine equivalents","University Hospitals Cleveland Medical Center|Martin Wieczorek","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UHCASEMC2","February 1, 2018","September 1, 2021","September 1, 2021","May 5, 2016",,"December 16, 2021","UH Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02762773"
143,"NCT00660933","Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia",,"Completed","No Results Available","Anemia|Puerperal Disorders","Drug: Iron sucrose|Drug: NaCl","To evaluate if intravenous iron administration is better than oral treatment to improve hemoglobin and hematocrit parameters in women with severe postpartum anemia|To compare if the administration of intravenous iron supplementation is better than the oral dosage to reestablish clinical symptoms of severe anemia minimizing its side-effects (weariness, depression, anxiety) or to avoid the need for blood transfusion","Hospital Clinic of Barcelona","Female","18 Years and older   (Adult, Older Adult)","Phase 4","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","POSTPARTFEEV","September 2005","September 2007","September 2007","April 17, 2008",,"March 8, 2016","Hospital Clínic of Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00660933"
144,"NCT02620943","Dietary Diversity is Associated With Maternal Anemia and Key Prenatal Outcomes in Ethiopia",,"Completed","No Results Available","Anemia|Low Birth Weight|Pre-Term Birth|Still Birth",,"Change in Anemia during pregnancy|Low birth weight|Pre-term birth|Still Birth","Dilla University|Addis Ababa University|African Population and Health Research Center|International Development Research Centre, Canada","Female","15 Years to 49 Years   (Child, Adult)",,"374","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAUT","August 2014","March 2015","March 2015","December 3, 2015",,"December 3, 2015","Addis Ababa University, Center for FDSC and Nutrition, Addis Ababa, Select State, Ethiopia",,"https://ClinicalTrials.gov/show/NCT02620943"
145,"NCT00813657","Resistance Exercise Training During Pregnancy: a Randomized Controlled Trial",,"Completed","No Results Available","Gestational Age|Birth Weight|Anaemia|Gestational Diabetes Mellitus|Type of Delivery","Behavioral: Exercise",,"Universidad Politecnica de Madrid","Female","25 Years to 35 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Primary Purpose: Prevention","01562","January 2000","March 2002","March 2002","December 23, 2008",,"December 23, 2008",,,"https://ClinicalTrials.gov/show/NCT00813657"
146,"NCT01832688","Assessment of the Nutritional Status of Pregnant Women and Optimization of Prenatal Care Services",,"Completed","No Results Available","Pregnancy","Other: Programmatic prenatal care optimization","Prevalence of inadequate gestational weight gain|Anemia prevalence|Access and adherence to prenatal iron and folic acid supplements|Prevalence of inadequate dietary diversity scores","University of California, Davis|Helen Keller International|Micronutrient Initiative","Female","Child, Adult, Older Adult",,"2306","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","447971|10-1335-UCALIF","February 2014","September 2015","September 2015","April 16, 2013",,"February 28, 2020","Helen Keller International, Zinder, Niger",,"https://ClinicalTrials.gov/show/NCT01832688"
147,"NCT03171909","Austrian Registry on the Outcome of Monochorionic Pregnancies","MonoReg","Recruiting","No Results Available","Twin Dichorionic Diamniotic Placenta|Twin Monochorionic Monoamniotic Placenta|Twin-To-Twin Transfusion Syndrome|Twin Pregnancy With Antenatal Problem",,"occurrence of specific complications|gestational age at delivery|birth weight|body length at birth|umbilical artery pH-value|cord blood hemoglobin levels|APGAR score|neonatal complications|long-term outcome","Medical University of Graz|Medical University of Vienna|Medical University Innsbruck|Johannes Kepler University of Linz|Paracelsus Medical University|Klinikum Klagenfurt am Wörthersee|Brothers of Saint John of God Eisenstadt|SMZ-Ost Donauspital|Hospital Hochsteiermark|Landesklinikum Sankt Polten|Klinikum Wels-Grieskirchen|Landeskrankenhaus Feldkirch|Landesklinkum Wiener Neustadt|Mödling Hospital","Female","18 Years to 50 Years   (Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1497/2016","May 1, 2017","January 2025","January 2025","May 31, 2017",,"May 31, 2017","Medical University of Graz, Graz, Styria, Austria|Brothers of Saint John of God Eisenstadt, Eisenstadt, Austria|Medical University Innsbruck, Innsbruck, Austria|Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria|Hospital Hochsteiermark, Leoben, Austria|Johannes Kepler University of Linz, Linz, Austria|Mödling Hospital, Mödling, Austria|Paracelsus Medical University, Salzburg, Austria|Landesklinikum Sankt Polten, St. Pölten, Austria|Medical University Vienna, Vienna, Austria|SMZ-Ost Donauspital, Vienna, Austria|Klinikum Wels-Grieskirchen, Wels, Austria|Klinikum Wiener Neustadt, Wiener Neustadt, Austria",,"https://ClinicalTrials.gov/show/NCT03171909"
148,"NCT03217656","The Jiaxing Birth Cohort in China","JBC","Recruiting","No Results Available","Childhood Obesity|Anemia|Pregnancy Complications|Pregnancy; Hypertension|Feeding Behavior","Other: No intervention","overweight and obesity","Zhejiang University|Jiaxing Maternity and Child Health Care Hospital|Qingdao University|Westlake University","All","Child, Adult, Older Adult",,"500000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZJU_JBC2013013","January 1999","January 2019","January 2029","July 14, 2017",,"January 23, 2018","Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03217656"
149,"NCT06261398","Better Birth Outcomes Through Technology, Education, and Reporting","BETTER","Recruiting","No Results Available","Pregnancy|Maternal Anemia|Pre-Term Birth|Hypertensive Disorders","Behavioral: BETTER: motivational interviewing and text messaging|Behavioral: Standard of care","Incidence of maternal anemia|Incidence of Pre-term birth|Incidence of Hypertensive disorders of pregnancy|Incidence of infection|Incidence of Cesarean Delivery|Incidence of Postpartum hemorrhage|Incidence Severe maternal morbidity|Incidence of maternal mortality|Incidence of Small for gestational age birth|Incidence of Large for gestational age|Incidence of NICU admission|Incidence of Perinatal mortality|Incidence of Prenatal care visits|Incidence of Antepartum admission|Length of stay (days)|Postpartum re-admission","Ohio State University|American Heart Association","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2023H0065","February 26, 2024","September 2027","March 2028","February 15, 2024",,"February 28, 2024","The Ohio State University Outpatient Care East, Columbus, Ohio, United States|McCampbell Hall, Columbus, Ohio, United States|The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT06261398"
150,"NCT02772016","Therapeutic Effect of Colla Corii Asini on Improving Anemia and Hemoglobin Composition in Pregnant Women With Thalassemia",,"Unknown status","No Results Available","Thalassemia","Drug: Colla corii asini","Hemoglobin(Hb)|Adult hemoglobin(HbA)|Fetal hemoglobin(HbF)|Minor adult hemoglobin(HbA2)|Serum iron(SI)|Serum ferritin(SF)|Adverse effect","Yanfang Li|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine","Female","20 Years to 35 Years   (Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH-1","March 2015","May 2016",,"May 13, 2016",,"May 13, 2016","the first affiliated hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02772016"
151,"NCT06138262","Preconception Nutrition Education Intervention for Prospective Brides",,"Completed","No Results Available","Health Education","Other: Health promotion of education pre-conception nutritional preparation","Haemoglobin Level|Body Mass Index|Midupper Arm Circumference (MUAC)","Indonesia University","Female","20 Years to 35 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2106769774","January 1, 2023","May 30, 2023","October 30, 2023","November 18, 2023",,"November 18, 2023","Puskesmas / Government First Level Health Facilities, Depok, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT06138262"
152,"NCT03558464","Effectiveness Study During the First 1,000 Days in Kenya",,"Completed","No Results Available","Stunting|Anemia|Micronutrient Deficiency","Dietary Supplement: Intervention (integrated package)|Other: Control","Stunting and length/height-for-age z-score|Maternal hemoglobin|Birth weight|Birth length|Head circumference at birth|Child hemoglobin|Child iron deficiency|Child vitamin A deficiency|Child diarrhea","Fabian Rohner|One Acre Fund|Children's Investment Fund Foundation|GroundWork","Female","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","1199","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","GW_1AF_KenEff_1000d","June 8, 2018","August 31, 2021","August 31, 2021","June 15, 2018",,"October 25, 2022","One Acre Fund, Kakamega, Kenya",,"https://ClinicalTrials.gov/show/NCT03558464"
153,"NCT04148859","Feto-Fetal Transfusion Syndrome in Multiple Pregnancies",,"Recruiting","No Results Available","Pregnant With Complication","Procedure: amnioreduction","The amniotic pressure|The removed amniotic volume|The umbilical artery S/D ratio","Tel-Aviv Sourasky Medical Center","Female","Child, Adult, Older Adult","Not Applicable","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-220","November 2004","November 2025","November 2025","November 4, 2019",,"November 4, 2019","Zoya Gordon, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT04148859"
154,"NCT05312814","Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management.","ZTWINS","Completed","No Results Available","Twin to Twin Transfusion Syndrome|Pregnancy Complications|Multiple Gestation; Maternal Care",,"Assess clinical utility of combining NIPT-based zygosity measurements with ultrasound chorionicity assessments for the management of twin pregnancies.|Frequency of monozygosity|Frequency of changed chorionicity assessment|Frequency of late TTTS diagnosis","Natera, Inc.","Female","18 Years to 55 Years   (Adult)",,"137","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","21-051-NPT","October 1, 2021","May 15, 2023","May 15, 2023","April 6, 2022",,"November 13, 2023","Rady Children's Specialists of San Diego, San Diego Perinatal Center, San Diego, California, United States|University of Colorado, Aurora, Colorado, United States|Anne Arundel Medical Center/Luminis Health, Annapolis, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Carnegie Imaging for Women, New York, New York, United States|University of Rochester, Rochester, New York, United States|UNC Chapel Hill, Chapel Hill, North Carolina, United States|Seven Hills/ Axia, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05312814"
155,"NCT03287882","Effect of Micronutrients and Life Skills Education on the Health and Nutrition of Adolescent and Young Women in Pakistan",,"Unknown status","No Results Available","Adolescents|Anemia|Pregnancy|Empowerment","Dietary Supplement: Multiple micronutrients (UNIMMAP composition)|Behavioral: Life skills based education","Anemia status|Low birth weight|Biomarkers: serum ferritin, serum transferrin receptor, hepcidin, serum retinol, serum 25(OH)D, alpha-glycolytic protein, C-reactive protein (women)|Anthropometrics: height (women)|Anthropometrics: middle upper arm circumference (women)|Anthropometrics: weight (women)|Gestational age|Preterm birth|Stillbirth|Small for gestational age|Birth size: length|Birth size: head circumference|Birth size: middle upper arm circumference|Birth size: weight|Birth defects|Infant growth: length|Infant growth: head circumference|Infant growth: middle upper arm circumference|Infant growth: weight|Age at marriage|Completion of 10th grade education|Use of sanitary pad during last menstrual period|Dietary intake: 24-hour recall (subgroup of women)","Aga Khan University|The Hospital for Sick Children|National Program for Family Planning and Primary Health Care|Bill and Melinda Gates Foundation","Female","15 Years to 24 Years   (Child, Adult)","Phase 3","25447","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","4324-Ped-ERC-16","June 30, 2017","March 12, 2021","February 2022","September 19, 2017",,"July 27, 2021","Matiari Research and Training Centre, Matiari, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT03287882"
156,"NCT00327639","Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto",,"Unknown status","No Results Available","Thalassemia|Fertility|Pregnancy",,,"University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Defined Population|Time Perspective: Other","00000","July 2005",,,"May 18, 2006",,"May 18, 2006","University Health Network, Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00327639"
157,"NCT04509375","Near-Infrared Spectroscopy and Cranial Doppler in Premature Newborns With Anemia",,"Unknown status","No Results Available","Anemia of Prematurity","Device: Cranial Doppler Ultrasonography|Device: Near-Infrared Spectroscopy","Gradual improvement in middle cerebral artery flow patterns obtained by cranial doppler ultrasound imaging|Gradual improvement in regional cerebral oxygen saturation measures obtained by near-infrared spectroscopy (NIRS)","Hacettepe University","All","1 Day to 28 Days   (Child)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KA-19030","March 14, 2019","June 23, 2021","June 23, 2021","August 12, 2020",,"August 12, 2020","Hacettepe University, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT04509375"
158,"NCT03574506","Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series",,"Unknown status","No Results Available","Atypical Hemolytic Uremic Syndrome|Pregnancy",,"Maternal mortality|ICU length of stay|Dosing and number of doses received","Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia|Alexion Pharmaceuticals, Inc.","Female","14 Years to 49 Years   (Child, Adult)",,"50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LS30885-1","April 15, 2018","August 30, 2020","November 30, 2020","July 2, 2018",,"June 2, 2020","Gestion Salud, Cartagena, Bolivar, Colombia",,"https://ClinicalTrials.gov/show/NCT03574506"
159,"NCT01666249","Clinical Efficacy of Postpartum Immunization of Rh and Coombs Negative Women With Sensitization Risk.",,"Suspended","No Results Available","Pregnancy; Fetomaternal Hemorrhage","Biological: Immunoglobulin Anti-RhD","Negative result for coombs test up to six months after immunization|Adverse Events Report","Azidus Brasil|Panamerican Medical Supply","Female","18 Years and older   (Adult, Older Adult)","Phase 3","347","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IMUPAN1011|Emenda 3.0 - 19/09/2017","April 2014","November 2014","December 2020","August 16, 2012",,"November 2, 2022","Centro de Pesquisa da MEAC - Maternidade Escola Assis Chateaubriand, Fortaleza, Ceara, Brazil|Instituto Tropical de Medicina Reprodutiva e Menopausa -INTRO, Cuiaba, Mato Grosso, Brazil|Associação Educadora São Carlos AESC - Centro de Pesquisa HRPC, Canoas, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital São Lucas (Puc-Rs), Porto Alegre, Rio Grande Do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT01666249"
160,"NCT06220461","Folic Acid Supplementation to Reduce Anemia in Extremely Preterm Infants","FASCINATE","Not yet recruiting","No Results Available","Extreme Prematurity|Anemia of Prematurity","Dietary Supplement: Folic acid","Hemoglobin level|Red blood cell transfusion","University of Calgary","All","Child, Adult, Older Adult","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","REB23-1665","March 11, 2024","July 31, 2027","July 31, 2028","January 24, 2024",,"March 5, 2024","Foothills Medical Centre, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT06220461"
161,"NCT05543499","Database of Monochorionic Pregnancies",,"Recruiting","No Results Available","Monochorionic Diamniotic Placenta|Monochorial Monoamniotic Placenta|Twin; Complicating Pregnancy|Twin to Twin Transfusion Syndrome|Twin Reversal Arterial Perfusion Syndrome",,"Number of participants with Preterm Delivery|Number of participant with Premature Spontaneous Rupture of the Membranes|Number of Infant Deaths","University of Miami","All","Child, Adult, Older Adult",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20210709","October 1, 2022","December 1, 2027","December 1, 2027","September 16, 2022",,"May 10, 2023","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05543499"
162,"NCT03818867","Emergency Cerclage in Twin Pregnancies at Imminent Risk of Preterm Birth: an Open-Label Randomised Controlled Trial","ENCIRCLE","Unknown status","No Results Available","Preterm Birth|Twin Pregnancy With Antenatal Problem|Twin to Twin Transfusion Syndrome","Procedure: Insertion of cervical cerclage","Time to delivery (from randomisation to birth).|Gestation at delivery|Preterm birth before 28, 32 and 34 weeks' gestation|Birthweight|Stillbirth|Neonatal death|Survival to discharge|Days of admission to the neonatal intensive care unit|Composite outcome|Days of maternal admission for preterm labour|Maternal morbidity (deﬁned as thromboembolic complications, chorioamnionitis, urinary tract infection treated with antibiotics, pneumonia, endometritis, eclampsia, HELLP syndrome, death, or any other significant morbidity)","St George's, University of London","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","17.004","May 15, 2017","July 2019","December 2019","January 28, 2019",,"January 28, 2019","St George's Hospital, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/67/NCT03818867/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03818867"
163,"NCT02840292","Effect of Maternal Hemoglobin on Neurobehavioural Development of Late Preterm Neonates : A Cohort Study",,"Completed","No Results Available","Anemia",,"Evaluation of neurobehavioral development|Comparison of NAPI Score","Lady Hardinge Medical College","All","34 Weeks to 37 Weeks   (Child)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Hemoglobin and Neurobehaviour","June 2014","September 2014","October 2014","July 21, 2016",,"July 21, 2016","Lady Hardinge Medical College, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT02840292"
164,"NCT00167388","The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants",,"Completed","Has Results","Anemia of Prematurity","Other: feed during blood transfusion","Change in Superior Mesenteric Artery Blood Flow Velocity From Pre-to-post Feed in the Anemic and the Transfused States","University of Pittsburgh|Irene McLeneham Young Investigator Award through Magee Womens Research Institute","All","25 Weeks to 38 Weeks   (Child)","Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","0404184","September 2005","November 2006","November 2006","September 14, 2005","July 21, 2017","July 21, 2017","Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00167388"
165,"NCT05496400","Anemia of Prematurity and Hemodynamics",,"Completed","No Results Available","Premature","Radiation: Echocardiographic and Doppler studies","1. Cardiac output:|2. Cerebral blood flow velocities|3. Intestinal blood flow velocities|4.Renal blood flow velocities","Marwa Mohamed Farag|Alexandria University","All","3 Weeks to 6 Weeks   (Child)",,"72","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0106769","July 1, 2021","February 1, 2022","August 1, 2022","August 11, 2022",,"August 12, 2022","Neonatal Intensive Care Unit (NICU) of Alexandria University Maternity Hospital., Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT05496400"
166,"NCT02101086","Autologous Cord Blood Transfusion in Preterm Infants",,"Completed","No Results Available","Anemia of Prematurity","Other: Blood transfusion","Number and percentage of participants that receive autologous transfusion with a decrease in allogeneic transfusion|The hemoglobin levels at postnatal 14th days|The hemoglobin levels at postnatal 28th days|The hemoglobin levels at postnatal 35th days|The hemoglobin, erythropoietin and reticulocyte counts at postconceptional 36 weeks|The hemoglobin, erythropoietin and reticulocyte counts at postconceptional 40 weeks|Developmental assessments of infants","Ankara University","All","up to 1 Year   (Child)","Not Applicable","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ankara University-06","March 2009","September 2010","January 2012","April 1, 2014",,"April 1, 2014","Ankara University School of Medicine, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT02101086"
167,"NCT04505514","Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage","IVIronPPH","Unknown status","No Results Available","Post Partum Hemorrhage|Anemia","Drug: Iron Isomaltoside 1000|Drug: Placebo|Drug: Iberet-Folic-500","Hemoglobin concentration (g/dL)|Serum iron concentration|Serum ferritin concentration|General fatigue score|Number of participants that had adverse effects to intravenous iron|Blood transfusion requirement","University of Malaya","Female","18 Years to 50 Years   (Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2020121-8204","August 1, 2020","October 31, 2022","December 31, 2022","August 10, 2020",,"August 12, 2020","University of Malaya Medical Centre, Petaling Jaya, Wilayah Persekutuan Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT04505514"
168,"NCT01813682","Effect of Iron-fortified TPN on Preterm Infants Anemia",,"Unknown status","No Results Available","Preterm Infants","Other: treatment group1|Other: treatment group2","anemia rate|iron status","qingya tang|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","1 Day to 3 Days   (Child)","Not Applicable","118","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","eoitopia","September 2012","December 2013","June 2014","March 19, 2013",,"March 21, 2013","Xinhua Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01813682"
169,"NCT04029142","Screening for Hemoglobinopathies in Pregnant Women",,"Completed","No Results Available","Hemoglobinopathies","Diagnostic Test: Review of routine lab data","identification of hemoglobinopathies","University Hospital, Basel, Switzerland","Female","Child, Adult, Older Adult",,"1785","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-01065; sp19Amstad","July 3, 2019","September 30, 2019","September 30, 2019","July 23, 2019",,"March 4, 2024","Frauenklinik University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT04029142"
170,"NCT00182390","Premature Infants in Need of Transfusion (PINT)",,"Completed","No Results Available","Anemia of Prematurity","Procedure: Red blood cell transfusion","Combined mortality or survival to tertiary hospital discharge without severe morbidity (BPD, severe ROP or brain injury)|Combined mortality or survival with neurodevelopmental disability (non-ambulatory cerebral palsy, blindness, deafness, cognitive delay)|growth in weight and head circumference|time to extubation|time on oxygen|length of hospital stay until discharge home|confirmed necrotizing enterocolitis|apnea requiring treatment|culture-proven infections|use of post-natal steroids|mean levels of hemoglobin|number of transfusions|number of donor exposures|serum ferritin levels|milder forms of cerebral palsy|milder neurologic disorder|personal and social functional capabilities|hydrocephalus requiring a shunt|seizure disorder|respiratory disease|iron nutritional status|physical growth including head size","McMaster University|Canadian Institutes of Health Research (CIHR)","All","up to 48 Hours   (Child)","Phase 3","424","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTMG-2001-PINT|CIHR MCT-41549|CIHR MCT-58455","February 2001","February 2003","November 2005","September 16, 2005",,"September 24, 2015","Albany Medical Center, Albany, New York, United States|Brooklyn Hospital Center, Brooklyn, New York, United States|Royal Women's Hospital, Melbourne, Victoria, Australia|Mercy Hospital for Women, Melbourne, Victoria, Australia|Royal Alexandra Hospital, Edmonton, Alberta, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster University, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Sunnybrook & Women's College Health Science Centre, Toronto, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00182390"
171,"NCT03361124","Oxytocin Dosing at Planned Cesarean Section and Anemia",,"Withdrawn","No Results Available","Blood Loss Anemia|Uterine Atony With Hemorrhage","Drug: Oxytocin","Blood loss in postpartum period defined by grams/hour|Change in Hemoglobin|Change in Hematocrit|Length of hospital stay|Need for additional uterotonics|Continuation of breastfeeding|Quantity of narcotic pain medications|Attendance at post-partum visit|Post-partum complications|Need for blood transfusion|Edinburgh post-partum depression scale >10","Milton S. Hershey Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","00006502","March 1, 2019","March 1, 2020","March 1, 2020","December 4, 2017",,"February 21, 2019",,,"https://ClinicalTrials.gov/show/NCT03361124"
172,"NCT06312644","Study of Ultomiris® (Ravulizumab) Safety in Pregnancy",,"Not yet recruiting","No Results Available","Ultomiris-exposed Pregnant/ Postpartum|Pregnancy|Paroxysmal Nocturnal Hemoglobinuria (PNH)|Atypical Hemolytic Uremic Syndrome (aHUS)|Generalized Myasthenia Gravis (gMG)|Neuromyelitis Optica Spectrum Disorder (NMOSD)","Other: Ultomiris","Number of Pregnancy Complications|Number of Maternal Complications|Fetal/Infant Outcomes","Alexion Pharmaceuticals, Inc.","Female","Child, Adult, Older Adult",,"300","Industry","Observational","Observational Model: Other|Time Perspective: Other","D9289C00007","March 29, 2024","October 21, 2033","October 21, 2033","March 15, 2024",,"March 15, 2024",,,"https://ClinicalTrials.gov/show/NCT06312644"
173,"NCT02535208","Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions",,"Completed","No Results Available","Anemia of Prematurity (AOP)","Other: Restrictive transfusions based on SCOR assessment|Other: Liberal transfusions","Average number of RBC transfusions received during neonatal intensive care unit (NICU) stay|Presence of common morbidities of prematurity|Difference in growth (weight) between the two groups at various timepoints|Difference in growth (length) between the two groups at various timepoints|Difference in growth (head circumference) between the two groups at various timepoints|Difference in development between the two groups","NYU Langone Health","All","up to 3 Days   (Child)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","14-01514","May 16, 2016","October 3, 2018","October 3, 2018","August 28, 2015",,"October 19, 2018","Bellevue Hospital Center, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02535208"
174,"NCT00929409","Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia",,"Terminated","No Results Available","Anemia, Iron-Deficiency|Puerperal Disorders|Depression, Postpartum","Drug: Ferric carboxymaltose|Drug: Ferrous sulfate tablets","Haemoglobin concentration|Ferritin|Fatigue|Quality of life|Post partum depression","Norwegian University of Science and Technology|St. Olavs Hospital|Sykehuset Innlandet HF|Sykehuset Buskerud HF","Female","18 Years to 45 Years   (Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4.2009.373|21830|09/03045-4|2008-008526-79","June 2009","July 2010","July 2010","June 29, 2009",,"February 17, 2012","Department of Obstetrics, Vestre Viken Hospital Trust, Drammen, Norway|Sykehuset Innlandet HF, Lillehammer, Norway|St Olavs Hospital, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT00929409"
175,"NCT02743572","Iron-fortified Parenteral Nutrition in the Prevention and Treatment of Anemia in Premature Infants",,"Completed","No Results Available","Premature Birth","Other: iron sucrose-1|Other: iron sucrose-2|Other: iron sucrose-3|Other: iron sucrose-4","Changes of iron status index before and after iron-fortified parenteral nutrition support|Changes of iron storage index before and after iron-fortified parenteral nutrition support","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","1 Hour to 48 Hours   (Child)","Not Applicable","129","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","XH-16-002","September 2015","May 2017","May 2017","April 19, 2016",,"March 7, 2018","Xinhua Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02743572"
176,"NCT03775954","Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise",,"Recruiting","No Results Available","High Risk Pregnancy|Congenital Heart Disease|Fetal Hydrops|Twin Monochorionic Monoamniotic Placenta|Gastroschisis|Fetal Demise|Stillbirth|Fetal Arrhythmia|Long QT Syndrome|Intrauterine Fetal Death|Sudden Infant Death|Pregnancy Loss|Twin Twin Transfusion Syndrome|Birth Defect|Fetal Cardiac Anomaly|Fetal Cardiac Disorder|Fetal Death|Brugada Syndrome","Diagnostic Test: Fetal Magnetocardiogram and Neonatal Electrocardiogram","Heart rate variability using fMCG|Cardiac conduction|Cardiac repolarization|Unique ""signature"" electrophysiologic abnormalities|Pregnancy outcomes","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|University of Wisconsin, Madison|Children's Hospital and Health System Foundation, Wisconsin|Shared Medical Technology, Inc.|Tristan Technologies, Inc","Female","18 Years and older   (Adult, Older Adult)",,"200","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRO00031598|R01HL143485","July 1, 2018","April 30, 2024","April 30, 2024","December 14, 2018",,"November 3, 2023","University of Wisconsin - Madison, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03775954"
177,"NCT06234332","Peking University Birth Cohort in Weifang (PKUBC-WF)",,"Not yet recruiting","No Results Available","Health Problems in Pregnancy|Pregnancy Outcomes|Gestational Diabetes|Gestational Hypertension|Preterm Birth|Obesity|Mother-Infant Interaction|Child Development|Anemia","Other: No Interventions","Numbers and morbidity of participants with pregnancy complications|Numbers and morbidity of participants with adverse pregnancy outcomes|Weight in kilogram changes during childhood|Height in centimeter changes during childhood|Early Child development|Incidence of diabetes mellitus in women|Incidence of hypertension in women|Incidence of child overweight and obesity|Incidence of autism spectrum disorder in children|Incidence of attention-deficit/hyperactivity disorder in children|Incidence of anxiety in adolescents|Incidence of depression in adolescents","Peking University|National Natural Science Foundation of China","All","18 Years and older   (Adult, Older Adult)",,"2800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PKUBC-WF","February 1, 2024","December 31, 2026","December 31, 2043","January 31, 2024",,"January 31, 2024","Peking University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT06234332"
178,"NCT03814395","Peking University Birth Cohort in Tongzhou","PKUBC-T","Active, not recruiting","No Results Available","Health Problems in Pregnancy|Pregnancy Outcomes|Gestational Diabetes|Gestational Hypertension|Preterm Birth|Obesity|Mother-Infant Interaction|Child Development|Anemia","Other: No intervention","Numbers of participants with pregnancy complications|Numbers of participants with adverse pregnancy outcomes|Weight in kilogram changes during childhood|Height in centimeter changes during childhood|Early Child development 1|Early Child development 2|Incidence of diabetes mellitus in women|Incidence of hypertension in women|Incidence of child overweight and obesity|The proportion of children with warning signs|Fetal Biparietal Diameter|Fetal Head Circumference|Fetal Abdominal Circumference|Fetal Femur Length|Fetal Humerus Length","Peking University|National Natural Science Foundation of China","Female","18 Years to 49 Years   (Adult)",,"5426","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NNSF81703240|81703240","June 28, 2018","August 27, 2019","August 28, 2025","January 24, 2019",,"November 18, 2023","Peking University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03814395"
179,"NCT03580941","Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy",,"Unknown status","No Results Available","Hemolytic-Uremic Syndrome",,"Incidence of TMAs|Need for additional interventions|Death|Length of stay in the ICU","Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia|Alexion Pharmaceuticals, Inc.","Female","14 Years to 49 Years   (Child, Adult)",,"75","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LS30885-2","April 15, 2018","August 30, 2020","November 30, 2020","July 10, 2018",,"June 2, 2020","Gestion Salud, Cartagena, Bolivar, Colombia",,"https://ClinicalTrials.gov/show/NCT03580941"
180,"NCT02611856","Monochorial-diamniotic Pregnancies Complicated With a Twin-to-twin Syndrome","STT","Unknown status","No Results Available","Twin to Twin Transfusion Syndrome",,"Composite measure of the cardiac function|Composite measure of the renal function|Composite measure of the glycoregulation","Assistance Publique - Hôpitaux de Paris|Société Française d'Hypentension Artérielle","All","4 Years to 8 Years   (Child)",,"179","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CRC05069","April 3, 2007","June 30, 2022","December 31, 2022","November 23, 2015",,"July 7, 2021","Hôpital Robert Debré, Paris, France",,"https://ClinicalTrials.gov/show/NCT02611856"
181,"NCT01018576","Delayed Cord Clamping in Premature Infants",,"Terminated","No Results Available","Hypothermia|Anemia","Other: Delayed cord clamping","Initial body temperature|Hematocrit at birth and 24 hours of age","University of California, Davis","All","up to 1 Minute   (Child)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","200916964","September 2009","September 2011","March 2012","November 23, 2009",,"December 2, 2014","UC Davis Medical Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01018576"
182,"NCT01393496","Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth Weight Infants","ETTNO","Completed","No Results Available","Anemia of Prematurity","Other: red blood cell transfusion","Incidence of death or major neurodevelopmental impairment","University Hospital Tuebingen|German Research Foundation","All","0 Days to 3 Days   (Child)","Phase 4","1013","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DFG Fr 1455/6-1|2010-021576-28","July 2011","April 30, 2017","October 31, 2018","July 13, 2011",,"September 16, 2021","Neonatalklinikken, Copenhagen, Denmark|University Hospital of Aachen, Aachen, Germany|Children's Hospital, Augsburg, Germany|Vivantes Children's Hospital, Berlin, Germany|Charité University Children's Hospital, Berlin, Germany|University Children's Hospital, Bochum, Germany|Children's Hospital, Cologne, Germany|University Children's Hospital, Cologne, Germany|Children's Hospital, Datteln, Germany|University Children's Hospital, Dresden, Germany|University of Duesseldorf, Duesseldorf, Germany|Helios Children's Hospital, Erfurt, Germany|Children's Hospital, Erlangen, Germany|University Children's Hospital, Essen, Germany|University Children's Hospital, Frankfurt, Germany|University Children's Hospital, Giessen, Germany|University of Greifswald, Greifswald, Germany|Children's Hospital Eppendorf, Hamburg, Germany|Children's Hospital Altona, Hamburg, Germany|Children's Hospital, Hannover, Germany|University Hospital of Leipzig, Leipzig, Germany|University of Luebeck, Luebeck, Germany|University Children's Hospital, Magdeburg, Germany|University Hospital of Marburg, Marburg, Germany|University Children's Hospital, Muenster, Germany|University Children's Hospital, Munich, Germany|Children's Hospital, Nuremberg, Germany|Children's Hospital St. Hedwig, Regensburg, Germany|DRK Kinderklinik, Siegen, Germany|Children's Hospital, Stuttgart, Germany|University Hospital of Tuebingen, Tuebingen, Germany|University Children's Hospital, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT01393496"
183,"NCT05590260","Prevention of Iron Deficiency Anemia Post-delivery","PRIORITY","Recruiting","No Results Available","Postpartum Anemia","Drug: IV iron infusion|Drug: Oral iron tablets","Number of women with non-anemic hemaglobin levels (Hb >11 g/dL)|Number of maternal deaths|Number of women who receive a blood transfusion post-discharge|Number of women who experience a postpartum hemorrhage requiring transfusion or major surgery|Number of women with hospitalization|Number of women with documentation of postpartum complications|Number of women screening positive for postpartum depression|Number of women with severe fatigue|Differences between treatment groups in infant-mother bonding scale scores|Differences in quality of life assessment scores|Prevalence of severe/moderate/mild anemia among women|Maternal - Change resulting in severe/moderate/mild anemia by treatment arm|Maternal - Hemoglobin concentration by mode of delivery|Maternal - Differences in ferritin and inflammatory markers by treatment group|Number of neonatal infant deaths|Number of infants with hospitalization|Number of women exclusive breastfeeding rate and intend to continue breastfeeding through 12 months post-delivery","NICHD Global Network for Women's and Children's Health|Thomas Jefferson University|University of North Carolina, Chapel Hill|Kinshasa School of Public Health|University of Alabama at Birmingham|University Teaching Hospital, Lusaka, Zambia|University of Colorado, Denver|Institute of Nutrition of Central America and Panama|University of Virginia|International Centre for Diarrhoeal Disease Research, Bangladesh|Columbia University|Aga Khan University|Boston University|Lata Medical Research Foundation, Nagpur|Indiana University|Moi University|RTI International|Bill and Melinda Gates Foundation|KLE University Jawaharlal Nehru Medical College","Female","15 Years to 49 Years   (Child, Adult)","Phase 3","4800","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP PRIORITY","May 30, 2023","October 1, 2025","December 1, 2025","October 21, 2022",,"December 11, 2023","ICDDRB, Dhaka, Bangladesh|Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the|INCAP, Guatemala City, Guatemala|KLE Society's Jawaharlal Nehru Medical College, Belgaum, Karnataka, India|Lata Medical Research Foundation, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya|The Aga Khan University, Karachi, Pakistan|University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT05590260"
184,"NCT00210743","Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.",,"Completed","No Results Available","Anemia|Kidney Diseases","Drug: epoetin alfa","The primary endpoint is the number of subjects who achieve a hemoglobin response after receiving PROCRIT every 2 weeks. Hemoglobin response is defined as achieving a target hemoglobin range of 11-12 g/dL for at least 2 consecutive weeks by Week 28.|The secondary endpoints include: the time to a hemoglobin response, the number of subjects achieving a 1 g/dL rise in hemoglobin, change in quality of life measurements, and the total study drug dose up to the time of response.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho Biotech Products, L.P.","All","18 Years and older   (Adult, Older Adult)","Phase 2","67","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR004600","May 2004",,"October 2005","September 21, 2005",,"May 23, 2011",,,"https://ClinicalTrials.gov/show/NCT00210743"
185,"NCT01019902","Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn",,"Completed","No Results Available","Anemia",,"Auditory Brainstem Responses (ABR) in Infant|Maternal Fe and micronutrient status (folate, B12, Fe, copper and zinc, hemoglobin, hematocrit,transferrin receptor, hepcidin, erythropoietin, ferritin, erythrocyte zinc protoporphyrin/heme ratios and c-reactive protein)|Neonatal Fe and micronutrient status|Placental Fe/copper/zinc content and expression of key iron transporters.","Cornell University|University of Rochester","All","1 Day to 18 Years   (Child, Adult)",,"144","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","RSRB00024804|2008-01857","October 2008","November 2012","October 2013","November 25, 2009",,"March 20, 2014","Highland Hospital, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01019902"
186,"NCT00782912","Postpartum Anemia and Postpartum Depression","PPADS","Completed","No Results Available","Postpartum Depression",,"Incidence of postpartum depression|Mean Edinburgh Postnatal Depression Scale results|Functional status|Lactation success","Unity Health Toronto","Female","Child, Adult, Older Adult",,"103","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","08-155","November 2008","October 2014","October 2014","October 31, 2008",,"February 22, 2019","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00782912"
187,"NCT03605511","TTP and aHUS in Complicated Pregnancies",,"Unknown status","No Results Available","Thrombotic Thrombocytopenic Purpura|Atypical Hemolytic Uremic Syndrome|Pre-Eclampsia|HELLP Syndrome|Thrombocytopenia|IUGR|Stillbirth|Thrombotic Microangiopathies","Diagnostic Test: ADAMTS 13, complement and angiogenic biomarkers","Frequency of TTP and aHUS in the cohort","University College, London","Female","16 Years and older   (Child, Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18/0217","September 21, 2018","March 14, 2020","March 14, 2020","July 30, 2018",,"September 25, 2018","University College London Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03605511"
188,"NCT06045052","Eltrombopag for Treatment of Fanconi Anemia",,"Completed","No Results Available","Fanconi Anemia","Drug: Eltrombopag","Assessing the efficacy of eltrombopag on hematopoiesis|Evaluation of the incidence of clonal evolution|Identification and tracking of adverse reactions associated with eltrombopag treatment in patients with Fanconi anemia graded|Determination of the proportion of grafted cells","Julian Sevilla|Hospital Infantil Universitario Niño Jesús, Madrid, Spain","All","4 Years to 17 Years   (Child)","Phase 2","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FANCREV","December 2, 2020","June 19, 2023","August 29, 2023","September 21, 2023",,"September 21, 2023","Hospital Infantil Universitario Niño Jesús (HIUNJ), Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT06045052"
189,"NCT01555255","Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria",,"Unknown status","No Results Available","Malaria|Placental Malaria|Malaria in Pregnancy",,"accuracy of diagnostic tests during gestation|association of placental malaria with infant birth weight|association of placental malaria with maternal hemoglobin|accuracy of diagnostic tests at delivery","Foundation for Innovative New Diagnostics, Switzerland|UNICEF|United Nations Development Programme|World Bank|World Health Organization","Female","16 Years to 44 Years   (Child, Adult)",,"1205","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RPC390","November 2010","March 2012","December 2012","March 15, 2012",,"April 23, 2015","IRSS, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso|Tororo District Hospital, Tororo, Tororo District, Uganda",,"https://ClinicalTrials.gov/show/NCT01555255"
190,"NCT01903148","Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations","ACERCA","Completed","Has Results","ANEMIA",,"% Patients Achieving Target Hemoglobin Levels|Hemoglobin Levels Per Type of Patients|Patients With Hb>12|% Patients With Erythropoiesis Stimulating Agents (ESA) Therapy|Iron Treatment|Patients With Hb<11","Fundación Senefro","All","18 Years and older   (Adult, Older Adult)",,"455","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","SEN-AEE-2011-01","October 2011","June 2012","June 2012","July 19, 2013","January 1, 2014","January 1, 2014","Hospital Puerto Real, Cadiz, Andalucía, Spain|Hospital de Jerez, Jerez, Andalucía, Spain|Clínico V. Victoria, Malaga, Andalucía, Spain|Hospital Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Virgen de la Luz, Toledo, Castilla la Mancha, Spain|Fundación Puigvert, Barcelona, Cataluña, Spain|Hospital Bellvige, Barcelona, Cataluña, Spain|Hospital Bellvitge, Barcelona, Cataluña, Spain|Hospital Clinic, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol, Barcelona, Cataluña, Spain|Hospital Valld'Hebron, Barcelona, Cataluña, Spain|Sagrat Cor, Barcelona, Cataluña, Spain|Clinica Girona, Gerona, Cataluña, Spain|Hospital Josep Trueta, Gerona, Cataluña, Spain|Hospital General de Alicante, Alicante, Comunidad Valenciana, Spain|Hospital de Castellón, Castellón, Comunidad Valenciana, Spain|Hospital Clínico de Valencia, Valencia, Comunidad Valenciana, Spain|Hospital Dr. Peset, Valencia, Comunidad Valenciana, Spain|Hospital La Fe, Valencia, Comunidad Valenciana, Spain|Arquitecto Marcide, Ferrol, Galicia, Spain|Complexo Hospitalario de Ourense, Orense, Galicia, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Galicia, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain|Hospital Universitario Nuestra Señora De Candelaria, Santa Cruz de Tenerife, Islas Canarias, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital La Princesa, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01903148"
191,"NCT03029208","Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)",,"Completed","Has Results","Anaemia","Drug: Daprodustat|Drug: Darbepoetin alfa|Drug: Iron therapy","Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52)|Average Monthly Intravenous Iron Dose (Milligrams) From Baseline to Week 52|Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Blood Pressure (MAP) at Week 52|Change From Baseline in SBP, DBP, MAP at End of Treatment|Blood Pressure (BP) Exacerbation Events Rate Per 100 Participant Years|Number of Participants With at Least One Blood Pressure Exacerbation Event During Study|Change From Baseline in Post-randomization Hgb at Week 52|Number of Hgb Responders (Hgb in the Analysis Range of 10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)|Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis|Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Superiority Analysis|Number of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria|Change From Baseline in Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52|Change From Baseline in Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52|Change From Baseline in Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52|Change From Baseline in Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52|Change From Baseline in EQ Visual Analogue Scale (EQ-VAS) at Week 52|Change From Baseline in Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Week 52|Change From Baseline in Patient Global Impression of Severity (PGI-S)|Plasma Concentration of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)|Observed Concentration at Dosing Interval (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)|Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)","GlaxoSmithKline","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201410|2016-000507-86","May 11, 2017","September 24, 2020","September 24, 2020","January 24, 2017","October 20, 2021","October 20, 2021","GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Cerritos, California, United States|GSK Investigational Site, Escondido, California, United States|GSK Investigational Site, Glendale, California, United States|GSK Investigational Site, La Palma, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Lynwood, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Whittier, California, United States|GSK Investigational Site, Middlebury, Connecticut, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Crystal Lake, Illinois, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Merrillville, Indiana, United States|GSK Investigational Site, Michigan City, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Lufkin, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Hampton, Virginia, United States|GSK Investigational Site, Ciudad Evita, Buenos Aires, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Morón, Buenos Aires, Argentina|GSK Investigational Site, Pergamino, Buenos Aires, Argentina|GSK Investigational Site, Pilar, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Formosa, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, San Miguel de Tucumán, Argentina|GSK Investigational Site, Adelaide, South Australia, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, St Albans, Victoria, Australia|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Kaiserslautern, Rheinland-Pfalz, Germany|GSK Investigational Site, Wiesbaden, Germany|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Chennai, India|GSK Investigational Site, Delhi, India|GSK Investigational Site, Gurgaon, India|GSK Investigational Site, Kozhikode, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Secunderabad, India|GSK Investigational Site, Thiruvananthapuram, India|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Cagliari, Sardegna, Italy|GSK Investigational Site, Anyang-Si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Bucheon-si,, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Suwon, Korea, Republic of|GSK Investigational Site, Ipoh, Malaysia|GSK Investigational Site, Kuala Lumpur, Malaysia|GSK Investigational Site, Penang, Malaysia|GSK Investigational Site, Torreon, Coahuila, Mexico|GSK Investigational Site, Ciudad De México, Estado De México, Mexico|GSK Investigational Site, Guadalajara., Jalisco, Mexico|GSK Investigational Site, Zapopan, Jalisco, Mexico|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Mérida, Yucatán, Mexico|GSK Investigational Site, Aguascalientes, Mexico|GSK Investigational Site, Tlalnepantla, Mexico|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Kolo, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Ostroda, Poland|GSK Investigational Site, Ostroleka, Poland|GSK Investigational Site, Szczecin, Poland|GSK Investigational Site, Irkutsk, Russian Federation|GSK Investigational Site, Mytishchi, Russian Federation|GSK Investigational Site, Omsk, Russian Federation|GSK Investigational Site, Smolensk, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Volzhskiy, Russian Federation|GSK Investigational Site, Cape Town., South Africa|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Puerto Real, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Doncaster, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Middlesbrough, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/08/NCT03029208/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/08/NCT03029208/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03029208"
192,"NCT03398824","Pilot Study of Metformin for Patients With Fanconi Anemia",,"Completed","Has Results","Fanconi Anemia","Drug: metformin HCl","Hematologic Response","Boston Children's Hospital","All","6 Years to 35 Years   (Child, Adult)","Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-P00026540","March 29, 2018","October 9, 2020","October 9, 2020","January 16, 2018","November 29, 2022","November 29, 2022","Boston Children's Hospital, Boston, Massachusetts, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/24/NCT03398824/Prot_SAP_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03398824"
193,"NCT00896740","Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants",,"Terminated","No Results Available","Fanconi Anemia","Genetic: microarray analysis|Procedure: biopsy","Comparison of Fanconi anemia (FA) hematopoietic cells vs normal hematopoietic cells|Comparison of FA hematopoietic cells from children with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) vs children (siblings) with FA but without MDS/AML|Comparison of FA cells from different complementation groups","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","1 Year to 55 Years   (Child, Adult)",,"90","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00000713|OHSU-HEM-01079-L|CDR0000445212","March 2002","September 2007","September 2007","May 12, 2009",,"December 4, 2017","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00896740"
194,"NCT04414527","Effects of Video-based Health Education on Maternal and Child Health in Ethiopia","MCH","Completed","No Results Available","Anemia|Antenatal Care|Birth Outcomes|Worm Infection|Bacterial Vaginoses|Exclusive Breastfeeding","Behavioral: Standard counselling|Behavioral: Health-Video","Adherence to iron and folic acid supplementation during pregnancy|Adherence to iron and folic acid supplementation post-partum|Maternal anemia during pregnancy|Maternal anemia post-partum|Early initiation|Exclusive breastfeeding|Dietary intake during six months pregnancy|Dietary intake at six months post-partum|Gestational weight gain|Maternal genital infections|Birth weight|Infant weight|Infant length|Infant anemia|Maternal parasitic infections|Infant parasitic infections|Maternal plasma ferritin|Infant plasma ferritin|Maternal soluble transferrin receptor|Infant soluble transferrin receptor|Maternal serum concentrations in Vitamin A (retinol)|Infant serum concentrations in Vitamin A (retinol)|Maternal serum concentrations in vitamin B12|Infant serum concentrations in vitamin B12","University Ghent|Flemish Interuniversity Council (VLIR)|Arba Minch University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","675","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BC-06756","March 13, 2020","July 31, 2021","July 31, 2021","June 4, 2020",,"December 6, 2021","Arba Minch University, Arba Minch, Dirashe District, Ethiopia",,"https://ClinicalTrials.gov/show/NCT04414527"
195,"NCT03814408","A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A",,"Unknown status","No Results Available","Fanconi Anemia Complementation Group A","Biological: RP-L102","Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0|Phenotypic correction of T-lymphocytes in peripheral blood after infusion of RP-L102|Phenotypic correction of hematopoietic cells in bone marrow after infusion of RP-L102|Engraftment of gene-corrected hematopoietic cells after infusion of RP-L102|Prevention or rescue of bone marrow failure after infusion of RP-L102","Rocket Pharmaceuticals Inc.","All","1 Year to 12 Years   (Child)","Phase 1","2","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RP-L102-0418","January 11, 2019","December 2020","March 2022","January 24, 2019",,"November 24, 2020","Stanford University Institute for Stem Cell Biology and Regenerative Medicine Lucille Packard Children's Hospital, Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03814408"
196,"NCT00630253","Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia",,"Completed","Has Results","Fanconi Anemia","Biological: Anti-Thymocyte Globulin|Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Hematopoietic Stem Cell Transplantation|Drug: Methylprednisolone|Drug: Filgrastim|Drug: Cyclosporine|Drug: Mycophenolate Mofetil","Number of Participants Experiencing Graft Failure|Number of Participants With Acute Graft-Versus-Host Disease (GVHD)|Number of Participants Experiencing Overall Survival|Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)|Number of Participants With Transplant Related Deaths","Masonic Cancer Center, University of Minnesota","All","up to 59 Years   (Child, Adult)","Phase 1|Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT2000-09|0001M34441","February 17, 2000","October 10, 2020","October 10, 2020","March 6, 2008","October 12, 2021","October 12, 2021","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/53/NCT00630253/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00630253"
197,"NCT04621331","Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD",,"Withdrawn","No Results Available","Anemia Associated With Chronic Kidney Disease","Drug: Roxadustat","Proportion of patients with mean Hb ≥ 11.0 g/dL|Mean change in Hb|Time to first Hb response (this only applies to NDD patients)","FibroGen|AstraZeneca","All","2 Years to 18 Years   (Child, Adult)","Phase 3","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FGN-PED-CLIN-02","May 23, 2022","May 23, 2022","May 23, 2022","November 9, 2020",,"July 5, 2022","Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York, New York, United States|Investigative site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04621331"
198,"NCT01720147","Quercetin in Children With Fanconi Anemia; a Pilot Study",,"Completed","No Results Available","Fanconi Anemia","Drug: Quercetin (dietary supplement)","Measure the ability to administer twice daily oral quercetin therapy in patients with Fanconi Anemia (FA).|Measure safety of oral quercetin therapy in patients with FA|To measure pharmacokinetics (PK) of oral quercetin therapy in patients with FA|To measure the impact of quercetin therapy on reduction of Reactive Oxygen Species (ROS).|Number of participants with improved hematopoiesis.|Measure the preservation of hematopoietic stem cell reserve in patients with FA|To measure the impact of quercetin therapy on changes in insulin sensitivity/glucose tolerance.","Children's Hospital Medical Center, Cincinnati|Food and Drug Administration (FDA)","All","Child, Adult, Older Adult","Phase 1","30","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2011-2049|1R01FD004383-01A1","July 2012","October 26, 2021","October 26, 2021","November 2, 2012",,"January 18, 2024","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01720147"
199,"NCT03351868","FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector",,"Unknown status","No Results Available","Fanconi Anemia","Genetic: Gene-modified autologous stem cells","Safety in patients using CTCAE version 4.0 standard to evaluate the level of adverse events|Treatment responses|Quality of life","Shenzhen Geno-Immune Medical Institute","All","2 Years to 20 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-17021","December 1, 2017","December 31, 2020","December 31, 2021","November 24, 2017",,"September 19, 2019","Capital Institute of Pediatrics affiliated Children's hospital, Beijing, Beijing, China|Beijing Children's Hospital, Beijing, Beijing, China|Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03351868"
200,"NCT00258427","Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia",,"Completed","Has Results","Fanconi Anemia","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Biological: Hematopoietic stem cell transplantation","Number of Participants Experiencing Graft Failure|Number of Participants Experiencing Chronic Graft-Versus-Host Disease|Number of Participants Experiencing Acute Graft-Versus-Host Disease|Number of Participants Experiencing Relapse|Number of Participants Experiencing Overall Survival|Number of Participants Experiencing Major Infections","Masonic Cancer Center, University of Minnesota","All","up to 44 Years   (Child, Adult)","Phase 2","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2002LS014|MT2002-02|0202M18741","March 26, 2002","October 10, 2020","October 10, 2020","November 24, 2005","December 2, 2021","December 2, 2021","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/27/NCT00258427/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00258427"
201,"NCT01071239","Hematopoietic Stem Cell Transplant for Fanconi Anemia","FA","Completed","No Results Available","Fanconi Anemia","Device: CliniMACs device|Drug: Busulfan|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: ATG","To measure the incidence and quality of engraftment and hematopoietic reconstitution.|The incidence of early transplant related mortality and incidence and severity of acute and chronic GVHD","Medical College of Wisconsin|Memorial Sloan Kettering Cancer Center","All","Child, Adult, Older Adult","Phase 2","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FA 08/89","April 2009","August 30, 2016","August 30, 2016","February 19, 2010",,"September 11, 2019","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01071239"
202,"NCT03029247","Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)",,"Completed","Has Results","Anaemia","Drug: Daprodustat|Drug: Epoetin alfa","Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57|Average of SBP, Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) Measured by ABPM Over 6-hour Post Dosing on Day 1|Average of Heart Rate (HR) Measured by ABPM Over 6 Hour Post Dosing on Day 1|Area Under the Effect Curve (AUEC) of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 1|AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 1|Average of DBP and MAP Measured by ABPM Over 6-hour Post Dosing on Day 57|Average of HR Measured by ABPM Over 6 Hour Post Dosing on Day 57|AUEC of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 57|AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 57|Change From Pre-dose in SBP, DBP and MAP at Day 1|Change From Pre-dose in HR at Day 1|Plasma Concentrations of Daprodustat|Plasma Concentrations of Metabolite GSK2391220|Plasma Concentrations of Metabolite GSK2506104|Plasma Concentrations of Metabolite GSK2487818|Plasma Concentrations of Metabolite GSK2506102|Plasma Concentrations of Metabolite GSK2531398|Plasma Concentrations of Metabolite GSK2531401|Maximum Plasma Concentration (Cmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401|Time of Occurrence of Cmax (Tmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401|Terminal Phase Half-life (t1/2) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401|Area Under Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401","GlaxoSmithKline|ERT: Clinical Trial Technology Solutions|Q2 Solutions|Quintiles, Inc.|HemoCue","All","40 Years and older   (Adult, Older Adult)","Phase 2","105","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205665","July 27, 2017","July 9, 2020","July 9, 2020","January 24, 2017","June 3, 2021","June 3, 2021","GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, DeLand, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, San Antonio, Texas, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/47/NCT03029247/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/47/NCT03029247/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03029247"
203,"NCT00317876","Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia",,"Completed","No Results Available","Fanconi Anemia","Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation","Conditioning-related toxicity|Graft rejection","Fred Hutchinson Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Phase 1","25","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","1288.00|FHCRC-1288.00|CDR0000481264","June 1998","July 2003",,"April 25, 2006",,"April 20, 2012","Seattle Cancer Care Alliance, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Universidade Federal do Parana, Curitiba, Parana, Brazil",,"https://ClinicalTrials.gov/show/NCT00317876"
204,"NCT01974271","An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)",,"Completed","No Results Available","Anemia",,"Percentage of patients with a variation of Hb level of +/- 1 g/dL between the first Mircera injection and Month 6|Percentage of patients with Hb value within the range of 10 - 12 g/dL|Change in Hb level|Monthly dose of Mircera|Safety: Incidence of adverse events","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)",,"661","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28980","January 2014","April 2015","April 2015","November 1, 2013",,"November 2, 2016","Aix En Provence, France|Ajaccio, France|Annonay, France|Arras, France|Auch, France|Aurillac, France|Beauvais, France|Beauvais, France|Bois Bernard, France|Bordeaux, France|Bourg En Bresse, France|Bourgoin Jallieu, France|Brest, France|Chamalieres, France|Chaumont, France|Clermont Ferrand, France|Clermont-ferrand, France|Colmar, France|Condom, France|Dijon, France|Dourlers, France|Epinal, France|Fleurance, France|Fourmies, France|GAP, France|Gradignan, France|Haguenau, France|La Roche Sur Yon, France|La Tronche, France|Le Mans, France|Le Puy En Velay, France|Libourne, France|Lille, France|Maubeuge, France|Meaux, France|Mirande, France|Montereau, France|Nantes, France|Nantes, France|Neuilly Sur Seine, France|Nimes, France|Nogaro, France|Noyal Pontivy, France|Olivet, France|Orleans, France|Paris, France|Paris, France|Paris, France|Paris, France|Pessac, France|Poitiers, France|Quimper, France|Quincy Sous Senart, France|Rambouillet, France|Rennes, France|Reze, France|Roubaix, France|Rouen, France|Saint Lo, France|Saint Marcel, France|Saint Nazaire, France|Saint Ouen, France|Salouel, France|Saran, France|St Brieuc, France|St Laurent Du Var, France|St Priest En Jarez, France|Stains, France|Strasbourg, France|Toulouse, France|Tourcoing, France|Valenciennes, France|Vandoeuvre-les-nancy, France|Vesoul, France|Villefranche de Rouergue, France|Yssingeaux, France",,"https://ClinicalTrials.gov/show/NCT01974271"
205,"NCT04248439","Gene Therapy for Fanconi Anemia, Complementation Group A",,"Active, not recruiting","No Results Available","Fanconi Anemia Complementation Group A","Biological: RP-L102","Bone Marrow (BM) Colony-Forming Cell (CFC) Mitomycin-C (MMC) resistance|Genetic Correction|Hematologic Stability- Hemoglobin|Hematologic Stability- Neutrophils|Hematologic Stability- Platelets|Phenotypic Correction|Safety of RP-L102|Tolerability of RP-L102|Overall survival|Bone Marrow Failure Free Survival|Hematological Malignancy Free Survival","Rocket Pharmaceuticals Inc.","All","1 Year and older   (Child, Adult, Older Adult)","Phase 2","5","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RP-L102-0319","July 15, 2020","May 2026","May 2026","January 30, 2020",,"April 10, 2024","Stanford University, Stanford, California, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04248439"
206,"NCT00399269","Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure",,"Completed","No Results Available","Anemia","Drug: Recombinant Human Erythropoietin alpha","Rise in Hemoglobin (Hb)/ Hematocrit (Hct) to therapeutic levels of 10 to 12 g/ dL|and/ or 30 to 36% respectively suggestive of normalized erythropoiesis at the end of study period of 12 Weeks.|OR|Rise in Hb by 1 g/ dL over two weeks of treatment with rHu-EPO.|Rise of Hemoglobin and Haematocrit in CRF patients without significant adverse events.","Cadila Pharnmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR - 50/9180","December 2006",,"June 2007","November 14, 2006",,"June 11, 2009","Dr. Shishir Gang, Nadiad, Gujarat, India",,"https://ClinicalTrials.gov/show/NCT00399269"
207,"NCT03409107","Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)",,"Completed","Has Results","Anaemia","Drug: Daprodustat (GSK1278863)|Drug: Placebo|Drug: Iron therapy","Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28)|Percentage of Participants With Hemoglobin Increase of >=1.0 Grams Per Deciliter From Baseline to Evaluation Period|Change From Baseline in Short Form-36 (SF-36) Questionnaire Vitality Domain Score by Traditional Scoring at Week 28|Percentage of Participants With Hgb Response (Hgb in the 11-12 Grams/Deciliter Range) During Evaluation Period (Week 24 to Week 28 Inclusive)|Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Hodges-Lehmann Estimate)|Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Mann-Whitney Estimate)|Change From Baseline in Post-randomization Hgb at Week 28|Rate of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria|Change From Baseline by Domain and Single Item Scores on the Chronic Kidney Disease -Anemia Questionnaire (CKD-AQ) Symptom Questionnaire|Change From Baseline in Patient Global Impression of Severity (PGI-S)|Change From Baseline in the SF-36 Physical Functioning Domain|Change From Baseline of the SF-36 Individual Items in the Vitality Domain|Number of Participants Currently Employed as Per Work Productivity and Activity Impairment Questionnaire: Anemic Symptoms Clinical Practice Version (WPAI-ANS-CPV)|Change From Baseline in WPAI-ANS-CPV: Percent Time Missed From Work|Change From Baseline in WPAI-ANS-CPV: Mean Hours Missed From Work in the Past 7 Days|Change From Baseline in WPAI: Percent Impairment at Work|Change From Baseline in WPAI: Percent Overall Work Impairment|Change From Baseline in WPAI: Percent Regular Daily Activity Impairment|Change From Baseline in EuroQol 5 Dimension 5 Level Health Utility Index (EQ-5D-5L) Utility Score|Change From Baseline in EuroQol Visual Analogue Scale (EQ-VAS) Score|Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Pressure (MAP) at Week 28|Percentage of Participants With at Least One Blood Pressure (BP) Exacerbation Event","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","614","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","205270|2017-002270-39","March 5, 2018","October 7, 2020","October 7, 2020","January 24, 2018","November 3, 2021","April 2, 2024","GSK Investigational Site, Homewood, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Downey, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Lynwood, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, Salinas, California, United States|GSK Investigational Site, Santa Ana, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Hartford, Connecticut, United States|GSK Investigational Site, Middlebury, Connecticut, United States|GSK Investigational Site, Coral Springs, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Kissimmee, Florida, United States|GSK Investigational Site, Lauderdale Lakes, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Adairsville, Georgia, United States|GSK Investigational Site, Macon, Georgia, United States|GSK Investigational Site, Macon, Georgia, United States|GSK Investigational Site, Statesboro, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Buckley, Michigan, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Saint Clair Shores, Michigan, United States|GSK Investigational Site, Brookhaven, Mississippi, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Rochester, New Hampshire, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Midwest City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Beaver, Pennsylvania, United States|GSK Investigational Site, Duncansville, Pennsylvania, United States|GSK Investigational Site, Scottdale, Pennsylvania, United States|GSK Investigational Site, Smithfield, Pennsylvania, United States|GSK Investigational Site, West Reading, Pennsylvania, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, DeSoto, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, McAllen, Texas, United States|GSK Investigational Site, Waxahachie, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, San Nicolas, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Sydney, New South Wales, Australia|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Parkville, Victoria, Australia|GSK Investigational Site, Murdoch, Western Australia, Australia|GSK Investigational Site, Fitzroy, Australia|GSK Investigational Site, Feira de Santana., Bahia, Brazil|GSK Investigational Site, Salvador, Bahia, Brazil|GSK Investigational Site, Vitoria, Espírito Santo, Brazil|GSK Investigational Site, Ribeirão Preto, São Paulo, Brazil|GSK Investigational Site, Santo André - SP, São Paulo, Brazil|GSK Investigational Site, Sao Jose do Rio Preto, São Paulo, Brazil|GSK Investigational Site, Sao Jose do Rio Preto, São Paulo, Brazil|GSK Investigational Site, São Bernardo do Campo, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Victoria, British Columbia, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Guelph, Ontario, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Sarnia, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montréal, Quebec, Canada|GSK Investigational Site, Quebec city, Quebec, Canada|GSK Investigational Site, St-Charles-Borromée, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Grenoble cedex 9, France|GSK Investigational Site, Le Mans cedex 9, France|GSK Investigational Site, Marseille cedex 5, France|GSK Investigational Site, Melun, France|GSK Investigational Site, Mulhouse cedex, France|GSK Investigational Site, Nantes Cedex 1, France|GSK Investigational Site, Nice Cedex 1, France|GSK Investigational Site, Saint-Priest en Jarez, France|GSK Investigational Site, Catanzaro, Calabria, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Mestre, Veneto, Italy|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Daegu-si, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Leon, Guanajuato, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Boca del Rio, Veracruz, Mexico|GSK Investigational Site, Córdoba, Veracruz, Mexico|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Guadalajara, Mexico|GSK Investigational Site, Merida, Mexico|GSK Investigational Site, Veracruz, Mexico|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Ciechanow, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Olawa, Poland|GSK Investigational Site, Pleszew, Poland|GSK Investigational Site, Sosnowiec, Poland|GSK Investigational Site, Swidnik, Poland|GSK Investigational Site, Szczecin, Poland|GSK Investigational Site, Tczew, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Brasov, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Cluj-Napoca, Romania|GSK Investigational Site, Craiova, Romania|GSK Investigational Site, Deva, Romania|GSK Investigational Site, Oradea, Romania|GSK Investigational Site, Targu Mures, Romania|GSK Investigational Site, Timisoara, Romania|GSK Investigational Site, Izhevsk, Russian Federation|GSK Investigational Site, Kaliningrad, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Krasnoyarsk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Pyatigorsk, Russian Federation|GSK Investigational Site, Pyatigorsk, Russian Federation|GSK Investigational Site, Rostov-on-Don, Russian Federation|GSK Investigational Site, Ryazan, Russian Federation|GSK Investigational Site, Saint Petersburg, Russian Federation|GSK Investigational Site, Saint Petersburg, Russian Federation|GSK Investigational Site, Stavropol, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Canterbury, Kent, United Kingdom|GSK Investigational Site, Derby, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Peterborough, United Kingdom|GSK Investigational Site, Plymouth, United Kingdom|GSK Investigational Site, Shrewsbury, United Kingdom|GSK Investigational Site, Swansea, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/07/NCT03409107/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/07/NCT03409107/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03409107"
208,"NCT05910853","Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia",,"Recruiting","No Results Available","Fanconi Anemia","Diagnostic Test: Specimen Donation","Biospecimen Samples collect from patients with Fanconi Anemia participants diagnosed with Fanconi Anemia.","Sanguine Biosciences","All","18 Years to 85 Years   (Adult, Older Adult)",,"8","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","SAN-09686","May 24, 2023","December 31, 2023","December 31, 2023","June 20, 2023",,"November 22, 2023","Sanguine Biosciences, Woburn, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05910853"
209,"NCT04069533","Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A",,"Active, not recruiting","No Results Available","Fanconi Anemia Complementation Group A","Biological: RP-L102","Phenotypic correction of bone marrow colony forming units after infusion of RP-L102|Phenotypic correction of T-lymphocytes in peripheral blood after infusion of RP-L102|Engraftment of gene-corrected hematopoietic cells after infusion of RP-L102|Prevention or rescue of bone marrow failure|Short- and long-term Safety","Rocket Pharmaceuticals Inc.","All","1 Year to 17 Years   (Child)","Phase 2","7","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RP-L102-0118|2018-002502-31","November 28, 2019","February 2025","February 2025","August 28, 2019",,"April 6, 2023","Hospital Infantil Universitario Niño Jesús (HIUNJ), Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04069533"
210,"NCT02876835","Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)",,"Completed","Has Results","Anaemia","Drug: Daprodustat|Drug: Darbepoetin alfa|Drug: Placebo|Drug: Iron Therapy","Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)|Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)|Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis)|Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period|Time to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period|Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period|Number of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)|Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period|Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period|Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period|Time to First Occurrence of Confirmed 40% Decline in eGFR During CV Events Follow-up Time Period|Time to First Occurrence of Chronic Dialysis During CV Events Follow-up Time Period|Time to First Occurrence of Kidney Transplant During CV Events Follow-up Time Period|Change From Baseline in Post-randomization Hgb Levels at Week 52|Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)|Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis|Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis|Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis|Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis|Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52|Change From Baseline in SBP, DBP, MAP at End of Treatment|Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years|Number of Participants With at Least One BP Exacerbation Event During Study|Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria|Change From Baseline in On-treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in On-treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in On-treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52|Change From Baseline in On-treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in On-treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in On-treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52|Change From Baseline in On-treatment EQ Visual Analogue Scale (EQ-VAS) at Week 52|Change From Baseline in On-treatment Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Weeks 8, 12, 28, 52|Change From Baseline in On-treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52|Change From Baseline in Post-randomization Estimated Glomerular Filtration Rate (eGFR) at Week 52","GlaxoSmithKline","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","3872","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200808|2016-000542-65","September 27, 2016","April 19, 2021","April 19, 2021","August 24, 2016","April 14, 2022","April 2, 2024","GSK Investigational Site, Andalusia, Alabama, United States|GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Huntsville, Alabama, United States|GSK Investigational Site, Glendale, Arizona, United States|GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Azusa, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Chula Vista, California, United States|GSK Investigational Site, Cudahy, California, United States|GSK Investigational Site, El Centro, California, United States|GSK Investigational Site, Escondido, California, United States|GSK Investigational Site, Glendale, California, United States|GSK Investigational Site, Granada Hills, California, United States|GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, La Palma, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Montebello, California, United States|GSK Investigational Site, National City, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Luis Obispo, California, United States|GSK Investigational Site, Simi Valley, California, United States|GSK Investigational Site, Tarzana, California, United States|GSK Investigational Site, Whittier, California, United States|GSK Investigational Site, Middlebury, Connecticut, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Cutler Bay, Florida, United States|GSK Investigational Site, Doral, Florida, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Homestead, Florida, United States|GSK Investigational Site, Hudson, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Lauderdale Lakes, Florida, United States|GSK Investigational Site, Miami Gardens, Florida, United States|GSK Investigational Site, Miami Lakes, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Port Charlotte, Florida, United States|GSK Investigational Site, South Miami, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Temple Terrace, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Nampa, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Crystal Lake, Illinois, United States|GSK Investigational Site, Mount Prospect, Illinois, United States|GSK Investigational Site, Quincy, Illinois, United States|GSK Investigational Site, Springfield, Illinois, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Jeffersonville, Indiana, United States|GSK Investigational Site, Michigan City, Indiana, United States|GSK Investigational Site, Des Moines, Iowa, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Hutchinson, Kansas, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Potomac, Maryland, United States|GSK Investigational Site, Takoma Park, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Pontiac, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Tupelo, Mississippi, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, North Platte, Nebraska, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Flushing, New York, United States|GSK Investigational Site, Laurelton, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Ridgewood, New York, United States|GSK Investigational Site, Yonkers, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Rocky Mount, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Grand Forks, North Dakota, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Mentor, Ohio, United States|GSK Investigational Site, Lawton, Oklahoma, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Roseburg, Oregon, United States|GSK Investigational Site, Bethlehem, Pennsylvania, United States|GSK Investigational Site, Doylestown, Pennsylvania, United States|GSK Investigational Site, Lancaster, Pennsylvania, United States|GSK Investigational Site, Upland, Pennsylvania, United States|GSK Investigational Site, Wyomissing, Pennsylvania, United States|GSK Investigational Site, Anderson, South Carolina, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Sumter, South Carolina, United States|GSK Investigational Site, Cordova, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Corpus Christi, Texas, United States|GSK Investigational Site, Corsicana, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Lufkin, Texas, United States|GSK Investigational Site, McAllen, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Temple, Texas, United States|GSK Investigational Site, Waxahachie, Texas, United States|GSK Investigational Site, Alexandria, Virginia, United States|GSK Investigational Site, Fairfax, Virginia, United States|GSK Investigational Site, Hampton, Virginia, United States|GSK Investigational Site, Salem, Virginia, United States|GSK Investigational Site, Bluefield, West Virginia, United States|GSK Investigational Site, Ciudad Evita, Buenos Aires, Argentina|GSK Investigational Site, Coronel Suarez, Buenos Aires, Argentina|GSK Investigational Site, Junín, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, Pergamino, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Corrientes, Argentina|GSK Investigational Site, Formosa, Argentina|GSK Investigational Site, La Plata, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Moron, Argentina|GSK Investigational Site, San Miguel de Tucumán, Argentina|GSK Investigational Site, Garran, Australian Capital Territory, Australia|GSK Investigational Site, Concord, New South Wales, Australia|GSK Investigational Site, Gosford, New South Wales, Australia|GSK Investigational Site, Kingswood, New South Wales, Australia|GSK Investigational Site, Kogarah, New South Wales, Australia|GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Wollongong, New South Wales, Australia|GSK Investigational Site, Nambour, Queensland, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Reservoir, Victoria, Australia|GSK Investigational Site, St Albans, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Liverpool, Australia|GSK Investigational Site, Aalst, Belgium|GSK Investigational Site, Baudour, Belgium|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Ieper, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Roeselare, Belgium|GSK Investigational Site, Ronse, Belgium|GSK Investigational Site, Sint-Niklaas, Belgium|GSK Investigational Site, Salvador, Bahia, Brazil|GSK Investigational Site, Curitiba, Paraná, Brazil|GSK Investigational Site, Curitiba, Paraná, Brazil|GSK Investigational Site, Curitiba, Paraná, Brazil|GSK Investigational Site, Passo Fundo, Rio Grande Do Sul, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Sao Jose do Rio Preto, São Paulo, Brazil|GSK Investigational Site, Votuporanga, São Paulo, Brazil|GSK Investigational Site, Belo Horizonte, Brazil|GSK Investigational Site, Brasilia, Brazil|GSK Investigational Site, Feira de Santana, Brazil|GSK Investigational Site, Joinville, Brazil|GSK Investigational Site, Juiz De Fora, Brazil|GSK Investigational Site, Sao Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Blagoevgrad, Bulgaria|GSK Investigational Site, Burgas, Bulgaria|GSK Investigational Site, Dobrich, Bulgaria|GSK Investigational Site, Gabrovo, Bulgaria|GSK Investigational Site, Lom, Bulgaria|GSK Investigational Site, Pazardzhik, Bulgaria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sliven, Bulgaria|GSK Investigational Site, Smolyan, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Stara Zagora, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Veliko Tarnovo, Bulgaria|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Barranquilla, Colombia|GSK Investigational Site, Bogotá, Colombia|GSK Investigational Site, Cali, Colombia|GSK Investigational Site, Floridablanca, Colombia|GSK Investigational Site, Medellin, Colombia|GSK Investigational Site, Beroun, Czechia|GSK Investigational Site, Cesky Krumlov, Czechia|GSK Investigational Site, Ivancice, Czechia|GSK Investigational Site, Jilemnice, Czechia|GSK Investigational Site, Marianske Lazne, Czechia|GSK Investigational Site, Novy Jicin, Czechia|GSK Investigational Site, Pardubice, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Sokolov, Czechia|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Holstebro, Denmark|GSK Investigational Site, Kolding, Denmark|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Jämejala Village, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Annonay, France|GSK Investigational Site, Boulogne Billancourt, France|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Clermont-Ferrand, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Montpellier, France|GSK Investigational Site, Mulhouse, France|GSK Investigational Site, Poitiers, France|GSK Investigational Site, Saint-Ouen, France|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Cloppenburg, Niedersachsen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Kaiserslautern, Rheinland-Pfalz, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Koeln, Germany|GSK Investigational Site, Wiesbaden, Germany|GSK Investigational Site, Alexandroupolis, Greece|GSK Investigational Site, Arta, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Efkarpia, Greece|GSK Investigational Site, Heraklion-Crete, Greece|GSK Investigational Site, Ioannina, Greece|GSK Investigational Site, Ioannina, Greece|GSK Investigational Site, Komotini, Greece|GSK Investigational Site, Larissa, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Patras, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Lai Chi kok, Hong Kong|GSK Investigational Site, New Territories, Hong Kong|GSK Investigational Site, Tsuen Wan, Hong Kong|GSK Investigational Site, Baja, Hungary|GSK Investigational Site, Balatonfured, Hungary|GSK Investigational Site, Esztergom, Hungary|GSK Investigational Site, Kecskemét, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Pecs, Hungary|GSK Investigational Site, Salgótarján, Hungary|GSK Investigational Site, Szigetvar, Hungary|GSK Investigational Site, Ahmedabad, India|GSK Investigational Site, Ahmedabad, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Calicut, India|GSK Investigational Site, Chandigarh, India|GSK Investigational Site, Chennai, Tamil Nadu, India|GSK Investigational Site, Chennai, India|GSK Investigational Site, Delhi, India|GSK Investigational Site, Ghaziabad, India|GSK Investigational Site, Gurgaon, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Jaipur, India|GSK Investigational Site, Jaipur, India|GSK Investigational Site, Lucknow, India|GSK Investigational Site, Manipal, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Nadiad, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Secunderabad, India|GSK Investigational Site, Trivandrum, India|GSK Investigational Site, Ashkelon, Israel|GSK Investigational Site, Hadera, Israel|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Kfar Saba, Israel|GSK Investigational Site, Nahariya, Israel|GSK Investigational Site, Nazareth, Israel|GSK Investigational Site, Poriya, Israel|GSK Investigational Site, Zerifin, Israel|GSK Investigational Site, Catanzaro, Calabria, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Piacenza, Emilia-Romagna, Italy|GSK Investigational Site, Reggio Emilia, Emilia-Romagna, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Lecco, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Foggia, Puglia, Italy|GSK Investigational Site, Cagliari, Sardegna, Italy|GSK Investigational Site, Imola, Italy|GSK Investigational Site, Mestre, Italy|GSK Investigational Site, Anyang-Si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Bucheon, Korea, Republic of|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Daejeon, Korea, Republic of|GSK Investigational Site, Goyang-si, Korea, Republic of|GSK Investigational Site, Ilsanseo-gu, Goyang-si,, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Jeonju-si, Korea, Republic of|GSK Investigational Site, Seongnam, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Suwon, Korea, Republic of|GSK Investigational Site, Suwon, Korea, Republic of|GSK Investigational Site, Uijeongbu-si, Korea, Republic of|GSK Investigational Site, Wonju-si, Korea, Republic of|GSK Investigational Site, Alor Setar, Malaysia|GSK Investigational Site, Ipoh, Malaysia|GSK Investigational Site, Kuala Lumpur, Malaysia|GSK Investigational Site, Kuantan, Malaysia|GSK Investigational Site, Lumut, Malaysia|GSK Investigational Site, Pahang, Malaysia|GSK Investigational Site, Penang, Malaysia|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Torreon, Coahuila, Mexico|GSK Investigational Site, Durango., Durango, Mexico|GSK Investigational Site, Ciudad De Mexico, Estado De México, Mexico|GSK Investigational Site, Leon, Guanajuato, Mexico|GSK Investigational Site, León, Guanajuato, Mexico|GSK Investigational Site, Guadalajara., Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Cuernavaca, Morelos, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Queretaro, Querétaro, Mexico|GSK Investigational Site, Culiacan, Sinaloa, Mexico|GSK Investigational Site, Culiacan, Sinaloa, Mexico|GSK Investigational Site, Mazatlán, Sinaloa, Mexico|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Aguascalientes, Mexico|GSK Investigational Site, Chihuahua, Mexico|GSK Investigational Site, Chihuahua, Mexico|GSK Investigational Site, Ciudad De México, Mexico|GSK Investigational Site, Ciudad De México, Mexico|GSK Investigational Site, Culiacan, Mexico|GSK Investigational Site, Tlalnepantla De Baz, Mexico|GSK Investigational Site, Veracruz, Mexico|GSK Investigational Site, Zapopan, Jalisco, Mexico|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Deventer, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Dunedin, New Zealand|GSK Investigational Site, Hamilton, New Zealand|GSK Investigational Site, Hastings, New Zealand|GSK Investigational Site, Otahuhu, New Zealand|GSK Investigational Site, Takapuna, Auckland, New Zealand|GSK Investigational Site, Baguio City, Benguet, Philippines|GSK Investigational Site, Cebu City, Philippines|GSK Investigational Site, Dasmarinas, Philippines|GSK Investigational Site, Iloilo City, Philippines|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Pasig, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, San Juan, Philippines|GSK Investigational Site, Sto Tomas, Philippines|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Brzeg, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Kielce, Poland|GSK Investigational Site, Kolobrzeg, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Radom, Poland|GSK Investigational Site, Szczecin, Poland|GSK Investigational Site, Zyrardow, Poland|GSK Investigational Site, Amadora, Portugal|GSK Investigational Site, Aveiro, Portugal|GSK Investigational Site, Covilhã, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Torres Novas, Portugal|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Bucuresti, Romania|GSK Investigational Site, Constanta, Romania|GSK Investigational Site, Oradea, Romania|GSK Investigational Site, Timisoara, Romania|GSK Investigational Site, Irkutsk, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Krasnodar, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Mytischi, Russian Federation|GSK Investigational Site, Omsk, Russian Federation|GSK Investigational Site, Podolsk, Russian Federation|GSK Investigational Site, Ryazan, Russian Federation|GSK Investigational Site, Smolensk, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Ulyanovsk, Russian Federation|GSK Investigational Site, Volzhsky, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Port Elizabeth, Eastern Cape, South Africa|GSK Investigational Site, Cape Town., South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Majadahonda, Madrid, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Burela, Spain|GSK Investigational Site, Caceres, Spain|GSK Investigational Site, Ciudad Real, Spain|GSK Investigational Site, Girona, Spain|GSK Investigational Site, Guadalajara, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Mollet del Valles, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Örebro, Sweden|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Keelung, Taiwan|GSK Investigational Site, New Taipei, Taiwan|GSK Investigational Site, Tainan, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taoyuan Hsien, Taiwan|GSK Investigational Site, Bangkoknoi, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiang Mai, Thailand|GSK Investigational Site, Khon Kaen, Thailand|GSK Investigational Site, Pathumthani, Thailand|GSK Investigational Site, Adana, Turkey|GSK Investigational Site, Ankara, Turkey|GSK Investigational Site, Antalya, Turkey|GSK Investigational Site, Edirne, Turkey|GSK Investigational Site, Eskisehir, Turkey|GSK Investigational Site, Istanbul, Turkey|GSK Investigational Site, Istanbul, Turkey|GSK Investigational Site, Istanbul, Turkey|GSK Investigational Site, Kayseri, Turkey|GSK Investigational Site, Cherkasy, Ukraine|GSK Investigational Site, Chernihiv, Ukraine|GSK Investigational Site, Chernivtsi, Ukraine|GSK Investigational Site, Ivano-Frankivsk, Ukraine|GSK Investigational Site, Kharkiv, Ukraine|GSK Investigational Site, Kherson, Ukraine|GSK Investigational Site, Kiev, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Lutsk, Ukraine|GSK Investigational Site, Mykolaiv, Ukraine|GSK Investigational Site, Poltava, Ukraine|GSK Investigational Site, Ternopil, Ukraine|GSK Investigational Site, Zaporizhzhia, Ukraine|GSK Investigational Site, Zaporizhzhia, Ukraine|GSK Investigational Site, Zhytomyr, Ukraine|GSK Investigational Site, Stevenage, Hertfordshire, United Kingdom|GSK Investigational Site, Preston, Lancashire, United Kingdom|GSK Investigational Site, Hampstead, London, United Kingdom|GSK Investigational Site, Liverpool, Merseyside, United Kingdom|GSK Investigational Site, Wolverhampton, West Midlands, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, Derby, United Kingdom|GSK Investigational Site, Doncaster, United Kingdom|GSK Investigational Site, Fife, United Kingdom|GSK Investigational Site, Glasgow., United Kingdom|GSK Investigational Site, Hull, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Middlesbrough, United Kingdom|GSK Investigational Site, Oxford, United Kingdom|GSK Investigational Site, Salford, United Kingdom|GSK Investigational Site, York, United Kingdom|GSK Investigational Site, Ha Noi City, Vietnam|GSK Investigational Site, Ha Noi, Vietnam|GSK Investigational Site, Hai Phong, Vietnam|GSK Investigational Site, Hanoi, Vietnam|GSK Investigational Site, Ho Chi Minh City, Vietnam|GSK Investigational Site, Ho Chi Minh, Vietnam","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/35/NCT02876835/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/35/NCT02876835/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02876835"
211,"NCT02174627","Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis",,"Completed","Has Results","Anemia","Drug: Roxadustat|Drug: Placebo","Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52|Percentage of Participants With Hb Response During the First 24 Weeks of Treatment|Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)|Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52|Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52|Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24|Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy|Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy|Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28|Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant|Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28","AstraZeneca|FibroGen","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","2781","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5740C00001","June 26, 2014","October 4, 2018","October 4, 2018","June 25, 2014","December 16, 2019","December 16, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, El Centro, California, United States|Research Site, Escondido, California, United States|Research Site, Glendale, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, National City, California, United States|Research Site, Northridge, California, United States|Research Site, Orange, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Dimas, California, United States|Research Site, San Francisco, California, United States|Research Site, San Luis Obispo, California, United States|Research Site, Upland, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Aventura, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Joliet, Illinois, United States|Research Site, La Grange, Illinois, United States|Research Site, Metairie, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Rockport, Maine, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Port Huron, Michigan, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Rochester, New Hampshire, United States|Research Site, Flushing, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Jacksonville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lufkin, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Saint George, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Salem, Virginia, United States|Research Site, Woodbridge, Virginia, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Ciudadela, Argentina|Research Site, La Plata, Argentina|Research Site, La Plata, Argentina|Research Site, Lanus, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Munro, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Isidro, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Feira de Santana, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Joinville, Brazil|Research Site, Juiz de Fora, Brazil|Research Site, Maringa, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Bernardo do Campo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Botevgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Samokov, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Silistra, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Kamloops, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Whitby, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Cali, Colombia|Research Site, Chia, Colombia|Research Site, Medellin, Colombia|Research Site, Zipaquira, Colombia|Research Site, Brno, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Ivancice, Czechia|Research Site, Praha, Czechia|Research Site, Rychnov nad Kneznou, Czechia|Research Site, Slany, Czechia|Research Site, Slavkov u Brna, Czechia|Research Site, Sumperk, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Berlin, Germany|Research Site, Cloppenburg, Germany|Research Site, Köln, Germany|Research Site, Ajka, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyula, Hungary|Research Site, Hatvan, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Polgár, Hungary|Research Site, Pécs, Hungary|Research Site, Salgótarján, Hungary|Research Site, Siófok, Hungary|Research Site, Tatabánya, Hungary|Research Site, Velence, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Ghaziabad NCR, India|Research Site, Hyderabad, India|Research Site, Hyderabad, India|Research Site, Kolkatta, India|Research Site, Lucknow, India|Research Site, Maharashtra, India|Research Site, Mumbai, India|Research Site, Mysore, India|Research Site, Nagpur, India|Research Site, Nagpur, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Vijayawada, India|Research Site, Vijayawada, India|Research Site, Vishakhapatnam, India|Research Site, Ansan-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of|Research Site, George Town, Malaysia|Research Site, Kubang Kerian, Malaysia|Research Site, Putrajaya, Malaysia|Research Site, Taiping, Malaysia|Research Site, Aguascalientes, Mexico|Research Site, Culiacán, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Minatitlán, Mexico|Research Site, México, Mexico|Research Site, Veracruz, Mexico|Research Site, Xalapa, Mexico|Research Site, Bellavista, Peru|Research Site, Ica, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Trujillo, Peru|Research Site, Cebu City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Iloilo, Philippines|Research Site, Quezon City, Philippines|Research Site, Ciechanów, Poland|Research Site, Końskie, Poland|Research Site, Poznań, Poland|Research Site, Sochaczew, Poland|Research Site, Tczew, Poland|Research Site, Łódź, Poland|Research Site, Cidra, Puerto Rico|Research Site, Rio Grande, Puerto Rico|Research Site, Rio Piedras, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, Toa Baja, Puerto Rico|Research Site, Arad, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Targu Mures, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Irkutsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kralovsky Chlmec, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Zvolen, Slovakia|Research Site, Almería, Spain|Research Site, Málaga, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Kaohsiung City, Taiwan|Research Site, Keelung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, New Taipei, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, TaoYuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Chernivtsi, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Khmelnytsky, Ukraine|Research Site, Kirovograd, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Rivne, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Can Tho, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Hochiminh, Vietnam|Research Site, Hochiminh, Vietnam|Research Site, Hue, Vietnam","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02174627"
212,"NCT00317239","VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease",,"Completed","Has Results","Anemia","Drug: Ferrous Sulfate tablets|Drug: Ferric Carboxymaltose (FCM)","Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL","American Regent, Inc.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","255","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1VIT04004","May 2005","February 2007","August 2007","April 24, 2006","November 25, 2013","February 20, 2018","Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00317239"
213,"NCT05900635","Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients",,"Recruiting","No Results Available","Anemia of Chronic Kidney Disease","Drug: Lactoferrin|Drug: Ferrous Glycine Sulfate","Comparison of the efficacy of the combination (lactoferrin plus ferrous glycine sulfate) versus ferrous glycine sulfate therapy in treatment of patients with iron deficiency anemia and CKD|Evaluation of tolerability and gastrointestinal adverse events","Alexandria University","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0107174","October 1, 2022","June 2023","September 2023","June 12, 2023",,"June 12, 2023","Kidney and Urology Center, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT05900635"
214,"NCT04437771","Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy",,"Enrolling by invitation","No Results Available","Fanconi Anemia Complementation Group A|Fanconi Anemia","Other: Safety and efficacy assessments","Monitor long term safety of patients through blood laboratory evaluations and general health status|Long term genetic correction assessed in bone marrow and blood|Replication competent lentivirus (RCL)|Insertion site analysis in blood|Phenotypic correction|Assessment for Malignancies|Hematologic stabilization","Rocket Pharmaceuticals Inc.","All","Child, Adult, Older Adult",,"9","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RP-L102-0116-LTFU","June 1, 2020","October 30, 2034","January 30, 2035","June 18, 2020",,"June 22, 2020","Hospital Infantil Universitario Niño Jesús (HIUNJ), Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04437771"
215,"NCT02678533","Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor","FancoMob","Completed","No Results Available","Fanconi Anemia","Drug: G-CSF|Drug: Plerixafor","level of CD34+ cells mobilization|number of treatment-related adverse events as a measure of tolerability","Assistance Publique - Hôpitaux de Paris|EuroFancolen","All","2 Years to 17 Years   (Child)","Phase 1|Phase 2","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P130103|2014-005264-14","February 10, 2017","November 20, 2018","May 3, 2019","February 9, 2016",,"December 22, 2021","Hôpital necker-Enfants malades, Paris, France",,"https://ClinicalTrials.gov/show/NCT02678533"
216,"NCT03206086","Eltrombopag for People With Fanconi Anemia",,"Recruiting","No Results Available","Fanconi Anemia","Drug: Eltrombopag","Proportion of drug responders|Toxicity profile|Toxicities with extended duration of therapy|Serum cytokine profile, i.e. TNFalpha, IFNgamma, TPO|Relapse|Multicolor flow cytometry of bone marrow cells|Impact of treatment and treatment response on quality of life|Impact of EPAG on other organ systems commonly involved in FA (e.g. skin lesions, endocrine dysfunction, and incidence of new head/neck, oropharyngeal, gastrointestinal, anogenital or skin cancers by clinical assessment)|Hematological responses|Evaluation of global transcriptome in HSPCs (single cell RNA seq)|Evaluation of DNA repair activity in HSPCs (Gamma H2AX Assay and comet assay)|Clonal evolution","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 99 Years   (Child, Adult, Older Adult)","Phase 2","35","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170121|17-H-0121","November 2, 2018","May 1, 2026","May 1, 2030","July 2, 2017",,"March 12, 2024","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03206086"
217,"NCT00586274","Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT","RAFHAS","Terminated","No Results Available","FANCONI ANEMIA","Procedure: CD34 selected haploidentical PBSCT|Drug: Fludarabine|Biological: T cell infusion|Biological: Campath 1h|Biological: anti-CD45","Determine # of donor lymphocytes that can be given to recipients of haplo-SCT with FA after depletion of recipient-reactive T lymphocytes by ex-vivo tx with a fixed dose of RFT5-dgA immunotoxin, and will result in Grade III/IV GVHD of < / = 25%.|To analyze immune reconstitution in these patients.|To measure their overall and disease free survival, at 100 days and at 1 year after transplant.","Baylor College of Medicine|University of Texas, Southwestern Medical Center at Dallas|Center for Cell and Gene Therapy, Baylor College of Medicine","All","up to 64 Years   (Child, Adult)","Phase 1","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-11428","March 2002","July 2009","July 2009","January 4, 2008",,"March 4, 2014","Texas Children's Hospital, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00586274"
218,"NCT00236964","Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis",,"Completed","No Results Available","Anemia","Drug: Iron Sucrose + Erythropoietin|Drug: Ferrous Sulfate + Erythropoietin","Mean Change in Hemoglobin and Serum Ferritin at day 43|Clinical success (change in Hgb > 12 & Change in Ferritin 180)|Maximum change in Hemoglobin during the study","American Regent, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1VEN99012","February 2001",,"May 2002","October 12, 2005",,"January 24, 2018",,,"https://ClinicalTrials.gov/show/NCT00236964"
219,"NCT04522375","A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia",,"Recruiting","No Results Available","Fanconi Anemia","Drug: FP-045","The Optimal Biologic Dose (OBP) of FP-045|stabilizing or improving cytopenia in FA|Safety and tolerability|pharmacokinetic profile","Foresee Pharmaceuticals Co., Ltd.","All","3 Years to 25 Years   (Child, Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FP045C-19-001","June 30, 2023","June 2025","December 2025","August 21, 2020",,"November 13, 2023","Lucille Packard Children's Hospital, Stanford University, Palo Alto, California, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States|St. Jude Childrens Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04522375"
220,"NCT03446612","Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)",,"Terminated","Has Results","Anaemia","Drug: Daprodustat|Drug: Darbepoetin alfa|Drug: Acetylcholine|Drug: Sodium nitroprusside|Drug: L-N-monomethyl arginine acetate (L-NMMA)","Change in FBF Ratio in Response to Acetylcholine (Day 1 to Day 42)|Change in the Absolute FBF From Day 1 to Day 42 in Response to Acetylcholine|Change in FBF Ratio in Response to Sodium Nitroprusside (Day 1 to Day 42)|Change in the Absolute FBF From Day 1 to Day 42 in Response to Sodium Nitroprusside|Change in FBF Ratio in Response to NG-monomethyl Arginine Acetate (L-NMMA) (Day 1 to Day 42)|Change in the Absolute FBF From Day 1 to Day 42 in Response to L-NMMA|Change in FBF Ratio in Response to Acetylcholine at Day 42 Versus (vs) Day 1 in Participants Treated With Daprodustat|Change in FBF Ratio in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Daprodustat|Change in FBF Ratio in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Daprodustat|Change in FBF Ratio in Response to Acetylcholine at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa|Change in FBF Ratio in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa|Change in FBF Ratio in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa|Change in the Absolute FBF in Response to Acetylcholine at Day 42 vs Day 1 in Participants Treated With Daprodustat|Change in the Absolute FBF in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Daprodustat|Change in the Absolute FBF in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Daprodustat|Change in the Absolute FBF in Response to Acetylcholine at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa|Change in the Absolute FBF in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa|Change in the Absolute FBF in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa|Change in Augmentation Index (AIx) From Day 1 to 42|Change in Pulse Wave Velocity (PWV) From Day 1 to Day 42|Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Any AE of Special Interest (AESI)|Number of Participants Discontinuing the Randomized Study Treatment","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205767|2017-002268-42","January 10, 2019","May 29, 2019","May 29, 2019","February 27, 2018","July 21, 2021","March 27, 2024","GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom|GSK Investigational Site, Edinburgh, United Kingdom|GSK Investigational Site, London, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/12/NCT03446612/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/12/NCT03446612/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03446612"
221,"NCT02127905","Unrelated HSCT in Patients With Fanconi Anemia",,"Withdrawn","No Results Available","Fanconi Anemia","Biological: CD34+ selected cells","Event free survival post stem cell transplant|Peripheral blood CBC counts for engraftment evaluation|Chimerism assay for engraftment evaluation|Graft Versus Host Disease (GVHD) surveillance after HSCT","Neena Kapoor, M.D.|Children's Hospital Los Angeles","All","8 Weeks to 21 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCI-10-00176","March 2011","March 2016","March 2016","May 1, 2014",,"July 11, 2017","Children's Hospital Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02127905"
222,"NCT03408639","Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients",,"Completed","Has Results","Anemia in End-Stage Renal Disease","Drug: CinnaPoietin®|Drug: Eprex®|Drug: Nephrovit|Drug: Vitamin B12 Injection","Mean Hb Change Level During the Last Four Weeks of Treatment|Mean Weekly Epoetin Dosage Per kg Body Weight During the Last Four Weeks of Treatment|The Proportion of Patients With Any Permanent or Transient Dose Change|The Proportion of Patients With Any Hb Measurement Outside the Target Range (10-12 g/dl)|The Proportion of Patients Needed Blood Transfusions|The Proportion of Patients With Treatment Success|The Proportion of Patients With Maintenance Success|The Percentage of Patients With Hb Measurements More Than 10.0 g/dl|The Percentage of Patients With Hematocrit Measurements More Than 30%|The Incidence of Hb Levels Above 13 g/dl|The Proportion of Patients With an Increase in Hb Concentration of > 1.0 g/dl for Four Consecutive Weeks|The Incidence of Adverse Events","Cinnagen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","156","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ERY.CIN.MA.94|IRCT201601156135N6","June 22, 2016","July 19, 2017","July 19, 2017","January 24, 2018","November 6, 2019","December 18, 2019","Javad-al-Aemeh clinic, Kerman, Iran, Islamic Republic of|SHAFA Hospital, Kerman, Iran, Islamic Republic of|Haj Ebrahimi dialysis center, Shiraz, Iran, Islamic Republic of|Ghiasi hospital, Tehran, Iran, Islamic Republic of|Hashemi Nezhad Hospital, Tehran, Iran, Islamic Republic of|Imam Hussein Hospital, Tehran, Iran, Islamic Republic of|Madar dialysis center, Tehran, Iran, Islamic Republic of|Milad Hospital, Tehran, Iran, Islamic Republic of","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/39/NCT03408639/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/39/NCT03408639/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03408639"
223,"NCT03475342","World Maternal Antifibrinolytic Trial_2","WOMAN-2","Completed","No Results Available","Intrapartum - Moderate and Severe Anaemia","Drug: Tranexamic Acid|Other: Placebo","Postpartum Haemorrhage (cause will be described)|Postpartum blood loss|Haemoglobin|Haemodynamic instability|Shock index|Quality of Life (maternal)|Expected side effects of trial medication|Exercise tolerance|Interventions to control primary postpartum haemorrhage (medical and surgical)|Receipt of blood product transfusion|Vascular occlusive events|Symptoms of anaemia|Organ disfunction|Sepsis|In hospital death|Length of hospital stay.|Admission to and time spent in higher level facility|Status of baby/ies|Thromboembolic events in breastfed babies|Adverse events","London School of Hygiene and Tropical Medicine|Wellcome Trust|Bill and Melinda Gates Foundation","Female","Child, Adult, Older Adult","Phase 3","15068","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","WOMAN_2|03475342","August 24, 2019","September 20, 2023","October 29, 2023","March 23, 2018",,"January 10, 2024","Mother & Child Hospital, Akure, Nigeria|University of Medical Sciences Teaching Hospital, Akure, Nigeria|Adeoyo Maternity Hospital, Ibadan, Nigeria|Ilorin General Hospital, Ilorin, Nigeria|Muhammad Abdullahi Wase Specialist Hospital, Kano, Nigeria|Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso, Nigeria|State Hospital, Oyo, Nigeria|Ayub Teaching Hospital (Unit A), Abbottabad, Pakistan|Ayub Teaching Hospital (Unit C), Abbottabad, Pakistan|Ayub Teaching Hospital Unit B, Abbottabad, Pakistan|Bahawalpur Victoria Hospital, Bahawalpur, Pakistan|Aziz Bhatti Teaching Hospital, Gujrat, Pakistan|MCH PIMS, Islamabad, Pakistan|Military Hospital, Islamabad, Pakistan|Civil Hospital, Karachi, Pakistan|Jinnah Postgraduate Medical Centre, Karachi, Pakistan|Koohi Goth Hospital, Karachi, Pakistan|Jinnah Hospital, Lahore, Pakistan|Services Hospital, Lahore, Pakistan|Sir Ganga Ram Hospital Unit 1, Lahore, Pakistan|Sir Ganga Ram Hospital Unit 2, Lahore, Pakistan|Sir Ganga Ram Hospital Unit 3, Lahore, Pakistan|Sir Ganga Ram Hospital Unit 4, Lahore, Pakistan|Chandka SMBBMU Sheikh Zaid Woman Hospital Unit 1, Larkana, Pakistan|Chandka SMBBMU Sheikh Zaid Woman Hospital Units 2 & 3, Lārkāna, Pakistan|Nishtar Hospital Unit 1, Multan, Pakistan|Nishtar Hospital Unit 2, Multān, Pakistan|Nishtar Hospital Unit 3, Multān, Pakistan|Bolan Medical Centre, Quetta, Pakistan|Benazir Bhutto Shaheed Hospital, Rawalpindi, Pakistan|Federal Government Polyclinic, Rawalpindi, Pakistan|Holy Family Hospital, Rawalpindi, Pakistan|Mount Meru Regional Referral Hospital, Arusha, Tanzania|Amana Regional Referral Hospital,, Dar Es Salaam, Tanzania|Muhimbili National Hospital, Dar Es Salaam, Tanzania|Temeke Regional Referral Hospital, Dar Es Salaam, Tanzania|Dodoma Regional Referral Hospital, Dodoma, Tanzania|Tumbi Regional Referral Hospital, Kibaha, Kibaha, Tanzania|Mwananyamala Regional Referral Hospital, Kinondoni, Tanzania|Mbeya Zonal Referral Hospital, Mbeya, Tanzania|Women and Newborn Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT03475342"
224,"NCT03400033","Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)",,"Completed","Has Results","Anaemia","Drug: Daprodustat tablets|Drug: Matching placebo tablets|Drug: Epoetin alfa vials|Drug: Saline vials or bags","Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52)|Mean Average Monthly On-treatment Intravenous (IV) Iron Dose Per Participant|Change From Baseline in Hemoglobin Levels at Week 52|Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)|Number of Hemoglobin Responders in the Hemoglobin Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)|Percentage of Participants Permanently Stopping Study Treatment Due to Meeting Rescue Criteria|Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52|Change From Baseline in SBP, DBP and MAP at End of Treatment|Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years|Number of Participants With at Least One BP Exacerbation Event During the Study|Change From Baseline at Weeks 8, 12, 28 and 52 in Patient Global Impression of Severity (PGI-S)|Pre-dose Trough Concentration (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)|Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)","GlaxoSmithKline","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","407","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","204837|2017-004372-56","September 5, 2018","June 19, 2020","June 19, 2020","January 17, 2018","July 12, 2021","July 12, 2021","GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, Middlebury, Connecticut, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Macon, Georgia, United States|GSK Investigational Site, Meridian, Idaho, United States|GSK Investigational Site, Pittsfield, Massachusetts, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, College Point, New York, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Lufkin, Texas, United States|GSK Investigational Site, Alexandria, Virginia, United States|GSK Investigational Site, Hampton, Virginia, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, Pergamino, Buenos Aires, Argentina|GSK Investigational Site, Sarandi, Buenos Aires, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Parkville, Victoria, Australia|GSK Investigational Site, Salvador, Bahia, Brazil|GSK Investigational Site, Curitiba, Paraná, Brazil|GSK Investigational Site, Passo Fundo, Rio Grande Do Sul, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Sao Jose do Rio Preto, São Paulo, Brazil|GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Oshawa, Ontario, Canada|GSK Investigational Site, Bayonne, France|GSK Investigational Site, Epagny Metz-Tessy, France|GSK Investigational Site, Le Mans, France|GSK Investigational Site, Nice Cedex 1, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Anyang-Si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Sandomierz, Poland|GSK Investigational Site, Tarnowskie Gory, Poland|GSK Investigational Site, Zyrardow, Poland|GSK Investigational Site, Constanta, Romania|GSK Investigational Site, Resita, Romania|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Kolomna, Russian Federation|GSK Investigational Site, Krasnodar, Russian Federation|GSK Investigational Site, Krasnogorsk, Russian Federation|GSK Investigational Site, Mytischi, Russian Federation|GSK Investigational Site, Novorossiysk, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Omsk, Russian Federation|GSK Investigational Site, Orenburg, Russian Federation|GSK Investigational Site, Penza, Russian Federation|GSK Investigational Site, Podolsk, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Ufa, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Almeria, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Granollers, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Manises (Valencia), Spain|GSK Investigational Site, Sanlúcar De Barrameda (Cádiz), Spain|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Swansea, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/33/NCT03400033/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/33/NCT03400033/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03400033"
225,"NCT01977573","A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)",,"Completed","Has Results","Anaemia","Drug: GSK1278863|Drug: rhEPO","Summary of Hemoglobin (Hgb) Concentration at Week 24|Number of Participants With Hemoglobin (Hgb) in the Target Range at Week 24|Number of Participants Reaching Pre-defined Hgb Stopping Criteria|Percent Change From Baseline in Hepcidin Concentration at Week 24|Maximum Observed Change From Baseline in Serum Erythropoietin (EPO)|Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)|Percentage of Time Within, Below, and Above Hemoglobin (Hgb) Target Range, Between Weeks 12 and 24|Change From Baseline in Ferritin Concentration at Week 24|Change From Baseline in Transferrin Concentration at Week 24|Percent Change From Baseline in Transferrin Saturation at Week 24|Change From Baseline in Total Iron at Week 24|Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 24|Change From Baseline in Reticulocyte Hemoglobin (CHr) at Week 24|Change From Baseline in Hematocrit at Week 24|Change From Baseline in Red Blood Cell Count at Week 24|Change From Baseline in Reticulocyte Cell Count at Week 24|Concentration of GSK1278863 and Relevant Metabolites as a Population Pharmacokinetic Endpoint|Mean Number of Dose Adjustments up to 24 Weeks|Number of Participants With Dose Adjustments up to 24 Weeks, as a Measure of Dose Adjustment Frequency|Timing of Dose Adjustments at Weeks 4, 8, 12, 16, and 20|Mean Total Cumulative Dose of GSK1278863 up to 24 Weeks|Mean Final Dose of GSK1278863 up to 24 Weeks|Number of Hemoglobin (Hgb) Excursions|Number of Hemoglobin (Hgb) Cycles up to 24 Weeks|Number of Dose Cycles up to 24 Weeks|Number of Participants With at Least One Hemoglobin (Hgb) Excursion up to 24 Weeks.|Number of Participants With at Least One Hemoglobin (Hgb) Cycle up to 24 Weeks|Number of Participants With at Least One Dose Cycle up to 24 Weeks|Number of Participants Receiving Additional Therapies of Blood Transfusions, Intravenous (IV) Iron or rhEPO at Any Time Post-Baseline|Number of Weeks Dose Withheld Because Hemoglobin (Hgb) Exceeded the Upper Limit","GlaxoSmithKline","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","113747","October 31, 2013","May 1, 2015","June 15, 2015","November 6, 2013","June 6, 2016","October 12, 2018","GSK Investigational Site, Peoria, Arizona, United States|GSK Investigational Site, Azusa, California, United States|GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, Laguna Hills, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Dimas, California, United States|GSK Investigational Site, West Hills, California, United States|GSK Investigational Site, Lauderdale Lakes, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Macon, Georgia, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Evergreen Park, Illinois, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Farmington, Missouri, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Bethlehem, Pennsylvania, United States|GSK Investigational Site, Uniontown, Pennsylvania, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Corsicana, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Temple, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Liverpool, New South Wales, Australia|GSK Investigational Site, Westmead, New South Wales, Australia|GSK Investigational Site, Adelaide, South Australia, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Pointe-Claire, Quebec, Canada|GSK Investigational Site, Cheb, Czechia|GSK Investigational Site, Liberec, Czechia|GSK Investigational Site, Louny, Czechia|GSK Investigational Site, Marianske Lazne, Czechia|GSK Investigational Site, Most, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Sokolov, Czechia|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Roskilde, Denmark|GSK Investigational Site, Amiens cedex 1, France|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Créteil Cedex, France|GSK Investigational Site, Lyon Cedex 03, France|GSK Investigational Site, Paris Cedex 15, France|GSK Investigational Site, Sainte Foy-Lès-Lyon, France|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Demmin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Székesfehérvár, Hungary|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Gifu, Japan|GSK Investigational Site, Gunma, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Shiga, Japan|GSK Investigational Site, Anyang-Si Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Daejeon, Korea, Republic of|GSK Investigational Site, Gwangju, Korea, Republic of|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Tarnow, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Zabrze, Poland|GSK Investigational Site, Izhevsk, Russian Federation|GSK Investigational Site, Kaluga, Russian Federation|GSK Investigational Site, Khantymansiysk, Russian Federation|GSK Investigational Site, Krasnodar, Russian Federation|GSK Investigational Site, Krasnoyarsk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, Ulyanovsk, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Alcala de Henares, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Cordoba, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, San Sebastian de los Reyes, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Karlstad, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Örebro, Sweden|GSK Investigational Site, Chelmsford, United Kingdom|GSK Investigational Site, Dorchester, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Hull, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01977573"
226,"NCT02652806","FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease",,"Completed","No Results Available","Anemia","Drug: FG-4592|Drug: Epoetin Alfa","Hb mean change from baseline|Mean change from baseline in low-density lipoprotein (LDL) cholesterol|Number of subjects with a Hb response|Percent of subjects with a Hb response|Effect on iron metabolism|Proportion of subjects with exacerbation of hypertension|Mean change from baseline in predialysis and postdialysis mean arterial blood pressure|Number of subjects with treatment-emergent adverse events (TEAEs).|Percent of subjects with treatment-emergent adverse events (TEAEs).|Changes from baseline in vital signs|Changes from baseline in ECG findings.|Changes from baseline in clinical laboratory values.|Number and % of subjects on rescue therapy during study treatment.|Time to rescue therapy from date of first dose during study treatment.","FibroGen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FGCL-4592-806","December 2015","January 24, 2017","June 14, 2017","January 12, 2016",,"August 24, 2017","The Second Hospital of Anhui Medical University, Hefei, Anhui, China|301 Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Pekingg University, People's Hospital, Beijing, Beijing, China|The First Affiliated hospital of Third Military Medical University (Southwest Hospital), Chongqing, Chongqing, China|Lan Zhou University Second Hospital, Lanzhou, Gansu, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|The First Affiliated hospital of Guangxi Medical University, Nanning, Guangxi, China|The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|The First Hospital of Baotou Medical School of Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Shandong Provincial Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medication, Shanghai, Shanghai, China|Huashan Hospital of Fudan University, Shanghai, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medication, Shanghai, Shanghai, China|The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital, Sichuan Universtiy, Chengdu, Sichuan, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Ningbo No.2 Hospital, Ningbo, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02652806"
227,"NCT04784052","Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab",,"Recruiting","No Results Available","Fanconi Anemia","Drug: JSP191|Device: CliniMACS Prodigy System|Biological: Depleted Stem Cell Transplant|Biological: Rabbit Anti-Thymoglobulin (rATG)|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Rituximab","Number of participants without grade 3 and 4 treatment-emergent adverse events (TEAEs) (infusion related reactions) following administration of JSP191|Number of participants without grade 3 and 4 treatment-emergent adverse events (TEAEs) (infusion related reactions) following infusion of TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic graft transplantation|Number of participants able to achieve donor engraftment|Number of participants who are able to have donor engraftment persist at the same rate or better compared to alternative hematopoietic cell transplant regimens for this patient population|Serum concentration of JSP191|Serum concentration of rATG|Serum concentration of fludarabine|Participants who do not develop mucositis|Participants who do not develop veno-occlusive disease (VOD)|Number of participants who achieve hematopoietic recovery|Number of participants who achieve donor engraftment|Number of participants who achieve immunologic recovery|Number of participants who develop Grade I-IV acute graft-vs-host disease (GvHD)|Number of participants who develop chronic graft-vs-host disease (GvHD)|Number of participants who achieve disease-free survival","Porteus, Matthew, MD|Stanford University","All","2 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-60108","December 7, 2021","April 2025","April 2028","March 5, 2021",,"December 14, 2023","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04784052"
228,"NCT02075463","Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia",,"Terminated","Has Results","Anemia","Drug: GSK1278863|Drug: Placebo","Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16|Change From Baseline in Hgb Levels at Week 16|Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time Point|Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16|Number of Participants With Hgb in the Target Range at Week 16|Number of Participants Reaching Pre-defined Hgb Stopping Criteria|Percent Change From Baseline in Hepcidin at Week 16|Change From Baseline in Ferritin at Week 16|Change From Baseline in Transferrin at Week 16|Percent Change From Baseline in Transferrin Saturation at Week 16|Change From Baseline in Total Iron at Week 16|Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 16|Reticulocyte Hgb Content (CHr) at Week 16|Mean Corpuscular Volume (MCV) at Week 16|Mean Corpuscular Hemoglobin (MCH) at Week 16|Change From Baseline in Hematocrit at Week 16|Change From Baseline in Red Blood Cell (RBC) at Week 16|Change From Baseline in Reticulocyte Number at Week 16|Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)|Maximum Observed Change From Baseline in Erythropoietin (EPO)|Final Dose of GSK1278863|Plasma Concentrations of GSK1278863 and Its Metabolites at the Indicated Time Points","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","114837","June 1, 2014","March 1, 2016","March 16, 2016","March 3, 2014","June 21, 2017","June 21, 2017","GSK Investigational Site, Azusa, California, United States|GSK Investigational Site, Glendale, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Simi Valley, California, United States|GSK Investigational Site, Middlebury, Connecticut, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Macon, Georgia, United States|GSK Investigational Site, Southgate, Michigan, United States|GSK Investigational Site, Saint Ann, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Amherst, New York, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Bethlehem, Pennsylvania, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02075463"
229,"NCT02689206","Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent",,"Completed","Has Results","Anaemia","Drug: GSK1278863|Drug: GSK1278863 matching Placebo","Change From Baseline in Hgb Levels at Day 29|Maximum Observed Change From Baseline in Plasma Erythropoietin (EPO)|Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)|Percent Change From Baseline in Hepcidin at Day 29|Change From Baseline in Hematocrit Levels|Change From Baseline in Red Blood Cell (RBC) Count|Change From Baseline in Reticulocyte Count|Change From Baseline in Reticulocyte Hemoglobin (CHr)|Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) and AUC From Time Zero to Infinity (AUC[0-inf]) of Dapro|Maximum Observed Concentration of Dapro in Plasma (Cmax)|Time to Reach Cmax (Tmax) and Apparent Terminal Half-life (t1/2) of Dapro|Number of Participants Who Discontinued Study Treatment|Number of Participants With AEs and Serious Adverse Events (SAEs)|Sodium, Potassium, Glucose, Calcium, Phosphate Levels in Blood at Indicated Time Points|Albumin and Protein Levels in Blood at Indicated Tme Points|Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (Alk. Phosph) Levels in Blood at Indicated Time Points|Bilirubin, Direct Bilirubin and Indirect Bilirubin Levels in Blood at Indicated Time Points|Change From Baseline in Sodium, Potassium, Glucose, Calcium and Phosphate Levels|Change From Baseline in Albumin and Protein Levels|Change From Baseline in ALT, AST, Alk. Phosph. Levels|Change From Baseline in Bilirubin, Direct Bilirubin, Indirect Bilirubin Levels|Leukocytes, Neutrophils, Basophils, Eosinophils,Lymphocytes, Monocytes, Platelet Levels in Blood at Indicated Time Points|Mean Corpuscular Hemoglobin (MCH) Levels in Blood at Indicated Time Points|Mean Corpuscular Hemoglobin Concentration (MCHC) Levels in Blood at Indicated Time Points|Mean Corpuscular Volume (MCV) Levels in Blood at Indicated Time Points|Erythrocyte Distribution Width Levels in Blood at Indicated Time Points|Change From Baseline in MCH Levels|Change From Baseline in MCHC Levels|Change From Baseline in MCV Levels|Change From Baseline in Erythrocyte Distribution Width Levels|Change From Baseline in Leukocytes, Neutrophils, Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets Levels|Number of Participants With Abnormal Electrocardiogram (ECG) Findings at Indicated Time Points|Change From Baseline in ECG Mean Heart Rate|Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval and QTcB|Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Pre-dialysis and Post-dialysis|Pulse Rate Values at Pre-dialysis and Post-dialysis|Weight Values at Post-dialysis|Change From Baseline in SBP and DBP Values at Pre-dialysis and Post-dialysis|Change From Baseline in Pulse Rate Value at Pre-dialysis and Post-dialysis|Change From Baseline in Weight at Post-dialysis","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","204836|2015-004790-32","February 17, 2016","January 25, 2017","January 25, 2017","February 23, 2016","May 21, 2018","February 25, 2020","GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, San Dimas, California, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Greenbelt, Maryland, United States|GSK Investigational Site, Roseville, Michigan, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Kiel, Schleswig-Holstein, Germany|GSK Investigational Site, Darmstadt, Germany|GSK Investigational Site, Krasnodar, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Mytischi, Russian Federation|GSK Investigational Site, Omsk, Russian Federation|GSK Investigational Site, Penza, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Almería, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Granollers, Barcelona, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Lleida, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Malaga, Spain|GSK Investigational Site, Manises (Valencia), Spain|GSK Investigational Site, San Sebastian de los Reyes, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Valladolid, Spain","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/06/NCT02689206/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/06/NCT02689206/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02689206"
230,"NCT02652819","FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis",,"Completed","No Results Available","Anemia","Drug: FG-4592|Drug: Placebo","Change in Hb from baseline to the average level|The proportion of subjects who achieve a confirmed Hb response|Proportion of subjects with mean Hb ≥10.0 g/dL|Mean change from baseline in low-density lipoprotein (LDL) cholesterol averaged|Effect on iron metabolism|Survey (SF-36) Physical Functioning (PF) subscore measured in Week 9 in the Full Analysis Set (FAS) subjects with baseline PF subscore below 35|Mean change from baseline in SF-36 vitality subscore measured in Week 9 in FAS subjects with baseline vitality subscore below 50.|Mean change from baseline in mean arterial blood pressure|Proportion of subjects who received rescue therapy (composite of blood transfusion, ESA use, and IV iron)|Percent of subjects with treatment-emergent adverse events (TEAEs).|Number of subjects with treatment-emergent adverse events (TEAEs).|Changes from baseline in vital signs|Changes from baseline in ECG findings|Changes from baseline in clinical laboratory values|Proportion of subjects on rescue therapy|Time to rescue therapy from date of first dose","FibroGen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","154","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FGCL-4592-808","December 2015","January 24, 2017","June 13, 2017","January 12, 2016",,"August 24, 2017","The Second Hospital of Anhui Medical University, Hefei, Anhui, China|301 Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Pekingg University, People's Hospital, Beijing, Beijing, China|The First Affiliated hospital of Third Military Medical University (Southwest Hospital), Chongqing, Chongqing, China|Lan Zhou University Second Hospital, Lanzhou, Gansu, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|The First Affiliated hospital of Guangxi Medical University, Nanning, Guangxi, China|The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|The First Hospital of Baotou Medical School of Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Shandong Provincial Hospital, Jinan, Shandong, China|Huashan Hospital of Fudan University, Shanghai, Shanghai, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medication, Shanghai, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medication, Shanghai, Shanghai, China|The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital, Sichuan Universtiy, Chengdu, Sichuan, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Ningbo No.2 Hospital, Ningbo, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02652819"
231,"NCT02019719","Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease",,"Completed","Has Results","Anaemia","Drug: GSK1278863|Drug: Placebo","Change From Baseline (CFB) in Hemaglobin (Hgb) at Week 4|CFB in Hgb Upto Week 8|Number of Participants Who Achieved Hgb Response at Week 4|Percentage of Participants Who Achieved Hgb Response at Week 4|Number of Participants Who Reached Pre-defined Hgb Stopping Criteria|Maximum Observed CFB in Erythropoietin (EPO) Upto Week 4|Maximum Observed Percent CFB in Peak Vascular Endothelial Growth Factor (VEGF) Upto Week 4|Percent CFB in Hepcidine Upto Week 4|CFB in Ferritin at Week 4|CFB in Total Iron Binding Capacity [TIBC], Unbound Iron Binding Capacity [UIBC] and Iron at Week 4|CFB in Transferrin at Week 4|Percent CFB in Transferrin Saturation (TS) at Week 4|Plasma Pharmacokinetic Concentration of GSK1278863 and Metabolites (M) at Week 4|Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) on Therapy|Number of Participants With Chemistry and Hematology Data of Potential Clinical Importance (PCI) Upto Week 4|Number of Participants With Vital Signs Parameters Systolic and Diastolic Blood Pressure (SBP,DBP) of PCI Upto Week 4|Number of Participants With Vital Sign Parameter Heart Rate (HR) of PCI Upto Week 4|Number of Participants With Abnormal Electrocardiogram (ECG) Findings Upto Week 4","GlaxoSmithKline","All","20 Years and older   (Adult, Older Adult)","Phase 2","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","116099","November 5, 2013","August 6, 2014","August 6, 2014","December 24, 2013","February 12, 2018","February 12, 2018","GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Niigata, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Toyama, Japan",,"https://ClinicalTrials.gov/show/NCT02019719"
232,"NCT05265325","A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis",,"Active, not recruiting","No Results Available","Renal Anemia","Drug: AND017 TIW|Drug: AND017 QW|Drug: epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars","Incidence of adverse events|Mean change from baseline in Hb at Week 6|Proportion of responders, during the entire study period.|Mean proportion of visits at which patients maintain Hb within the target range from baseline during the fixed-dose period and titration period|Proportion of patients with a mean Hb between 10.0-11.0 g/dL inclusive during Week 14-20|Change in Hb from baseline to the mean Hb levels over Week 14-20|Mean Hb levels and mean change from baseline in Hb level at each visit|Cumulative response rate over the entire study period","Kind Pharmaceuticals LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AND017-MN-202","May 3, 2023","March 2024","April 2024","March 3, 2022",,"February 22, 2024","US Renal Care - Pine Bluff, Pine Bluff, Arkansas, United States|North America Research Institute, Riverside, California, United States|Rocky Mountain Kidney Care, Lone Tree, Colorado, United States|Nephrology and Hypertension Specialists, Dalton, Georgia, United States|High Desert Nephrology Associates, Gallup, New Mexico, United States|Nephrology Associates of Western New York, Cheektowaga, New York, United States|Nephrology Consultants of Northwest Ohio - Toledo, Toledo, Ohio, United States|South Texas Renal Care Group - San Saba, San Antonio, Texas, United States|Clinical Advancement Center PLLC, San Antonio, Texas, United States|South Texas Renal Care Group, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05265325"
233,"NCT06115421","Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients",,"Recruiting","No Results Available","Anemia in Dialysis-dependent CKD Patients","Drug: Roxadustat","Changes in hemoglobin level from baseline|Iron metabolism parameters change from the baseline|Safety profile|Time to achieve and maintain HB target|The need for rescue therapy|The minimum effective dose in combination with iron is needed to achieve the HB target.|Change in hepcidin level in the intervention group|Change in the Quality of Life (QoL) of the patients after the completion of the study period","Alexandria University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","72","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0201793","May 24, 2023","March 2024","May 2024","November 3, 2023",,"February 1, 2024","Alexandria University, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT06115421"
234,"NCT01977482","Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia",,"Completed","Has Results","Anaemia","Drug: GSK1278863|Drug: Placebo|Drug: rhEPO","Change From Baseline in Hemoglobin (Hgb) at Week 4|Hgb Concentration at Week 24|Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24|Number of Participants With Hgb in the Target Range at Week 24|Number of Participants Reaching Pre-defined Hgb Stopping Criteria|Maximum Observed Change From Baseline in Erythropoietin (EPO)|Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)|Population Plasma PK Parameters of GSK1278863 and Metabolites|Percent Change From Baseline in Hepcidin at Week 24|Change From Baseline in Ferritin at Week 24|Change From Baseline in Transferrin at Week 24|Percent Change From Baseline in Transferrin Saturation at Week 24|Change From Baseline in Total Iron at Week 24|Change From Baseline in Total Iron Binding Capacity at Week 24|Change From Baseline in Reticulocyte Hemoglobin at Week 24|Change From Baseline in Hematocrit at Week 24|Change From Baseline in Red Blood Cells at Week 24|Change From Baseline in Reticulocyte Count at Week 24","GlaxoSmithKline","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","113633","November 1, 2013","February 1, 2015","February 6, 2015","November 6, 2013","February 14, 2017","June 8, 2018","GSK Investigational Site, Azusa, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Dimas, California, United States|GSK Investigational Site, West Hills, California, United States|GSK Investigational Site, Lauderdale Lakes, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Macon, Georgia, United States|GSK Investigational Site, Evergreen Park, Illinois, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Farmington, Missouri, United States|GSK Investigational Site, Amherst, New York, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Temple, Texas, United States|GSK Investigational Site, Liverpool, New South Wales, Australia|GSK Investigational Site, Westmead, New South Wales, Australia|GSK Investigational Site, Woolloongabba, Queensland, Australia|GSK Investigational Site, Adelaide, South Australia, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Liberec, Czechia|GSK Investigational Site, Louny, Czechia|GSK Investigational Site, Most, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Sokolov, Czechia|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Roskilde, Denmark|GSK Investigational Site, Amiens cedex 1, France|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Paris Cedex 15, France|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Demmin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Esztergom, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Niigata, Japan|GSK Investigational Site, Wakayama, Japan|GSK Investigational Site, Yamagata, Japan|GSK Investigational Site, Anyang-Si Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Daejeon, Korea, Republic of|GSK Investigational Site, Gwangju, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Stavanger, Norway|GSK Investigational Site, Trondheim, Norway|GSK Investigational Site, Tønsberg, Norway|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Tarnow, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Zabrze, Poland|GSK Investigational Site, Kaluga, Russian Federation|GSK Investigational Site, Krasnodar, Russian Federation|GSK Investigational Site, Krasnogorsk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Mytischi, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Alcala de Henares, Spain|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Almería, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Córdoba, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, San Sebastian de los Reyes, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Karlstad, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Örebro, Sweden|GSK Investigational Site, Chelmsford, United Kingdom|GSK Investigational Site, Dorchester, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Hull, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01977482"
235,"NCT01587924","4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease",,"Completed","Has Results","Anaemia","Drug: GSK1278863|Drug: rhEPO","Modeled Hemoglobin (Hgb) Change From Baseline (Pre-dose on Day 1) at 4 Weeks of Treatment|Hgb Variability Over 4 Weeks|Evaluation of Change From Baseline in Hepcidin Over Period|Evaluation of Change From Baseline (Pre-dose on Day 1) in High Sensitivity C-Reactive Protein (hsCRP) Over 4 Weeks|Change From Baseline for Erythropoeitin (EPO) Over Period|Evaluation of Change From Baseline (Pre-dose on Day 1) for Peak Vascular Endothelial Growth Factor (VEGF) Over 4 Weeks|Evaluation of Change From Baseline (Pre-dose on Day 1) for Hematocrit Over 4 Weeks|Residual Standard Deviation in Hgb (From the Linear Regression)|Number of Days Spent Within Hgb Range ( ±0.5 g/dL and ±1 g/dL ) From Baseline Hgb|Evaluation of Change From Baseline (Pre-dose on Day 1) in Ferritin Over 4 Weeks|Evaluation of Change From Baseline (Pre-dose on Day 1) for Transferrin Over 4 Weeks|Change From Baseline (Pre-dose on Day 1) for Transferrin Saturation Over 4 Weeks|Change From Baseline (Pre-dose on Day 1) for Total Iron Over 4 Weeks|Change From Baseline (Pre-dose on Day 1) in Total Iron Binding Capacity Over 4 Weeks|Change From Baseline (Pre-dose on Day 1) for Red Blood Cells (RBCs) Over 4 Weeks|Change From Baseline (Pre-dose on Day 1) for Reticulocytes Over 4 Weeks|Number of Participants Reaching Hgb Stopping Criteria|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants Discontinuing the Study Treatment Due to AEs|Mean Plasma Concentration of GSK1278863 and GSK1278863 Metabolites Over 4 Weeks|Number of Participants With Abnormal Hematology and Clinical Chemistry Parameters of Potential Clinical Concern (PCI)|Number of Participants With Abnormal Vital Signs of PCI|Number of Participants With Electrocardiogram (ECG) Findings Over Period","GlaxoSmithKline|PPD","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","116582","May 23, 2012","May 27, 2013","May 27, 2013","April 30, 2012","September 12, 2017","November 14, 2017","GSK Investigational Site, Paragould, Arizona, United States|GSK Investigational Site, Tempe, Arizona, United States|GSK Investigational Site, Pine Bluff, Arkansas, United States|GSK Investigational Site, Azusa, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Lynwood, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, West Hills, California, United States|GSK Investigational Site, Whittier, California, United States|GSK Investigational Site, Arvada, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Westminster, Colorado, United States|GSK Investigational Site, Waterbury, Connecticut, United States|GSK Investigational Site, Coral Springs, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Spring Hill, Florida, United States|GSK Investigational Site, Macon, Georgia, United States|GSK Investigational Site, Gurnee, Illinois, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Southgate, Michigan, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Greenville, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Killeen, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Odense, Denmark|GSK Investigational Site, Roskilde, Denmark|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Aschaffenburg, Bayern, Germany|GSK Investigational Site, Oberschleissheim, Bayern, Germany|GSK Investigational Site, Demmin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Lehrte, Niedersachsen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Karlstad, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01587924"
236,"NCT01587898","4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis",,"Completed","Has Results","Anaemia","Drug: GSK1278863|Other: Placebo","Modeled Hgb Change From Baseline Over 4 Weeks of Treatment|Model-Adjusted Maximum Hgb Changes Over 4 Weeks|Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb|Percentage of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb|Number of Participants Who Reached Hgb Stopping Criteria|Change From Baseline in Hepcidin at Week 2 and Week 4|Change From Baseline in Ferritin at Week 2 and Week 4|Change From Baseline in Transferrin at Week 2 and Week 4|Change From Baseline in Transferrin Saturation at Week 2 and Week 4|Change From Baseline in Total Iron Binding Capacity at Week 2 and Week 4|Change From Baseline in Total Iron at Week 2 and Week 4|Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 2 and Week 4|Change From Baseline in Hematocrit and Reticulocytes Over 4 Weeks|Change From Baseline in Erythropoietin at Week 2 and Week 4|Change From Baseline in Red Blood Cells Count Over 4 Weeks|Change From Baseline in Vascular Endothelial Growth Factor (VEGF) at Week 2 and Week 4|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants Discontinuing the Study Treatment Due to AEs|Absolute Values of Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) at Baseline (Day 1), Week 2, 4, and 6|Absolute Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Baseline (Day 1), Week 2, 4, and 6|Absolute Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Baseline (Day 1), Week 2, 4, and 6|Absolute Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Baseline (Day 1), Week 2, 4, and 6|Absolute Values of Urine Total Protein/Creatinine Ratio at Baseline (Day 1), Week 2, 4, and 6|Change From Baseline Values of ALT, ALP, AST, CK at Week 2, 4, and 6|Change From Baseline Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Week 2, 4, and 6|Change From Baseline Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Week 2, 4, and 6|Change From Baseline Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Week 2, 4, and 6|Change From Baseline Values of Urine Total Protein/Creatinine Ratio at Week 2, 4, and 6|Absolute Values of Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, WBC Count (Absolute) at Baseline, Week 1, 2, 3, 4, and 6|Absolute Values of Mean Corpuscle Volume at Baseline, Week 1, 2, 3, 4 and 6|Absolute Values of Mean Corpuscle Hgb Concentration at Baseline (Day 1), Week 1, 2, 3, 4, and 6|Absolute Values of Reticulocyte Count at Baseline (Day 1), Week 1, 2, 3, 4, and 6|Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, WBC Count (Absolute) at Week 1, 2, 3, 4, and 6|Change From Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6|Change From Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6|Absolute Values of Systolic Blood Pressure and Diastolic Blood Pressure Baseline, Week 1, Week 2, Week 3, Week 4 and Week 6|Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at Week 1, 2, 3, 4, and 6|Absolute Values of Heart Rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6|Change From Baseline in Heart Rate at Week 1, 2, 3, 4, and 6|Absolute Electrocardiogram (ECG) Parameter Values at Baseline (Screening), Week 2, 4, and 6|Change From Baseline in ECG Parameters at Week 2, 4 and 6|Mean Maximum Plasma Concentration (Cmax) of GSK1278863 and GSK1278863 Metabolites|Mean Steady State Area Under the Curve (AUC) of GSK1278863 and GSK1278863 Metabolites","GlaxoSmithKline|PPD","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","116581","May 17, 2012","May 7, 2013","May 7, 2013","April 30, 2012","November 9, 2017","November 9, 2017","GSK Investigational Site, Azusa, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Chino, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, North Hollywood, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, San Dimas, California, United States|GSK Investigational Site, West Hills, California, United States|GSK Investigational Site, Yuba City, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Daytona Beach, Florida, United States|GSK Investigational Site, Edgewater, Florida, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Port Charlotte, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Evanston, Illinois, United States|GSK Investigational Site, Gurnee, Illinois, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Bethlehem, Pennsylvania, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Uniontown, Pennsylvania, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Corsicana, Texas, United States|GSK Investigational Site, Greenville, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Temple, Texas, United States|GSK Investigational Site, Silverdale, Washington, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Aschaffenburg, Bayern, Germany|GSK Investigational Site, Demmin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Lehrte, Niedersachsen, Germany|GSK Investigational Site, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT01587898"
237,"NCT02228655","An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD",,"Terminated","No Results Available","Anemia in Chronic Kidney Disease","Drug: FMX-8","Change in hemoglobin concentration","FerruMax Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FX-C-888","October 2014","April 2015","July 2015","August 29, 2014",,"February 2, 2016","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02228655"
238,"NCT00243399","Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia",,"Completed","No Results Available","Fanconi Anemia","Drug: Oxandrolone","Toxicity associated with oxandrolone therapy in patients with Fanconi Anemia|Hematologic response rate in Fanconi Anemia patients receiving oxandrolone therapy","Children's Hospital Medical Center, Cincinnati|FDA Office of Orphan Products Development","All","Child, Adult, Older Adult","Phase 1","10","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2539|FD-R-002539-01","July 2004","December 2009","January 2010","October 24, 2005",,"July 15, 2011","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00243399"
239,"NCT00965666","Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia",,"Completed","No Results Available","Fanconi Anemia","Drug: Etanercept","To assess toxicity of Etanercept (Enbrel) in children with Fanconi Anemia (FA) and early marrow failure.|To assess efficacy of Etanercept (Enbrel) in improving hematopoiesis (i.e. peripheral counts) in patients with FA.|Correlation of biological studies to measure the impact of Etanercept (Enbrel) on Tumor Necrosis Factor - alpha (TNF-alpha) production.","Children's Hospital Medical Center, Cincinnati|Amgen","All","4 Years and older   (Child, Adult, Older Adult)","Early Phase 1","3","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","05-07-24","October 2005","October 2010","October 2010","August 25, 2009",,"September 14, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00965666"
240,"NCT05035641","A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients",,"Completed","No Results Available","Renal Anemia","Drug: AND017|Drug: Placebo","Safety Evaluations|Rate of rise in hemoglobin for each of 3 dose levels as compared with placebo from baseline to 5 weeks after TIW oral dosing|Hb response to treatment during Period 1|Percentage of responder patients|Percentage of visits at which patients maintain hemoglobin between 10.0-11.0 g/dL after achieving hemoglobin ≥10.0 g/dL|Change from baseline in Hb|Change in hemoglobin levels from baseline to the mean of weeks 10-13|Percentage of patients who maintain hemoglobin between 10.0-11.0g/dL at each visit|Mean Hb levels at weeks 6-14 including the average of weeks 10-13|Cumulative incidence of lack of response over the entire treatment period|To assess changes in the levels of PD indicator - EPO|To assess changes in the levels of PD indicator - hepcidin|To assess iron utilization parameter during treatment - transferrin level|To assess iron utilization parameter during treatment - total iron-binding capacity (TIBC)|To assess iron utilization parameter during treatment - transferrin saturation (TSAT)|To assess iron utilization parameters during treatment - ferritin|To assess iron utilization parameters during treatment - serum iron","Kind Pharmaceuticals LLC","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 2","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AND017-MN-201","October 18, 2021","July 5, 2023","July 24, 2023","September 5, 2021",,"October 4, 2023","Amicis Research Center, Northridge, California, United States|Clinical Site Partners, Winter Park, Florida, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|Elite Research Center, Flint, Michigan, United States|Metrolina Nephrology Associates, Charlotte, North Carolina, United States|Southeast Renal Research Institute, Chattanooga, Tennessee, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, United States|Peking University People's Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05035641"
241,"NCT04656171","Microcephaly, Fanconi Anemia and Praxial Disorders","MicroFancII","Withdrawn","No Results Available","Fanconi Anemia","Radiation: MRI of the hand and forearm,","measurement of fine motor praxia","Assistance Publique - Hôpitaux de Paris","All","5 Years to 21 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","APHP200090|N° IDRCB: 2019-A03171-56","January 30, 2023","January 30, 2023","January 30, 2023","December 7, 2020",,"February 3, 2023","Robert Drbré Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04656171"
242,"NCT00687258","Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients","Vi-E","Completed","No Results Available","Anemia","Device: VitabranE ViE","The primary outcome measure will be the ESA resistance index, a combined variable calculated by dividing the weekly ESA dose by haemoglobin level and end-dialysis body weight.|Inflammatory status (CRP and IL-6) and oxidative stress markers (Vitamin E levels, TAC, Protein carbonyls and AOPP, AGEs).","A. Manzoni Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Vit E-Rif01-1","July 2006","March 2007","July 2007","May 30, 2008",,"September 25, 2020","Alessandro Manzoni Hospital, Nephrology and Dialysis Department, Lecco, Italy",,"https://ClinicalTrials.gov/show/NCT00687258"
243,"NCT02829320","Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents",,"Completed","Has Results","Anaemia","Drug: GSK1278863|Drug: Iron","Change From Baseline in Hgb at Week 4|Number of Participants by Hgb Change From Baseline Category at Week 4|Hgb Values at the Indicated Time Points|Change From Baseline in Hgb at the Indicated Time Points|Number of Participants Who Had Hgb Level Within the Target Range (10.0-12.0 g/dL)|Time to Reach the Lower Target Hgb Level (10.0 g/dL)|Number of Participants Who Had Hgb Level of Less Than 7.5 g/dL|Number of Participants Who Had Hgb Increase of More Than 2 g/dL Over Any 4 Weeks|Number of Participants Who Had Hgb Level of More Than 13.0 g/dL|Number of Episodes of Achieving Hgb Level of More Than 13.0 g/dL|Area Under the Concentration-time Curve (AUC) From Time Zero to 4 Hours (AUC [0-4]) of GSK1278863|Maximum Observed Concentration (Cmax) of GSK1278863|Monthly Average Dose of Intravenous (IV) Iron During the Treatment Period|Number of Participants Who Used Iron During the Treatment Period|Change From Baseline in Ferritin|Percent Change From Baseline in TSAT|Percent Change From Baseline in Hepcidin|Change From Baseline in Serum Iron|Change From Baseline in Total Iron Binding Capacity (TIBC)|Dose Level of GSK1278863 at Indicated Time Points|Number of Participants With Frequency of Dose Adjustments|Duration of Treatment Interruption Due to Hgb >13 g/dL","GlaxoSmithKline","All","20 Years and older   (Adult, Older Adult)","Phase 3","28","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","204716","August 8, 2016","May 16, 2017","October 17, 2017","July 12, 2016","July 13, 2018","December 3, 2019","GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kagoshima, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Mie, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Oita, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Shiga, Japan|GSK Investigational Site, Yamagata, Japan","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/20/NCT02829320/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/20/NCT02829320/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02829320"
244,"NCT02969655","A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)",,"Completed","Has Results","Anaemia","Drug: Daprodustat small|Drug: Daprodustat small placebo|Drug: Daprodustat large|Drug: Daprodustat large placebo|Drug: Darbepoetin alfa|Drug: Darbepoetin alfa placebo","Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)|Percentage of Participants With Mean Hgb in the Target Range (10.0-12.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)|Change From Baseline in Hgb (Hgb Increase Rate) at Week 4|Percentage of Participants by Hgb Change From Baseline Category at Week 4|Distribution of Daprodustat Dose Level by Visit|Distribution of Darbepoetin Alfa Dose Level by Visit|Duration of Treatment Interruption Due to Hgb >13 g/dL|Number of Dose Adjustments for Daprodustat|Hgb Values at Each Assessment Visit|Change From Baseline in Hgb Values at Each Assessment Visit|Percentage of Participants Who Had Hgb Level Within the Target Range (10.0-12.0 g/dL) at Each Assessment Visit|Percentage of Time in Hgb Target Range (10.0 to 12.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)|Number of Participants Who Had an Hgb Level of Less Than 7.5 g/dL|Number of Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks|Number of Participants Who Had an Hgb Level of More Than 13.0 g/dL|Number of Episodes With Hgb Level of More Than 13.0 g/dL|Area Under Plasma Concentration Curve From Time Zero to 4 Hours (AUC [0 - 4]) of Plasma Daprodustat|Maximum Concentration (Cmax) of Plasma Daprodustat","GlaxoSmithKline","All","20 Years and older   (Adult, Older Adult)","Phase 3","271","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201754","November 21, 2016","July 2, 2018","July 2, 2018","November 21, 2016","November 29, 2019","November 27, 2020","GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Fukui, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukushima, Japan|GSK Investigational Site, Fukushima, Japan|GSK Investigational Site, Gunma, Japan|GSK Investigational Site, Gunma, Japan|GSK Investigational Site, Gunma, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Okayama, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Shizuoka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Toyama, Japan|GSK Investigational Site, Toyama, Japan|GSK Investigational Site, Yamagata, Japan|GSK Investigational Site, Yamaguchi, Japan","""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/55/NCT02969655/SAP_000.pdf|""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/55/NCT02969655/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02969655"
245,"NCT04959578","Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease",,"Completed","No Results Available","Anemia of Chronic Kidney Disease","Drug: Recombinant human erythropoietin|Drug: Darbepoetin Alfa","Mean change in hemoglobin (Hb) between baseline and the evaluation period|Incidence of treatment-related adverse events in both groups during study period","Rufaida Mazahir|Sir Ganga Ram Hospital","All","1 Year to 18 Years   (Child, Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC/01/18/1317","February 1, 2018","January 31, 2019","January 31, 2019","July 13, 2021",,"July 13, 2021","Sir Ganga Ram Hospital, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04959578"
246,"NCT00595127","Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine",,"Completed","Has Results","Fanconi Anemia","Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total body irradiation (TBI)","Incidence & Quality of Engraftment & Hematopoietic Reconstitution","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Miltenyi Biotec, Inc.","All","Child, Adult, Older Adult","Not Applicable","21","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-062","June 2001","May 2013","May 2013","January 16, 2008","August 10, 2016","August 10, 2016","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00595127"
247,"NCT00317226","Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease",,"Completed","Has Results","Anemia","Drug: Ferric Carboxymaltose (FCM)","Incidence of Treatment-emergent Adverse Events","American Regent, Inc.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","145","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1VIT05005","June 2005","March 2007","September 2007","April 24, 2006","June 10, 2015","February 20, 2018","Luitpold Pharmaceuticals Inc., Norristown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00317226"
248,"NCT05598515","Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia",,"Recruiting","No Results Available","Fanconi Anemia","Behavioral: Time-Restricted Feeding","Number of participants with neuroinflammation","Children's Hospital Medical Center, Cincinnati","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2022-0751","November 11, 2022","October 2025","October 2025","October 28, 2022",,"January 16, 2024","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05598515"
249,"NCT01146574","A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.",,"Completed","Has Results","Anemia","Biological: Sotatercept|Biological: Placebo","Observed Maximum Concentration (Cmax)|Time to Maximum Concentration (Tmax)|Area Under Curve (AUC)-28 Days|AUCinf: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity|Apparent Total Clearance (CL/F)|Apparent Volume of Distribution Based on Terminal Phase (Vz/F)|Terminal Half-Life (t1/2,z)|The Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)|Number of Participants With Hemoglobin > 12g/dL|Proportion of Participants With Rise in Hemoglobin > 2 g/dL During 4 Week Period|Blood Pressure Changes From Baseline|Changes in Follicle Stimulating Hormone (FSH)|Number of Participants With Hemoglobin > 10g/dL|Number of Participants With Change From Baseline Hemoglobin ≥ 1g/dL|Number of Participants With Hemoglobin > 10g/dL and Change From Baseline Hemoglobin ≥ 1g/dL|Length of Time to Rescue Therapy|Change From Baseline in Hemoglobin Values","Celgene|Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ACE-011-REN-001","June 30, 2010","March 7, 2016","March 7, 2016","June 17, 2010","March 1, 2024","March 1, 2024","North American Research Institute, Azusa, California, United States|West Glendale Dialysis, Glendale, California, United States|California Institute of Renal Research, La Mesa, California, United States|Academic Medical Center, Los Angeles, California, United States|Academic Medical Research Institute, Los Angeles, California, United States|Nephrology Specialist Medical Group, Orange, California, United States|Pines Clinical Research Inc., Pembroke Pines, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|Fresenius Medical Care North America MI, Kalamazoo, Michigan, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States|Nephrology and Hypertension Associates, LTD, Tupelo, Mississippi, United States|St. Louis University Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Kidney Specialists of Southen Nevada, Las Vegas, Nevada, United States|Brookview Hill Research Associates, LLC, Winston-Salem, North Carolina, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|Northeast Clinical Research Center, Bethlehem, Pennsylvania, United States|Nephrology Associates, PC, Nashville, Tennessee, United States|Corva Kidney Center Webster, Houston, Texas, United States|Beechnut Dialysis Center, Houston, Texas, United States|Miracle Medical Clinic, Houston, Texas, United States|Gessner Dialysis Center, Houston, Texas, United States|Tyler Nephrology Associates, PC, Tyler, Texas, United States|University of Virginia at University Ave., Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01146574"
250,"NCT02468414","TARGTEPO Treatment for Anemia in PD US Trial",,"Terminated","Has Results","Anemia of End Stage Renal Disease","Biological: MDGN201 TARGTEPO","Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum EPO Levels Above Baseline.","Aevi Genomic Medicine, LLC, a Cerecor company|Medgenics Medical Israel Ltd.|Avalo Therapeutics, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MG-EP-RF-04","June 2015","May 2016","September 2016","June 10, 2015","July 13, 2017","March 28, 2022","Clinical Advancement Center, PLLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02468414"
251,"NCT01331018","Gene Therapy for Fanconi Anemia",,"Active, not recruiting","No Results Available","Fanconi Anemia","Procedure: Bone Marrow Aspiration|Biological: Filgrastim|Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Drug: Methylprednisolone|Drug: Plerixafor|Drug: Prednisone","Toxicity of gene transfer|Hematological and non-hematological organ toxicity|Development of insertional mutagenesis or hematologic malignancy|Development of replication competent lentivirus|Efficacy of G-CSF and plerixafor mobilization in Fanconi anemia (FA) patients|Efficacy of lineage depletion of bone marrow or mobilized cell product|Transduction efficiency|Detectable levels of transduced cells in blood and marrow|Improved blood counts|Demonstrable functional expression by growth of recipient cells in mitomycin C","Fred Hutchinson Cancer Center|National Heart, Lung, and Blood Institute (NHLBI)|Rocket Pharma Limited","All","4 Years and older   (Child, Adult, Older Adult)","Phase 1","3","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2097.00|NCI-2011-00202|RG9212015","February 22, 2012","July 17, 2032","July 17, 2032","April 7, 2011",,"July 11, 2023","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01331018"
252,"NCT04059913","Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease",,"Completed","No Results Available","CKD Anemia in Dialysis Participants","Drug: Roxadustat","Part 1 (ESA Naïve): Percentage of Participants who Achieved Hb ≥110 g/L in the First 20 Weeks|Part 1 (ESA Treated): Percentage of Participants who Achieved Mean Hb ≥100 g/L Averaged Over Weeks 17 to 21 Visits|Part 2: Mean Hb Value Averaged Over Weeks 33 to 37 Visits|Part 1: Mean Change in Hb Level From Baseline to Average Over Weeks 17 to 21 Visits|Part 1 (ESA-Naïve): Percentage of Participants With Mean Hb (Averaged Weeks 17 to 21 Visits) ≥100 g/L|Part 2: Percentage of Participants With Mean Hb (Averaged Weeks 33 to 37 Visits) ≥100 g/L","FibroGen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","318","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FGCL-4592-818","June 11, 2019","November 19, 2021","December 17, 2021","August 16, 2019",,"May 6, 2022","Investigational Site, Hefei, Anhui, China|Investigational Site, Lanzhou, Gansu, China|Investigational Site, Guangzhou, Guangdong, China|Investigational Site, Shenzhen, Guangdong, China|Investigational Site, Nanning, Guangxi Province, China|Investigational Site, Zhengzhou, Henan, China|Investigational Site, Wuhan, Hubei, China|Investigational Site, Changsha, Hunan, China|Investigational Site, Baotou, Inner Mongolia Autonomous Region, China|Investigational Site, Nanjing, Jiangsu, China|Investigational Site, Nanchang, Jiangxi, China|Investigational Site, Chang chun, Jilin, China|Investigational Site, Shenyang, Liaoning, China|Investigational Site, Shenyang, Liaoning, China|Investigational Site, Taiyuan, Shanxi, China|Investigational Site, Xi'an, Shanxi, China|Investigational Site, Xi'an, Shanxi, China|Investigational Site, Chengdu, Sichuan, China|Investigational Site, Chengdu, Sichuan, China|Investigational Site, Hangzhou, Zhejiang, China|Investigational Site, Beijing, China|Investigational Site, Beijing, China|Investigational Site, Beijing, China|Investigational Site, Shanghai, China|Investigational Site, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT04059913"
253,"NCT00236977","Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia",,"Completed","Has Results","Anemia","Drug: Venofer|Drug: Ferrous Sulfate","Patients With an Increase in Hemoglobin >= 1gm/dL.|Number of Subjects With a Clinical Response|Highest Change From Baseline in Hemoglobin (g/dL) up to Day 56|Highest Change From Baseline in Ferritin (ng/mL) up to Day 56|Mean Change in Ferritin (ng/mL) From Baseline to Day 56|Mean Change From Baseline in Serum Transferrin Saturation (TSAT) (%) at Day 56|Mean Change From Baseline in Hemoglobin (g/dL) at Day 56","American Regent, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1VEN03027","August 2003","October 2004","October 2004","October 12, 2005","March 9, 2010","October 6, 2020","Luitpold Pharmaceuticals, Valley Forge, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00236977"
254,"NCT03643601","A Non-interventional, Epidemiological, Registry-based Evaluation of Anaemia in Swedish Patients With Chronic Kidney Disease","ASK","Completed","No Results Available","Chronic Kidney Disease Associated Anemia","Other: Non-Interventional","Iron use in erythropoiesis stimulating agent (ESA) treated patients in the prevalent non-dialysis dependent (ND) population|Iron use in ESA treated patients in the prevalent dialysis dependent (DD) population|Proportion of non-dialysis dependent (ND) patients on low, normal, high dose erythropoiesis stimulating agent (ESA)|Proportion of dialysis dependent (DD) patients on low, normal, high dose ESA|ESA use in ND patients at each CKD stage|ESA use in DD patients|Proportion of ND patients treated with ESAs at each chronic kidney disease (CKD) stage with or without oral/IV iron|Proportion of DD patients treated with ESAs at each chronic kidney disease (CKD) stage with or without oral/IV iron|Proportion of ESA treated ND patients within Haemoglobin (Hb) levels within pre-specified target range|Proportion of ESA treated DD patients within Haemoglobin (Hb) levels within pre-specified target range|Proportion of ND patients with anemia who are not treated with ESAs|Proportion of DD patients with anemia who are not treated with ESAs|Proportion of ESA treated ND patients with low or medium and high C-reactive protein (CRP)|Proportion of ESA treated DD patients with low or medium and high CRP|Proportion of ESA treated ND patients with hyperlipidemia (HDL/LDL) and/or taking lipid lowering preparations|Proportion of ESA treated DD patients with hyperlipidemia (HDL/LDL) and/or taking lipid lowering preparations|Proportion of ESA treated ND patients with high blood pressure and/or taking anti-hypertensive medication|Proportion of ESA treated DD patients with high blood pressure and/or taking anti-hypertensive medication|Number of ND patients with serious cardiovascular events|Number of DD patients with serious cardiovascular events|Number of ND patients with serious thromboembolic events|Number of DD patients with serious thromboembolic events|All cause mortality: ND|All cause mortality: DD|Correlation between ESA dose and Hb level in relation to CKD severity (stage 3,4, 5 and DD)|Correlation between Haemoglobin (Hb) level and CKD severity: ND|Correlation between ESA dose and C-reactive protein (CRP) level: ND|Correlation between ESA dose and CRP level: DD|Relationship between ESA dose and occurrence of Cardiovascular (CV) events in ND population|Relationship between Hb level and occurrence of CV events in ND population|Relationship between Hb level and occurrence of CV events in DD population","Astellas Pharma a/s|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)",,"14415","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","1517-MA-3139-SN","September 24, 2018","December 4, 2018","December 4, 2018","August 23, 2018",,"December 18, 2019","SE46001, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03643601"
255,"NCT01750190","A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis",,"Completed","Has Results","CKD Anemia","Drug: Roxadustat|Drug: Placebo","United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy|Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy|Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy|Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN)|Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy|Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28|Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)|Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment|Number (%) of Participants Who Received Rescue Therapy in the First 24 Weeks and in the First 52 Weeks of Treatment|Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28|Number (%) of Participants Who Experienced Exacerbation of Hypertension|Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28","FibroGen|Astellas Pharma Europe B.V.|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","922","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FGCL-4592-060","November 5, 2012","September 24, 2018","September 24, 2018","December 17, 2012","October 1, 2021","October 1, 2021","Investigational Site, Huntsville, Alabama, United States|Investigational Site, Tempe, Arizona, United States|Investigational Site, Alhambra, California, United States|Investigational Site, Chula Vista, California, United States|Investigational Site, Inglewood, California, United States|Investigational Site, La Mesa, California, United States|Investigational Site, La Palma, California, United States|Investigational Site, Lynwood, California, United States|Investigational Site, Northridge, California, United States|Investigational Site, Paramount, California, United States|Investigational Site, Riverside, California, United States|Investigational Site, Roseville, California, United States|Investigational Site, San Dimas, California, United States|Investigational Site, Whittier, California, United States|Investigational Site, Coral Gables, Florida, United States|Investigational Site, Cutler Bay, Florida, United States|Investigational Site, Hialeah, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Ocala, Florida, United States|Investigational Site, Pembroke Pines, Florida, United States|Investigational Site, South Miami, Florida, United States|Investigational Site, Winter Park, Florida, United States|Investigational Site, Augusta, Georgia, United States|Investigational Site, Caldwell, Idaho, United States|Investigational Site, Shreveport, Louisiana, United States|Investigational Site, Baltimore, Maryland, United States|Investigational Site, Boston, Massachusetts, United States|Investigational Site, Detroit, Michigan, United States|Investigational Site, Flint, Michigan, United States|Investigational Site, Flint, Michigan, United States|Investigational Site, Pontiac, Michigan, United States|Investigational Site, Roseville, Michigan, United States|Investigational Site, Saint Louis, Missouri, United States|Investigational Site, New Brunswick, New Jersey, United States|Investigational Site, Albuquerque, New Mexico, United States|Investigational Site, Bronx, New York, United States|Investigational Site, Mineola, New York, United States|Investigational Site, Asheville, North Carolina, United States|Investigational Site, Raleigh, North Carolina, United States|Investigational Site, Rocky Mount, North Carolina, United States|Investigational Site, Winston-Salem, North Carolina, United States|Investigational Site, Beaver, Pennsylvania, United States|Investigational Site, Orangeburg, South Carolina, United States|Investigational Site, Sumter, South Carolina, United States|Investigational Site, Nashville, Tennessee, United States|Investigational Site, Arlington, Texas, United States|Investigational Site, Corsicana, Texas, United States|Investigational Site, Dallas, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, San Antonio, Texas, United States|Investigational Site, Fairfax, Virginia, United States|Investigational Site, Morgantown, West Virginia, United States|Investigational Site, Ciudad Evita, Buenos Aires, Argentina|Investigational Site, Moron, Buenos Aires, Argentina|Investigational Site, González Catán, Provincia De Buenos Aires, Argentina|Investigational Site, Junin, Provincia De Buenos Aires, Argentina|Investigational Site, Pergamino, Provincia De Buenos Aires, Argentina|Investigational Product, Villa Domínico, Provincia De Buenos Aires, Argentina|Investigational Site, Ciudad de Cordoba, Provincia De Cordoba, Argentina|Investigational Site, Buenos Aires, Argentina|Investigational Site, Buenos Aires, Argentina|Investigational Site, Buenos Aires, Argentina|Investigational Site, Cordoba, Argentina|Investigational Site, Cordoba, Argentina|Investigational site, Cordoba, Argentina|Investigational Site, Corrientes, Argentina|Investigational Site, Mendoza, Argentina|Investigational Site, Salta, Argentina|Investigational Site, Santa Fe, Argentina|Investigational Site, Liverpool, New South Wales, Australia|Investigational Site, Gosford, Australia|Investigational Site, Hobart, Australia|Investigational Site, Launceston, Australia|Investigational Site, Melbourne, Australia|Investigational Site, New Lambton Heights, Australia|Investigational Site, Randwick, Australia|Investigational Site, Temuco, Region De La Araucania, Chile|Investigational Site, Santiago, Region Metropolitana, Chile|Investigational Site, Barranquilla, Atlantico, Colombia|Investigational Site, Bogota, Cundinamarca, Colombia|Investigational Site, Hong Kong, Pokfulam, Hong Kong|Investigational Site, Chai Wan, Hong Kong|Investigational Site, Shatin, Hong Kong|Investigational Site, Tai Po, Hong Kong|Investigational Site, Anyang-Si, Gyeonggi-Do, Korea, Republic of|Investigational Site, Goyang-Si, Gyeonggi-Do, Korea, Republic of|Investigational Site, Guri-Si, Gyeonggi-Do, Korea, Republic of|Investigational Site, Seongnam-Si, Gyeonggi-Do, Korea, Republic of|Investigational Site, Busan, Korea, Republic of|Investigational Site, Seoul, Korea, Republic of|Investigational Site, Seoul, Korea, Republic of|Investigational Site, Seoul, Korea, Republic of|Investigational Site, Seoul, Korea, Republic of|Investigational Site, Seoul, Korea, Republic of|Investigational Site, Seoul, Korea, Republic of|Investigational Site, Seoul, Korea, Republic of|Investigational Site, Alor Setar, Malaysia|Investigational Site, Kajang, Malaysia|Investigational Site, Kuala Lumpur, Malaysia|Investigational Site, Kuala Lumpur, Malaysia|Investigational Site, Kuching, Malaysia|Investigational Site, Pulau Pinang, Malaysia|Investigational Site, Sungai Petani, Malaysia|Investigational Site, Taiping, Malaysia|Investigational Site, Mexico City, Distrito Federal, Mexico|Investigational Site, Guadalajara, Jalisco, Mexico|Investigational Site, Monterrey, Nuevo Leon, Mexico|Investigational Site, Merida, Yucatan, Mexico|Investigational Site, Aguascalientes, Mexico|Investigational Site, San Luis Potosi, Mexico|Investigational Site, Auckland, New Zealand|Investigational Site, Hamilton, New Zealand|Investigational Site, Tauranga, New Zealand|Investigational Site, Bellavista, Callao, Peru|Investigational Site, San Martin de Porres, Lima, Peru|Investigational site, Lima, Peru|Investigational Site, Lima, Peru|Investigational Site, Dasmarinas, Cavite, Philippines|Investigational Site, Davao City, Davao, Philippines|Investigational site, Pasig, Philippines|Investigational Site, Quezon City, Philippines|Investigational Site, Quezon City, Philippines|Investigational Site, Ponce, Puerto Rico|Investigational Site, San Juan, Puerto Rico|Investigational Site, Singapore, Singapore|Investigational Site, Singapore, Singapore|Investigational Site, Singapore, Singapore|Investigational Site, Changhua, Taiwan|Investigational Site, Hualien City, Taiwan|Investigational Site, Kaohsiung, Taiwan|Investigational Site, Kaohsiung, Taiwan|Investigational Site, Kaohsiung, Taiwan|Investigational Site, Taichung, Taiwan|Investigational Site, Taichung, Taiwan|Investigational Site, Tainan City, Taiwan|Investigational Site, Tainan, Taiwan|Investigational Site, Taipei, Taiwan|Investigational Site, Taipei, Taiwan|Investigational Site, Taipei, Taiwan|Investigational Site, Bangkok, Thailand|Investigational Site, Bangkok, Thailand|Investigational Site, Chiang Mai, Thailand","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/90/NCT01750190/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/90/NCT01750190/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01750190"
256,"NCT00395993","Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding",,"Completed","Has Results","Anemia","Drug: Ferric Carboxymaltose (FCM)|Drug: Ferrous Sulfate tablets","Number of Subjects Achieving 'Clinical Success'. Clinical Success is Defined as an Increase in Hemoglobin of ≥ 2.0 g/dL","American Regent, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","456","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1VIT04002/003","May 2005","April 2006","June 2006","November 6, 2006","November 18, 2013","February 20, 2018","Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00395993"
257,"NCT02378662","TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)",,"Terminated","Has Results","Anemia of End Stage Renal Disease","Biological: MDGN201 TARGTEPO","Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum Erythropoietin (EPO) Levels Above Baseline","Aevi Genomic Medicine, LLC, a Cerecor company|Medgenics Medical Israel Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MG-EP-RF-03","April 2015","January 2016","June 2016","March 4, 2015","October 19, 2018","October 19, 2018","Barzili Medical Center, Ashkelon, Israel|Assaf Harofeh Medical Center, Zrifin, Israel",,"https://ClinicalTrials.gov/show/NCT02378662"
258,"NCT05082571","Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease","CONVERSION","Suspended","No Results Available","Anemia of Chronic Kidney Disease","Drug: vadadustat","Mean Change in Hemoglobin (Hb) Values Between Baseline and the Primary Evaluation Period (Average Hb From Weeks 21 to 28)|Time to Achieve Hb Levels of ≥10.0 grams/deciliters (g/dL)|Number of Participants With Mean Hb Values Within the Target Range During the Primary Evaluation Period|Number of Participants With Mean Hb Values Within the Target Range During the Extension Period|Number of Participants With Treatment-emergent Adverse Events and who Discontinued From the Study due to Adverse Events|Maximum Observed Plasma Concentration (Cmax) of Vadadustat and its Metabolites|Time to Reach Cmax (Tmax) of Vadadustat and its Metabolites|Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration (AUC 0-t) of Vadadustat and its Metabolites|Terminal Elimination Half-Life (t1/2) of Vadadustat and its Metabolites|Change From Baseline in Serum Erythropoietin (EPO)|Change From Baseline in Reticulocyte Count|Change From Baseline in Hb levels","Akebia Therapeutics","All","4 Months to 16 Years   (Child)","Phase 3","71","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0041","January 2025","July 2026","October 2026","October 19, 2021",,"October 10, 2023","Research Site, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05082571"
259,"NCT01119612","Prenatal Iron Supplements: Safety and Efficacy in Tanzania","MAL1","Completed","No Results Available","Malaria|Anemia","Dietary Supplement: Iron|Other: Placebo","Incidence of placental malaria|Placental malaria parasite density|Infant birth weight|Maternal hemoglobin|Low birth weight|Maternal malaria infection|Maternal anemia","Harvard School of Public Health (HSPH)|Muhimbili University of Health and Allied Sciences","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HD061232","September 2010","March 2013","May 2013","May 7, 2010",,"April 24, 2015","Muhimbili University of Health And Allied Sciences, Dar es Salaam, Tanzania",,"https://ClinicalTrials.gov/show/NCT01119612"
260,"NCT01191983","A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy",,"Completed","No Results Available","Anemia","Drug: Methoxy polyethylene glycol-epoetin beta [Mircera]","Mean time taken to achieve target hemoglobin (Hb) levels range (10-12 g/dL) During Efficacy Evaluation Period (EEP)|Change in Hb Concentration Between Baseline and EEP|Percentage of Participants Maintaining Hb Concentration Within the Target Range (10-12 g/dL) During EEP|Percentage of Participants With Adverse Events|Percentage of Participants With Red Blood Cell Transfusion During Treatment Period|Percentage of Participants with anti-epoetin antibodies|Short Form-36 Health Survey (SF-36) score","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","102","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML25276","August 13, 2010","April 23, 2018","April 23, 2018","August 31, 2010",,"July 18, 2018","Osmania General Hospital; Department of Nephrology, Hyderabad, Andhra Pradesh, India|Pushpawati Singhania Research Institute; Nephrology, New Delhi, Delhi, India|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Vijayratna Diabetes Diagnosis & Treatment Center, Ahmedabad, India|M S Ramaiah Memorial Hospital, Bangalore, India|North Delhi Diabetes Centre, Delhi, India|MAX Balaji Hospital, Delhi, India|Dr.Modi's Clinic, Hyderabad, India|IPGMER & SSKM Hospital; Rheumatology and Clinical Immunology Centre, Kolkata, India|Apex Kidney Care Pvt. Ltd., Sushrut Hospital, Mumbai, India|Diab Care Centre, Mumbai, India|Sanjeevani Hospital, Mumbai, India|Sahyadri Speciality Hospital, Pune, India|Diabetes Care & Research Centre, Pune, India",,"https://ClinicalTrials.gov/show/NCT01191983"
261,"NCT02931071","Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1",,"Completed","No Results Available","Fanconi Anemia","Drug: filgrastim|Drug: plerixafor","Toxicity of the mobilization procedure according to National Cancer Institute (CTC NCI, versión 3.0)|Percentage of patients that reach >5 CD34+ cells/mcl after treatment with filgrastim and plerixafor|Percentage of patients that reach a total CD34+ yield >4x10E6/kg, using the estimated weight of the patient in 5 years|Percentage of samples in which the recovery of CD34+ cells after the immunomagnetic selection procedure is >50%|Percentage of patients in which the CD34+ cells after the immunomagnetic selection is ³ 4x10E6/kg, using the projected weight at 5 years","Hospital Universitari Vall d'Hebron Research Institute|CIEMAT|CIBERER","All","2 Years to 64 Years   (Child, Adult)","Phase 2","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FANCOSTEM-1|2011-006197-88","September 2013","October 2018","October 2018","October 12, 2016",,"May 27, 2020","Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02931071"
262,"NCT05082584","Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents","CORRECTION","Suspended","No Results Available","Anemia of Chronic Kidney Disease","Drug: Vadadustat","Mean Change in Hemoglobin (Hb) Values Between Baseline and the Primary Evaluation Period (Average Hb From Weeks 21 to 28)|Time to Achieve First Hb Levels ≥10.0 grams/deciliters (g/dL)|Number of Participants With Mean Hb Values Within the Target Range During the Primary Evaluation Period|Number of Participants With Mean Hb Values Within the Target Range During the Extension Period|Number of Participants With Treatment-emergent Adverse Events and who Discontinued From the Study due to Adverse Events|Maximum Observed Plasma Concentration (Cmax) of Vadadustat and its Metabolites|Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration (AUC 0-t) of Vadadustat and its Metabolites|Time to Reach Cmax (Tmax) of Vadadustat and its Metabolites|Terminal Elimination Half-Life (t1/2) of Vadadustat and its Metabolites|Change From Baseline in Serum Erythropoietin (EPO)|Change From Baseline in Reticulocyte Count|Change From Baseline in Hb levels","Akebia Therapeutics","All","4 Months to 16 Years   (Child)","Phase 3","71","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0042","January 2025","July 2026","October 2026","October 19, 2021",,"October 10, 2023","Research Site, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05082584"
263,"NCT00752609","Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.",,"Completed","Has Results","Anemia","Drug: Peginesatide","Mean Change in Hemoglobin Between Baseline and the Evaluation Period|Percentage of Participants With Hemoglobin Within the Target Range of 10.0 to 12.0 g/dL During the Evaluation Period|Percentage of Participants With a Change in Hemoglobin From Baseline to the Evaluation Period Within 1 g/dL|Percentage of Participants With Red Blood Cell Transfusions|Mean Hemoglobin During 4-week Intervals|Percentage of Participants With Target Hemoglobin of 10.0 to 12.0 g/dL by 4-week Intervals.|Percentage of Participants With Dose Adjustments During the Study","Takeda|Affymax","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","102","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFX01_202|2008-003459-64|U1111-1114-1500","September 2008","December 2009","December 2009","September 15, 2008","July 27, 2012","July 27, 2012","Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|Middlebury, Connecticut, United States|Lauderdale Lakes, Florida, United States|Shreveport, Louisiana, United States|Dearborn, Michigan, United States|Columbus, Mississippi, United States|Mineola, New York, United States|Arlington, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00752609"
264,"NCT04502537","Roxadustat for Anemia in Patients With CKD",,"Unknown status","No Results Available","Anemia of Chronic Kidney Disease","Drug: Roxadustat|Drug: erythropoietin","Mean value of Hb levels over time|Achievement rate for target Hb level|Mean Hb levels at 4 weeks after using roxadustat|Mean Hb levels at 8 weeks after using roxadustat|the dose of Roxadustat used|Change from baseline in Hemoglobin (Hb) levels|the proportion of patients with different Hb levels|The proportion of patients with low response to ESA|Concentration of Serum iron|Number of Participants with adverse events","Shenzhen Second People's Hospital","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20203357012","February 1, 2021","June 30, 2023","September 30, 2023","August 6, 2020",,"January 22, 2021","Shenzhen Second People's Hospital, Shenzhen, China",,"https://ClinicalTrials.gov/show/NCT04502537"
265,"NCT04667533","Desidustat in the Treatment of Chemotherapy Induced Anemia",,"Completed","No Results Available","Anemia of Chronic Kidney Disease|Chemotherapy Effect","Drug: Desidustat","To evaluate Adverse event of Desidustat following a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.|Change of hemoglobin measurement from baseline","Zydus Lifesciences Limited","All","19 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DESI.20.001","November 11, 2020","March 27, 2022","May 10, 2022","December 14, 2020",,"May 18, 2022","HCG Manavata Cancer Centre,, Nashik, Mahar Ashtra, India",,"https://ClinicalTrials.gov/show/NCT04667533"
266,"NCT01964196","ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-",,"Completed","No Results Available","Anemia in Chronic Kidney Disease Patients Not on Dialysis","Drug: ASP1517|Drug: Placebo","Rate of rise in Hb (g/dL/week) at Week 6|Percentage of cumulative number of responder patients|Percentage of visits at which patients maintain Hb between 10.0-12.0 g/dL after achieving Hb ≥10.0 g/dL for each patients|Percentage of patients who maintain Hb between 10.0-12.0 g/dL at each visit|Change from baseline in Hb|Safety assessed as the incidence of adverse events, vital signs, 12-lead ECGs and lab-tests","Astellas Pharma Inc","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 2","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1517-CL-0303","September 17, 2013","July 6, 2015","December 1, 2015","October 17, 2013",,"April 12, 2021","Chubu, Japan|Hokkaido, Japan|Kansai, Japan|Kanto, Japan|Kyushu, Japan|Shikoku, Japan|Tohoku, Japan",,"https://ClinicalTrials.gov/show/NCT01964196"
267,"NCT03992066","Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease",,"Completed","No Results Available","Anemia Associated With Chronic Kidney Disease","Drug: Vadadustat|Drug: Darbepoetin alfa|Drug: Epoetin alfa","Mean area under concentration-time curve from time 0 to the last quantifiable concentration (AUClast)|Area under concentration-time curve from time 0 to infinity (AUCinf)|Maximum observed concentration (Cmax)|Time to maximum observed concentration (Tmax)|Terminal half-life (t½)|Apparent clearance (CL/F) or clearance (CL)|Apparent volume of distribution (Vd/F) or volume of distribution (Vd)|Tmax for vadadustat metabolite(s)|AUClast for vadadustat metabolite(s)|AUCinf for vadadustat metabolite(s)|Cmax for vadadustat metabolite(s)|Serum erythropoietin concentration for the erythropoiesis-stimulating agent treatment group|Hepcidin concentration|Serum erythropoietin concentration|Iron concentration|Ferritin concentration|Total iron-binding capcity|Transferrin saturation|Hemoglobin concentration|Reticulocyte concentration|Number of participants with any treatment-emergent adverse event|Number of participants with clinically significant electrocardiogram findings|Number of participants with clinically significant vital sign values|Number of participants with clinically significant clinical laboratory values","Akebia Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0034","May 28, 2019","May 5, 2020","July 15, 2020","June 19, 2019",,"September 16, 2020","Research Site, Escondido, California, United States|Research Site, Denver, Colorado, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Kansas City, Missouri, United States|Research Site, Midwest City, Oklahoma, United States|Research Site, Providence, Rhode Island, United States|Research Site, Chattanooga, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03992066"
268,"NCT04655027","A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)",,"Completed","No Results Available","Anemia of Chronic Kidney Disease","Drug: Roxadustat|Drug: rHuEPO","Difference from baseline to Day 15 in log-transformed area under curve (AUC) of GI iron absorption (0-3 hours)|Difference from baseline to Day 15 in log-transformed AUC of iron absorption (0-3 hours)|Difference from baseline to Day 15 in serum iron|Difference from baseline to Day 15 in ferritin|Difference from baseline to Day 15 in total iron binding capacity (TIBC)|Difference from baseline to Day 15 in transferrin saturation (TSAT)|Difference from baseline to Day 15 in transferrin|Difference from baseline to Day 15 in soluble transferrin receptor|Difference from baseline to Day 15 in hepcidin levels|Number of patients with adverse events (AEs) and serious adverse events (SAEs)","AstraZeneca|Parexel","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 4","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5741C00002","February 22, 2021","October 12, 2021","October 12, 2021","December 4, 2020",,"October 26, 2021","Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Guangzhou, China|Research Site, Jinan, China|Research Site, Shenyang, China|Research Site, Wuhan, China",,"https://ClinicalTrials.gov/show/NCT04655027"
269,"NCT04885647","A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease",,"Completed","No Results Available","Renal Anemia of Chronic Kidney Disease","Drug: YPEG-rhEPO","Changes of mean hemoglobin compared to baseline.|Proportion of patients with hemoglobin keeping within the target range (the target hemoglobin range is defined as hemoglobin keeping between 100g/L and 120g/L).|Proportion of patients with hemoglobin fluctuations within ±10g/L compared to baseline.|Mean time of hemoglobin keeping within the target range.|Mean time from baseline to the first dose adjustment.|Changes of hemoglobin compared to baseline at the time of first dose adjustment.|Proportion of patients with dose adjustment.|Proportion of patients requiring blood transfusion.","Xiamen Amoytop Biotech Co., Ltd.|First Affiliated Hospital of Zhejiang University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TB1901EPO","March 12, 2021","January 5, 2022","January 5, 2022","May 13, 2021",,"December 16, 2022","Beijing Anzhen Hospital,Capital Medical University, Beijing, Beijing, China|The Second Affiliated Hospital Of Chongqing Medical University, Chongqing, Chongqing, China|The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Sun Yat sen University, Guanzhou, Guangdong, China|Renmin Hospital of Wuhan University/Hubei General Hospital, Wuhan, Hubei, China|The Third Xiangya Hospital Of Central South University, Changsha, Hunan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|The First Affiliated Hospital Of Baotou Medical college,Inner Mongolia University Of Science and Technology, Hohhot, Inner Mongol, China|Huai'an Second People's Hospital/The Affiliated Huaian Hospital Of Xuzhou Medical University, Huai'an, Jiangsu, China|Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China|Xi'an Gaoxin Hospital, Xi'an, Shanxi, China|The First Affiliated Hospital Of Chengdu Medical college, Chengdu, Sichuan, China|Tianjin First Central Hospital, Tianjin, Tianjin, China|Tianjin People's Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Lishui Municipal Central Hospital, Lishui, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04885647"
270,"NCT00462384","A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.",,"Terminated","Has Results","Anemia","Drug: Methoxy Polyethylene Glycol-epoetin Beta","Mean Change in Hemoglobin Concentration Between Baseline and the Efficacy Evaluation Period (EEP)|Time to Achievement of Response|Percentage of Participants Maintaining Hemoglobin Concentration Within Hemoglobin Range 11.0 to 13.0 g/dL Throughout the EEP|Percentage of Participants Maintaining Average Hemoglobin Concentration Within Hemoglobin Range 11.0 to 13.0 g/dL During the EEP|Time Spent in Hemoglobin Range of 11.0 to 13.0 g/dL During the EEP","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","39","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML20659","February 2008","April 2011","April 2011","April 19, 2007","April 1, 2016","April 1, 2016","Tallinn, Estonia|Tallinn, Estonia|Tartu, Estonia|HUS, Finland|Joensuu, Finland|Jyväskylä, Finland|Kajaani, Finland|Kotka, Finland|Porvoo, Finland|Tampere, Finland|Turku, Finland|Jurmala, Latvia|Liepaja, Latvia|Riga, Latvia|Riga, Latvia|Valmiera, Latvia|Ventspils, Latvia|Honefoss, Norway|Lillehammer, Norway|Oslo, Norway|Stavanger, Norway|Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT00462384"
271,"NCT00576602","A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant",,"Terminated","No Results Available","Anemia","Drug: methoxy polyethylene glycol-epoetin beta [Mircera]|Drug: Supportive treatment","Change in Hb concentration between baseline and efficacy evaluation period (EEP).|Change in Hb concentration, percentage of patients maintaining average Hb concentration within target range, percentage of patients requiring dose adjustments, incidence of RBC transfusions.|SF36|AEs, laboratory parameters.","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MH21299","December 2007","July 2008","July 2008","December 19, 2007",,"November 4, 2016","Edegem, Belgium|Gent, Belgium|Leuven, Belgium|Amiens, France|Caen, France|Le Kremlin-Bicetre, France|Nice, France|Paris, France|Toulouse, France|Tours, France|Berlin, Germany|Frankfurt AM Main, Germany|Kaiserslautern, Germany|Kiel, Germany|Munchen, Germany|Bari, Italy|Barcelona, Spain|Santander, Spain|Sevilla, Spain|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00576602"
272,"NCT01887600","Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis","ALPS","Completed","Has Results","Anemia in Chronic Kidney Disease in Non-dialysis Patients","Drug: Roxadustat|Drug: Placebo","Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response|Hb Change From Baseline (BL) to the Average Hb in Weeks 28-52 Regardless of Rescue Therapy|Hb Change From BL to the Average Hb in Weeks 28-36 Without Having Received Rescue Therapy Within 6 Weeks Prior to and During 8-Week Evaluation Period|Change From BL in Low-Density Lipoprotein (LDL) Cholesterol (Regardless of Fasting Status) to the Average LDL Cholesterol of Weeks 12 to 28|Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron)|Change From BL in Short Form (SF)-36 Vitality (VT) Sub-score to the Average VT Sub-score of Weeks 12 to 28|Change From BL in SF-36 Physical Functioning (PF) Sub-score to the Average PF Sub-score of Weeks 12 to 28|Change From BL in Mean Arterial Pressure (MAP) to the Average MAP of Weeks 20 to 28|Time to First Occurrence of Hypertension|Rate of Progression of CKD Measured by Annualized Estimated Glomerular Filtration Rate (eGFR) Slope Over Time|Average Level of Hb Over Weeks 28 to 36 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period|Average Level of Hb Over Weeks 44 to 52 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period|Average Level of Hb Over Weeks 96 to 104 Without Use of Rescue Therapy Within 6 Weeks Prior to and During the Evaluation Period|Time to Achieve the First Hb Response Without Rescue Therapy, as Defined by Primary Endpoint|Hb Change From BL to Each Post-Dosing Time Point|Hb Change From BL to the Average Hb Value of Weeks 28-36 Regardless of the Use of Rescue Therapy|Hb Change From BL to the Average Hb Value of Weeks 44-52 Regardless of the Use of Rescue Therapy|Hb Change From BL to the Average Hb Value of Weeks 96-104 Regardless of the Use of Rescue Therapy|Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 28-36 Without Use of Rescue Therapy|Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 44-52 Without Use of Rescue Therapy|Percentage of Hb Values Within 10.0-12.0 g/dL in Weeks 96-104 Without Use of Rescue Therapy|Time to First Hospitalization|Number of Days of Hospitalization Per Patient Exposure Year (PEY)|Time to First Use of Rescue Therapy (Composite of RBC, Transfusions, ESA Use, and IV Iron) in the First 24 Weeks of Treatment|Time to First Use of RBC Transfusions|Mean Monthly Number of RBC Packs|Mean Monthly Volume of Blood Transfused|Time to First Use of ESA Rescue Therapy|Time to First Use of IV Iron|Change From BL to Each Post-Dosing Visit in Total Cholesterol|Change From BL to Each Post-Dosing Visit in Low Density Lipoprotein (LDL)/High-Density Lipoprotein (HDL) Ratio|Change From BL to Each Post-Dosing Visit in Non-HDL Cholesterol|Change From BL to Each Post-Dosing Visit in Apolipoproteins A1 (ApoA1)|Change From BL to Each Post-Dosing Visit in Apolipoproteins B (ApoB)|Change From BL to Each Post-Dosing Visit in Ratio ApoB/ApoA1|Percentage of Participants With Mean LDL Cholesterol <100 mg/dL Calculated Over Weeks 12 to 28|Percentage of Participants Who Have Achieved Antihypertensive Treatment Goal in CKD Participants Over Weeks 12-28|Change From BL to the Average Value of Weeks 12-28 in Quality of Life (QoL) SF-36 Physical Component Score (PCS)|Change From BL to the Average Value of Weeks 12-28 in Anemia Subscale (Ans) of Functional Assessment of Cancer Therapy (FACT-An) Score|Change From BL to the Average Value of Weeks 12-28 in Total FACT-An Score|Change From BL to the Average Value of Weeks 12-28 in the Euroqol Questionnaire - 5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score|Change From BL to the Average Value of Weeks 12-28 in Overall Work Impairment Due to Anaemic Symptoms|Percentage of Participants in Each Category in Patients' Global Impression of Change (PGIC)|Change From BL to Each Study Visit in Serum Hepcidin|Change From BL to Each Study Visit in Serum Ferritin|Change From BL to Each Study Visit in Serum Transferrin Saturation (TSAT)|Change From BL to Each Study Visit in Serum HbA1c Level|Change From BL to Each Study Visit in Fasting Blood Glucose|Change From BL to Each Study Visit in Albumin/Creatinine Ratio in Urine|Change From BL to Each Study Visit in Serum Creatinine (Cr) Ratio|Time to Doubling of Serum Creatinine or Chronic Dialysis or Renal Transplant Compared to Baseline|Time to CKD Progression (Composite of Doubling Serum Creatinine, Chronic Dialysis or Renal Transplant, and Death)|Time to at Least 40% Decrease in eGFR From Baseline, Chronic Dialysis or Renal Transplant","Astellas Pharma Europe B.V.|FibroGen|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","594","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1517-CL-0608|2012-005180-27","September 3, 2013","November 1, 2017","November 1, 2017","June 27, 2013","December 17, 2020","February 10, 2021","Site BY37503, Brest, Belarus|Site BY37504, Gomel, Belarus|Site BY37501, Grodno, Belarus|Site BY37506, Minsk, Belarus|Site BY37507, Minsk, Belarus|Site BY37505, Minsk, Belarus|Site BY37502, Vitebsk, Belarus|Site BE32004, Brussels, Flemish Brabant, Belgium|Site BE32002, Antwerp, Belgium|Site BE32012, Baudour, Belgium|Site BE32017, Bonheiden, Belgium|Site BE32014, Ieper, Belgium|Site BE32013, Liege, Belgium|Site BG35923, Pazardjik, Bulgaria|Site BG35906, Sofia, Bulgaria|Site BG35908, Sofia, Bulgaria|Site BG35910, Sofia, Bulgaria|Site BG35907, Stara Zagora, Bulgaria|Site BG35916, Varna, Bulgaria|Site BG35903, Veliko Tarnovo, Bulgaria|Site CO57007, Barranquilla, Colombia|Site CO57008, Barranquilla, Colombia|Site CO57002, Pereira, Colombia|Site DO17101, La Fe Santo Domingo, Dominican Republic|Site DO17102, Santiago de los Caballeros, Dominican Republic|Site DO17104, Santo Domingo, Dominican Republic|Site DO17103, Santo Domingo, Dominican Republic|Site EE37201, Tallinn, Estonia|Site GE99503, Tbilisi, Georgia|Site GE99504, Tbilisi, Georgia|Site GE99502, Tbilisi, Georgia|Site GR30003, Heraklion, Greece|Site GR30002, Patras, Greece|Site GR30001, Thessaloniki, Greece|Site GT50209, Chiquimula, Guatemala|Site GT50202, Ciudad de Guatemala, Guatemala|Site GT50208, Ciudad de Guatemala, Guatemala|Site GT50207, Ciudad de Guatemala, Guatemala|Site GT50201, Ciudad de Guatemala, Guatemala|Site GT50205, Guatemala, Guatemala|Site GT50206, Guatemala, Guatemala|Site GT50203, Guatemala, Guatemala|Site HU36029, Budapest, Hungary|Site HU36025, Gyor, Hungary|Site HU36026, Kaposvar, Hungary|Site HU36027, Kistarcsa, Hungary|Site HU36008, Pecs, Hungary|Site HU36028, Szent, Hungary|Site HU36003, Zalsaegerszeg, Hungary|Site IT39001, Bari, Italy|Site IT39008, Lecco, Italy|Site IT39006, Milano, Italy|Site IT39037, Modena, Italy|Site IT39036, Pavia, Italy|Site PA50703, Ciudad de Colon, Panama|Site PA50701, Ciudad de Panama, Panama|Site PE51001, Iquitos, Peru|Site PE51002, Trujillo, Peru|Site PL48001, Krakow, Malopolska, Poland|Site PL48002, Katowice, Poland|Site PL48012, Lodz, Poland|Site PL48008, Lodz, Poland|Site PL48057, Nowy Tomyśl, Poland|Site PL48013, Szczecin, Poland|Site PL48007, Tarnow, Poland|Site PL48005, Warszawa, Poland|Site PL48004, Warszawa, Poland|Site PL48006, Wroclaw, Poland|Site PL48014, Zamosc, Poland|Site RO40005, Timisoara, Timis, Romania|Site RO40001, Brasov, Romania|Site RO40021, Bucharest, Romania|Site RO40012, Bucuresti, Romania|Site RO40003, Bucuresti, Romania|Site RO40004, Oradea, Romania|Site RU70024, Chelyabinsk, Russian Federation|Site RU70054, Irkutsk, Russian Federation|Site RU70008, Kaluga, Russian Federation|Site RU70051, Moscow, Russian Federation|Site RU70007, Moscow, Russian Federation|Site RU70005, Moscow, Russian Federation|Site RU70048, Moscow, Russian Federation|Site RU70047, Moscow, Russian Federation|Site RU70003, Nizhny Novgorod, Russian Federation|Site RU70004, Omsk, Russian Federation|Site RU70043, Petrozavodsk, Russian Federation|Site RU70014, Rostov-on-don, Russian Federation|Site RU70022, Saint Petersburg, Russian Federation|Site RU70011, Saint Petersburg, Russian Federation|Site RU70002, Saint Petersburg, Russian Federation|Site RU70045, Saint-Petersburg, Russian Federation|Site RU70060, Saratov, Russian Federation|Site RU70006, Smolensk, Russian Federation|Site RU70057, Yaroslavl, Russian Federation|Site RU70001, Yaroslavl, Russian Federation|Site RS38102, Belgrade, Serbia|Site RS38104, Belgrade, Serbia|Site RS38105, Belgrade, Serbia|Site RS38103, Belgrade, Serbia|Site RS38117, Krusevac, Serbia|Site RS38101, Nis, Serbia|Site RS38116, Zrenjanin, Serbia|Site ZA27001, Observatory, Cape Town, South Africa|Site ZA27004, Bloemfontein, Free State, South Africa|Site ZA27002, Durban, Kwa Zulu Natal, South Africa|Site ZA27008, Durban, South Africa|Site ZA27006, Parow, South Africa|Site ZA27007, Port Elizabeth, South Africa|Site ES34010, Alcorcon, Madrid, Spain|Site ES34011, Galdakao, Vizcaya, Spain|Site ES34002, Badalona-Barcelona, Spain|Site ES34003, Barcelona, Spain|Site ES34006, Barcelona, Spain|Site ES34007, Ciudad Real, Spain|Site TR90003, Ankara, Turkey|Site TR90016, Edirne, Turkey|Site TR90024, Kocaeli, Turkey|Site TR90020, Malatya, Turkey|Site UA38009, Lviv, Lvivska, Ukraine|Site UA38021, Cherkasy, Ukraine|Site UA38003, Chernivtsi, Ukraine|Site UA38006, Dnepropetrovsk, Ukraine|Site UA38016, Ivano-Frankivsk, Ukraine|Site UA38011, Kharkiv, Ukraine|Site UA38015, Kherson, Ukraine|Site UA38010, Kyiv, Ukraine|Site UA38012, Kyiv, Ukraine|Site UA38017, Kyiv, Ukraine|Site UA38007, Mykolaiv, Ukraine|Site UA38008, Odessa, Ukraine|Site UA38019, Odessa, Ukraine|Site UA38001, Ternopil, Ukraine|Site UA38018, Uzhgorod, Ukraine|Site UA38002, Zaporizhzhya, Ukraine|Site GB44008, Cambridge, United Kingdom|Site GB44001, Swansea, United Kingdom|Site GB44005, Welwyn Garden City, United Kingdom|Site GB44004, Westcliff-on-Sea, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/00/NCT01887600/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/00/NCT01887600/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01887600"
273,"NCT00352976","TBI Dose De-escalation for Fanconi Anemia",,"Completed","Has Results","Fanconi Anemia","Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Total Body Irradiation|Procedure: Bone Marrow Transplantation|Drug: Mycophenolate Mofetil|Drug: Sirolimus","Number of Participant With Neutrophil Recovery|Number of Participants Experiencing Grade ≥3 Regimen Related Toxicity|Number of Participants With Secondary Graft Failure at 100 Days|Number of Participants Experiencing Acute Graft-versus-host Disease (GVHD)|Number of Participants Experiencing Chronic GVHD|Number of Participants Experiencing Overall Survival|Number of Participants Experiencing Infections by Day 100|Number of Participants Experiencing Infections by Day 180|Number of Participants Experiencing Infections by Day 365|Average Immunoglobulin G (IgG) Levels as a Measure of Immune Reconstitution After Transplant, by 100 Days|Average IgG Levels as a Measure of Immune Reconstitution After Transplant, by 180 Days|Average IgG Levels as a Measure of Immune Reconstitution After Transplant by 365 Days|Average IgA Levels as a Measure of Immune Reconstitution After Transplant by 100 Days|Average IgA Levels as a Measure of Immune Reconstitution After Transplant by 180 Days|Average IgA Levels as a Measure of Immune Reconstitution After Transplant by 365 Days|Average IgM Levels as a Measure of Immune Reconstitution After Transplant by 100 Days|Average IgM Levels as a Measure of Immune Reconstitution After Transplant by 180 Days|Average IgM Levels as a Measure of Immune Reconstitution After Transplant by 365 Days","Masonic Cancer Center, University of Minnesota","All","Child, Adult, Older Adult","Phase 2|Phase 3","83","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT2006-05|0605M85788","May 18, 2006","October 9, 2020","October 9, 2020","July 17, 2006","November 24, 2021","November 24, 2021","University of Minnesota Medical Center, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/76/NCT00352976/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00352976"
274,"NCT00272857","Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia",,"Completed","No Results Available","Fanconi Anemia","Genetic: Retrovirus Construct","Safety of gene transfer methods|Short-term and long-term engraftment of gene-corrected autologous hematopoietic cells (all measured at Year 1)|Frequency and function of the integrated recombinant Fanconi vector|Efficiency of engraftment of multilineage gene corrected clones|Lineage contribution and longevity of molecularly distinguishable gene marked clones|Development of myelodysplastic syndrome or overt leukemia (all measured at Year 1)","Boston Children's Hospital|National Heart, Lung, and Blood Institute (NHLBI)|Children's Hospital Medical Center, Cincinnati","All","1 Year to 35 Years   (Child, Adult)","Phase 1","3","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","382|R01HL081499|CCHMCEH002|R01HL081499-01A1","August 2004","October 2007","October 2007","January 9, 2006",,"June 23, 2017","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00272857"
275,"NCT02779764","A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment",,"Completed","No Results Available","Hemodialysis Patients With Renal Anemia","Drug: roxadustat","Hemoglobin (Hb) Response Rate from Week 18 to Week 24|Hb Response Rate from Week 46 to Week 52|Average Hb from Week 18 to Week 24|Average Hb from Week 46 to Week 52|Change from baseline in the average Hb from Week 18 to Week 24|Change from baseline in the average Hb from Week 46 to Week 52|Proportion of participants with Hb values within the target value in each post-dosing time point|Change from baseline in Hb to each post-dosing time point|Proportion of measurement points with target Hb level from Week 18 to Week 24|Proportion of measurement points with target Hb level from Week 46 to Week 52|Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment|Average hematocrit level|Average reticulocyte level|Average Fe level|Average ferritin level|Average transferrin level|Average total iron binding capacity level|Average soluble transferrin receptor level|Average transferrin saturation level|Average reticulocyte hemoglobin content level|Quality of life assessed by SF-36|Quality of life assessed by EQ-5D|Quality of life assessed by FACT-An|Number of hospitalizations|Safety assessed by incidence of adverse events|Number of participants with abnormal Vital signs and/or adverse events related to treatment|Safety assessed by standard 12-lead electrocardiogram|Number of participants with abnormal Laboratory values and/or adverse events related to treatment","Astellas Pharma Inc|FibroGen","All","20 Years and older   (Adult, Older Adult)","Phase 3","164","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1517-CL-0312","May 16, 2016","May 16, 2017","November 28, 2017","May 20, 2016",,"January 2, 2020","Site JP00017, Aichi, Japan|Site JP00005, Fukuoka, Japan|Site JP00004, Gunma, Japan|Site JP00006, Gunma, Japan|Site JP00018, Hokkaido, Japan|Site JP00019, Hokkaido, Japan|Site JP00021, Hokkaido, Japan|Site JP00023, Hyogo, Japan|Site JP00008, Ibaraki, Japan|Site JP00020, Ishikawa, Japan|Site JP00010, Kumamoto, Japan|Site JP00022, Kumamoto, Japan|Site JP00024, Kumamoto, Japan|Site JP00016, Kyoto, Japan|Site JP00002, Nagano, Japan|Site JP00012, Nagano, Japan|Site JP00015, Nagano, Japan|Site JP00003, Niigata, Japan|Site JP00025, Osaka, Japan|Site JP00007, Saitama, Japan|Site JP00009, Shizuoka, Japan|Site JP00014, Tokyo, Japan|Site JP00013, Tottori, Japan|Site JP00011, Wakayama, Japan|Site JP00001, Yamaguchi, Japan",,"https://ClinicalTrials.gov/show/NCT02779764"
276,"NCT02021409","Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934","DIALOGUE 2","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: BAY85-3934|Biological: Darbepoetin alfa","Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period|Maintenance in hemoglobin target range (10.0 to 12.0 g/dL)|Change in hemoglobin level|Number of patients with hemoglobin levels outside the target range|Dose level in the evaluation period|Duration of exposure on each dose level|Number of subjects requiring titration of dose|Number of participants with serious adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15261|2013-001192-21","January 28, 2014","October 15, 2015","November 23, 2015","December 27, 2013",,"September 19, 2019","Gosford, New South Wales, Australia|Reservoir, Victoria, Australia|Dobrich, Bulgaria|Lovech, Bulgaria|Montana, Bulgaria|Pazardjik, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Grenoble Cedex 9, France|Pierre Benite Cedex, France|Bonn, Nordrhein-Westfalen, Germany|Baja, Hungary|Budapest, Hungary|Esztergom, Hungary|Kaposvar, Hungary|Pecs, Hungary|Szigetvar, Hungary|Ashkelon, Israel|Hadera, Israel|Kfar Saba, Israel|Nahariya, Israel|Napoli, Campania, Italy|Brescia, Lombardia, Italy|Cremona, Lombardia, Italy|Lecco, Lombardia, Italy|Pavia, Lombardia, Italy|Livorno, Toscana, Italy|Kitakyushu, Fukuoka, Japan|Okawa, Fukuoka, Japan|Muroran, Hokkaido, Japan|Morioka, Iwate, Japan|Fujisawa, Kanagawa, Japan|Kuwana, Mie, Japan|Chiba, Japan|Fukuoka, Japan|Nagano, Japan|Bucheon-si, Gyeonggido, Korea, Republic of|Bialystok, Poland|Radom, Poland|Bucharest, Romania|Bucharest, Romania|Oradea, Romania|Targu-Mures, Romania|L'Hospitalet de Llobregat, Barcelona, Spain|San Sebastián de los Reyes, Madrid, Spain|Madrid, Spain|Ankara Univ. Medical Faculty, Ankara, Turkey|Baskent University Medical Faculty, Ankara, Turkey|Sifa University Medical Faculty, Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02021409"
277,"NCT04707768","Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects",,"Completed","No Results Available","Anemia Associated With Chronic Kidney Disease (CKD)","Drug: Vadadustat|Drug: Mircera®","Mean change in hemoglobin (Hb) between Baseline (average pretreatment Hb) and the primary evaluation period (average Hb from Weeks 20 to 26, inclusive)|Number of participants with treatment-emergent non-serious adverse events and treatment-emergent serious adverse events|Mean change in Hb between Baseline (average pretreatment Hb) and the secondary evaluation period (average Hb from Weeks 46 to 52, inclusive)","Akebia Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","456","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0039","June 18, 2021","December 15, 2022","January 30, 2023","January 13, 2021",,"December 18, 2023","Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Pine Bluff, Arkansas, United States|Research Site, El Centro, California, United States|Research Site, Escondido, California, United States|Research Site, Fresno, California, United States|Research Site, Granada Hills, California, United States|Research Site, Porterville, California, United States|Research Site, San Diego, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Hockessin, Delaware, United States|Research Site, Bradenton, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site#1, Coral Springs, Florida, United States|Research Site#2, Coral Springs, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Buford, Georgia, United States|Research Site, Dalton, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Nampa, Idaho, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Plymouth, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Rochester Hills, Michigan, United States|Research Site, Saint Clair Shores, Michigan, United States|Research Site, Brookhaven, Mississippi, United States|Research Site, Columbus, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, North Platte, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Gallup, New Mexico, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Kinston, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Kittanning, Pennsylvania, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Mansfield, Texas, United States|Research Site, Mission, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Alexandria, Virginia, United States|Research Site, Salem, Virginia, United States|Research Site, Woodbridge, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04707768"
278,"NCT00548691","Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients",,"Completed","Has Results","Anemia","Drug: Ferric Carboxymaltose|Drug: Standard Medical Care (SMC)","Incidence of Treatment-emergent Serious Adverse Events (SAE's)","American Regent, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","513","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1VIT07018","October 2007","January 2009","July 2009","October 24, 2007","May 13, 2015","February 20, 2018","Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00548691"
279,"NCT00479115","Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100",,"Completed","Has Results","Fanconi Anemia","Drug: AMD3100|Device: AmCell CliniMACs","Number of Participants Who Safely Received AMD3100 Used in Combination With Standard Dose G-CSF|Number of Participants for Whom a Sufficient Number of CD34+ Cells Were Mobilized Into the Peripheral Blood|Number of Participants for Whom the Target Number of Hematopoietic Cells Were Collected by Peripheral Blood Apheresis|Number of Participants for Whom the Target Number of CD34+ Cells Were Collected From Their Bone Marrow|Number of Participants for Whom the Target Number of CD34+ Cells Were Isolated.|Number of Participants Whose Product Was Used for Preclinical Biological Investigations.","Children's Hospital Medical Center, Cincinnati|National Heart, Lung, and Blood Institute (NHLBI)","All","1 Year to 30 Years   (Child, Adult)","Phase 1|Phase 2","1","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CCHMCEH004|R01HL081499","May 2007","December 2010","December 2010","May 25, 2007","October 30, 2020","October 30, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00479115"
280,"NCT01695759","Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.",,"Terminated","No Results Available","Chronic Kidney Disease|Anemia","Drug: Epoetin alpha|Drug: Eprex","Change of hemoglobin levels at correction phase (baseline vs end of treatment)|Maintenance of hemoglobin levels|Adjustment of EPO dose required during correction and/or maintenance phase|Transfusion needs|Report of Adverse Events","Azidus Brasil|Blau Farmaceutica S.A.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","EPOBLA1011|Emenda 04 - 11/May/2015","December 2013","December 2014","January 2018","September 28, 2012",,"August 20, 2018","Clínica Senhor do Bomfim Ltda, Feira de Santana, Bahia, Brazil|Instituto Scribner de Ensino, Pesquisa, Ciência e Tecnologia, Curitiba, Parana, Brazil|Fundação Universitária de Caxias do Sul - Instituto de Pesquisa Clínica para Estudos Multicêntricos, Caxias do Sul, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|União Brasileira de Educação e Assistência Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Fundação Pró-Rim, Joinville, Santa Catarina, Brazil|Hospital de Ensino Padre Anchieta, São Bernardo do Campo, São Paulo, Brazil|CMIN - Clínica De Medicina Interna E Nefrologia, São Paulo, Brazil|Fundação Oswaldo Cruz (Hospital do Rim e Hipertensão), São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência São Paulo (Hospital Beneficência Portuguesa), São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01695759"
281,"NCT00167206","Stem Cell Transplantation for Fanconi Anemia",,"Terminated","Has Results","Fanconi Anemia","Procedure: Hematopoietic Stem Cell Transplant|Procedure: Thymic Shielding During Radiation|Procedure: Total Body Irradiation|Drug: Cyclophosphamide, Fludarabine","Number of Patients Who Exhibited Hematopoietic Recovery and Engraftment|Number of Patients Who Exhibited Secondary Graft Failure|Number of Patients With Acute Graft Versus-Host Disease (aGVHD)|Number of Patients With Chronic Graft Versus-Host Disease (GVHD)|Number of Patients Who Exhibited Regimen-related Toxicity (RRT)|Immune Reconstitution - Mean Value (1 Year)|Immune Reconstitution - Mean Value (2 Years)|Number of Patients Alive at 1 Year|Number of Patients Alive at 2 Years","Masonic Cancer Center, University of Minnesota","All","1 Day to 18 Years   (Child, Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0312M54991|MT2003-18","March 2004","December 2008","December 2008","September 14, 2005","November 26, 2009","August 26, 2019","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00167206"
282,"NCT00271089","Blood Cell Collection for Future Use in Individuals With Fanconi Anemia",,"Completed","No Results Available","Fanconi Anemia","Procedure: PBSC Collection|Procedure: Bone Marrow Harvest|Device: CliniMacs Cell Selection System","CD34+ cell collection","National Heart, Lung, and Blood Institute (NHLBI)|Children's Hospital Medical Center, Cincinnati","All","1 Year to 35 Years   (Child, Adult)","Not Applicable","40","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","378|CCHMCEH001|R01HL081499-01A1","August 2004",,"October 2007","December 30, 2005",,"July 12, 2016","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00271089"
283,"NCT05585645","A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)","CKD","Active, not recruiting","No Results Available","Anemia|Chronic Kidney Disease Requiring Chronic Dialysis","Biological: Stimus (NNG-DEPO)","The mean change Hemoglobin level from baseline to Week 24|Proportion of patients achieving 1 g/dL rise in Hb from baseline during 24 weeks after treatment|Proportion of patients achieving Hb within the target range (10 - 12 g/dL) at week 24.|Proportion of patients need for blood transfusion during 24 weeks after treatment.|4. The mean dose of NNG-DEPO/Aranesp administered for achievement of Hb in the target Hb levels (10 - 12 g/dL) during 24 weeks.|Time to initial achievement of Hb ≥ 11 g/dL.|Proportion of the adverse events (AE) including physical examinations, vital signs, and clinical laboratory investigations.|Proportion of patients positive with anti-Darbepoetin alfa antibody after treatment.","Nanogen Pharmaceutical Biotechnology Joint Stock Company|Vietstar Biomedical Research|MEDPHASE CLINICAL RESEARCH CONSULTANT COMPANY LIMITED|CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING COMPANY LIMITED|MedProve Inc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","214","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NNG06-02","August 8, 2019","November 30, 2022","December 31, 2022","October 19, 2022",,"January 6, 2023","NANOGEN Pharmaceutical Biotechnology JSC, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT05585645"
284,"NCT05745883","Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia",,"Recruiting","No Results Available","Chronic Kidney Diseases|Anemia of Chronic Kidney Disease","Drug: DISC-0974|Drug: Placebo","Incidence of treatment-emergent adverse events|Incidence of clinically abnormal vital signs|Incidence of abnormal laboratory test results|Incidence of clinically abnormal physical exam|Incidence of clinically abnormal electrocardiograms|Change from baseline in concentration of iron laboratory parameter|Change from baseline in concentration of hematologic laboratory parameters|Cmax-Maximum drug concentration measured in plasma|Tmax-Time of maximum drug concentration|AUC-Area under the drug concentration time curve|T½ - Elimination half life of the drug|CL/F-Apparent drug clearance|Vd/F-Apparent volume of distribution of the drug","Disc Medicine, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DISC-0974-103","April 4, 2023","September 2024","May 2025","February 27, 2023",,"April 1, 2024","Rocky Mountain Kidney Care - Lone Tree, Lone Tree, Colorado, United States|Accel Research, DeLand, Florida, United States|Total Research Group, Miami, Florida, United States|Flourish Research, Winter Park, Florida, United States|Nephrology and Hypertension Specialists, PC-Dalton, Dalton, Georgia, United States|Boise Kidney & Hypertension PLLC, Nampa, Idaho, United States|Center for Advanced Kidney Research PLC, Saint Clair Shores, Michigan, United States|Centricity Research, Columbus, Ohio, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, United States|Endeavor Clinical Trials, San Antonio, Texas, United States|Washington Nephrology Associates, LLP, Alexandria, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05745883"
285,"NCT02952092","A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia",,"Completed","No Results Available","Hemodialysis Chronic Kidney Disease Patients With Anemia","Drug: roxadustat|Drug: Darbepoetin alfa","Change from baseline in the average hemoglobin (Hb)|Average Hb from Week 18 to Week 24|Proportion of participants with the target Hb level from Week 18 to Week 24|Proportion of participants with the target Hb level at each week|Change from week 0 in Hb levels to each week|Proportion of measurement points with the target Hb level from Week 18 to Week 24|Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment|Average hematocrit level|Average reticulocyte level|Average iron (Fe) level|Average ferritin level|Average transferrin level|Average total iron binding capacity level|Average soluble transferrin receptor level|Average transferrin saturation level|Average reticulocyte hemoglobin content level|Quality of life assessed by SF-36|Quality of life assessed by EQ-5D-5L|Quality of life assessed by FACT-An|Number of hospitalizations|Duration of hospitalizations|Plasma concentration of unchanged ASP1517|Safety assessed by incidence of adverse events|Number of participants with abnormal Laboratory values and/or adverse events related to treatment|Number of participants with abnormal Vital signs and/or adverse events related to treatment|Number of participants with abnormal 12-lead electrocardiogram (ECG) values|Safety assessed by ophthalmological examination: fundoscopy|Safety assessed by ophthalmological examination: Optical coherence tomography|Safety assessed by ophthalmological examination: visual acuity","Astellas Pharma Inc|FibroGen","All","20 Years and older   (Adult, Older Adult)","Phase 3","303","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1517-CL-0307","November 30, 2016","March 13, 2018","March 15, 2018","November 2, 2016",,"September 30, 2022","Site JP00008, Aichi, Japan|Site JP00018, Aichi, Japan|Site JP00020, Aichi, Japan|Site JP00032, Aichi, Japan|Site JP00033, Aichi, Japan|Site JP00040, Aichi, Japan|Site JP00004, Ehime, Japan|Site JP00055, Ehime, Japan|Site JP00009, Fukui, Japan|Site JP00059, Fukui, Japan|Site JP00014, Fukuoka, Japan|Site JP00049, Fukuoka, Japan|Site JP00010, Fukushima, Japan|Site JP00056, Fukushima, Japan|Site JP00057, Fukushima, Japan|Site JP00030, Gifu, Japan|Site JP00050, Gifu, Japan|Site JP00011, Gunma, Japan|Site JP00026, Gunma, Japan|Site JP00037, Gunma, Japan|Site JP00003, Hokkaido, Japan|Site JP00031, Hokkaido, Japan|Site JP00038, Hokkaido, Japan|Site JP00048, Hokkaido, Japan|Site JP00017, Ibaraki, Japan|Site JP00041, Ibaraki, Japan|Site JP00042, Ibaraki, Japan|Site JP00045, Ibaraki, Japan|Site JP00046, Ibaraki, Japan|Site JP00047, Ibaraki, Japan|Site JP00054, Ibaraki, Japan|Site JP00058, Ibaraki, Japan|Site JP00043, Kagoshima, Japan|Site JP00005, Kanagawa, Japan|Site JP00028, Kumamoto, Japan|Site JP00029, Kumamoto, Japan|Site JP00006, Kyoto, Japan|Site JP00002, Nagano, Japan|Site JP00012, Nagano, Japan|Site JP00027, Nagano, Japan|Site JP00051, Nagano, Japan|Site JP00013, Nagasaki, Japan|Site JP00001, Niigata, Japan|Site JP00034, Niigata, Japan|Site JP00036, Okayama, Japan|Site JP00007, Osaka, Japan|Site JP00015, Osaka, Japan|Site JP00016, Saitama, Japan|Site JP00035, Saitama, Japan|Site JP00044, Tokushima, Japan|Site JP00052, Tokyo, Japan|Site JP00053, Tokyo, Japan|Site JP00021, Toyama, Japan|Site JP00022, Toyama, Japan|Site JP00039, Toyama, Japan|Site JP00024, Yamagata, Japan|Site JP00025, Yamaguchi, Japan",,"https://ClinicalTrials.gov/show/NCT02952092"
286,"NCT02780726","A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia",,"Completed","No Results Available","Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia","Drug: roxadustat","Hemoglobin (Hb) Response Rate from Week 18 to Week 24|Hb Response rate|Average Hb levels from week 18 to week 24|Change from baseline in the average Hb levels of week 18 to week 24|Rate of rise in Hb levels (g/dL/week)|Proportion of time points with target Hb levels|Proportion of participants who achieve the target Hb level at each week|Proportion of participants who achieve the lower limit of the target Hb level|Time to achieve the lower limit of the target Hb level|Change from baseline in Hb level at each week|Efficacy assessed by hematocrit|Efficacy assessed by reticulocytes/ erythrocytes|Efficacy assessed by Iron (Fe)|Efficacy assessed by ferritin|Efficacy assessed by transferrin|Efficacy assessed by total iron binding capacity|Efficacy assessed by soluble transferrin receptor|Efficacy assessed by transferrin saturation|Efficacy assessed by reticulocyte hemoglobin content|Quality of life assessed by SF-36|Quality of life assessed by EQ-5D|Quality of life assessed by FACT-An|Occurrence of hospitalizations|Safety assessed by incidence of adverse events|Number of participants with abnormal Vital signs and/or adverse events related to treatment|Safety assessed by standard 12-lead electrocardiogram|Number of participants with abnormal Laboratory values and/or adverse events related to treatment|Plasma concentration of unchanged ASP1517","Astellas Pharma Inc|FibroGen","All","20 Years and older   (Adult, Older Adult)","Phase 3","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1517-CL-0302","June 22, 2016","August 2, 2017","August 2, 2017","May 23, 2016",,"December 20, 2019","Site JP00002, Aichi, Japan|Site JP00004, Aichi, Japan|Site JP00010, Aichi, Japan|Site JP00013, Aichi, Japan|Site JP00001, Fukuoka, Japan|Site JP00005, Fukuoka, Japan|Site JP00012, Hokkaido, Japan|Site JP00014, Hokkaido, Japan|Site JP00006, Ishikawa, Japan|Site JP00008, Kanagawa, Japan|Site JP00003, Nagano, Japan|SIte JP00015, Okayama, Japan|Site JP00009, Osaka, Japan|Site JP00007, Tokushima, Japan|Site JP00011, Toyama, Japan",,"https://ClinicalTrials.gov/show/NCT02780726"
287,"NCT04484857","Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","ASPEN","Completed","Has Results","Anemia Associated With End Stage Renal Disease","Drug: Roxadustat","Percentage of Participants With Mean Hb Value ≥10 g/dL|Mean Hb Change From Baseline to Average Hb From Weeks 16-24","FibroGen|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","283","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FGCL-4592-096","July 22, 2020","July 9, 2021","September 17, 2021","July 24, 2020","July 26, 2022","July 26, 2022","Alaska, Anchorage, Alaska, United States|Investigator Site, Pine Bluff, Arkansas, United States|Investigational Site, Cerritos, California, United States|Investigational Site, Victorville, California, United States|Investigational Site, Denver, Colorado, United States|Investigational Site, Hartford, Connecticut, United States|Investigational Site, Coral Gables, Florida, United States|Investigational Site, Hollywood, Florida, United States|Investigator Site, Dalton, Georgia, United States|Investigational Site, Statesboro, Georgia, United States|Investigational Site, Roseville, Michigan, United States|Investigational Site, Kansas City, Missouri, United States|Investigational Site, Las Vegas, Nevada, United States|Investigator Site, Gallup, New Mexico, United States|Investigational Site, Bronx, New York, United States|Investigational Site, Austin, Texas, United States|Investigator Site, Dallas, Texas, United States|Investigational Site, El Paso, Texas, United States|Investigational Site, Houston, Texas, United States|Investigator Site, San Antonio, Texas, United States|Investigator Site, San Antonio, Texas, United States|Investigator Site, San Antonio, Texas, United States|Investigational Site, San Antonio, Texas, United States|Investigational Site, San Antonio, Texas, United States|Investigator Sites, San Antonio, Texas, United States|Investigational Site, Norfolk, Virginia, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/57/NCT04484857/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/57/NCT04484857/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04484857"
288,"NCT01975818","Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","DIALOGUE4","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY 85-3934)|Biological: Epoetin alfa/beta","Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period|Mean of the hemoglobin (Hb) levels in the target range (10.0 to 11.0 g/dL)|Mean of the hemoglobin levels in the target range (9.5 to 11.5 g/dL)|Change from baseline in Hb during active treatment|Number of patients with hemoglobin levels outside the target range|Dose level in the evaluation period|Duration of exposure on each dose level|Number of subjects requiring titration of dose|Number of participants with serious adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16208","October 28, 2013","October 23, 2015","December 15, 2015","November 5, 2013",,"September 20, 2019","Azusa, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Lynwood, California, United States|Northridge, California, United States|San Dimas, California, United States|Whittier, California, United States|Whittier, California, United States|New Port Richey, Florida, United States|Pembroke Pines, Florida, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Creve Coeur, Missouri, United States|Eatontown, New Jersey, United States|Brooklyn, New York, United States|Buffalo, New York, United States|Fresh Meadows, New York, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Nashville, Tennessee, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Grand Prairie, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Mansfield, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Muroran, Hokkaido, Japan|Himeji, Hyogo, Japan|Kuwana, Mie, Japan|Kyoto, Japan|Nagano, Japan",,"https://ClinicalTrials.gov/show/NCT01975818"
289,"NCT00590460","Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia","Mafia","Terminated","Has Results","Fanconi Anemia|Severe Aplastic Anemia","Biological: CAMPATH-1H|Biological: Anti-CD45|Drug: Fludarabine|Procedure: Stem cell infusion","Number of Patients With Donor Engraftment|Number of Patients With Graft Failure|Patients With Treated Related Death|Days to Absolute Neutrophil Count (ANC) of 500/mm3|Days to Platelet Count of 20,000/mm3 Without Transfusions|Patients With Grade II - IV Acute Graft Versus Host Disease (GVHD)|Number of Patients Alive at 1 Year Post Transplant|Patients With Limited Chronic GVHD From Day 100 to 365|Patients With Extensive Chronic GVHD From Day 100 to 365|Patients With Grade III - IV Acute GVHD","Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine","All","Child, Adult, Older Adult","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-9938","July 2001","September 2009","September 2009","January 10, 2008","August 9, 2012","May 24, 2018","Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00590460"
290,"NCT06016036","SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease",,"Completed","No Results Available","Renal Anemia in Non-dialysis Chronic Kidney Disease","Drug: SAL-0951|Drug: Placebo","Difference in mean Hb concentration levels from baseline at weeks 7-9|double-blind phase：The cumulative percentage of subjects who achieved Hb response at any time from treatment to week 9|Double-blind phase：Proportion of subjects with average Hb level ≥100 g/L at week 7-9|Double-blind phase：Proportion of average Hb concentration ≥100g/L and ≤120g/L in week 9|Double-blind phase：By week 9, the cumulative proportion of subjects whose Hb increased by ≥10 g/L and whose Hb reached ≥100g/L|Double-blind phase：By week 9, the cumulative proportion of Hb > 130 g/L|Double-blind phase：Proportion of subjects receiving intravenous iron at week 9","Shenzhen Salubris Pharmaceuticals Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SAL0951A301","December 8, 2020","October 8, 2021","February 21, 2022","August 29, 2023",,"August 29, 2023","Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT06016036"
291,"NCT03428594","CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis",,"Completed","No Results Available","Anemia of Chronic Kidney Disease","Biological: CKD-11101|Biological: NESP","Changed amount of mean hemoglobin level in evaluation period compared to the baseline|Mean administration dose in evaluation period: Mean dose administered in Weeks 20 - 24|Ratio of subjects who achieve target level of hemoglobin during the evaluation period|Mean hemoglobin levels at Weeks 20 and 24|Ratio of subjects who maintain hemoglobin level ≥ 10g/dl during maintenance period and evaluation period (interval of every 2 weeks)|Ratio of subjects who changed dose during maintenance period and evaluation period|Ratio of subjects who receive transfusion during maintenance period and evaluation period|Number of red blood cell transfusion per subject during maintenance period and evaluation period","Chong Kun Dang Pharmaceutical","All","19 Years and older   (Adult, Older Adult)","Phase 3","403","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","136Ane14004","June 2015","June 2017","June 2017","February 9, 2018",,"February 9, 2018",,,"https://ClinicalTrials.gov/show/NCT03428594"
292,"NCT04925011","Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD",,"Unknown status","No Results Available","Anemia Associated With Chronic Kidney Disease","Drug: Roxadustat","Proportion of patients with mean Hb ≥ 11.0 g/dL|Mean change in Hb","Mao Jianhua|The Children's Hospital of Zhejiang University School of Medicine","All","2 Years to 18 Years   (Child, Adult)","Phase 3","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Roxadustat for pediatric CKD","September 1, 2021","June 30, 2022","December 30, 2022","June 14, 2021",,"August 9, 2021","Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04925011"
293,"NCT02064426","Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","DIALOGUE5","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)|Biological: Epoetin alfa/beta","Change in local laboratory hemoglobin level from baseline|Number of participants with serious adverse events as a measure of safety and tolerability|Maintenance in hemoglobin target range (10.0 to 11.0 g/dL)|Maintenance in hemoglobin target range (9.5 to 11.5 g/dL)|Duration of treatment exposure|Number of subjects requiring titration of dose|Change of reticulocyte count from baseline of this study|Change of reticulocyte count from baseline of study 16208|Change of red blood cell count from baseline of this study|Change of red blood cell count from baseline of study 16208|Change of hematocrit from baseline of this study|Change of hematocrit from baseline of study 16208|Change of central laboratory hemoglobin level from baseline of this study|Change of central laboratory hemoglobin level from baseline of study 16208","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16209","March 13, 2014","October 19, 2016","November 16, 2016","February 17, 2014",,"September 20, 2019","Azusa, California, United States|Long Beach, California, United States|Lynwood, California, United States|Northridge, California, United States|San Dimas, California, United States|Whittier, California, United States|Whittier, California, United States|New Port Richey, Florida, United States|Pembroke Pines, Florida, United States|Detroit, Michigan, United States|Creve Coeur, Missouri, United States|Buffalo, New York, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Nashville, Tennessee, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Grand Prairie, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Mansfield, Texas, United States|Muroran, Hokkaido, Japan|Kuwana, Mie, Japan|Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT02064426"
294,"NCT02780141","A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia",,"Completed","No Results Available","ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia","Drug: roxadustat","Hemoglobin (Hb) Response rate|Average Hb level from Week 18 to 24|Change from baseline in the average Hb level from Week 18 to 24|Proportion of participants with the target Hb level from Week 18 to 24|Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment|Proportion of measurement points with the target Hb level|Proportion of participants with the target Hb level at each week|Proportion of participants with the lower limit of the target Hb level|Time to achieve the lower limit of the target Hb level|Change from baseline in Hb levels to each week|Average hematocrit level|Average reticulocyte level|Average iron (Fe) level|Average ferritin level|Average transferrin level|Average total iron binding capacity level|Average soluble transferrin receptor level|Average transferrin saturation level|Average reticulocyte hemoglobin content level|Quality of life assessed by EQ-5D-5L|Quality of life assessed by FACT-An|Number of hospitalizations|Duration of hospitalizations|Safety assessed by incidence of adverse events|Number of participants with abnormal Laboratory values and/or adverse events related to treatment|Number of participants with abnormal Vital signs and/or adverse events related to treatment|Safety assessed by standard 12-lead electrocardiogram|Plasma concentration of unchanged ASP1517","Astellas Pharma Inc|FibroGen","All","20 Years and older   (Adult, Older Adult)","Phase 3","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1517-CL-0308","June 2, 2016","December 12, 2017","December 12, 2017","May 23, 2016",,"January 2, 2020","Site JP00003, Aichi, Japan|Site JP00005, Aichi, Japan|Site JP00042, Aichi, Japan|Site JP00044, Aichi, Japan|Site JP00020, Chiba, Japan|Site JP00010, Ehime, Japan|Site JP00021, Ehime, Japan|Site JP00013, Fukuoka, Japan|Site JP00011, Fukushima, Japan|Site JP00035, Fukushima, Japan|Site JP00017, Gifu, Japan|Site JP00033, Gifu, Japan|Site JP00012, Gunma, Japan|Site JP00016, Gunma, Japan|Site JP00025, Gunma, Japan|Site JP00046, Hiroshima, Japan|Site JP00015, Hokkaido, Japan|Site JP00023, Hokkaido, Japan|Site JP00028, Hokkaido, Japan|Site JP00038, Hokkaido, Japan|Site JP00040, Hokkaido, Japan|Site JP00045, Hokkaido, Japan|Site JP00034, Hyogo, Japan|Site JP00008, Ibaraki, Japan|Site JP00018, Ibaraki, Japan|Site JP00027, Ibaraki, Japan|Site JP00030, Ibaraki, Japan|Site JP00022, Ishikawa, Japan|Site JP00041, Kagoshima, Japan|Site JP00031, Kumamoto, Japan|Site JP00037, Kumamoto, Japan|Site JP00009, Nagano, Japan|Site JP00014, Nagano, Japan|Site JP00026, Nagano, Japan|Site JP00047, Nagano, Japan|Site JP00002, Niigata, Japan|Site JP00029, Niigata, Japan|Site JP00039, Okayama, Japan|Site JP00024, Okinawa, Japan|Site JP00036, Osaka, Japan|Site JP00006, Saitama, Japan|Site JP00032, Shizuoka, Japan|Site JP00043, Tokushima, Japan|Site JP00048, Tokyo, Japan|Site JP00007, Tottori, Japan|Site JP00019, Toyama, Japan|Site JP00004, Yamaguchi, Japan",,"https://ClinicalTrials.gov/show/NCT02780141"
295,"NCT01719146","Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease",,"Completed","No Results Available","Anemia of End Stage Renal Disease","Other: Specimen collection","Hemoglobin Concentration (g/dL)","University of Louisville|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)",,"134","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","12.0149|R01DK093832","January 2013","June 5, 2021","June 5, 2021","November 1, 2012",,"October 27, 2022","University of Louisville, University Kidney Center, Louisville, Kentucky, United States|Western New England Renal and Transplant Associates, Springfield, Massachusetts, United States|Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01719146"
296,"NCT04410198","Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants",,"Completed","Has Results","Anemia Associated With End Stage Renal Disease (ESRD)","Drug: Roxadustat","Percentage of Participants With Mean Hb Value ≥10 g/dL|Mean Hb Change From Baseline to Average Hb From Weeks 16-24","FibroGen|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","203","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FGCL-4592-097","May 26, 2020","June 30, 2021","October 11, 2021","June 1, 2020","September 13, 2022","September 13, 2022","Investigational Site, Englewood, Colorado, United States|Investigational Site, Caldwell, Idaho, United States|Investigational Site, Baton Rouge, Louisiana, United States|Investigational Site, Kalamazoo, Michigan, United States|Investigational Site, Tupelo, Mississippi, United States|Investigational Site, Saint Ann, Missouri, United States|Investigational Site, Las Vegas, Nevada, United States|Investigational Site, Sugar Land, Texas, United States|Investigational Site, Saint George, Utah, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/98/NCT04410198/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/98/NCT04410198/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04410198"
297,"NCT00609544","Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia",,"Withdrawn","No Results Available","Chronic Kidney Disease|Anemia","Drug: Rilonacept","Change in blood hemoglobin concentration.","Regeneron Pharmaceuticals|Syneos Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IL1T-AN-0704",,,,"February 7, 2008",,"April 19, 2011","Alexander City, Alabama, United States|Muscle Shoals, Alabama, United States|Cerritos, California, United States|Long Beach, California, United States|Los Alampios, California, United States|Thousand Palms, California, United States|Colorado Springs, Colorado, United States|Lauderdale Lakes, Florida, United States|Pembroke Pines, Florida, United States|Tampa, Florida, United States|Blue Ridge, Georgia, United States|Jonesboro, Georgia, United States|Portland, Maine, United States|Queens, New York, United States|Mooresville, North Carolina, United States|Shelby, North Carolina, United States|Allentown, Pennsylvania, United States|Harrisburg, Pennsylvania, United States|Orangeburg, South Carolina, United States|Sumter, South Carolina, United States|Barlett, Tennessee, United States|Clarksville, Tennessee, United States|Collierville, Tennessee, United States|Crossville, Tennessee, United States|Memphis, Tennessee, United States|Ogden, Utah, United States|Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00609544"
298,"NCT02185911","Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis","ADAPTATION","Completed","No Results Available","Anaemia|Chronic Kidney Disease (CKD)",,"Monthly Haemoglobin values|Doses of darbepoetin alfa/other ESAs over time|Haemoglobin values|Change in Haemoglobin values|Increase in haemoglobin from baseline|Haemoglobin excursions|First haemoglobin within 10-12g/dL|first dose frequency change after third dose of darbepoetin alfa QM|Subjects remaining on darbepoetin alfa QM|TSAT, ferritin and albumin values|Iron Use|Transfusions|Hospitalisations","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)",,"308","Industry","Observational","Observational Model: Cohort","20130301","June 2014","April 2015","April 2015","July 10, 2014",,"March 8, 2016","Research Site, Feldkirch, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Dobrich, Bulgaria|Research Site, Montana, Bulgaria|Research Site, Pazardjik, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Brno, Czech Republic|Research Site, Havlickuv Brod, Czech Republic|Research Site, Nove Mesto na Morave, Czech Republic|Research Site, Trebic, Czech Republic|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Baja, Hungary|Research Site, Kecskemet, Hungary|Research Site, Szeged, Hungary|Research Site, Szigetvar, Hungary|Research Site, Szombathely, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Albano Laziale RM, Italy|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Sieradz, Poland|Research Site, Stalowa Wola, Poland|Research Site, Cordoba, Andalucía, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain",,"https://ClinicalTrials.gov/show/NCT02185911"
299,"NCT04470063","Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.",,"Unknown status","No Results Available","Anemia Associated Chronic Kidney Disease","Drug: DDO-3055 tablets|Drug: Placebo","The incidence and severity of adverse events to assess safety and tolerability.","Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DDO-3055-104","November 17, 2020","December 31, 2021","December 31, 2021","July 14, 2020",,"October 26, 2021","Beijing Friendship Hospital,Capital Medical University, Beijing, Beijing, China|Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Sun Yat Sen memorial hospital Sun Yat Sen university, Guangzhou, Guangdong, China|The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Cangzhou People's Hospital, Cangzhou, Henbei, China|Yichang Central People's Hospital, Yichang, Hubei, China|Zhongda Hospital Southeast Universtiy, Nanjing, Jiangsu, China|The Second Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China|Shandong Qianfo Mountain hospital, Jinan, Shandong, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT04470063"
300,"NCT02817555","Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients",,"Completed","Has Results","Anemia|Chronic Kidney Disease","Drug: Epoetin Alfa|Drug: Darbepoetin alfa","Cost of Erythropoiesis Stimulating Agent|Hemoglobin|Ferritin|Transferrin Saturation (TSAT)|Iron Dose|Iron Cost","Andrea L Woodland|Eastern Health, Canada","All","19 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIC10.104","September 2010","May 2013","May 2013","June 29, 2016","September 10, 2019","September 10, 2019",,,"https://ClinicalTrials.gov/show/NCT02817555"
301,"NCT00717366","Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis",,"Completed","Has Results","Renal Anemia","Drug: Methoxy Polyethylene Glycol-Epoetin Beta","Change in Average Hb Concentration Between Baseline and Evaluation Period|Number of Participants With an Average Hb Concentration During the Evaluation Period Within ±1 g/dL of Their Baseline Hb|Number of Participants With an Average Hb Concentration During the Evaluation Period Above, Within or Below the Range of 10-12 g/dL|Number of Participants With Blood Transfusions|Change in Average Reticulocyte Count Between the Baseline and Evaluation Period|Maximum Observed Serum Concentration (Cmax) of MIRCERA|Area Under the Serum Concentration-Time Curve From 0 to 672 Hours (AUC0-672h) of MIRCERA|Time to Reach Cmax (Tmax) of MIRCERA|Apparent Terminal Phase Half-Life (t1/2) of MIRCERA","Hoffmann-La Roche","All","5 Years to 17 Years   (Child)","Phase 2","64","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NH19707|2007-007758-70","July 2008","March 2016","March 2016","July 17, 2008","September 8, 2017","September 8, 2017","Royal Children'S Hospital; Department of Nephrology, Parkville, Victoria, Australia|Hôpital Enfants Reine Fabiola, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Hopital Femme Mere Enfant; Ped Nephrologie Rhumatologie, Bron, France|Hopital Jeanne De Flandre; Cons Pediatrie, Lille, France|Hopital Timone Enfants; Nephrologie Hemodialyse, Marseille, France|Hopital Arnaud De Villeneuve; Pediatrie I, Montpellier, France|Hôpital Robert Debré; Nephrologie pediatrique, Paris, France|Hopital Armand Trousseau; Pediatrie Nephrologie, Paris, France|Höpital Hautepierre; Pediatrie 1, Strasbourg, France|KfH Nierenzentrum für Kinder und Jugendliche, Hamburg, Germany|KfH-Nierenzentrum fur Kinder und Jugendliche, Heidelberg, Germany|Klinik der Uni zu Köln; Kinderklinik, Köln, Germany|Kinderklinik Memmingen; Kinderdialysezentrum, Memmingen, Germany|KfH-Nierenzentrum für Kinder und Jugendliche, Münster, Germany|Semmelweis University; 1st Department of Pediatrics, Pediatric Nephrology Center, Budapest, Hungary|Ospedale Pediatrico Bambino Gesu; U.O. Di Nefrologia E Dialisi, Roma, Lazio, Italy|IRCCS G. Gaslini; U.O. Nefrologia, Dialisi e Trapianto, Genova, Liguria, Italy|Ospedale Infantile Regina Margherita; U.O. Autonoma di Nefrologia, Dialisi e Trapianto, Torino, Piemonte, Italy|A.O. Di Padova; Dipartimento Di Pediatria U.O. Di Nefrologia Pediatrica, Dialisi e Trapianto, Padova, Veneto, Italy|Uniwersyteckie Centrum Kliniczne; Klinika Chorob Nerek i Nadciśnienia Dzieci i Mlodziezy, Gdansk, Poland|Instytut ""Centrum Zdrowia Matki Polki; Klinika Nefrologii i Dializoterapii, Lodz, Poland|Dzieciecy Szpital Kliniczny; Klinika Nefrologii Dzieciecej, Lublin, Poland|SPSZOZ Zdroje Oddzial Pediatrii; Nefrologii i Toksykologii ze Stacja Dializ, Szczecin, Poland|Wojewodzki Szpital Dzieciecy; Osrodek Chorob Nerek i Dializoterapii, Torun, Poland|Instytut Pomnik-Centrum Zdrowia Dziecka, Klinika Nefrologii, Transp. Nerek i Nadcisnienia Tetniczego, Warszawa, Poland|Akademia Medyczna im. Piastow Slaskich; Katedra i Klinika Nefrologii Pediatrycznej, Wroclaw, Poland|Fundeni Clinical Institute, Bucharest, Romania|St. Maria Emergency Clinical Hospital for Children, Iasi, Romania|DGCB St. Vladimir; Pediatric nephrologist, Moscow, Russian Federation|SBIH Children City Hospital #1; Dialysis department, Saint-Petersburg, Russian Federation|Hospital Universitari Vall d'Hebron; Servicio de Nefrologia, Barcelona, Spain|Hospital Universitario La Paz: Nefrologia Pediatrica, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Nefrologia Pediatrica, Sevilla, Spain|Hospital Universitario la Fe; Servicio de Nefrologia Pediatrica, Valencia, Spain|Chulalongkorn university Faculty of Medicine;Department of Pediatrics, Bangkok, Thailand|Siriraj Hospital, Faculty of Medicine; Department of Pediatrics, Bangkok, Thailand|Kiev city childrens nephrological center of hospital #1; Nephrology and RRT, Kiev, Ukraine|Public Institution Zaporizhzhia City Multispecialty Children's Hospital #5; Allergologic, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT00717366"
302,"NCT00924781","A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)",,"Terminated","Has Results","Anemia|Chronic Kidney Disease","Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|Drug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|Drug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline","Change From Baseline in Hemoglobin (Hg) Level at Week 4|Number of Participants With Composite Events of Death, Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)|Number of Participants With Composite Events of Transfusion-Related Adverse Experiences|Number of Participants With Composite Events of Infusion Reactions|Number of Participants With Events of Death, MI, CVA, Peripheral Vascular Thromboses, Vascular Access Thrombosis, Congestive Heart Failure (CHF), Hypertension, Seizure, or Pure Red Cell Aplasia|Number of Participants With Confirmed, Treatment Emergent Antibodies to MK2578|Change From Baseline in Hg Level at Week 12","Merck Sharp & Dohme LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2578-003|2009_603","June 2009","April 2010","May 2010","June 19, 2009","March 29, 2012","November 1, 2015",,,"https://ClinicalTrials.gov/show/NCT00924781"
303,"NCT00548860","Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients",,"Completed","Has Results","Anemia","Drug: Ferric Carboxymaltose|Drug: Standard Medical Care (SMC)","Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.","American Regent, Inc.","Female","Child, Adult, Older Adult","Phase 3","2018","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1VIT07017","October 2007","March 2009","July 2009","October 24, 2007","May 29, 2015","February 20, 2018","Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00548860"
304,"NCT02021318","Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","Dolomites","Completed","Has Results","Anemia in Chronic Kidney Disease in Non-dialysis Patients","Drug: Roxadustat|Drug: Darbepoetin alfa","Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy|Change From Baseline in Hb to the Average Hb of Weeks 28 to 36 Without Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period|Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28|Time to First Intravenous Iron Use|Change From Baseline in Short Form-36 (SF-36) Physical Functioning (PF) Sub-Score to the Average PF Sub Score in Weeks 12 to 28|Change From Baseline in SF-36 Vitality (VT) Sub-Score to the Average VT Sub-Score in Weeks 12 to 28|Change From Baseline in Mean Arterial Pressure (MAP) to the Average MAP Value in Weeks 20 to 28: Per Protocol Set|Time to First Occurrence of Hypertension During Weeks 1 to 36: Per Protocol Set|Change From Baseline in MAP to the Average MAP Value in Weeks 20 to 28: Full Analysis Set|Time to First Occurrence of Hypertension During Weeks 1 to 36: Full Analysis Set|Change From Baseline in Hb to the Average Hb Value of Weeks 28 to 52 Regardless of Rescue Therapy|Time to First Hb Response During First 24 Weeks of Treatment Regardless of Administration of Rescue Therapy|Time to First Hb Response During First 24 Weeks of Treatment Without Rescue Therapy|Hb Level Averaged Over Weeks 28 to 36, 44 to 52, 72 to 80 and 96 to 104 Without Rescue Therapy|Change From Baseline in Hb to Each Postdosing Time Point Regardless Use of Rescue Therapy|Change From Baseline in Hb to Average Hb Value of Weeks 28 to 36, 44 to 52, 72 to 80, 96 to 104 Regardless of Use of Rescue Therapy|Percentage of Hb Values >=10 g/dL and Within 10.0 to 12.0 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy|Time to First Hb Rate of Rise > 2 g/dL Within 4 Weeks|Number of Hospitalizations|Number of Days of Hospitalization Per Year|Time to First Hospitalization|Time to First Use of RBC Transfusion|Number of RBC Packs|Volume of RBC Transfused|Number of Particpants Who Received RBC Transfusions|Time to First Use of Rescue Therapy|Number of Participants Who Received Rescue Therapy (Composite of RBC Transfusions (All Participants) and Darbepoetin Alfa Use (Roxadustat Treated Participants Only)|Mean Monthly Intravenous Iron Per Participant During Weeks 37 to 52 and 53 to 104|Time to First Use of IV Iron Supplementation|Percentage of Participants With Oral Iron Use Only|Change From Baseline to Weeks 8, 28, 52 and 104 in Total Cholesterol|Change From Baseline to Weeks 8, 28, 52 and 104 in LDL-C/High-Density Lipoprotein Cholesterol (HDL-C) Ratio|Change From Baseline to Weeks 8, 28, 52 and 104 in Non-HDL Cholesterol|Change From Baseline to Weeks 8, 28, 52 and 104 in Apolipoproteins A1 (ApoA1)|Change From Baseline to Weeks 8, 28, 52 and 104 in Apolipoproteins B (ApoB)|Change From Baseline to Weeks 8, 28, 52 and 104 in ApoB/ApoA1 Ratio|Number of Participants With Mean LDL Cholesterol < 100 mg/dL|Number of Participants Who Had Achieved Antihypertensive Treatment Goal|Change From Baseline to the Average of Weeks 12 to 28 and 36 to 52 in SF-36 Physical Component Score (PCS)|Change From Baseline to the Average of Weeks 12 to 28 and 36 to 52 in Anemia Subscale (AnS) (Additional Concerns) of Functional Assessment of Cancer Therapy-Anemia (FACT-An) Score|Change From Baseline to the Average Value of Weeks 12 to 28 and 36 to 52 in FACT-An Total Score|Change From Baseline to the Average Value of Weeks 12 to 28 and 36 to 52 in FACT-An Trial Outcome Index (TOI) Score|Change From Baseline to the Average Value of Weeks 12 to 28 in Euroqol Questionnaire-5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score|Change From Baseline to the Average Value of Weeks 12 to 28 and 36 to 52 in Work Productivity and Activity Impairment-Anemic Symptoms (WPAI:ANS) Score: Percent Work Time Missed|Change From Baseline to the Average Value of Weeks 12 to 28 and 36 to 52 in WPAI:ANS Score: Percent Impairment While Working|Change From Baseline to the Average Value of Weeks 12 to 28 and 36 to 52 in WPAI:ANS Score: Percent Overall Work Impairment|Change From Baseline to the Average Value of Weeks 12 to 28 and 36 to 52 in WPAI:ANS Score: Percent Activity Impairment|Percentage of Participants With Improvements Measured by Patients' Global Impression of Change (PGIC)|Change From Baseline to Each Scheduled Measurement in Serum Ferritin|Change From Baseline to Each Scheduled Measurement in Transferrin Saturation (TSAT)|Change From Baseline to Each Scheduled Measurement in Glycated Hemoglobin (HbA1c)|Change From Baseline to Each Scheduled Measurement in Fasting Blood Glucose|Change From Baseline to Each Scheduled Measurement in Estimated Glomerular Filtration Rate (eGFR)|Rate of Progression of Chronic Kidney Disease Measured by eGFR Slope Over Time|Change From Baseline to Each Scheduled Measurement in Urine Albumin/Creatinine Ratio (UACR)|Time to Doubling of Serum Creatinine or Chronic Dialysis or Renal Transplant Compared to Baseline|Number of Participants With End Stage Renal Disease (ESRD)|Time to Chronic Kidney Disease Progression (Composite of Doubling Serum Creatinine, Chronic Dialysis or Renal Transplant, and Death)|Time to Chronic Dialysis or Renal Transplant or Death|Time to at Least 40% Decrease in eGFR From Baseline, Chronic Dialysis or Renal Transplant|Number of Participants With Treatment Emergent Adverse Events (TEAEs)","Astellas Pharma Europe B.V.|FibroGen|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","616","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1517-CL-0610|2013-000951-42","March 12, 2014","March 23, 2018","November 6, 2019","December 27, 2013","March 29, 2021","May 13, 2021","Site AT43009, Vienna, Austria|Site BY37503, Brest, Belarus|Site BY37501, Grodno, Belarus|Site BY37506, Minsk, Belarus|Site BY37507, Minsk, Belarus|Site BY37505, Minsk, Belarus|Site BY37502, Vitebsk, Belarus|Site BG35907, Sofia, Bulgaria|Site BG35927, Sofia, Bulgaria|Site BG35916, Varna, Bulgaria|Site HR38505, Karlovac, Croatia|Site HR38504, Slavonski Brod, Croatia|Site HR38510, Zagreb, Croatia|Site HR38502, Zagreb, Croatia|Site HR38509, Zagreb, Croatia|Site CZ42018, Novy Jicin, CZ, Czechia|Site CZ42008, Liberec, Czechia|Site CZ42021, Prague, Czechia|Site FI35810, Helsinki, Finland|Site FR33004, Avignon, France|Site FR33009, Colmar, France|Site FR33010, Grenoble, France|Site FR33062, Limoges, France|Site FR33012, Lyon, France|Site FR33007, Saint-Priest-en-Jarez, France|Site GE99503, Tbilisi, Georgia|Site GE99504, Tbilisi, Georgia|Site GE99502, Tbilisi, Georgia|Site DE49073, Cloppenburg, Germany|Site DE49054, Düsseldorf, Germany|Site DE49065, Hamburg, Germany|Site DE49075, Heilbronn, Germany|Site DE49057, Hoyerswerda, Germany|Site HU36028, Budapest, Hungary|Site HU36029, Budapest, Hungary|Site HU36027, Kistarcsa, Hungary|Site HU36008, Pecs, Hungary|Site HU36046, Velence, Hungary|Site IE35301, Cork, Ireland|Site IL97202, Be'er Ya'akov, Israel|Site IL97215, Haifa, Israel|Site LV37101, Riga, Latvia|Site LV37104, Ventspils, Latvia|Site ME38202, Niksic, Montenegro|Site ME38201, Podgorica, Montenegro|Site NL31005, Utrecht, Netherlands|Site MK38901, Skopje, North Macedonia|Site MK38903, Struga, North Macedonia|Site PL48001, Krakow, Poland|Site PL48066, Pulawy, Poland|Site PL48013, Szczecin, Poland|Site PL48007, Tarnow, Poland|Site PL48004, Warszawa, Poland|Site PL48009, Wroclaw, Poland|Site PL48059, Zamosc, Poland|Site PT35120, Almada, Portugal|Site PT35131, Braga, Portugal|Site PT35112, Carnaxide, Portugal|Site PT35119, Evora, Portugal|Site PT35118, Lisboa, Portugal|Site PT35133, Matosinhos, Portugal|Site PT35122, Setubal, Portugal|Site PT35132, Vila Nova de Gaia, Portugal|Site RO40003, Bucharest, Romania|Site RO40021, Bucharest, Romania|Site RO40012, Bucuresti, Romania|Site RO40004, Oradea, Romania|Site RU70024, Chelyabinsk, Russian Federation|Site RU70054, Irkutsk, Russian Federation|Site RU70047, Moscow, Russian Federation|Site RU70006, Moscow, Russian Federation|Site RU70003, Nizhny Novgorod, Russian Federation|Site RU70004, Omsk, Russian Federation|Site RU70014, Rostov-on-Don, Russian Federation|Site RU70011, Saint Petersburg, Russian Federation|Site RU70002, Saint Petersburg, Russian Federation|Site RU70060, Saratov, Russian Federation|Site RU70057, Yaroslavl, Russian Federation|Site RU70001, Yaroslavl, Russian Federation|Site RS38102, Belgrade, Serbia|Site RS38105, Belgrade, Serbia|Site RS38103, Belgrade, Serbia|Site RS38104, Belgrade, Serbia|Site RS38117, Krusevac, Serbia|Site RS38101, Nis, Serbia|Site SK42109, Kosice, Slovakia|Site SK42102, Košice, Slovakia|Site SK42113, Puchov, Slovakia|Site SK42116, Senica, Slovakia|Site SI38615, Jesenice, Slovenia|Site SI38603, Maribor, Slovenia|Site SI38619, Slovenj Gradec, Slovenia|Site SI38609, Šempeter pri Gorici, Slovenia|Site ES34049, Ferrol, A Coruna, Spain|Site ES34026, Barcelona, Spain|Site ES34039, Cordoba, Spain|Site ES34054, Girona, Spain|Site ES34017, Jaen, Spain|Site ES34037, Madrid, Spain|Site ES34010, Madrid, Spain|Site ES34030, Majadahonda, Spain|Site ES34041, Santiago de Compostela, Spain|Site UA38009, Lviv, Lvivska, Ukraine|Site UA38021, Cherkasy, Ukraine|Site UA38006, Dnipropetrovsk, Ukraine|Site UA38016, Ivano-Frankivsk, Ukraine|Site UA38011, Kharkiv, Ukraine|Site UA38017, Kiev, Ukraine|Site UA38007, Mykolaiv, Ukraine|Site UA38008, Odessa, Ukraine|Site UA38001, Ternopil, Ukraine|Site UA38018, Uzhgorod, Ukraine|Site GB44098, Dorchester, Dorset, United Kingdom|Site GB44064, Birmingham, United Kingdom|Site GB44099, Dartford, United Kingdom|Site GB44102, Kings Lynn, United Kingdom|Site GB44081, Leicester, United Kingdom|Site GB44086, London, United Kingdom|Site GB44006, London, United Kingdom|Site GB44082, London, United Kingdom|Site GB44097, Nottingham, United Kingdom|Site GB44100, Orpington, United Kingdom|Site GB44101, Preston, United Kingdom|Site GB44080, Stoke-on-Trent, United Kingdom|Site GB44001, Swansea, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/18/NCT02021318/Prot_002.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/18/NCT02021318/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT02021318"
305,"NCT01768351","Paricalcitol Effect on Anemia in CKD",,"Completed","No Results Available","Anemia|Chronic Kidney Disease","Drug: Paricalcitol|Drug: Calcitriol","Modification in hemoglobin levels|Modifications in urinary protein excretion","Federico II University","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCX1234|paranemia","October 2010","March 2011","October 2012","January 15, 2013",,"July 30, 2014","Federico II University, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT01768351"
306,"NCT03799627","Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa","FO2RWARD-2","Completed","Has Results","Anemia|Dialysis-dependent Chronic Kidney Disease","Drug: Vadadustat|Drug: Epoetin Alfa|Drug: Vadadustat TIW","Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP)|Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values|Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values|Number of Participants Classified as Hb Outliers|Number of Participants With Hb Values Within the Target Range at the PEP|Mean Change in Hb From the PEP to the Secondary Evaluation Period (SEP) in Participants Who Transitioned to Three Times Per Week (TIW) Vadadustat Dosing After Week 12|Mean Change in Hb Between Baseline and the SEP|Number of Participants With Hb Values Within the Target Range at the SEP|Number of Participants With Hb Values Within the Target Range at the SEP in Participants Who Transitioned to TIW Vadadustat Dosing|Number of Participants With a Mean Increase in Hb From Baseline to the PEP ≥0.5 g/dL or With Hb Values Within the Target Range at the PEP|Number of Participants With a Mean Increase in Hb From Baseline to the SEP ≥0.5 g/dL or With Hb Values Within the Target Range at the SEP|Number of Participants Requiring at Least One Intravenous (IV) Elemental Iron Supplementation|Number of Participants Requiring Erythropoiesis-stimulating Agent (ESA) Rescue|Number of Participants Requiring Red Blood Cell (RBC) Transfusion|Mean Serum Concentration of Erythropoietin (EPO) for Vadadustat Treatment Groups by Strata of Epoetin Alfa Dose Group|Mean Change From Baseline in Reticulocyte Count|Mean Change From Baseline in Iron Concentration|Mean Change From Baseline in Ferritin Concentration|Mean Change From Baseline in Total Iron Binding Capacity|Mean Change From Baseline in Hepcidin Concentration|Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Vadadustat Following a Single Dose|Geometric Mean Area Under the Concentration-time Curve (AUC) From Time 0 to 24 Hours (AUC0-24) of Vadadustat Following a Single Dose|Median Terminal Half-life (t1/2) of Vadadustat Following a Single Dose|Median Time to Reach Cmax (Tmax) of Vadadustat Following a Single Dose|Geometric Mean Elimination Rate Constant (λz) of Vadadustat Following a Single Dose|Geometric Mean Apparent Total Body Clearance (CLss/F) of Vadadustat Following a Single Dose|Geometric Mean Apparent Volume of Distribution (Vz/F) of Vadadustat Following a Single Dose","Akebia Therapeutics","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","175","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0025","January 31, 2019","June 5, 2020","July 15, 2020","January 10, 2019","September 29, 2022","September 29, 2022","Research Site, Fresno, California, United States|Research Site, Granada Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Riverside, California, United States|Research Site #1, San Dimas, California, United States|Research Site #2, San Dimas, California, United States|Research Site, San Gabriel, California, United States|Research Site, Tarzana, California, United States|Research Site, Vacaville, California, United States|Research Site, Victorville, California, United States|Research Site, Denver, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Hartford, Connecticut, United States|Research Site, Coral Gables, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Statesboro, Georgia, United States|Research Site, Roseville, Michigan, United States|Research Site #1, Minneapolis, Minnesota, United States|Research Site #2, Minneapolis, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bronx, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Wauwatosa, Wisconsin, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/27/NCT03799627/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/27/NCT03799627/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03799627"
307,"NCT04155125","A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient",,"Completed","No Results Available","Anaemia Associated With Chronic Kidney Disease","Drug: efepoetin alfa|Drug: Mircera","To assess the efficacy of efepoetin alfa in the treatment of anaemia associated with CKD as measured by haemoglobin (Hb) response rate at the end of correction treatment evaluation period|Characterise safety and tolerability of subcutaneous efepoetin alfa is being measured by based on the frequency of adverse events and on the number of out of range laboratory values.","PT Kalbe Genexine Biologics|Novotech (Australia) Pty Limited","All","18 Years and older   (Adult, Older Adult)","Phase 3","391","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GXE4KGBio-001","July 2, 2020","March 30, 2022","June 30, 2023","November 7, 2019",,"December 22, 2023","Renal Research Gosford, Gosford, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Rspad Gatot Soebroto, Jakarta Pusat, Indonesia|Rumah Sakit Islam Jakarta Cempaka Putih, Jakarta Pusat, Indonesia|Rumah Sakit Islam Jakarta Pondok Kopi, Jakarta Pusat, Indonesia|Rumah Sakit Pgi Cikini, Jakarta Pusat, Indonesia|Rumah Sakit Umum Pusat Fatmawati, Jakarta Pusat, Indonesia|Rumah Sakit Umum Pusat Nasional Dr Cipto Mangunkusumo, Jakarta Pusat, Indonesia|Chungnam National University Hospital, Daejeon, Korea, Republic of|Korea University Ansan Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea Incheon St. Mary'S Hospital, Incheon, Korea, Republic of|Chungnam National University Sejong Hospital, Sejong, Korea, Republic of|Kyung Hee University Hospital At Gangdong, Seoul, Korea, Republic of|The Catholic University of Korea Eunpyeong St. Mary'S Hospital, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary'S Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Yeouido St. Mary'S Hospital, Seoul, Korea, Republic of|Seri Manjung Hospital, Seri Manjung, Perak, Malaysia|University of Malaya Medical Centre, Kuala Lumpur, Selangor, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Malaysia|Hospital Kajang, Kajang, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Malaysia|Hospital Serdang, Serdang, Malaysia|Hospital Sibu, Sibu, Malaysia|M3 Dialysis Center, Bacolod City, Philippines|Baguio General Hospital Medical Center, Baguio, Philippines|Norzel Medical and Diagnostic Clinic, Cebu City, Philippines|De La Salle Medical and Health Sciences Institute, Dasmariñas, Philippines|Davao Doctors Hospital, Davao City, Philippines|West Visayas State University Hospital, Iloilo City, Philippines|National Kidney and Transplant Institute, Quezon, Philippines|Changhua Christian Hospital, Changhua, Taiwan|Hualien Tzu Chi Hospital, Hualien City, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Kaohsiung Chang Gung Hospital, Kaohsiung, Taiwan|Keelung Chang Gung Memorial Hospital, Keelung, Taiwan|Taiching Veterans General Hospital, Taichung, Taiwan|Kuang Tien General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Far Eastern Memorial Hospital, Taipei, Taiwan|Taipei Medical University - Shuang Ho Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan|Vajira Hospital, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Thammasat University Hospital, Pathum Thani, Thailand|Songklanagarind Hospital, Songkhla, Thailand|Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand",,"https://ClinicalTrials.gov/show/NCT04155125"
308,"NCT02444845","Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan",,"Completed","No Results Available","Anemia, Diabetes, Kidney Disease, Chronic, Hypertension",,"Number of patients with anemia secondary to CKD|Use of treatment modalities for the management of anemia secondary to CKD","Hoffmann-La Roche","All","40 Years and older   (Adult, Older Adult)",,"246","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ML27762","May 2011","August 2012","August 2012","May 15, 2015",,"March 20, 2018","Islamabad, Pakistan|Karachi, Pakistan|Lahore, Pakistan",,"https://ClinicalTrials.gov/show/NCT02444845"
309,"NCT03461146","Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan",,"Completed","Has Results","Anemia; Hemodialysis Dependent Chronic Kidney Disease","Drug: MT-6548","Mean Hb Level of Week 20 and Week 24|Hb Level at Each Assessment Time Point|Percentage of Subjects With Hb Level at Each Assessment Time Point Within the Target Range During the Treatment Period|Time to Reach the Target Hb Range|Rate of Increase in Hb Level","Mitsubishi Tanabe Pharma Corporation","All","20 Years and older   (Adult, Older Adult)","Phase 3","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT-6548-J04","March 5, 2018","December 3, 2018","December 17, 2018","March 9, 2018","May 7, 2021","December 29, 2023","Research site, Aichi, Japan|Research site, Chiba, Japan|Research site, Fukushima, Japan|Research site, Gunma, Japan|Research site, Hokkaido, Japan|Research site, Hyogo, Japan|Research site, Ibaraki, Japan|Research site, Kagoshima, Japan|Research site, Nagano, Japan|Research site, Okayama, Japan|Research site, Okinawa, Japan|Research site, Osaka, Japan|Research site, Saitama, Japan|Research site, Shiga, Japan|Research site, Shizuoka, Japan|Research site, Yamagata, Japan","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/46/NCT03461146/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/46/NCT03461146/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03461146"
310,"NCT02625844","Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia",,"Completed","Has Results","Renal Anemia of Chronic Kidney Disease","Other: No intervention","Average Observed Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents (ESAs)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)",,"110","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ML25720","September 2011","August 2012","August 2012","December 9, 2015","March 3, 2016","March 3, 2016","Bjelovar, Croatia|Split, Croatia|Zadar, Croatia|Zagreb, Croatia",,"https://ClinicalTrials.gov/show/NCT02625844"
311,"NCT03329196","Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan",,"Completed","Has Results","Anemia; Non-dialysis Dependent Chronic Kidney Disease","Drug: MT-6548|Drug: Darbepoetin alfa","Mean Hb Level of Week 20 and Week 24|Mean Hb Level of Week 48 and Week 52|Hb Level at Each Assessment Time Point|Percentage of Subjects With Hb Level at Each Assessment Time Point Within the Target Range During the Treatment Period|Time to Reach the Target Hb Range in Correction Group Only|Rate of Increase in Hb Level in Correction Group Only","Mitsubishi Tanabe Pharma Corporation","All","20 Years and older   (Adult, Older Adult)","Phase 3","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT-6548-J01","October 30, 2017","January 8, 2019","August 9, 2019","November 1, 2017","April 12, 2021","December 28, 2023","Research site, Aichi, Japan|Research site, Chiba, Japan|Research site, Fukui, Japan|Research site, Fukuoka, Japan|Research site, Fukushima, Japan|Research site, Gunma, Japan|Research site, Hiroshima, Japan|Research site, Hokkaido, Japan|Research site, Hyogo, Japan|Research site, Ibaraki, Japan|Research site, Kagoshima, Japan|Research site, Kanagawa, Japan|Research site, Kochi, Japan|Research site, Kumamoto, Japan|Research site, Kyoto, Japan|Research site, Miyagi, Japan|Research site, Nagano, Japan|Research site, Nagasaki, Japan|Research site, Nara, Japan|Research site, Niigata, Japan|Research site, Oita, Japan|Research site, Okayama, Japan|Research site, Okinawa, Japan|Research site, Osaka, Japan|Research site, Saga, Japan|Research site, Saitama, Japan|Research site, Shiga, Japan|Research site, Shizuoka, Japan|Research site, Tokyo, Japan|Research site, Toyama, Japan|Research site, Yamanashi, Japan","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/96/NCT03329196/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/96/NCT03329196/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03329196"
312,"NCT03402386","Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan",,"Completed","Has Results","Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease","Drug: MT-6548","Mean Hb Level of Week 20 and Week 24|Hb Level at Each Assessment Time Point|Percentage of Subjects With Hb Level at Each Assessment Time Point Within the Target Range During the Treatment Period|Time to Reach the Target Hb Range in Correction Group Only|Rate of Increase in Hb Level in Correction Group Only","Mitsubishi Tanabe Pharma Corporation","All","20 Years and older   (Adult, Older Adult)","Phase 3","42","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT-6548-J02","January 3, 2018","November 22, 2018","December 20, 2018","January 18, 2018","July 6, 2021","December 28, 2023","Research site, Aichi, Japan|Research site, Chiba, Japan|Research site, Fukuoka, Japan|Research site, Fukushima, Japan|Research site, Gunma, Japan|Research site, Hokkaido, Japan|Research site, Hyogo, Japan|Research site, Ibaraki, Japan|Research site, Kagoshima, Japan|Research site, Kanagawa, Japan|Research site, Kyoto, Japan|Research site, Nagano, Japan|Research site, Nara, Japan|Research site, Okayama, Japan|Research site, Okinawa, Japan|Research site, Shiga, Japan|Research site, Tokyo, Japan","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/86/NCT03402386/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/86/NCT03402386/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03402386"
313,"NCT01763242","Study of the Effect of Synchronised Anaemia Management in Chronic Kidney Disease","EMAN-Anaemia","Completed","No Results Available","Kidney Failure, Chronic|Anemia","Other: EMAN","Haemoglobin|All Cause Hospitalisation|Outpatient Review Numbers|Primary Care review Numbers|Cardiovascular Hospitalisation|Cerebrovascular Hospitalisation|Peripheral Vascular Hospitalisation|Thrombosis Events|Renal Replacement Therapy Commencement|Deaths|Quality of Life|Missed Doses of ESA|Fe Targets|Blood Transfusion Numbers|Fe Transfusion Numbers|Total Adverse Events|Anaemia Co-Ordinator Time|Pharmacy Time|Courier Costs|Ambulance Transfer Numbers|Cardiac and Vascular Biomarker Analysis","Western Health, Australia","All","18 Years and older   (Adult, Older Adult)","Phase 4","102","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HREC: 2010.267","December 2011","December 2012","December 2012","January 8, 2013",,"January 8, 2013","Western Health, Footscray, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01763242"
314,"NCT03439137","Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan",,"Completed","Has Results","Anemia; Hemodialysis Dependent Chronic Kidney Disease","Drug: MT-6548|Drug: Darbepoetin alfa|Drug: MT-6548-matching placebo|Drug: Darbepoetin alfa-matching placebo","Mean Hb Level of Week 20 and Week 24|Mean Hb Level of Week 48 and Week 52|Hb Level at Each Assessment Time Point|Percentage of Subjects With Hb Level at Each Assessment Time Point Within the Target Range During the Treatment Period","Mitsubishi Tanabe Pharma Corporation","All","20 Years and older   (Adult, Older Adult)","Phase 3","323","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MT-6548-J03","February 14, 2018","December 12, 2018","July 16, 2019","February 20, 2018","April 12, 2021","December 28, 2023","Research site, Aichi, Japan|Research site, Chiba, Japan|Research site, Fukui, Japan|Research site, Fukuoka, Japan|Research site, Fukushima, Japan|Research site, Gunma, Japan|Research site, Hiroshima, Japan|Research site, Hokkaido, Japan|Research site, Hyogo, Japan|Research site, Ibaraki, Japan|Research site, Kagawa, Japan|Research site, Kagoshima, Japan|Research site, Kanagawa, Japan|Research site, Kumamoto, Japan|Research site, Kyoto, Japan|Research site, Miyagi, Japan|Research site, Nagano, Japan|Research site, Nagasaki, Japan|Research site, Oita, Japan|Research site, Okayama, Japan|Research site, Okinawa, Japan|Research site, Osaka, Japan|Research site, Saitama, Japan|Research site, Shiga, Japan|Research site, Shizuoka, Japan|Research site, Tokushma, Japan|Research site, Tokyo, Japan|Research site, Yamagata, Japan","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/37/NCT03439137/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/37/NCT03439137/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03439137"
315,"NCT02128074","A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia",,"Completed","Has Results","Anemia of Chronic Kidney Disease","Drug: KRX-0502","Change in Hemoglobin From Baseline to the End of 8-week Treatment Period","Keryx Biopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KRX-0502-207","April 2014","November 2014","November 2014","May 1, 2014","August 24, 2018","August 24, 2018","Barzilai Medical Center, Ashkelon, Israel|Western Galilee Hospital, Nahariya, Israel|Nazareth Hospital- EMMS, Nazareth, Israel",,"https://ClinicalTrials.gov/show/NCT02128074"
316,"NCT01264679","A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease",,"Terminated","Has Results","Iron Deficiency Anemia","Drug: Ferumoxytol","Mean Change In Hemoglobin From Baseline To Week 5|Proportion Of Participants With An Increase In Hemoglobin From Baseline To Week 5 And To Week 7|Mean Change In TSAT From Baseline To Week 5 And To Week 7","AMAG Pharmaceuticals, Inc.","All","6 Months to 17 Years   (Child)","Phase 3","8","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMAG-FER-CKD-253","December 27, 2011","April 24, 2015","April 24, 2015","December 22, 2010","November 6, 2017","April 28, 2022","AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01264679"
317,"NCT05970172","A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Disease|Renal Anemia","Drug: Roxadustat","Change from baseline in Hb level to the average Hb level over treatment weeks 20 to 24|Pharmacokinetics (PK) of roxadustat in plasma: Maximum concentration (Cmax)|PK of roxadustat in plasma: Area under the plasma-concentration time curve (AUC)|PK of roxadustat in plasma: Apparent total clearance (CL/F)|PK of roxadustat in plasma: Time of the maximum concentration (Tmax)|Hb levels at all timepoints|Dose titration history at all timepoints|Number of participants with treatment-emergent adverse events (TEAEs)|Number of participants with treatment-emergent cardiovascular AEs|Number of participants with treatment-emergent thrombotic AEs|Number of participants with laboratory value abnormalities and/or AEs|Number of participants with vital sign abnormalities and/or AEs|Change from baseline in growth parameter value: Height|Change from baseline in growth parameter value: Weight|Number of participants with physical examinations abnormalities and/or AEs|Percentage of participants with Hb response|Mean monthly intravenous (IV) iron use|Mean Monthly total IV iron dosage|Percentage of participants using IV iron|Percentage of participants using oral iron|Percentage of participants using rescue therapy|Palatability questionnaire|Change from baseline in Pediatric Quality of Life (PedsQL) Inventory Score|Change from baseline in PedsQL Multidimensional Fatigue Scale questionnaire QoL Score","Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","All","2 Years to 17 Years   (Child)","Phase 3","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1517-CL-1003","January 16, 2024","November 30, 2025","June 30, 2026","August 1, 2023",,"April 15, 2024","Site BE32003, Leuven, Belgium|Site DK45001, Aarhus, Denmark|Site DE49001, Tubingen, Germany|Site NO47002, Oslo, Norway|Site RO40002, Clug Napoca, Romania|Site RO40001, Timisoara, Romania|Site SK42101, Bratislava, Slovakia|Site SP34001, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT05970172"
318,"NCT00364845","STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients",,"Terminated","Has Results","Anemia|Chronic Kidney Disease","Drug: Darbepoetin alfa|Drug: Placebo","Short Form 36 Health Survey Questionnaire (SF-36) Vitality Subscale Score at Week 24|Number of Participants With Hemoglobin (Hb) ≥ 110 g/L|Mean Hemoglobin During the Evaluation Period|Euroqol 5 Dimension (EQ-5D) Utility Score at Week 24","Amgen","All","70 Years and older   (Older Adult)","Phase 3","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20050122","September 2006","December 2008","February 2009","August 16, 2006","May 21, 2014","May 21, 2014",,,"https://ClinicalTrials.gov/show/NCT00364845"
319,"NCT01155375","A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease",,"Terminated","Has Results","Iron Deficiency Anemia","Drug: Ferumoxytol|Drug: Oral Iron","Mean Change In Hemoglobin From Baseline To Week 5|Pharmacokinetics: Area Under The Curve Of Ferumoxytol","AMAG Pharmaceuticals, Inc.","All","6 Months to 17 Years   (Child)","Phase 3","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMAG-FER-CKD-251","October 17, 2011","June 24, 2014","June 24, 2014","July 1, 2010","November 6, 2017","April 4, 2022","AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01155375"
320,"NCT01379963","A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)",,"Completed","Has Results","Anemia, Kidney Disease, Chronic",,"Percentage of Participants Who Achieved a 3-month Hemoglobin Level Stabilization in the Range of 11-12 Grams Per Deciliter (g/dL)|Percentage of Participants Who Achieved a 6-month Hemoglobin Level Stabilization in the Range of 11-12 g/dL","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)",,"780","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ML22014","April 30, 2009","February 28, 2011","February 28, 2011","June 23, 2011","December 24, 2015","July 13, 2017","General Hospital of Artas; Nephrology, Arta, Greece|Pantokrator Private Clinic; Nephrology, Athens, Greece|Attikon Center; Nephrology, Athens, Greece|Athinaiki Private Clinic, Athens, Greece|Kyanos Stavros Private Hospital; Nephrologic Clinic, Athens, Greece|Iaso General Private Clinic; Nephrology, Athens, Greece|Iatriko Athinon Clinic Dafnis; Nephrology Department, Daphni-athens, Greece|Timios Stavros Clinic; Nephrology Department, Egaleo, Greece|Kyanous Stavros of Patras, Renal Disease Therapy Unit, Patra, Greece|Olympion Therapeytirion; Nefrology, Patra, Greece|Iasis Private Clinic, Pireus, Greece|General Hospital Of Chalkidikis; Dialysis Center Unit, Polygyros, Greece|Diavalkaniko Kentro; Nephrology, Thessaloniki, Greece|General Hospital of Thessalonikis G.Papanikolaou; Nephrology, Thessaloniki, Greece|Alfa Nefrodynamiki; Nefrology, Thessaloniki, Greece|Thessaliki Nossileytiki; Nephrology, Volos, Greece|General Hospital of Volos; Nephrology, Volos, Greece",,"https://ClinicalTrials.gov/show/NCT01379963"
321,"NCT01519947","A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis","ALTITUD","Completed","Has Results","Anemia, Kidney Disease, Chronic","Drug: Methoxy polyethylene glycol-epoetin beta","Mean Dose Required to Achieve Target Hemoglobin of 11-12 g/dL|Change in Hemoglobin Concentration|Percentage of Participants Achieving Target Hemoglobin Concentration 11-12 g/dL After 3 and 6 Months of Treatment|Percentage of Participants With Adverse Events|Percentage of Participants Requiring Dose Adjustments|Incidence of Red Blood Cell Transfusions","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","87","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML25754","May 30, 2012","May 30, 2015","May 30, 2015","January 27, 2012","December 27, 2018","June 19, 2019","Clínica San Cosme Centro Especializado en el Tratamiento de Enfermedades Renales S.C, Aguascalientes, Mexico|Nefros Investigación S.C., Delegación Coyoacan, Mexico|Centro de hemodialisis del norte S.C., Mexicali, Mexico|Hospital Angeles Lindavista;Nefrologia, Mexico City, Mexico|Hospital Star Medica Morelia, Morelia, Mexico|Unidad De Dialisis La Loma S.C., Pureto Vallarta, Mexico|Hospital Regional De Alta Especialidad De Veracruz; Nephrology, Veracruz, Mexico",,"https://ClinicalTrials.gov/show/NCT01519947"
322,"NCT02648347","Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease",,"Completed","Has Results","Anemia|Non-Dialysis-Dependent Chronic Kidney Disease","Drug: Vadadustat|Drug: Darbepoetin alfa","Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)|Median Time to First Major Adverse Cardiovascular Event (MACE)|Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)|Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis|Median Time to First Cardiovascular MACE|Median Time to First Cardiovascular Death|Median Time to First All-cause Mortality","Akebia Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","1751","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0014|2015-004265-81","December 2015","June 4, 2020","July 31, 2020","January 7, 2016","June 27, 2022","June 27, 2022","Research Site, Huntsville, Alabama, United States|Research Site, Tuscumbia, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Bakersfield, California, United States|Research Site #1, Chula Vista, California, United States|Research Site #2, Chula Vista, California, United States|Research Site #1, Fountain Valley, California, United States|Research Site #2, Fountain Valley, California, United States|Research Site, Glendale, California, United States|Research Site, Granada Hills, California, United States|Research Site, La Mesa, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site #2, Northridge, California, United States|Research Site, Northridge, California, United States|Research Site, Riverside, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, Salinas, California, United States|Research Site, San Diego, California, United States|Research Site #1, San Dimas, California, United States|Research Site #2, San Dimas, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Monica, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Upland, California, United States|Research Site #1, Whittier, California, United States|Research Site #2, Whittier, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Westminster, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Cooper City, Florida, United States|Research Site #1, Coral Gables, Florida, United States|Research Site #2, Coral Gables, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site #1, Hialeah, Florida, United States|Research Site #2, Hialeah, Florida, United States|Research Site #3, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site #1, Hollywood, Florida, United States|Research Site #2, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site #1, Jacksonville, Florida, United States|Research Site #2, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site #1, Miami, Florida, United States|Research Site #2, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site #1, Miami, Florida, United States|Research Site #2, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Sweetwater, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site #1, Augusta, Georgia, United States|Research Site #2, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site #1, Columbus, Georgia, United States|Research Site #2, Columbus, Georgia, United States|Research Site #1, Lawrenceville, Georgia, United States|Research Site #2, Lawrenceville, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, McHenry, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Jeffersonville, Indiana, United States|Research Site #1, Merrillville, Indiana, United States|Research Site #2, Merrillville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site #1, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Takoma Park, Maryland, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Plymouth, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Roseville, Michigan, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site #1, Las Vegas, Nevada, United States|Research Site #2, Las Vegas, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Berlin, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Santa Fe, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Flushing, New York, United States|Research Site, Laurelton, New York, United States|Research Site, New York, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site #1, Greenville, North Carolina, United States|Research Site #2, Greenville, North Carolina, United States|Research Site, Kinston, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, DeSoto, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Gonzales, Texas, United States|Research Site, Greenville, Texas, United States|Research Site, Greenville, Texas, United States|Research Site #1, Houston, Texas, United States|Research Site #2, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lewisville, Texas, United States|Research Site #1, McAllen, Texas, United States|Research Site #2, McAllen, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sherman, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Arlington, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Hampton, Virginia, United States|Research Site, Lansdowne Town Center, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Salem, Virginia, United States|Research Site, Woodbridge, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Wenatchee, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Junin, Buenos Aires, Argentina|Research Site, Junin, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Pergamino, Buenos Aires, Argentina|Research Site, Ramos Mejia, Buenos Aires, Argentina|Research Site, San Miguel, Buenos Aires, Argentina|Research Site, San Nicolas, Buenos Aires, Argentina|Research Site, Sarandi, Buenos Aires, Argentina|Research Site, Temperley, Buenos Aires, Argentina|Research Site, Godoy Cruz, Mendoza, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Salta, Argentina|Research Site, San Luis, Argentina|Research Site, Camperdown, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, Cairns, Queensland, Australia|Research Site, Gold Coast, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Feira de Santana, Bahia, Brazil|Research Site, Itabuna, Bahia, Brazil|Research Site, Fortaleza, Ceará, Brazil|Research Site, Fortaleza, Ceará, Brazil|Research Site, Vitória, Espírito Santo, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Juiz de Fora, Minas Gerais, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site #1, Curitiba, Paraná, Brazil|Research Site #2, Curitiba, Paraná, Brazil|Research Site, Maringá, Paraná, Brazil|Research Site, Rio de Janeiro, Rio Do Janeiro, Brazil|Research Site, Canoas, Rio Grande Do Sul, Brazil|Research Site, Caxias do Sul, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Criciúma, Santa Catarina, Brazil|Research Site, Joinville, Santa Catarina, Brazil|Research Site, Botucatu, Sao Paulo, Brazil|Research Site, Campinas, Sao Paulo, Brazil|Research Site, Santo André, Sao Paulo, Brazil|Research Site, Santo André, Sao Paulo, Brazil|Research Site, São Bernardo do Campo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, Dobrich, Bulgaria|Research Site, Lom, Bulgaria|Research Site, Silistra, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site #1, Sofia, Bulgaria|Research Site #2, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Varna, Bulgaria|Research Site #1, Veliko Tarnovo, Bulgaria|Research Site #2, Veliko Tarnovo, Bulgaria|Research Site, Vidin, Bulgaria|Research Site, Pontoise, Val d'Oise, France|Research Site #1, Baja, Hungary|Research Site #2, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szigetvar, Hungary|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Nahariya, Israel|Research Site, Ramat Gan, Israel|Research Site, Rishon Lezion, Israel|Research Site, Piedimonte Matese, Caserta, Italy|Research Site, San Giovanni Rotondo, Foggia, Italy|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Cremona, Italy|Research Site, Genova, Italy|Research Site, Lecco, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Napoli, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Bucheon-si, Gyeonggi-do, Korea, Republic of|Research Site, Guri-si, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kota Bahru, Kelantan, Malaysia|Research Site, Kuantan, Pahang, Malaysia|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Acapulco de Juarez, Guerrero, Mexico|Research Site, Pachuca, Hidalgo, Mexico|Research Site, Pachuca, Hidalgo, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Morelia, Michoacán, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, San Juan del Rio, Queretaro, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Culiacán, Sinaloa, Mexico|Research Site, Mazatlan, Sinaloa, Mexico|Research Site, Chihuahua, Mexico|Research Site, Chihuahua, Mexico|Research Site, Durango, Mexico|Research Site, Veracruz, Mexico|Research Site, Hamilton, New Zealand|Research Site, New Plymouth, New Zealand|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Nowa Sol, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Caguas, Puerto Rico|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Pushkin, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tosno, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Port Elizabeth, Eastern Cape, South Africa|Research Site, Bloemfontein, Free State, South Africa|Research Site, Brandfort, Free State, South Africa|Research Site #1, Pretoria, Gauteng, South Africa|Research Site #2, Pretoria, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Vereeniging, Gauteng, South Africa|Research Site #1, Durban, KwaZulu-Natal, South Africa|Research Site #2, Durban, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Tongaat, KwaZulu-Natal, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, George, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Elche, Alicante, Spain|Research Site, Torrevieja, Alicante, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, L'Hospitalet de Llobregat, Barcelona, Spain|Research Site, Malaga, Málaga, Spain|Research Site, Almeria, Spain|Research Site, Almeria, Spain|Research Site, Badajoz, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kropyvnytskyi, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mykolaiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zhytomyr, Ukraine|Research Site, Aberdeen, Grampian Region, United Kingdom|Research Site, London, Greater London, United Kingdom|Research Site, London, Greater London, United Kingdom|Research Site, Salford, Greater Manchester, United Kingdom|Research Site, Stevenage, Hertfordshire, United Kingdom|Research Site, Leicester, Leicestershire, United Kingdom|Research Site, Doncaster, South Yorkshire, United Kingdom|Research Site, Sheffield, South Yorkshire, United Kingdom|Research Site, Swansea, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/47/NCT02648347/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/47/NCT02648347/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02648347"
323,"NCT00559273","A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis",,"Completed","Has Results","Renal Anemia, Chronic","Drug: Methoxy polyethylene glycol-epoetin beta|Drug: Darbepoetin alfa","Percentage of Participants With Hemoglobin (Hb) Response|Change in Hemoglobin (Hb) Concentration Between Baseline and Evaluation Period|Hemoglobin (Hb) Concentration Over the Time|Time to Hemoglobin Response|Percentage of Participants With Red Blood Cell (RBC) Transfusions|Percentage of Participants Who Had at Least 1 Hemoglobin Value Exceeding 12.0 g/dL|Percentage of Participants With Stable Hemoglobin Response|Percentage of Participants Who Required Dose Adjustments to Achieve a Stabilized Response","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NH20052","December 2007","October 2009","October 2009","November 16, 2007","November 1, 2016","November 1, 2016","Adelaide, Australia|Clayton, Australia|Gosford, Australia|Parkville, Australia|Reservoir, Australia|Aalst, Belgium|Roeselare, Belgium|Edmonton, Alberta, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Cahors, France|Clermont-ferrand, France|Limoges, France|Lyon, France|Nice, France|Paris, France|Berlin, Germany|Bonn, Germany|Heilbronn, Germany|Homburg/saar, Germany|Alexandroupolis, Greece|Larissa, Greece|Thessaloniki, Greece|Volos, Greece|Hong Kong, Hong Kong|Baja, Hungary|Budapest, Hungary|Esztergom, Hungary|Hatvan, Hungary|Szigetvar, Hungary|Haifa, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Como, Italy|Lecco, Italy|Lodi, Italy|Mestre, Italy|Modena, Italy|Pavia, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Radom, Poland|Rzeszow, Poland|Sieradz, Poland|Szczecin, Poland|Warszawa, Poland|Wroclaw, Poland|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Saratov, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Palma de Mallorca, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Taichung, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Nakhon Ratchasima, Thailand|Pathumthani, Thailand",,"https://ClinicalTrials.gov/show/NCT00559273"
324,"NCT02892149","Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)",,"Completed","Has Results","Anemia|Dialysis-Dependent Chronic Kidney Disease","Drug: Vadadustat|Drug: Darbepoetin alfa","Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)|Median Time to First Major Adverse Cardiovascular Event (MACE)|Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)|Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis|Median Time to First Cardiovascular MACE|Median Time to First Cardiovascular Death|Median Time to First All-cause Mortality","Akebia Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","3554","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0017|2016-001360-11","August 2016","January 16, 2020","March 30, 2020","September 8, 2016","June 28, 2022","June 28, 2022","Research Site, Huntsville, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Pine Bluff, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site #1, Bakersfield, California, United States|Research Site #2, Bakersfield, California, United States|Research Site, Canyon Country, California, United States|Research Site, Chula Vista, California, United States|Research Site, Downey, California, United States|Research Site, El Centro, California, United States|Research Site, Escondido, California, United States|Research Site, Fairfield, California, United States|Research Site, Glendale, California, United States|Research Site #1, Granada Hills, California, United States|Research Site #2, Granada Hills, California, United States|Research Site, La Habra, California, United States|Research Site, La Mesa, California, United States|Research Site, Lakewood, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site #1, Montebello, California, United States|Research Site, Monterey Park, California, United States|Research Site, Newhall, California, United States|Research Site #1, Northridge, California, United States|Research Site #2, Northridge, California, United States|Research Site, Riverside, California, United States|Research Site, Riverside, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site #1, San Dimas, California, United States|Research Site #2, San Dimas, California, United States|Research Site, Simi Valley, California, United States|Research Site, Tarzana, California, United States|Research Site, Whittier, California, United States|Research Site, Whittier, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Westminster, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site #1, Lauderdale Lakes, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site #1, Columbus, Georgia, United States|Research Site #2, Columbus, Georgia, United States|Research Site #1, Lawrenceville, Georgia, United States|Research Site #2, Lawrenceville, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Statesboro, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Merrillville, Indiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Takoma Park, Maryland, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Port Huron, Michigan, United States|Research Site, Roseville, Michigan, United States|Research Site, Columbus, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Gallup, New Mexico, United States|Research Site, Santa Fe, New Mexico, United States|Research Site, Astoria, New York, United States|Research Site, Bronx, New York, United States|Research Site, Flushing, New York, United States|Research Site, Great Neck, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site #1, Charlotte, North Carolina, United States|Research Site #2, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site #1, New Bern, North Carolina, United States|Research Site #2, New Bern, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site #1, Chattanooga, Tennessee, United States|Research Site #2, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Duncanville, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Greenville, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site #2, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Saint George, Utah, United States|Research Site, South Burlington, Vermont, United States|Research Site, Hampton, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Research Site, Junin, Buenos Aires, Argentina|Research Site, Pergamino, Buenos Aires, Argentina|Research Site, Sarandi, Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Salta, Argentina|Research Site, San Luis, Argentina|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Wahroonga, New South Wales, Australia|Research Site, Cairns, Queensland, Australia|Research Site, Launceston, Tasmania, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Feira de Santana, Bahia, Brazil|Research Site, Itabuna, Bahia, Brazil|Research Site, Fortaleza, Ceará, Brazil|Research Site, Vitória, Espírito Santo, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Juiz de Fora, Minas Gerais, Brazil|Research Site, Juiz de Fora, Minas Gerais, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Maringá, Paraná, Brazil|Research Site, Canoas, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Criciúma, Santa Catarina, Brazil|Research Site, Joinville, Santa Catarina, Brazil|Research Site, Santo André, Sao Paulo, Brazil|Research Site, Santo André, Sao Paulo, Brazil|Research Site, São Bernardo do Campo, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, Byala, Bulgaria|Research Site, Cherven bryag, Bulgaria|Research Site, Dobrich, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Silistra, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Vidin, Bulgaria|Research Site, Vratsa, Bulgaria|Research Site, Halifax, Nova Scotia, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Marseille, Bouches-du-Rhône, France|Research Site, Bordeaux, Gironde, France|Research Site, Saint-Priest-En-Jarez, Loire, France|Research Site, Reims, Marne, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Villingen-Schwenningen, Baden Wuerttemberg, Germany|Research Site, Rostock, Mecklenburg Vorpommern, Germany|Research Site, Duesseldorf, Nordrhein Westfalen, Germany|Research Site, Berlin, Germany|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar- Saba, Israel|Research Site, Rishon Lezion, Israel|Research Site, Bari, Italy|Research Site, Genova, Italy|Research Site, Lecco, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Chuncheon, Gangwon-do, Korea, Republic of|Research Site, Bucheon-si, Gyeonggi-do, Korea, Republic of|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Guri, Gyeonggi-do, Korea, Republic of|Research Site, Seongnam-si,, Gyeonggi-do, Korea, Republic of|Research Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Pachuca, Hidalgo, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Morelia, Michoacán, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Biala Podlaska, Poland|Research Site, Golub Dobrzyn, Poland|Research Site, Kolobrzeg, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Beja, Portugal|Research Site, Leiria, Portugal|Research Site, Loures, Portugal|Research Site, Ekaterinburg, Russian Federation|Research Site #2, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novorossiysk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site #1, Belgrade, Serbia|Research Site #2, Belgrade, Serbia|Research Site #3, Belgrade, Serbia|Research Site #4, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Zajecar, Serbia|Research Site, Brovary, Ukraine|Research Site #1, Cherkassy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Mykolaiv, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zhytomyr, Ukraine|Research Site, Cambridge, Cambridgeshire, United Kingdom|Research Site, London, Greater London, United Kingdom|Research Site, Stevenage, Hertfordshire, United Kingdom|Research Site, Kettering, Leicestershire, United Kingdom|Research Site, Doncaster, South Yorkshire, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/49/NCT02892149/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/49/NCT02892149/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02892149"
325,"NCT04649411","Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease",,"Not yet recruiting","No Results Available","Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease","Drug: ferric citrate|Drug: standard of care","Number of Participants with Serious and Non-serious Treatment-emergent Adverse Events|Number of Participants with Clinically Significant Laboratory Abnormalities or Changes in Laboratory Results|Number of Participants with Treatment-emergent Adverse Events Leading to the Discontinuation of Ferric Citrate|Change from Baseline in Hemoglobin to Week 24/Early Termination Visit|Change from Baseline in Transferrin Saturation (TSAT) to Week 24/Early Termination Visit|Change from Baseline in Ferritin to Week 24/Early Termination Visit|Change from Baseline in Serum Phosphorus to Week 24/Early Termination Visit|Change from Baseline in Calcium to Week 24/Early Termination Visit|Change from Baseline in Bicarbonate to Week 24/Early Termination Visit","Keryx Biopharmaceuticals","All","6 Years to 18 Years   (Child, Adult)","Phase 3","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KRX-0502-309","January 2025","January 2027","March 2027","December 2, 2020",,"October 23, 2023",,,"https://ClinicalTrials.gov/show/NCT04649411"
326,"NCT01888445","A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug",,"Completed","No Results Available","Renal Anemia Associated With Chronic Renal Failure (CRF)","Drug: roxadustat|Drug: darbepoetin alfa","Rate of rise in hemoglobin (g/dL/week)|Cumulative number of responder patients|Percent of visits at which patients maintain hemoglobin between 10.0-12.0 g/dL after achieving hemoglobin ≥10.0 g/dL for each patients|Percent of patients who maintain hemoglobin between 10.0-12.0 g/dL at each visit","Astellas Pharma Inc","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1517-CL-0304","March 28, 2013","September 15, 2014","September 15, 2014","June 27, 2013",,"January 2, 2020","Chubu, Japan|Chugoku, Japan|Hokuriku, Japan|Kansai, Japan|Kanto, Japan|Kyushu, Japan|Shikoku, Japan|Tohoku, Japan",,"https://ClinicalTrials.gov/show/NCT01888445"
327,"NCT00925587","Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease",,"Completed","Has Results","Anemia|Chronic Kidney Disease","Drug: darbepoetin alfa","Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33)|Achievement of Both a Hb >= 10.0 g/dL and a >= 1.0 g/dL Increase From Baseline at Any Time Point Following de Novo Darbepoetin Alfa Administration.|Hb at Baseline|Hb at Week 3|Hb at Week 5|Hb at Week 7|Hb at Week 9|Hb at Week 11|Hb at Week 13|Hb at Week 15|Hb at Week 17|Hb at Week 19|Hb at Week 21|Hb at Week 23|Hb at Week 25|Hb at Week 27|Hb at Week 29|Hb at Week 31|Hb at Week 33|Darbepoetin Alfa Dose at Week 1|Darbepoetin Alfa Dose at Week 3|Darbepoetin Alfa Dose at Week 5|Darbepoetin Alfa Dose at Week 7|Darbepoetin Alfa Dose at Week 9|Darbepoetin Alfa Dose at Week 11|Darbepoetin Alfa Dose at Week 13|Darbepoetin Alfa Dose at Week 15|Darbepoetin Alfa Dose at Week 17|Darbepoetin Alfa Dose at Week 19|Darbepoetin Alfa Dose at Week 21|Darbepoetin Alfa Dose at Week 23|Darbepoetin Alfa Dose at Week 25|Darbepoetin Alfa Dose at Week 27|Darbepoetin Alfa Dose at Week 29|Darbepoetin Alfa Dose at Week 31|Darbepoetin Alfa Dose During the Evaluation Period (Average of Weeks 29-33)|Ratio of Darbepoetin Alfa Dose to Baseline at Week 3|Ratio of Darbepoetin Alfa Dose to Baseline at Week 5|Ratio of Darbepoetin Alfa Dose to Baseline at Week 7|Ratio of Darbepoetin Alfa Dose to Baseline at Week 9|Ratio of Darbepoetin Alfa Dose to Baseline at Week 11|Ratio of Darbepoetin Alfa Dose to Baseline at Week 13|Ratio of Darbepoetin Alfa Dose to Baseline at Week 15|Ratio of Darbepoetin Alfa Dose to Baseline at Week 17|Ratio of Darbepoetin Alfa Dose to Baseline at Week 19|Ratio of Darbepoetin Alfa Dose to Baseline at Week 21|Ratio of Darbepoetin Alfa Dose to Baseline at Week 23|Ratio of Darbepoetin Alfa Dose to Baseline at Week 25|Ratio of Darbepoetin Alfa Dose to Baseline at Week 27|Ratio of Darbepoetin Alfa Dose to Baseline at Week 29|Ratio of Darbepoetin Alfa Dose to Baseline at Week 31|Dose of Darbepoetin Alfa at the First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)|Time to First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)|Ratio of Darbepoetin Alfa Dose to Baseline at the Evalaution Period (Average of Weeks 29-33)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","358","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20060163|2006-003173-27","June 2009","April 2012","May 2012","June 22, 2009","June 4, 2014","June 4, 2014","Research Site, Gosford, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, Cairns, Queensland, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Reservoir, Victoria, Australia|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, LiÃ¨ge, Belgium|Research Site, Roeselare, Belgium|Research Site, Pleven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Brno, Czech Republic|Research Site, Chrudim, Czech Republic|Research Site, Jilemnice, Czech Republic|Research Site, Kladno, Czech Republic|Research Site, Liberec 1, Czech Republic|Research Site, Novy Jicin, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 4 - Nusle, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Praha 8, Czech Republic|Research Site, Slavkov u Brna, Czech Republic|Research Site, Sternberk, Czech Republic|Research Site, Usti nad Orlici, Czech Republic|Research Site, Roskilde, Denmark|Research Site, Viborg, Denmark|Research Site, Ã…rhus, Denmark|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Annonay, France|Research Site, Creil, France|Research Site, Grenoble, France|Research Site, Metz, France|Research Site, Montivilliers, France|Research Site, Nice, France|Research Site, Poissy, France|Research Site, Reims Cedex, France|Research Site, Rouen Cedex, France|Research Site, Saint Priest en Jarez, France|Research Site, Bernkastel-Kues, Germany|Research Site, Coesfeld, Germany|Research Site, DÃ¼sseldorf, Germany|Research Site, Hamburg, Germany|Research Site, Leverkusen, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Pecs, Hungary|Research Site, Szekszard, Hungary|Research Site, Szombathely, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ashkelon, Israel|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Albano Laziale RM, Italy|Research Site, Ancona, Italy|Research Site, Cagliari, Italy|Research Site, Firenze, Italy|Research Site, Lecco, Italy|Research Site, Napoli, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Torino, Italy|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Valmiera, Latvia|Research Site, Ventspils, Latvia|Research Site, Saltillo, Coahuila, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Queretaro, QuerÃ©taro, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Choszczno, Poland|Research Site, Golub-Dobrzyn, Poland|Research Site, Koscierzyna, Poland|Research Site, Koszalin, Poland|Research Site, Legnica, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Zamosc, Poland|Research Site, Evora, Portugal|Research Site, Faro, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, SetÃºbal, Portugal|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Timisoara, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Krgujevac, Serbia|Research Site, Zemun, Serbia|Research Site, Bratislava, Slovakia|Research Site, Galanta, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Sala, Slovakia|Research Site, Trstena, Slovakia|Research Site, Zvolen, Slovakia|Research Site, Jesenice, Slovenia|Research Site, Novo mesto, Slovenia|Research Site, Sempeter pri Gorici, Slovenia|Research Site, Slovenj Gradec, Slovenia|Research Site, JaÃ©n, AndalucÃ-a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Galdakao, PaÃ-s Vasco, Spain|Research Site, Madrid, Spain|Research Site, Birmingham, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Shrewsbury, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Stoke On Trent, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00925587"
328,"NCT02680574","Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)",,"Completed","Has Results","Anemia|Non-Dialysis-Dependent Chronic Kidney Disease","Drug: Vadadustat|Drug: Darbepoetin alfa","Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)|Median Time to First Major Adverse Cardiovascular Event (MACE)|Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)|Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis|Median Time to First Cardiovascular MACE|Median Time to First Cardiovascular Death|Median Time to First All-cause Mortality","Akebia Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","1725","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0015|2015-004774-14","February 2016","June 18, 2020","July 31, 2020","February 11, 2016","June 27, 2022","June 27, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Tuscumbia, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Bakersfield, California, United States|Research Site #1, Chula Vista, California, United States|Research Site #2, Chula Vista, California, United States|Research Site, El Centro, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Glendale, California, United States|Research Site, Granada Hills, California, United States|Research Site, La Mesa, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site #1, Northridge, California, United States|Research Site #2, Northridge, California, United States|Research Site, Riverside, California, United States|Research Site, Roseville, California, United States|Research Site, Salinas, California, United States|Research Site, San Diego, California, United States|Research Site #1, San Dimas, California, United States|Research Site #2, San Dimas, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Monica, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Whittier, California, United States|Research Site, Whittier, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Westminster, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Cooper City, Florida, United States|Research Site #1, Coral Gables, Florida, United States|Research Site #2, Coral Gables, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site #1, Hialeah, Florida, United States|Research Site #2, Hialeah, Florida, United States|Research Site #3, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site #1, Hollywood, Florida, United States|Research Site #2, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site #1, Jacksonville, Florida, United States|Research Site #2, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site #1, Miami Lakes, Florida, United States|Research Site #2, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site #1, Miami, Florida, United States|Research Site #2, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site #1, Miami, Florida, United States|Research Site #2, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site #1, Miami, Florida, United States|Research Site #2, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site #1, Columbus, Georgia, United States|Research Site #2, Columbus, Georgia, United States|Research Site #1, Lawrenceville, Georgia, United States|Research Site #2, Lawrenceville, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Elk Grove Village, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, McHenry, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Jeffersonville, Indiana, United States|Research Site #1, Merrillville, Indiana, United States|Research Site #2, Merrillville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Takoma Park, Maryland, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Plymouth, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Port Huron, Michigan, United States|Research Site, Roseville, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site #1, Las Vegas, Nevada, United States|Research Site #2, Las Vegas, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Berlin, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Santa Fe, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Flushing, New York, United States|Research Site, Laurelton, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site #1, Greenville, North Carolina, United States|Research Site #2, Greenville, North Carolina, United States|Research Site, Jacksonville, North Carolina, United States|Research Site, Kinston, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Sumter, South Carolina, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, DeSoto, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Gonzales, Texas, United States|Research Site, Greenville, Texas, United States|Research Site, Greenville, Texas, United States|Research Site, Houston, Texas, United States|Research Site #1, Houston, Texas, United States|Research Site #2, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lewisville, Texas, United States|Research Site #1, McAllen, Texas, United States|Research Site #2, McAllen, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sherman, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Saint George, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Alexandria, Virginia, United States|Research Site, Arlington, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Hampton, Virginia, United States|Research Site, Lansdowne Town Center, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Salem, Virginia, United States|Research Site, Woodbridge, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Wenatchee, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Junin, Buenos Aires, Argentina|Research Site, Junin, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Pergamino, Buenos Aires, Argentina|Research Site, Ramos Mejia, Buenos Aires, Argentina|Research Site, San Miguel, Buenos Aires, Argentina|Research Site, San Nicolas, Buenos Aires, Argentina|Research Site, Sarandi, Buenos Aires, Argentina|Research Site, Temperley, Buenos Aires, Argentina|Research Site, Godoy Cruz, Mendoza, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Salta, Argentina|Research Site, San Luis, Argentina|Research Site, Camperdown, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Cairns, Queensland, Australia|Research Site, Gold Coast, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Launceston, Tasmania, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Perth, Western Australia, Australia|Research Site, St. Pölten, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Feira de Santana, Bahia, Brazil|Research Site, Itabuna, Bahia, Brazil|Research Site, Salvador, Bahia, Brazil|Research Site, Fortaleza, Ceará, Brazil|Research Site, Fortaleza, Ceará, Brazil|Research Site, Vitória, Espírito Santo, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Juiz de Fora, Minas Gerais, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site #1, Curitiba, Paraná, Brazil|Research Site #2, Curitiba, Paraná, Brazil|Research Site, Maringá, Paraná, Brazil|Research Site, Rio de Janeiro, Rio Do Janeiro, Brazil|Research Site, Caxias do Sul, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Criciúma, Santa Catarina, Brazil|Research Site, Joinville, Santa Catarina, Brazil|Research Site, Botucatu, Sao Paulo, Brazil|Research Site, Campinas, Sao Paulo, Brazil|Research Site, Santo André, Sao Paulo, Brazil|Research Site, Santo André, Sao Paulo, Brazil|Research Site, São Bernardo do Campo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, Byala, Bulgaria|Research Site, Cherven bryag, Bulgaria|Research Site, Lom, Bulgaria|Research Site, Silistra, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site #1, Sofia, Bulgaria|Research Site #2, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Vratsa, Bulgaria|Research Site, Scarborough, Ontario, Canada|Research Site, Concepción, Chile|Research Site, Puerto Varas, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Espinal, Colombia|Research Site, Manizales, Colombia|Research Site #1, Medellin, Colombia|Research Site #2, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Ceske Budejovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Lille, Alpes De Haute Provence, France|Research Site, Saint-Priest-En-Jarez, Loire, France|Research Site, Reims Cedex, Marne, France|Research Site, Pontoise, Val d'Oise, France|Research Site, Créteil Cedex, Val De Marne, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Villingen-Schwenningen, Baden Wuerttemberg, Germany|Research Site, Rostock, Mecklenburg Vorpommern, Germany|Research Site, Duesseldorf, Nordrhein Westfalen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site #1, Baja, Hungary|Research Site #2, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szigetvar, Hungary|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Nahariya, Israel|Research Site, Ramat Gan, Israel|Research Site, Rishon Lezion, Israel|Research Site, Piedimonte Matese, Caserta, Italy|Research Site, San Giovanni Rotondo, Foggia, Italy|Research Site, Bari, Italy|Research Site, Lecco, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site #1, Napoli, Italy|Research Site #2, Napoli, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Bucheon-si, Gyeonggi-do, Korea, Republic of|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Guri-si, Gyeonggi-do, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Alor Setar, Kedah, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Pulau Pinang, Malaysia|Research Site, Torreon, Coahuila, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Acapulco de Juarez, Guerrero, Mexico|Research Site #1, Pachuca, Hidalgo, Mexico|Research Site #2, Pachuca, Hidalgo, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Morelia, Michoacán, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, San Juan del Rio, Queretaro, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Culiacán, Sinaloa, Mexico|Research Site, Mazatlan, Sinaloa, Mexico|Research Site, Chihuahua, Mexico|Research Site, Chihuahua, Mexico|Research Site, Durango, Mexico|Research Site, Veracruz, Mexico|Research Site, Hamilton, New Zealand|Research Site, New Plymouth, New Zealand|Research Site, Nowa Sol, Poland|Research Site, Caguas, Puerto Rico|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site #1, Bucuresti, Romania|Research Site #2, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Oradea, Romania|Research Site, Timisoara, Romania|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Pushkin, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site #1, Belgrade, Serbia|Research Site #2, Belgrade, Serbia|Research Site #3, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Lazarevac, Serbia|Research Site, Nis, Serbia|Research Site, Zajecar, Serbia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Galanta, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trstena, Slovakia|Research Site, Bloemfontein, Free State, South Africa|Research Site, Brandfort, Free State, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Vereeniging, Gauteng, South Africa|Research Site #1, Durban, KwaZulu-Natal, South Africa|Research Site #2, Durban, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Tongaat, KwaZulu-Natal, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Elche, Alicante, Spain|Research Site, Torrevieja, Alicante, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, L'Hospitalet de Llobregat, Barcelona, Spain|Research Site, Malaga, Málaga, Spain|Research Site, Almeria, Spain|Research Site, Almeria, Spain|Research Site, Badajoz, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Ankara, Turkey|Research Site, Erciyes, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Kocaeli, Turkey|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kropyvnytskyi, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mykolaiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Exeter, Devon, United Kingdom|Research Site, London, Greater London, United Kingdom|Research Site, London, Greater London, United Kingdom|Research Site, Salford, Greater Manchester, United Kingdom|Research Site, Stevenage, Hertfordshire, United Kingdom|Research Site, Leicester, Leicestershire, United Kingdom|Research Site, King's Lynn, Norfolk, United Kingdom|Research Site, Doncaster, South Yorkshire, United Kingdom|Research Site, Swansea, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/74/NCT02680574/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/74/NCT02680574/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02680574"
329,"NCT02865850","Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)",,"Completed","Has Results","Anemia|Dialysis-Dependent Chronic Kidney Disease","Drug: Vadadustat|Drug: Darbepoetin alfa","Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)|Median Time to First Major Adverse Cardiovascular Event (MACE)|Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)|Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis|Median Time to First Cardiovascular MACE|Median Time to First Cardiovascular Death|Median Time to First All-cause Mortality","Akebia Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","369","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0016|2016-000838-21","July 2016","January 31, 2020","March 30, 2020","August 15, 2016","July 18, 2022","July 18, 2022","Research Site, Huntsville, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Canyon Country, California, United States|Research Site, Downey, California, United States|Research Site, Glendale, California, United States|Research Site, Granada Hills, California, United States|Research Site, La Mesa, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Montebello, California, United States|Research Site, Monterey Park, California, United States|Research Site, Newhall, California, United States|Research Site #1, Northridge, California, United States|Research Site #2, Northridge, California, United States|Research Site, Riverside, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Dimas, California, United States|Research Site, Whittier, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Westminster, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Coral Gables, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site #2, Lawrenceville, Georgia, United States|Research Site, Statesboro, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Takoma Park, Maryland, United States|Research Site, Roseville, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Astoria, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site #1, Chattanooga, Tennessee, United States|Research Site #2, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Hampton, Virginia, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Research Site, Junin, Buenos Aires, Argentina|Research Site, Pergamino, Buenos Aires, Argentina|Research Site, Temperley, Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Salta, Argentina|Research Site, San Luis, Argentina|Research Site, Fortaleza, Ceará, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Juiz de Fora, Minas Gerais, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Maringá, Paraná, Brazil|Research Site, Canoas, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Joinville, Santa Catarina, Brazil|Research Site, Santo André, Sao Paulo, Brazil|Research Site, São Bernardo do Campo, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, Villingen-Schwenningen, Baden Wuerttemberg, Germany|Research Site, Rostock, Mecklenburg Vorpommern, Germany|Research Site, Duesseldorf, Nordrhein Westfalen, Germany|Research Site, San Giovanni Rotondo, Foggia, Italy|Research Site, Genova, Italy|Research Site, Lecco, Italy|Research Site, Napoli, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Chuncheon, Gangwon-do, Korea, Republic of|Research Site, Seongnam-si,, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Zapopan, Jalisco, Mexico|Research Site, Morelia, Michoacán, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Golub Dobrzyn, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Leiria, Portugal|Research Site, Loures, Portugal|Research Site #2, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Brovary, Ukraine|Research Site, Cherkassy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Mykolaiv, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zhytomyr, Ukraine","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/50/NCT02865850/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/50/NCT02865850/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02865850"
330,"NCT03242967","Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)","TRILOGY","Withdrawn","No Results Available","Anemia|Dialysis-Dependent Chronic Kidney Disease","Drug: Vadadustat|Drug: Darbepoetin alfa","Mean change in Hb between baseline and the primary evaluation period|Mean change in Hb between baseline and the secondary evaluation period|Proportion of subjects with mean Hb within the target range during the primary evaluation period|Adverse Events (AEs) and Serious Adverse Events (SAEs)","Akebia Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0023","August 2017","February 12, 2018","February 12, 2018","August 8, 2017",,"November 5, 2018","Research Site, Northridge, California, United States",,"https://ClinicalTrials.gov/show/NCT03242967"
331,"NCT03054350","Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)",,"Completed","Has Results","Anemia|Dialysis Dependent Chronic Kidney Disease","Drug: Vadadustat|Drug: Placebo","Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period|Time to Reach the Target Hb Level of 10.0 to 12.0 g/dL From Baseline up to Week 16|Mean Hb Levels at the End of the Primary Efficacy Period|Mean Hb Levels at the End of the Dose Adjustment and Maintenance Period|Number of Participants Who Achieved the Target Hb Level of 10.0 to 12.0 g/dL at the End of the Dose Adjustment and Maintenance Period|Mean Change in Hb Between Pre-treatment and the End of the Dose Adjustment and Maintenance Period|Mean Change in Red Blood Cell (RBC) Count and Absolute Reticulocyte Count From Baseline to the End of the Primary Efficacy Period|Mean Change in RBC Count and Absolute Reticulocyte Count From Baseline to the End of the Dose Adjustment and Maintenance Period|Mean Change in Hematocrit and Reticulocytes From Baseline to the End of the Primary Efficacy Period|Mean Change in Hematocrit and Reticulocytes From Baseline to the End of the Dose Adjustment and Maintenance Period|Mean Change in Iron and Total Iron Binding Capacity (TIBC) From Baseline to the End of the Primary Efficacy Period|Mean Change in Iron and TIBC From Baseline to the End of the Dose Adjustment and Maintenance Period|Mean Change in Transferrin Saturation (TSAT) From Baseline to the End of the Primary Efficacy Period|Mean Change in TSAT From Baseline to the End of the Dose Adjustment and Maintenance Period|Mean Change in Ferritin and Hepcidin From Baseline to the End of the Primary Efficacy Period|Mean Change in Ferritin and Hepcidin From Baseline to the End of the Dose Adjustment and Maintenance Period|Number of Participants Who Required Rescue With a RBC Transfusion From Baseline to the End of the Primary Efficacy Period|Number of Participants Who Required Rescue With RBC Transfusion From Baseline to the End of the Dose Adjustment and Maintenance Period|Number of Participants Who Required Rescue With Erythropoiesis-Stimulating Agents (ESAs) From Baseline to the End of the Primary Efficacy Period|Number of Participants Who Required Rescue With ESAs From Baseline to the End of the Dose Adjustment and Maintenance Period|Number of the Participants With the Indicated Number of Dose Adjustments From Baseline to the End of the Dose Adjustment and Maintenance Period|Plasma Concentration Profile of Vadadustat and Its Metabolites Using a Pre-dose Sample From Week 4|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) in the Primary Efficacy Period|Number of Participants With TEAEs and Treatment-emergent SAEs in the Dose Adjustment and Maintenance Period","Akebia Therapeutics","All","20 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","AKB-6548-CI-0022","December 2016","October 24, 2017","January 24, 2018","February 15, 2017","April 8, 2021","April 8, 2021","Aichi, Japan|Ehime, Japan|Fukui, Japan|Hiroshima, Japan|Hokkaido, Japan|Hyogo, Japan|Ibaraki, Japan|Kagoshima, Japan|Kochi, Japan|Miyagi, Japan|Nagano, Japan|Nagasaki, Japan|Niigata, Japan|Oita, Japan|Okinawa, Japan|Osaka, Japan|Saitama, Japan|Shizuoka, Japan","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/50/NCT03054350/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/50/NCT03054350/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03054350"
332,"NCT03054337","Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)",,"Completed","Has Results","Anemia|Non-dialysis Dependent Chronic Kidney Disease","Drug: Vadadustat|Drug: Placebo","Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period|Time to Reach the Target Hb Level of 10.0 to 12.0 g/dL From Baseline up to Week 16|Mean Hb Levels at the End of the Primary Efficacy Period|Mean Hb Levels at the End of the Dose Adjustment and Maintenance Period|Number of Participants Who Achieved the Target Hb Level of 10.0 to 12.0 g/dL at the End of the Dose Adjustment and Maintenance Period|Mean Change in Hb Between Pre-treatment and the End of the Dose Adjustment and Maintenance Period|Mean Change in Red Blood Cell (RBC) Count and Absolute Reticulocyte Count From Baseline to the End of the Primary Efficacy Period|Mean Change in RBC Count and Absolute Reticulocyte Count From Baseline to the End of the Dose Adjustment and Maintenance Period|Mean Change in Hematocrit and Reticulocytes From Baseline to the End of the Primary Efficacy Period|Mean Change in Hematocrit and Reticulocytes From Baseline to the End of the Dose Adjustment and Maintenance Period|Mean Change in Iron and Total Iron Binding Capacity (TIBC) From Baseline to the End of the Primary Efficacy Period|Mean Change in Iron and TIBC From Baseline to the End of the Dose Adjustment and Maintenance Period|Mean Change in Transferrin Saturation (TSAT) From Baseline to the End of the Primary Efficacy Period|Mean Change in TSAT From Baseline to the End of the Dose Adjustment and Maintenance Period|Mean Change in Ferritin and Hepcidin From Baseline to the End of the Primary Efficacy Period|Mean Change in Ferritin and Hepcidin From Baseline to the End of the Dose Adjustment and Maintenance Period|Number of Participants Who Required Rescue With Erythropoiesis-stimulating Agents (ESAs) From Baseline to the End of the Primary Efficacy Period|Number of Participants Who Required Rescue With ESAs From Baseline to the End of the Dose Adjustment and Maintenance Period|Number of Participants Who Required Rescue With a RBC Transfusion From Baseline to the End of the Primary Efficacy Period|Number of Participants Who Required Rescue With a RBC Transfusion From Baseline to the End of the Dose Adjustment and Maintenance Period|Number of the Participants With the Indicated Number of Dose Adjustments From Baseline to the End of the Dose Adjustment and Maintenance Period|Number of Participants Who Maintained Iron Sufficiency From Baseline to Week 6|Number of Participants Who Maintained Iron Sufficiency From Baseline to Week 16|Plasma Concentration Profile of Vadadustat and Its Metabolites Using a Pre-dose Sample From Week 4|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) in the Primary Efficacy Period|Number of Participants With TEAEs and Treatment-emergent SAEs in the Dose Adjustment and Maintenance Period","Akebia Therapeutics","All","20 Years and older   (Adult, Older Adult)","Phase 2","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AKB-6548-CI-0021","October 2016","July 4, 2017","August 28, 2017","February 15, 2017","April 8, 2021","April 8, 2021","Aichi, Japan|Chiba, Japan|Ehime, Japan|Gunma, Japan|Hiroshima, Japan|Hokkaido, Japan|Hyogo, Japan|Ibaraki, Japan|Kanagawa, Japan|Nagano, Japan|Nara, Japan|Niigata, Japan|Oita, Japan|Okayama, Japan|Okinawa, Japan|Osaka, Japan|Shiga, Japan|Tokushima, Japan","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/37/NCT03054337/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/37/NCT03054337/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03054337"
333,"NCT03140722","Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents",,"Terminated","Has Results","Anemia|Dialysis-Dependent Chronic Kidney Disease","Drug: vadadustat|Drug: epoetin alfa","Change From Baseline in Hemoglobin (Hb) Over Time During the Treatment Period|Number of Participants Demonstrating Incremental Increases in Hb From Baseline Over Time During the Treatment Period|Number of Participants With Hb Values Within the Target Range of 10.0-11.0 Grams Per Deciliter (g/dL) During the Treatment Period|Number of Participants Receiving Epoetin Alfa Rescue|Number of Participants Receiving Red Blood Cell Transfusion|Number of Participants With Specified Levels of Various Biomarkers, Including C-reactive Protein, Hepcidin, and Vascular Endothelial Growth Factor|Mean Weekly Dose of Intravenous Elemental Iron Administered|Number of Participants Maintaining Iron Sufficiency (Defined as Ferritin ≥100 Nanograms Per Milliliter and Transferrin Saturation ≥20%)|Number of Participants Utilizing Resources|Number of Participants With Treatment-emergent Adverse Events","Akebia Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0018","May 2, 2017","March 21, 2018","March 21, 2018","May 4, 2017","February 21, 2021","February 21, 2021","Research Site, Bakersfield, California, United States|Research Site, Elk Grove, California, United States|Research Site, Encino, California, United States|Research Site, Escondido, California, United States|Research Site, Lynwood, California, United States|Research Site, San Diego, California, United States|Research Site, San Luis Obispo, California, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Statesboro, Georgia, United States|Research Site, Detroit, Michigan, United States|Research Site, Bronx, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Newport News, Virginia, United States|Research Site, Norfolk, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/22/NCT03140722/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03140722"
334,"NCT01906489","20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia",,"Completed","Has Results","Anemia|Chronic Kidney Disease","Drug: AKB-6548|Drug: Placebo","Percentage of Participants Achieving a Successful Hemoglobin Response|Percentage of Participants With Hemoglobin Value ≥13.0 g/dL at Any Time During the Study|Percentage of Participants Achieving a Successful Hemoglobin Response, Determined Solely Based on the Hemoglobin Value|Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Treatment naïve Group|Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Previously Treated Group|Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Actively Treated Group|Percentage of Participants Achieving a Successful Hemoglobin Response, Analyzed in mITT Population|Change From Baseline in Hemoglobin|Absolute Values of Hemoglobin|Change From Baseline in Hematocrit|Absolute Values of Hematocrit|Change From Baseline in Red Blood Cell Count|Absolute Values of Red Blood Cell Count|Change From Baseline in Reticulocyte Count|Absolute Values of Reticulocyte Count|Percentage of Participants Who Received ESA Rescue|Mean Number of ESA Rescue Doses Administered Per Participant|Percentage of Participants Who Received Packed Red Blood Cell Transfusion Rescue|Number of Packed Red Blood Cell Transfusion Administered Per Participant|Time to First Transfusion or ESA Rescue Medication Intake|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values|Number of Participants With Clinically Significant Changes From Baseline in Vital Signs|Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings|Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings","Akebia Therapeutics","All","18 Years to 82 Years   (Adult, Older Adult)","Phase 2","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AKB-6548-CI-0007","July 23, 2013","September 3, 2014","September 3, 2014","July 24, 2013","July 1, 2022","July 21, 2022","Glendale, Arizona, United States|Tucson, Arizona, United States|Azusa, California, United States|Chula Vista, California, United States|Downey, California, United States|El Centro, California, United States|La Mesa, California, United States|Long Beach, California, United States|Riverside, California, United States|Sacramento, California, United States|San Diego, California, United States|Arvada, Colorado, United States|Westminster, Colorado, United States|Lauderdale Lakes, Florida, United States|Port Charlotte, Florida, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Macon, Georgia, United States|Meridian, Idaho, United States|Evergreen Park, Illinois, United States|Lafayette, Louisiana, United States|Shreveport, Louisiana, United States|Detroit, Michigan, United States|Lansing, Michigan, United States|Petoskey, Michigan, United States|Pontiac, Michigan, United States|Farmington, Missouri, United States|Kansas City, Missouri, United States|Las Vegas, Nevada, United States|Albuquerque, New Mexico, United States|Flushing, New York, United States|Mineola, New York, United States|New Rochelle, New York, United States|Rosedale, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Rocky Mount, North Carolina, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Columbia, South Carolina, United States|Knoxville, Tennessee, United States|Arlington, Texas, United States|Austin, Texas, United States|Edinburg, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Saint George, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01906489"
335,"NCT02136563","Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents","BRIGHTEN","Completed","No Results Available","Renal Anemia|Chronic Kidney Disease",,"Deterioration of renal function|Cardiovascular disease events|Declination rate of estimated glomerular filtration rate(eGFR)|Safety assessment for every adverse event resulting from darbepoetin alfa administration","Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Niigata University","All","20 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TRIGU1318|UMIN000013464","April 2014","August 2019","August 2019","May 13, 2014",,"June 18, 2020","Niigata University Graduate School of Medicine, Niigata, Japan",,"https://ClinicalTrials.gov/show/NCT02136563"
336,"NCT01422824","An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis",,"Completed","Has Results","Anemia, Kidney Disease, Chronic",,"Number of Participants With Adverse Events (AEs)|Hemoglobin Levels","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)",,"185","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25067","June 2010","January 2014","January 2014","August 24, 2011","March 28, 2016","March 28, 2016","Delcevo, Macedonia, The Former Yugoslav Republic of|Prilep, Macedonia, The Former Yugoslav Republic of|Skopje, Macedonia, The Former Yugoslav Republic of|Stip, Macedonia, The Former Yugoslav Republic of|Struga, Macedonia, The Former Yugoslav Republic of|Strumica, Macedonia, The Former Yugoslav Republic of",,"https://ClinicalTrials.gov/show/NCT01422824"
337,"NCT03619850","A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)",,"Recruiting","No Results Available","Chronic Kidney Disease; Iron Deficiency Anemia","Drug: Ferumoxytol|Drug: Iron sucrose","Hemoglobin change of at least 0.5 g/dL from Baseline to Week 5|Incidence of Treatment Emergent Adverse Events|Incidence of adverse events of special interest (AESI)","AMAG Pharmaceuticals, Inc.","All","2 Years to 17 Years   (Child)","Phase 3","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMAG-FER-CKD-354","August 13, 2018","August 31, 2023","August 31, 2023","August 8, 2018",,"July 19, 2023","Memorial Healthcare System, Hollywood, Florida, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Montefiore Medical Center (MMC) - The Children's Hospital at Montefiore (CHAM), Bronx, New York, United States|The Feinstein Institute Medical Research Organization of Northwell Health, Inc., Lake Success, New York, United States|Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York, New York, United States|Akron Nephrology Associates, Inc., Akron, Ohio, United States|West Virginia University, Morgantown, West Virginia, United States|Semmelweis Egyetem - Altalanos Orvostudomanyi Kar (SE AOK) - I. sz. Gyermekgyogyaszati Klinika, Budapest, Hungary|University Of Szeged, Szeged, Hungary|Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, Lithuania|Klaipeda Children's Hospital, Klaipėda, Lithuania|Vsl Vilniaus Universiteto Vaiku Ligonine (VUVL) (Vilnius University Children's Hospital), Vilnius, Lithuania|Instituto Mexicano De Trasplantes S.C, Cuernavaca, Mexico|JM Research, SC, Cuernavaca, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico|Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics), Mexico City, Mexico|Uniwersytecki Szpital Kliniczny Im. Zamenhofa w Bialystoku, Białystok, Poland|Specjalistyczne Gabinety Sp. z o.o, Kraków, Poland|University Children Hospital, Kraków, Poland|Polish Mother's Memorial Hospital Research Institute, Łódź, Poland",,"https://ClinicalTrials.gov/show/NCT03619850"
338,"NCT01244763","Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia",,"Completed","Has Results","Chronic Kidney Disease|Anemia","Drug: Roxadustat","Number (%) of Participants With an Hb Response by Week 17|Number (%) of Participants With an Hb Response by Weeks 5, 9, 13, 17, 21, and 25|Change From Baseline in Hb at Weeks 5, 9, 13, 17, 21, and 25|Number (%) of Participants With Mean Hb Between 11-12, 11-13, and 10.5-13 g/dL During Weeks 5-8, 9-12, 9-16, 13-16, 17-20, 17-24, 21-24, and 25-28|Number (%) of Participants With 2 Consecutive Hb Values Between 11-12, 11-13, and 10.5-13 g/dL During Weeks 5-8, 9-12, 13-16, 9-16, 17-20, 17-24, 21-24, and 25-28|Number (%) of Participants Who Achieve Maximum Hb Between 11-12, 11-13, and 10.5-13 g/dL by Weeks 5, 9, 13, 17, 21, and 25|Number (%) of Participants With Maximum Hb <11, >12, >13, and >14 g/dL During Weeks 5-8, 9-12, 9-16, 13-16, 17-20, 17-24, 21-24, and 25-28|Median Time to Hb Response: Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL|Median Initial Hb Responsive Time: Time to Initial Hb Increase ≥1.0 g/dL From Baseline|Median Initial Hb Responsive Dose: Dose at Which Initial Hb Increases to ≥1.0 g/dL From Baseline|Change in Hb After Reaching a Hb Response of ≥11.0 g/dL and an Increase in Hb by ≥1.0 g/dL by Week|Mean Hb Values From Participants Who Reached Hb >11.0 g/dL in the Hb 11-12, 11-13, and 10.5-13 g/dL Categories|Mean of Weekly Hb Values <10.5, >13, and >14 g/dL During Weeks 13-17 and 18-25|Number (%) of Participants Requiring Rescue Therapy|Number (%) of Participants Requiring Therapeutic Phlebotomy|Number (%) of Participants Withdrawn From the Study Due to Inadequate Efficacy|Number (%) of Participants With Dose Changes During Weeks 1-4, 5-12, 13-16, and 17-24|Weekly Total Dose and Cumulative Total Dose (mg/kg) When First Achieving Hb Response (Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL)|Mean Weekly Dose After Achieving First Hb Response (Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL)|Change From Baseline in Hb Stratified by Baseline Ferritin >100 Nanograms/Milliliter (ng/mL) and Transferrin Saturation >20% at Week 16 and Week 24","FibroGen|Astellas Pharma Inc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FGCL-4592-041","October 29, 2010","June 13, 2012","June 13, 2012","November 19, 2010","February 10, 2022","February 10, 2022","Mobile, Alabama, United States|Pine Bluff, Arkansas, United States|Azusa, California, United States|Chula Vista, California, United States|Downey, California, United States|Northridge, California, United States|Paramount, California, United States|Riverside, California, United States|Whittier, California, United States|Yuba City, California, United States|Fort Lauderdale, Florida, United States|Lauderdale Lakes, Florida, United States|Pembroke Pines, Florida, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Meridian, Idaho, United States|Wichita, Kansas, United States|Baton Rouge, Louisiana, United States|Shreveport, Louisiana, United States|Bethesda, Maryland, United States|Detroit, Michigan, United States|Lincoln, Nebraska, United States|Mount Laurel, New Jersey, United States|Mineola, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Raleigh, North Carolina, United States|Canton, Ohio, United States|Orangeburg, South Carolina, United States|Knoxville, Tennessee, United States|Arlington, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Fairfax, Virginia, United States|Caguas, Puerto Rico|Ponce, Puerto Rico|San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01244763"
339,"NCT02079896","Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients",,"Completed","No Results Available","Anemia|End Stage Renal Disease","Drug: Lexaptepid pegol (NOX-H94)|Drug: Placebo","Number of adverse events|Pharmacokinetics|Pharmacodynamics|Efficacy","TME Pharma AG","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SNOXH94C301|2013-003585-14","May 2014","November 2015","November 2015","March 6, 2014",,"November 24, 2015","Dialysis Unit, Düsseldorf, Germany|University Hospital, Halle, Germany|Hospital, Leipzig, Germany|Dialysis Unit, Villingen-Schwenningen, Germany|Hospital, Siena, Italy|Hospital, Swansea, Wales, United Kingdom|Hospital, Leicester, United Kingdom|Hospital, London, United Kingdom|King's College London, London, United Kingdom|Lister Hospital, Stevenage, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02079896"
340,"NCT02439697","A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients",,"Completed","No Results Available","Anemia|End Stage Renal Failure on Dialysis","Other: Darbepoetin alfa","Haemoglobin|Variability in haemoglobin level|average weekly dose of erythropoietin|safety profile of NESP|Subjective assessment of fatigue|Subjective assessment of pain","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Version 1.2 18thApril, 2015","November 2015","November 2017","November 2017","May 12, 2015",,"June 4, 2018","Division of Nephrology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT02439697"
341,"NCT02260193","16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis",,"Completed","Has Results","Anemia|End Stage Renal Disease","Drug: AKB-6548","Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average|Change From Pre-dose Average in Hgb Level to The End-of-study Average|Change From Mid-study Average in Hgb Level to The End-of-study Average|Change From Baseline in Hgb|Change From Baseline in Hematocrit|Change From Baseline in Red Blood Cell (RBC) Count|Change From Baseline in Absolute Reticulocyte Count|Change From Baseline in Percent Reticulocyte Count|Change From Baseline in Reticulocyte Hgb Content|Change From Baseline in Ferritin|Change From Baseline in Hepcidin|Change From Baseline in Total Iron-Binding Capacity (TIBC)|Change From Baseline in Transferrin Saturation (TSAT)|Change From Baseline in Iron|Number of Participants Who Received Erythropoiesis-stimulating Agent (ESA) Rescue Therapy|Number of Participants Who Received Blood Transfusion Rescue Therapy|Mean Plasma Concentrations of Vadadustat|Mean Plasma Concentrations of Vadadustat-O-Glucuronide Metabolite|Mean Plasma Concentrations of Vadadustat-Acyl-Glucuronide Metabolite|Number of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Changes From Baseline in Vital Signs|Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values|Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings","Akebia Therapeutics","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","94","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0011","September 10, 2014","July 22, 2015","July 22, 2015","October 9, 2014","July 1, 2022","July 1, 2022","El Granada, California, United States|Long Beach, California, United States|San Dimas, California, United States|Santa Clarita, California, United States|Whittier, California, United States|Arvada, Colorado, United States|Westminster, Colorado, United States|Naples, Florida, United States|North Miami Beach, Florida, United States|Augusta, Georgia, United States|Astoria, New York, United States|Arlington, Texas, United States|Grand Prairie, Texas, United States|Greenville, Texas, United States|Houston, Texas, United States|Mechanicsville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02260193"
342,"NCT00994318","Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)","FIND-CKD","Completed","Has Results","Iron Deficiency Anaemia|Chronic Kidney Disease","Drug: FCM (Ferric carboxymaltose) high ferritin target|Drug: FCM (Ferric carboxymaltose) low ferritin target|Drug: Oral Iron (Ferrous sulphate)","Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger","Vifor Pharma|American Regent, Inc.|ICON Clinical Research","All","18 Years and older   (Adult, Older Adult)","Phase 3","626","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FER-CKD-01","December 2009","February 2013","February 2014","October 14, 2009","May 7, 2014","May 20, 2014","Trial Management Associates, Wilmington, North Carolina, United States|Gosford Hospital - Renal Research, Gosford, Australia|Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin IV, Innsbruck, Austria|RHMS Baudour - Department of Nephrology and Dialysis, Baudour, Belgium|Nemocnice s poliklinikou v Novem Jicine, p.o. p.o. Interni oddeleni - nefrologie a dialyza, Novy Jicin, Czech Republic|Lillebalt Frederica Sygehus Department of Nephrology, Frederica, Denmark|CHU grenoble - Service de Nephrologie, Grenoble Cedex, France|Praxis Dr. Kraatz, Demmin, Germany|General Hospital of Arta - Nephrology Department, Arta, Greece|Ospedali Riuniti Anzio-Nettuno ASL ROMA H U.O. Nefrologia e Dialisi, Anzio, Italy|Meander Medisch Centrum - Locatie Amersfoort Lichtenberg, Amersfoort, Netherlands|St. Olav's Hospital, Trondheim, Norway|Miedzyleski Szpital Spec. Oddzial I Wewnetrzny I Nefrologii, Warszawa, Poland|Hospital Santa Maria - Nefrologia, Lisboa, Portugal|Spitalul Clinic de Nefrologie""Dr Carol Davila"", Bucuresti, Romania|Hospital Universitario Marqués de Valdecilla - Servicio de Nefrología, Santander, Spain|Karolinska University Hospital, Stockholm, Sweden|Cukurova University Medical Faculty Balcali Hospital - Department of Nephrology, Adana, Turkey|King's College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00994318"
343,"NCT01381094","42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia",,"Completed","Has Results","Anemia|Kidney Disease","Drug: AKB-6548|Drug: Placebo","Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6)|Change From Baseline in Hgb at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Hematocrit (HCT) at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Red Blood Cell (RBC) Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Absolute Reticulocyte Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Reticulocyte Hgb Content at Week 6|Maximum Change From Baseline in Hgb|Maximum Change From Baseline in HCT|Maximum Change From Baseline in RBC Count|Maximum Change in Absolute Reticulocyte Count From Baseline|Number of Participants With Absolute Change From Baseline in Hgb ≥ 0.4, 0.6, 0.8, and 1.0 g/dL at the End of Dosing Period|Number of Participants With Change From Baseline in Hgb ≥5.0, 7.5, and 10.0% by the End of Dosing Period|Number of Participants With Change From Baseline in HCT ≥5.0, 7.5, and 10.0% by the End of Dosing Period|Number of Participants With Change From Baseline in RBC Count ≥5.0, 7.5, and 10.0% by the End of Dosing Period|Number of Participants With Change From Baseline in Reticulocyte Count ≥6000, 12000, and 18000 Cells/uL by the End of Dosing Period|Change From Baseline in Total Iron at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Unsaturated Iron Binding Capacity at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Iron Saturation at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Ferritin at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Erythropoietin at Week 2, Week 6, and Follow-up Visit (up to Week 8)|Change From Baseline in Hepcidin at Week 6|Mean Plasma Vadadustat Concentrations on Week 2 and Week 4|Mean Plasma Vadadustat Acyl-Glucuronide Concentrations on Week 2 and Week 4|Number of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Parameter|Number of Participants With Clinically Significant Abnormal 12-Electrocardiogram (ECG) Findings|Mean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval|Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values","Akebia Therapeutics","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","93","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AKB-6548-CI-0005","June 15, 2011","February 16, 2012","February 16, 2012","June 27, 2011","July 1, 2022","July 1, 2022","Pine Bluff, Arkansas, United States|Covina, California, United States|Los Angeles, California, United States|Lynwood, California, United States|Riverside, California, United States|San Dimas, California, United States|Whittier, California, United States|Coral Springs, Florida, United States|Lauderdale Lakes, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Augusta, Georgia, United States|Macon, Georgia, United States|Wichita, Kansas, United States|Shreveport, Louisiana, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|Pontiac, Michigan, United States|Warren, Michigan, United States|Bethpage, New York, United States|Mineola, New York, United States|Wilmington, North Carolina, United States|Oklahoma City, Oklahoma, United States|Knoxville, Tennessee, United States|Austin, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01381094"
344,"NCT01235936","Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia",,"Completed","Has Results","Anemia|Kidney Disease","Drug: AKB-6548","Mean Change From Baseline in Hemoglobin (Hgb) on Day 29|Mean Change From Baseline in Hematocrit on Day 29|Mean Change From Baseline in Total Red Blood Cell (RBC) Count on Day 29|Mean Change From Baseline in Absolute Reticulocyte Count on Day 29|Mean Change From Baseline in Reticulocyte Hemoglobin (Hgb) Content on Day 29|Number of Participants With Absolute Change From Baseline in Hemoglobin (Hgb) at Day 29|Number of Participants With the Percentage Change From Baseline in Hemoglobin (Hgb) at Day 29|Number of Participants With Percentage Change From Baseline in Hematocrit at Day 29|Number of Participants With Percentage Change From Baseline in Red Blood Cell (RBC) Count at Day 29|Number of Participants With Change From Baseline in Absolute Reticulocyte Count at Day 29|Change From Baseline in Ferritin on Day 29|Change From Baseline in Iron on Day 29|Change From Baseline in Total Iron Binding Capacity on Day 29|Change From Baseline in Transferrin Saturation on Day 29|Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values|Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values|Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings|Mean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval|Mean Trough Concentrations of Vadadustat at Day 8, 15, 22 and 29","Akebia Therapeutics","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKB-6548-CI-0004","October 21, 2010","April 13, 2011","May 2011","November 8, 2010","July 1, 2022","July 1, 2022","Augusta, Georgia, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01235936"
345,"NCT02278341","Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","Pyrenees","Completed","Has Results","Anemia|End Stage Renal Disease (ESRD)","Drug: Roxadustat|Drug: Epoetin alfa|Drug: Darbepoetin alfa|Drug: Iron","Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)]|Change From BL to the Average Hb in Weeks 28 to 52 Regardless of Rescue Therapy [US (FDA)]|Percentage of Participants With Hb Response During Weeks 28 to 36|Change From BL in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28|Mean Monthly Intravenous (IV) Iron Use|Change From BL in Short Form-36 (SF-36) Health Survey Physical Functioning (PF) Sub-score to the Average of Weeks 12 to 28|Change From BL in SF-36 Vitality (VT) Sub-score to the Average of Weeks 12 to 28|Change From BL in Mean Arterial Pressure (MAP) to the Average of Weeks 20 to 28|Time to First Occurrence of an Increase in Blood Pressure|Change From BL in Mean Arterial Pressure (MAP) to the Average MAP Value of Weeks 20 to 28|Percentage of Participants With a Hb Response During Weeks 28 and 36 Regardless of Use of Rescue Therapy|Change From BL in Hb to Each Postdosing Time Point|Hb Level Averaged Over Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy|Change From BL in Hb to the Average of Weeks 28 to 36, 44 to 52, and 96 to 104 Regardless of the Use of Rescue Therapy|Percentage of Hb Values ≥ 10 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy|Percentage of Hb Values Within 10.0 to 12.0 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy|Number of Hospitalizations|Number of Days of Hospitalization Per Year|Time to First Hospitalization|Time to First Use of Rescue Therapy|Time to First RBC Transfusion|Mean Monthly Number of RBC Packs Per Participant|Mean Monthly Volume of RBC Transfusion Per Participant|Time to First Use of IV Iron Supplementation|Mean Monthly Intravenous (IV) Iron Per Participant During Weeks 37-52 and Weeks 53-104|Percentage of Participants With Oral Iron Use Only|Change From BL to Each Post-dosing Study Visit in Total Cholesterol|Change From BL to Each Post-dosing Study Visit in LDL-C/High-density Lipoprotein Cholesterol (HDL-C) Ratio|Change From BL to Each Postdosing Study Visit in Non-HDL Cholesterol|Change From BL to Each Postdosing Study Visit in Apolipoproteins A1 (ApoA1)|Change From BL to Each Postdosing Study Visit in Apolipoproteins B (ApoB)|Change From BL to Each Postdosing Study Visit in ApoB/ApoA1 Ratio|Number of Participants With Mean LDL Cholesterol < 100 mg/dL Over Weeks 12 to 28|Number of Participants With CKD Who Achieved Antihypertensive Treatment Goal|Change From BL to the Average of Weeks 12 to 28 in SF-36 Physical Component Score (PCS)|Change From BL to the Average of Weeks 12 to 28 in Anemia Subscale (AnS) (""Additional Concerns"") of Functional Assessment of Cancer Therapy-Anemia (FACT-An) Score|Change From BL to the Average Value of Weeks 12 to 28 in Total FACT-An Score|Change From BL to the Average of Weeks 12 to 28 in Euroqol Questionnaire-5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score|Percentage of Participants With Improvements Measured by Patients' Global Impression of Change (PGIC)|Change From BL in Serum Hepcidin|Change From BL in Serum Ferritin|Change From BL in Transferrin Saturation (TSAT)|Change From BL in Glycated Hemoglobin (HbA1c) Level to Weeks 12, 28, 36, 44, 52, 60, 84, 104 and EOS (up to Week 108)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","Astellas Pharma Europe B.V.|FibroGen|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","838","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1517-CL-0613|2013-001497-16","November 21, 2014","June 8, 2017","July 6, 2018","October 30, 2014","August 26, 2020","February 4, 2021","Site BE32004, Brussels, Flemish Brabant, Belgium|Site BE32001, Aalst, Belgium|Site BE32019, Antwerpen, Belgium|Site BE32002, Antwerp, Belgium|Site BE32012, Baudour, Belgium|Site BE32017, Bonheiden, Belgium|Site BE32003, Leuven, Belgium|Site BE32013, Liege, Belgium|Site BE32011, Roeselare, Belgium|Site BG35925, Blagoevgrad, Bulgaria|Site BG35931, Haskovo, Bulgaria|Site BG35915, Pleven, Bulgaria|Site BG35909, Plovdiv, Bulgaria|Site BG35919, Plovdiv, Bulgaria|Site BG35920, Rousse, Bulgaria|Site BG35938, Shumen, Bulgaria|Site BG35924, Sofia, Bulgaria|Site BG35906, Sofia, Bulgaria|Site BG35921, Sofia, Bulgaria|Site BG35907, Stara Zagora, Bulgaria|Site BG35916, Varna, Bulgaria|Site BG35918, Varna, Bulgaria|Site BG35903, Veliko Tarnovo, Bulgaria|Site BG35937, Yambol, Bulgaria|Site HR38509, Zagreb, Grad Zagreb, Croatia|Site HR38508, Cakovec, Croatia|Site HR38505, Karlovac, Croatia|Site HR38507, Osijek, Croatia|Site HR38506, Rijeka, Croatia|Site HR38504, Slavonski Brod, Croatia|Site HR38501, Zadar, Croatia|Site CZ42008, Liberec, Czechia|Site CZ42021, Praha 6, Czechia|Site CZ42015, Rakovnik, Czechia|Site FR33005, Amiens cedex 1, France|Site FR33010, La Tronche, France|Site FR33055, Saint Ouen, France|Site FR33007, Saint Priez En Jarez, France|Site FR33056, Valenciennes, France|Site GE99503, Tbilisi, Georgia|Site GE99504, Tbilisi, Georgia|Site GE99508, Tbilisi, Georgia|Site DE49056, Dormagen, Nordrhein-Westfalen, Germany|Site DE49067, Berlin, Germany|Site DE49073, Cloppenburg, Germany|Site DE49008, Dresden, Germany|Site DE49054, Dusseldorf, Germany|Site DE49020, Frankfurt am Main, Germany|Site DE49065, Hamburg, Germany|Site DE49075, Heilbronn, Germany|Site DE49001, Kaiserslautern, Germany|Site DE49070, Muenchen, Germany|Site DE49002, Solingen, Germany|Site DE49071, Villingen-Schwenningen, Germany|Site HU36033, Baja, Hungary|Site HU36036, Esztergom, Hungary|Site HU36031, Gyor, Hungary|Site HU36026, Kaposvar, Hungary|Site HU36027, Kistarcsa, Hungary|Site HU36032, Pecs, Hungary|Site HU36035, Pecs, Hungary|Site HU36034, Salgotarjan, Hungary|Site HU36004, Szeged, Hungary|Site HU36046, Szekesfehervar, Hungary|Site HU36006, Szombathely, Hungary|Site HU36003, Zalsaegerszeg, Hungary|Site IT39028, Prato, Frazione Di Galciana, Italy|Site IT39039, Cremona, Lombardia, Italy|Site IT39014, Mestre, Venezia, Italy|Site IT39010, Brescia, Italy|Site IT39008, Lecco, Italy|Site IT39006, Milano, Italy|Site IT39037, Modena, Italy|Site IT39022, Padova, Italy|Site IT39036, Pavia, Italy|Site IT39005, Roma, Italy|Site IT39035, Torino, Italy|Site IT39032, Trieste, Italy|Site PL48002, Katowice, Poland|Site PL48001, Krakow, Poland|Site PL48013, Szczecin, Poland|Site PL48005, Warszawa, Poland|Site PL48006, Wroclaw, Poland|Site PL48009, Wroclaw, Poland|Site PL48014, Zamosc, Poland|Site PT35121, Almada, Portugal|Site PT35127, Aveiro, Portugal|Site PT35139, Cascais, Portugal|Site PT35117, Faro, Portugal|Site PT35128, Gaeiras, Portugal|Site PT35114, Leiria, Portugal|Site PT35102, Porto, Portugal|Site PT35122, Setubal, Portugal|Site RO40018, Bucharest, Romania|Site RO40015, Bucharest, Romania|Site RO40019, Bucharest, Romania|Site RO40003, Bucuresti, Romania|Site RO40004, Oradea, Romania|Site RU70008, Kaluga, Russian Federation|Site RU70051, Moscow, Russian Federation|Site RU70005, Moscow, Russian Federation|Site RU70003, Nizhny Novgorod, Russian Federation|Site RU70004, Omsk, Russian Federation|Site RU70014, Rostov-on-Don, Russian Federation|Site RU70072, Saint Petersburg, Russian Federation|Site RU70002, Saint Petersburg, Russian Federation|Site RU70011, Saint-Petersburg, Russian Federation|Site RU70050, Saint-Petersburg, Russian Federation|Site RU70030, Sankt-Peterburg, Russian Federation|Site RU70006, Smolensk, Russian Federation|Site RU70037, Volgograd, Russian Federation|Site RU70001, Yaroslavl, Russian Federation|Site RS38102, Belgrade, Serbia|Site RS38105, Belgrade, Serbia|Site RS38120, Belgrade, Serbia|Site RS38104, Belgrade, Serbia|Site RS38117, Krusevac, Serbia|Site RS38101, Nis, Serbia|Site RS38116, Zrenjanin, Serbia|Site SK42102, Koshice, Slovakia|Site SK42119, Levice, Slovakia|Site SK42120, Lučenec, Slovakia|Site SK42113, Puchov, Slovakia|Site SK42116, Senica, Slovakia|Site ES34041, Santiago de Compostela, A Coruna, Spain|Site ES34009, El Ejido, Almeria, Spain|Site ES34010, Alcorcon, Madrid, Spain|Site ES34030, Majadahonda, Madrid, Spain|Site ES34011, Galdakao, Vizcaya, Spain|Site ES34002, Badalona-Barcelona, Spain|Site ES34008, Barcelona, Spain|Site ES34006, Barcelona, Spain|Site ES34017, Jaen, Spain|Site ES34037, Madrid, Spain|Site ES34052, Valencia, Spain|Site GB44087, Brighton, EastSussex, United Kingdom|Site GB44011, Canterbury, Kent, United Kingdom|Site GB44080, Stoke on Trent, Staffordshire, United Kingdom|Site GB44008, Cambridge, United Kingdom|Site GB44010, Hull, United Kingdom|Site GB44081, Leicester, United Kingdom|Site GB44079, Liverpool, United Kingdom|Site GB44001, Swansea, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/41/NCT02278341/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/41/NCT02278341/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02278341"
346,"NCT00964691","A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands","IPTpRCT","Terminated","No Results Available","Malaria|Malaria in Pregnancy","Drug: Sulphadoxine-pyrimethamine|Drug: Chloroquine prophylaxis","Placental malaria among primigravidae at time of delivery|Low birth weight among primigravidae|Maternal anaemia (Hb <11 g/dl) in the third trimester|Maternal anaemia (Hb <11 g/dl) at delivery|Malaria parasitemia at delivery","Ministry of Health and Medical Services, Solomon Islands|World Health Organization","Female","15 Years to 49 Years   (Child, Adult)","Phase 4","2504","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","01-2009","August 2009","August 2010","August 2010","August 25, 2009",,"July 7, 2010","Honiara City Council, Honiara, Solomon Islands",,"https://ClinicalTrials.gov/show/NCT00964691"
347,"NCT04925661","HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia",,"Unknown status","No Results Available","Chronic Kidney Diseases|Renal Anemia","Drug: HEC53856|Drug: Roxadustat|Drug: Placebo","Incidence of Adverse Events|AUC0-t|Cmax|Tmax|T½|Vz/F|Changes in mean hemoglobin|Hemoglobin response|E-AUC0-t|Emax|E-Tmax|Serum lipid|Indicators of iron|High-sensitivity C-reactive protein|Reticulocytes|VEGF","Sunshine Lake Pharma Co., Ltd.|Nicoya Therapeutics (Shanghai) Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HEC53856-RAD-102","September 29, 2021","December 26, 2022","May 10, 2023","June 14, 2021",,"June 24, 2021","The sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China|Zhejiang Provincal People's Hospital, Hangzhou, China|The People's Hospital of Guangxi Zhuang Autonmous Region, Nanning, China|Huashan Hospital, Shanghai, China|Ruijin Hospital, Shanghai, China|First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|The First Affiliated Hospital of Xiamen University, Xiamen, China|The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China",,"https://ClinicalTrials.gov/show/NCT04925661"
348,"NCT02366325","Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis",,"Unknown status","No Results Available","Chronic Renal Failure|Anemia","Drug: EPO-018B","Percentage of participants who achieved a target hemoglobin response during the study|Percentage of participants who response to study drug.|Average reticulocytes and hemoglobin change from baseline|Incidence of adverse events and serious adverse events","Jiangsu Hansoh Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-EPOP2a","July 2014","December 2015","December 2015","February 19, 2015",,"February 19, 2015","Changzheng Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02366325"
349,"NCT03214627","Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial","ANEMEX","Terminated","No Results Available","Anemia|End Stage Renal Disease","Device: Anemia Control Model (ACM)|Drug: IV iron|Drug: Erythropoiesis-Stimulating Agent (ESA)","Change in the proportion of patients with haemoglobin within the target range as compared to the historical control period (non-inferiority testing)|Change in the proportion of patients with haemoglobin within the target range as compared to historical control period (superiority testing)|Change in haemoglobin fluctuations as compared to historical control period|Change in cumulative ESA dose as compared to historical control period|Change in cumulative IV iron dose as compared to historical control period","Vifor Fresenius Medical Care Renal Pharma|Worldwide Clinical Trials|Fresenius Medical Care Deutschland GmbH","All","19 Years to 90 Years   (Adult, Older Adult)","Not Applicable","88","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","VEN-DEV-401","December 10, 2018","May 21, 2019","May 21, 2019","July 11, 2017",,"January 7, 2020","Kings College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03214627"
350,"NCT00111995","Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis",,"Completed","No Results Available","Chronic Renal Failure|Anemia","Drug: Aranesp®","Mean hemoglobin level during the evaluation period|The nature, frequency, severity, relationship to treatment, and outcome of adverse events with specific attention to hypertensive events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention","20010125","May 2002",,,"May 30, 2005",,"August 8, 2008",,,"https://ClinicalTrials.gov/show/NCT00111995"
351,"NCT00446576","The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease",,"Completed","No Results Available","Anemia","Drug: Epoetin Alfa","Absolute change in left ventricular mass index|Incidence of Left Ventricular hypertrophy QoL assessment (FACIT-Fatigue Scale and KDQOL-SFÒ) The change in pulse pressure during the study period. Morbidity and mortality during the study-period Deterioration of renal function Days in hospital","Janssen-Cilag B.V.","All","18 Years to 73 Years   (Adult, Older Adult)","Phase 3","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR005599","November 1999",,"April 2003","March 13, 2007",,"February 1, 2011",,,"https://ClinicalTrials.gov/show/NCT00446576"
352,"NCT01428154","Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease",,"Withdrawn","No Results Available","Anemia|Chronic Kidney Disease","Drug: Darbepoetin alfa","Number of subjects with clinically significant changes in physical examinations, laboratory safety tests, and vital signs|Number of subjects with treatment-emergent adverse events|Maximum observed concentration (Cmax) of darbepoetin alfa|Time at which maximum concentration is observed (Tmax) of darbepoetin alfa|Area under the concentration curve (AUC) of darbepoetin alfa|Terminal half-life (t½) of darbepoetin alfa|Clearance (CL) of darbepoetin alfa|Change in reticulocytes|Change in hemoglobin concentration|Change in iron|Change in ferritin|Change in transferrin saturation","Amgen","All","up to 1 Year   (Child)","Phase 1","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090302","April 2016","November 2016","November 2016","September 2, 2011",,"June 17, 2016",,,"https://ClinicalTrials.gov/show/NCT01428154"
353,"NCT03418168","A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects","MIYABI PD","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)","Responder rate: proportion of responders among the subjects|Mean Hb (Hemoglobin) level|Change in mean Hb level|Rate of rise in Hb (Hemoglobin) level (g/dL/week)|Proportion of subjects who meet each component of the response|Hb level|Change in Hb level|Proportion of subjects with mean hemoglobin levels are in the target range|Proportion of subjects with mean hemoglobin levels are above the target range|Proportion of subjects with mean hemoglobin levels are below the target range|Proportion of subjects with hemoglobin levels in the target range|Proportion of subjects with hemoglobin levels above the target range|Proportion of subjects with hemoglobin levels below the target range|Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week|Percentage of days in the target Hb range during the evaluation period|Percentage of days in the target Hb range during the treatment period|Rate of rise in Hb level (g/dL/week) between each consecutive visits|Percentage of Hb levels in target range during the evaluation period|Percentage of Hb levels in target range during the treatment period|Proportion of subjects who received at least one rescue treatment|Proportion of subjects whose Hb level was ≥ 13.0 g/dL or < 8.0 g/dL|Number of participants with serious adverse events|Maximum concentration (Cmax) of Molidustat|Area under the concentration-time curve (AUC) of Molidustat|EPO (Erythropoietin) serum concentration of Molidustat","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","51","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19353","February 22, 2018","July 25, 2019","July 29, 2019","February 1, 2018",,"January 29, 2021","Kainan Hospital, Yatomi, Aichi, Japan|Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|JCHO Kyushu Hospital, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Elm Grove Clinic, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Fujisawa City Hospital, Fujisawa, Kanagawa, Japan|Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan|Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan|Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan|Tohoku Medical and Pharmaceutical University Hospital, Sendai, Miyagi, Japan|Niigata Prefectural Shibata Hospital, Shibata, Niigata, Japan|National Hospital Organization Beppu Medical Center, Beppu, Oita, Japan|Okinawa prefectural Chubu Hospital, Uruma, Okinawa, Japan|Fuchu Hospital, Izumi, Osaka, Japan|Fukui-ken Saiseikai Hospital, Fukui, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Asahi University Hospital, Gifu, Japan|National Hospital Organization Kyoto Medical Center, Kyoto, Japan|Nara Prefecture General Medical Center, Nara, Japan|Niigata City General Hospital, Niigata, Japan|Japanese Red Cross Oita Hospital, Oita, Japan|Osaka General Medical Center, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT03418168"
354,"NCT03351166","A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects","MIYABI HD-C","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)","Rate of rise in Hb (Hemoglobin) level (g/dL/week)|Responder rate: proportion of responders among the subjects|Proportion of subjects who meet each component of the response|Cumulative proportion of subjects who achieve the lower limit of the target Hb range at least once at each visit|Hb level|Change in Hb level|Proportion of subjects whose mean hemoglobin levels are above the target range during the evaluation period|Proportion of subjects whose mean hemoglobin levels are below the target range during the evaluation period|Proportion of subjects whose mean hemoglobin levels are in the target range during the evaluation period|Proportion of subjects with hemoglobin levels above the target range|Proportion of subjects with hemoglobin levels below the target range|Proportion of subjects with hemoglobin levels in the target range|Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week|Number of participants with serious adverse events|Maximum concentration (Cmax) of Molidustat|Area under the concentration-time curve (AUC) of Molidustat|EPO (Erythropoietin) serum concentration of Molidustat","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19351","January 22, 2018","October 23, 2018","November 20, 2018","November 22, 2017",,"January 29, 2021","Houshikai Kano hospital, Kasuya-gun, Fukuoka, Japan|Matsunami General Hospital, Hashima-gun, Gifu, Japan|Asahikawa-Kosei General Hospital, Asahikawa, Hokkaido, Japan|Ishikari Hospital, Ishikari, Hokkaido, Japan|Itami Kidney Clinic, Noboribetsu, Hokkaido, Japan|Souen Central Hospital, Sapporo, Hokkaido, Japan|Takasago Seibu Hospital, Takasago, Hyogo, Japan|Japanese Red Cross Koga Hospital, Koga, Ibaraki, Japan|Mito Kyodo General Hospital, Mito, Ibaraki, Japan|Tokiwa Clinic, Totte, Ibaraki, Japan|Tsuchiura Beryl Clinic, Tsuchiura, Ibaraki, Japan|Kikuchi Medical Clinic, Tsukuba, Ibaraki, Japan|Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan|Iida Hospital, Iida, Nagano, Japan|Toyonaka Keijinkai Clinic, Toyonaka, Osaka, Japan|Kodaira Kitaguchi Clinic, Kodaira, Tokyo, Japan|Medical corporation association Shunshin-kai Inage hospital, Chiba, Japan|Fukuoka Renal Clinic, Fukuoka, Japan|Ohmiya Chuo General Hospital, Saitama, Japan|Yamagata Tokushukai Hospital, Yamagata, Japan",,"https://ClinicalTrials.gov/show/NCT03351166"
355,"NCT00046969","Epoetin Beta in Treating Anemia in Patients With Cervical Cancer",,"Completed","No Results Available","Anemia|Cervical Cancer","Biological: epoetin beta|Drug: cisplatin|Radiation: brachytherapy|Radiation: radiation therapy","Number of treatment failures within 6 months after beginning radiochemotherapy (RCT) (stage I)|Overall survival after RCT (stage II)|Progression/relapse-free survival|Overall response rate to RCT|Overall survival after RCT (stage I)|Frequency and localization of relapses and/or metastases|Change in hemoglobin from baseline during therapy|Quality of life as assessed by the Functional Assessment of Cancer Therapy-Anemia|Type, frequency, and degree of adverse events|Safety|Vital signs|Number of treatment failures within 6 months after beginning RCT (stage II)","AGO Study Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 4","450","Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Supportive Care","AGOSG-OVAR-MO16375-MARCH|CDR0000257189|EU-20217|ROCHE-MO16375|ROCHE-RO2053859","July 2002",,"June 2007","January 27, 2003",,"May 30, 2013","Martin Luther Universitaet, Halle, Germany",,"https://ClinicalTrials.gov/show/NCT00046969"
356,"NCT01555515","Epodure Therapy of Anemia in End Stage Renal Disease on Dialysis With Epodure Skin Implant",,"Terminated","No Results Available","Anemia|End Stage Renal Disease","Procedure: implantation of autologous skin graft after ex-vivo treatment|Biological: Subcutan implantation of autologus skin graft after ex-vivo treatment","Hg maintenance with in the range of 10-12 gr/dl for the duration of 6 month|REDUCING THE AMOUNT OF EXOGENOUS EPO ADMINISTRATION","Medgenics Medical Israel Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","4","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MG-001-03","March 2012","June 2013","April 2014","March 15, 2012",,"September 13, 2016",,,"https://ClinicalTrials.gov/show/NCT01555515"
357,"NCT03350321","A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects","MIYABI ND-C","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)|Drug: Darbepoetin alfa","Mean Hb (Hemoglobin) level|Change in hemoglobin level from baseline to the average during the evaluation period|Responder rate: proportion of responders among the subjects|Rate of rise in Hb (Hemoglobin) level (g/dL/week)|Proportion of subjects who meet each component of the response|Cumulative proportion of subjects who achieve the lower limit of the target Hb range at least once|Change in Hb level|Hb level|Proportion of subjects whose mean hemoglobin level is in the target range|Proportion of subjects whose mean hemoglobin level is above the target range|Proportion of subjects whose mean hemoglobin level is below the target range|Proportion of subjects with hemoglobin levels in the target range|Proportion of subjects with hemoglobin levels above the target range|Proportion of subjects with hemoglobin levels below the target range|Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week|Number of participants with serious adverse events|Maximum concentration (Cmax)|Area under the concentration-time curve (AUC)|EPO (Erythropoietin) serum concentration","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19349","December 12, 2017","May 17, 2019","October 11, 2019","November 22, 2017",,"January 29, 2021","Kainan Hospital, Yatomi, Aichi, Japan|Seikeikai New Tokyo Heart Clinic, Matsudo, Chiba, Japan|Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan|Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan|National Fukuoka-Higashi Medical Center, Koga, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|St.Mary's Hospital, Kurume, Fukuoka, Japan|Matsunami Health Promotion Clinic, Hashima-gun, Gifu, Japan|Gifu Prefectural Tajimi Hospital, Tajimi, Gifu, Japan|Mazda Hospital of Mazda Motor Corporation, Aki-gun, Hiroshima, Japan|Nippon Kokan Fukuyama Hospital, Fukuyama, Hiroshima, Japan|Teine Keijinkai Clinic, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|National Hospital Organization Kobe Medical Center, Kobe, Hyogo, Japan|National hospital Organization Mito Medical Center, Higashiibaraki, Ibaraki, Japan|Mito Kyodo General Hospital, Mito, Ibaraki, Japan|KenAiKai medical corporation Akiyama clinic, Takamatsu, Kagawa, Japan|Ikeda Hospital, Kanoya, Kagoshima, Japan|Fujisawa City Hospital, Fujisawa, Kanagawa, Japan|Koukan Clinic, Kawasaki, Kanagawa, Japan|Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan|Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan|Arao Municipal Hospital, Arao, Kumamoto, Japan|Kumamoto Rosai Hospital, Yatsushiro, Kumamoto, Japan|Uji-Tokushukai Medical Center, Uji, Kyoto, Japan|JCHO Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan|Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan|Asama Nanroku Komoro Medical Center, Komoro, Nagano, Japan|Niigata Prefectural Shibata Hospital, Shibata, Niigata, Japan|Okinawa prefectural Chubu Hospital, Uruma, Okinawa, Japan|Osaka Saiseikai Senri Hospital, Suita, Osaka, Japan|Osaka Pref. Saiseikai Tondabayashi Hospital, Tondabayashi, Osaka, Japan|Kitasato University Medical Center, Kitamoto, Saitama, Japan|Iwata City Hospital, Iwata, Shizuoka, Japan|Toshima Hospital, Itabashi-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|Showa University Koto Toyosu Hospital, Koto-ku, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan|University of Yamanashi Hospital, Chuo, Yamanashi, Japan|Fukui Prefectural Hospital, Fukui, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Asahi University Hospital, Gifu, Japan|National Hospital Organization Kochi National Hospital, Kochi, Japan|Nara Prefecture General Medical Center, Nara, Japan|Japanese Red Cross Oita Hospital, Oita, Japan|Kitano Hospital, Osaka, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka Red Cross Hospital, Osaka, Japan|Nippon Life Hospital, Osaka, Japan|Chibune Clinic, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|Social Corporation Keigakukai Minamiosaka Hospital, Osaka, Japan|Shizuoka Saiseikai General Hospital, Shizuoka, Japan|Suruga Clinic, Shizuoka, Japan|Wakayama Medical University Hospital, Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT03350321"
358,"NCT04128943","Electronic Patient-reported Outcome Monitoring in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria","ePRO-AA-PNH","Completed","No Results Available","Aplastic Anemia|Paroxysmal Nocturnal Hemoglobinuria","Other: symptom questionnaire|Other: recording of vital signs|Other: European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire|Other: interview","recruitment with the ePRO application (number)|usability of the ePRO application|acceptability of the ePRO application|Change in quality of life assessed by the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire (EORTC QLQ-C30 questionnaire)","University Hospital, Basel, Switzerland|ProPatient foundation of the University Hospital Basel|Novartis","All","18 Years and older   (Adult, Older Adult)",,"9","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-01563; me18Drexler","November 1, 2019","July 6, 2020","July 6, 2020","October 16, 2019",,"October 5, 2020","Division of Hematology, University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT04128943"
359,"NCT02879305","Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)",,"Completed","Has Results","Anaemia|Aspergillosis, Allergic Bronchopulmonary","Drug: Daprodustat|Drug: rhEPO|Drug: Placebo|Drug: Iron therapy","Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis|Mean Change From Baseline in Hemoglobin (Hgb) Levels During Evaluation Period (Week 28 to Week 52)|Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period: Superiority Analysis|Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period|Mean Average Monthly On-treatment IV Iron Dose Per Participant|Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period|Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period|Number of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)|Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period|Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period|Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period|Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period|Change From Baseline in Post-randomization Hemoglobin Levels at Week 52|Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)|Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis|Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis|Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis|Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis|Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52|Change From Baseline in SBP, DBP, MAP at End of Treatment|Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years|Number of Participants With at Least One BP Exacerbation Event During Study|Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria|Change From Baseline in On-Treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in On-Treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in On-Treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52|Change From Baseline in On-Treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in On-Treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52|Change From Baseline in On-Treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52|Change From Baseline in On-Treatment EuroQol Visual Analogue Scale (EQ-VAS) at Week 52|Change From Baseline in On-Treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52","GlaxoSmithKline","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","2964","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200807|2016-000541-31","September 28, 2016","November 9, 2020","November 9, 2020","August 25, 2016","December 3, 2021","December 3, 2021","GSK Investigational Site, Huntsville, Alabama, United States|GSK Investigational Site, Pine Bluff, Arkansas, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Cerritos, California, United States|GSK Investigational Site, Chula Vista, California, United States|GSK Investigational Site, El Centro, California, United States|GSK Investigational Site, Escondido, California, United States|GSK Investigational Site, Fairfield, California, United States|GSK Investigational Site, Fountain Valley, California, United States|GSK Investigational Site, Glendale, California, United States|GSK Investigational Site, Granada Hills, California, United States|GSK Investigational Site, Hacienda Heights, California, United States|GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, La Palma, California, United States|GSK Investigational Site, Lakewood, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Lynwood, California, United States|GSK Investigational Site, Montebello, California, United States|GSK Investigational Site, Monterey Park, California, United States|GSK Investigational Site, Moreno Valley, California, United States|GSK Investigational Site, Norco, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, Ontario, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Luis Obispo, California, United States|GSK Investigational Site, Santa Clarita, California, United States|GSK Investigational Site, Simi Valley, California, United States|GSK Investigational Site, Tarzana, California, United States|GSK Investigational Site, Whittier, California, United States|GSK Investigational Site, Whittier, California, United States|GSK Investigational Site, Yorba Linda, California, United States|GSK Investigational Site, Middlebury, Connecticut, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Lauderdale Lakes, Florida, United States|GSK Investigational Site, Miami Gardens, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Port Charlotte, Florida, United States|GSK Investigational Site, Spring Hill, Florida, United States|GSK Investigational Site, Winter Park, Florida, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Meridian, Idaho, United States|GSK Investigational Site, Crystal Lake, Illinois, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Jeffersonville, Indiana, United States|GSK Investigational Site, Merrillville, Indiana, United States|GSK Investigational Site, Michigan City, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Greenbelt, Maryland, United States|GSK Investigational Site, Takoma Park, Maryland, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Pontiac, Michigan, United States|GSK Investigational Site, Roseville, Michigan, United States|GSK Investigational Site, Gulfport, Mississippi, United States|GSK Investigational Site, Tupelo, Mississippi, United States|GSK Investigational Site, Florissant, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Portsmouth, New Hampshire, United States|GSK Investigational Site, Gallup, New Mexico, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Flushing, New York, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Ridgewood, New York, United States|GSK Investigational Site, Yonkers, New York, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Clyde, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Roseburg, Oregon, United States|GSK Investigational Site, Bethlehem, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Anderson, South Carolina, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Sumter, South Carolina, United States|GSK Investigational Site, Cordova, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Beaumont, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Lufkin, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Alexandria, Virginia, United States|GSK Investigational Site, Fairfax, Virginia, United States|GSK Investigational Site, Hampton, Virginia, United States|GSK Investigational Site, Salem, Virginia, United States|GSK Investigational Site, Bluefield, West Virginia, United States|GSK Investigational Site, Shorewood, Wisconsin, United States|GSK Investigational Site, Burzaco, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Evita, Buenos Aires, Argentina|GSK Investigational Site, Pergamino, Buenos Aires, Argentina|GSK Investigational Site, Pilar, Buenos Aires, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Formosa, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Moron, Argentina|GSK Investigational Site, San Miguel de Tucumán, Argentina|GSK Investigational Site, Concord, New South Wales, Australia|GSK Investigational Site, Kingswood, New South Wales, Australia|GSK Investigational Site, Kogarah, New South Wales, Australia|GSK Investigational Site, Liverpool, New South Wales, Australia|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Westmead, New South Wales, Australia|GSK Investigational Site, Wollongong, New South Wales, Australia|GSK Investigational Site, Birtinya, Queensland, Australia|GSK Investigational Site, Herston, Queensland, Australia|GSK Investigational Site, Woolloongabba, Queensland, Australia|GSK Investigational Site, Adelaide, South Australia, Australia|GSK Investigational Site, Clayton, Victoria, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, St Albans, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Murdoch, Australia|GSK Investigational Site, Graz, Austria|GSK Investigational Site, St. Pölten, Austria|GSK Investigational Site, Wien, Austria|GSK Investigational Site, Wien, Austria|GSK Investigational Site, Baudour, Belgium|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Hasselt, Belgium|GSK Investigational Site, Ieper, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Roeselare, Belgium|GSK Investigational Site, Salvador, Bahia, Brazil|GSK Investigational Site, Curitiba, Paraná, Brazil|GSK Investigational Site, Curitiba, Paraná, Brazil|GSK Investigational Site, Passo Fundo, Rio Grande Do Sul, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Joinville, Santa Catarina, Brazil|GSK Investigational Site, Sao Jose do Rio Preto, São Paulo, Brazil|GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil|GSK Investigational Site, Feira de Santana, Brazil|GSK Investigational Site, Porto Alegre, Brazil|GSK Investigational Site, Porto Alegre, Brazil|GSK Investigational Site, Sao Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Blagoevgrad, Bulgaria|GSK Investigational Site, Dobrich, Bulgaria|GSK Investigational Site, Gabrovo, Bulgaria|GSK Investigational Site, Lom, Bulgaria|GSK Investigational Site, Lovech, Bulgaria|GSK Investigational Site, Montana, Bulgaria|GSK Investigational Site, Pazardzhik, Bulgaria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Ruse, Bulgaria|GSK Investigational Site, Smolyan, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Veliko Tarnovo, Bulgaria|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Beroun, Czechia|GSK Investigational Site, Frýdek-mistek, Czechia|GSK Investigational Site, Ivancice, Czechia|GSK Investigational Site, Jilemnice, Czechia|GSK Investigational Site, Marianske Lazne, Czechia|GSK Investigational Site, Pardubice, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Sokolov, Czechia|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Holstebro, Denmark|GSK Investigational Site, Kolding, Denmark|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Svendborg, Denmark|GSK Investigational Site, Parnu, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Annonay, France|GSK Investigational Site, Bois-Guillaume, France|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Boulogne Billancourt, France|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Mulhouse, France|GSK Investigational Site, Poitiers, France|GSK Investigational Site, Reims, France|GSK Investigational Site, Tours cedex 9, France|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Bad Koenig, Hessen, Germany|GSK Investigational Site, Wiesbaden, Hessen, Germany|GSK Investigational Site, Rostock, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Cloppenburg, Niedersachsen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Kaiserslautern, Rheinland-Pfalz, Germany|GSK Investigational Site, Kiel, Schleswig-Holstein, Germany|GSK Investigational Site, Dieburg, Germany|GSK Investigational Site, Freiburg, Germany|GSK Investigational Site, Minden, Germany|GSK Investigational Site, Alexandroupolis, Greece|GSK Investigational Site, Arta, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Heraklion-Crete, Greece|GSK Investigational Site, Ioannina, Greece|GSK Investigational Site, Ioannina, Greece|GSK Investigational Site, Komotini, Greece|GSK Investigational Site, Larissa, Greece|GSK Investigational Site, Patras, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Egri, Hungary|GSK Investigational Site, Esztergom, Hungary|GSK Investigational Site, Kecskemet, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Szigetvar, Hungary|GSK Investigational Site, Ahmedabad, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Calicut, India|GSK Investigational Site, Chennai, Tamil Nadu, India|GSK Investigational Site, Chennai, India|GSK Investigational Site, Delhi, India|GSK Investigational Site, Gurgaon, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Jaipur, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Nadiad, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Secunderabad, India|GSK Investigational Site, Trivandrum, India|GSK Investigational Site, Catanzaro, Calabria, Italy|GSK Investigational Site, Reggio Calabria, Calabria, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Piacenza, Emilia-Romagna, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Bergamo, Lombardia, Italy|GSK Investigational Site, Lecco, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Monza, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Seriate, Lombardia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Foggia, Puglia, Italy|GSK Investigational Site, Cagliari, Sardegna, Italy|GSK Investigational Site, Imola, Italy|GSK Investigational Site, Mestre, Italy|GSK Investigational Site, Anyang-Si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Bucheon-si,, Korea, Republic of|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Daegu-si, Korea, Republic of|GSK Investigational Site, Daejeon, Korea, Republic of|GSK Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Goyang-si, Korea, Republic of|GSK Investigational Site, Goyang-si, Korea, Republic of|GSK Investigational Site, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Suwon, Korea, Republic of|GSK Investigational Site, Uijeongbu-si, Korea, Republic of|GSK Investigational Site, Wonju-si, Korea, Republic of|GSK Investigational Site, Batu Caves, Malaysia|GSK Investigational Site, Ipoh, Malaysia|GSK Investigational Site, Johor Bahru, Malaysia|GSK Investigational Site, Kuala Lumpur, Malaysia|GSK Investigational Site, Pahang, Malaysia|GSK Investigational Site, Penang, Malaysia|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Durango., Durango, Mexico|GSK Investigational Site, Ciudad De México, Estado De México, Mexico|GSK Investigational Site, Cuautitlan Izcalli, Estado De México, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Queretaro, Querétaro, Mexico|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Aguascalientes, Mexico|GSK Investigational Site, Chihuahua, Mexico|GSK Investigational Site, Chihuahua, Mexico|GSK Investigational Site, México, D.F., Mexico|GSK Investigational Site, Zapopan, Jalisco, Mexico|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Deventer, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Hamilton, New Zealand|GSK Investigational Site, Hastings, New Zealand|GSK Investigational Site, Otahuhu, New Zealand|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Stavanger, Norway|GSK Investigational Site, Biala Podlaska, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Grojec, Poland|GSK Investigational Site, Kielce, Poland|GSK Investigational Site, Kolobrzeg, Poland|GSK Investigational Site, Kolo, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Olkusz, Poland|GSK Investigational Site, Pruszkow, Poland|GSK Investigational Site, Tomaszow Mazowiecki, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Zary, Poland|GSK Investigational Site, Amadora, Portugal|GSK Investigational Site, Corroios., Portugal|GSK Investigational Site, Covilhã, Portugal|GSK Investigational Site, Forte Da Casa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Mirandela, Portugal|GSK Investigational Site, Portimão, Portugal|GSK Investigational Site, Vila Franca de Xira, Portugal|GSK Investigational Site, Vila Real (Lordelo), Portugal|GSK Investigational Site, Arad, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Resita, Romania|GSK Investigational Site, Targu-Jiu, Romania|GSK Investigational Site, Irkutsk, Russian Federation|GSK Investigational Site, Krasnodar, Russian Federation|GSK Investigational Site, Mytischi, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Omsk, Russian Federation|GSK Investigational Site, Orenburg, Russian Federation|GSK Investigational Site, Penza, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Volzhsky, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Cape Town., South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Majadahonda, Madrid, Spain|GSK Investigational Site, Alcala de Henares, Spain|GSK Investigational Site, Aranda de Duero, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Ciudad Real, Spain|GSK Investigational Site, Girona, Spain|GSK Investigational Site, Guadalajara, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Manises (Valencia), Spain|GSK Investigational Site, Mollet del Valles, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Sabadell, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Valladolid, Spain|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Örebro, Sweden|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Keelung, Taiwan|GSK Investigational Site, New Taipei City, Taiwan|GSK Investigational Site, New Taipei City, Taiwan|GSK Investigational Site, New Taipei, Taiwan|GSK Investigational Site, Tainan, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taoyuan Hsien, Taiwan|GSK Investigational Site, Zhongzheng Dist., Taipei, Taiwan|GSK Investigational Site, Adana, Turkey|GSK Investigational Site, Ankara, Turkey|GSK Investigational Site, Antalya, Turkey|GSK Investigational Site, Edirne, Turkey|GSK Investigational Site, Eskisehir, Turkey|GSK Investigational Site, Kayseri, Turkey|GSK Investigational Site, Chernihiv, Ukraine|GSK Investigational Site, Chernivtsi, Ukraine|GSK Investigational Site, Ivano-Frankivsk, Ukraine|GSK Investigational Site, Kherson, Ukraine|GSK Investigational Site, Kiev, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Mykolaiv, Ukraine|GSK Investigational Site, Ternopil, Ukraine|GSK Investigational Site, Zaporizhzhia, Ukraine|GSK Investigational Site, Zaporizhzhia, Ukraine|GSK Investigational Site, Zhytomyr, Ukraine|GSK Investigational Site, Stevenage, Hertfordshire, United Kingdom|GSK Investigational Site, Preston, Lancashire, United Kingdom|GSK Investigational Site, Wolverhampton, West Midlands, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Derby, United Kingdom|GSK Investigational Site, Doncaster, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Fife, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Hull, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Oxford, United Kingdom|GSK Investigational Site, Salford, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/05/NCT02879305/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/05/NCT02879305/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02879305"
360,"NCT04231292","A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis",,"Unknown status","No Results Available","Patient of Anemia in Chronic Renal Failure With Hemodialysis","Drug: RD01|Drug: Recombinant Human Erythropoiesis Injection (CHO cell)|Drug: placebo","Primary efficacy index : The change of hemoglobin concentration of experimental group from baseline to the end of 4th and 6th week|Primary efficacy index: The difference of hemoglobin concentration between the experimental group and the placebo group at the end of 4th and 6th week;|Primary efficacy index: hemoglobin concentration change from baseline to the end of first stage|Primary efficacy index: hemoglobin concentration change from baseline to the evaluation periods in the second stage (39th ~46th week)|Secondary efficacy index: the optimal dosage|Secondary efficacy index: maintenance rate|Secondary efficacy index : Proportion of subjects with unstable Hb during the evaluation period|Secondary efficacy index: proportion of times of Hb remains within the target range|Secondary efficacy index: EPO dose conversion coefficient of RD01|Safety indicator: adverse events|Immunogenicity indicator: incidence of anti-RD01 antibodies|Maximum Plasma Concentration (Cmax)|Area Under the Curve (AUC)","Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SZSBE-RD01-HD-II-01","March 1, 2020","June 30, 2020","December 31, 2022","January 18, 2020",,"January 18, 2020","Renal Rheumatology and Immunology department Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04231292"
361,"NCT00001399","Gene Therapy for the Treatment of Fanconi's Anemia Type C",,"Completed","No Results Available","Fanconi's Anemia|Pancytopenia","Drug: Transduced CD34+ Cells",,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","5 Years and older   (Child, Adult, Older Adult)","Phase 1","9","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","940033|94-H-0033","December 3, 1993",,"February 11, 2009","November 4, 1999",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001399"
362,"NCT03552393","Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.",,"Completed","Has Results","Anemia|Renal Insufficiency, Chronic","Drug: Mircera","Change in Hemoglobin (Hb) Concentration Between the Baseline and the Evaluation Period for Each Patient|Number of Participants With an Average Hb Concentration During the Evaluation Period Within ± 1 g/dL of Their Baseline Hb and Above, Within or Below the Range of 10-12 g/dL|Mean Hb Values and Change From Baseline|Change in Mircera Dose Over Time|Ratio of Mircera Starting Dose (Week 1) to the Dose at Week 17|Number of Participants With Adverse Events by Severity as Assessed by Highest World Health Organization (WHO) Toxicity Grade|Bioavailability (F) of Mircera in Pediatric Participants Based on Population PK Model","Hoffmann-La Roche","All","3 Months to 17 Years   (Child)","Phase 2","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NH19708|2016-004779-39","August 3, 2018","July 19, 2021","July 19, 2021","June 11, 2018","March 7, 2022","March 7, 2022","University of Alabama at Birmingham; Pediatric Nephrology, Birmingham, Alabama, United States|Loma Linda University health, Loma Linda, California, United States|Emory University School of Med; Pediatrics, Atlanta, Georgia, United States|Children'S Mercy Hospital; Pediatric Nephrology, Kansas City, Missouri, United States|RWJBarnabas Health, West Orange, New Jersey, United States|East Carolina University; Brody School of Medicine, Greenville, North Carolina, United States|UT Southwestern Medical Center; Pediatrics Dept., Dallas, Texas, United States|Hopital Jeanne De Flandre; Pediatrie, Lille, France|Gh Necker Enfants Malades; Nephrologie, Paris, France|Höpital Hautepierre; Pediatrie 1, Strasbourg, France|Semmelweis University; 1st Department of Pediatrics, Pediatric Nephrology Center, Budapest, Hungary|Debreceni Egyetem Klinikai Központ; Gyermekklinika, Debrecen, Hungary|Clinica Pediatrica II De Marchi, Milano, Lombardia, Italy|Ospedale Infantile Regina Margherita; U.O. Autonoma di Nefrologia, Dialisi e Trapianto, Torino, Piemonte, Italy|Vilnius University Children's Hospital, Vilnius, Lithuania|Uniwersyteckie Centrum Kliniczne; Klinika Chorob Nerek i Nadciśnienia Dzieci i Mlodziezy, Gdansk, Poland|Uniwersytecki Szpital Dziecięcy w Krakowie; Oddz.Nefrologii i Nadciśnienia Tętniczego/Stacja Dializ, Kraków, Poland|Instytut ""Centrum Zdrowia Matki Polki; Klinika Pediatrii i Immunologii i Nefrologii, Lodz, Poland|Szpital Specjalistyczny dla Dzieci i Doroslych; Oddzial Kliniczny Pediatrii i Nefrologii, Torun, Poland|Szpital Kliniczny nr 1 im. prof. Szyszko; Oddz. Nefrologii Dzieciecej z Pododdziałem Dializoterapii, Zabrze, Poland|Hospital Universitari Vall d'Hebron; Servicio de Nefrologia, Barcelona, Spain|Hospital Universitario Virgen del Rocio; Servicio de Nefrologia Pediatrica, Sevilla, Spain","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT03552393/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT03552393/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03552393"
363,"NCT05304442","IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department",,"Recruiting","No Results Available","Anemia, Iron Deficiency|Uterine Bleeding","Drug: Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]|Drug: Ferrous Sulfate 65 mg elemental iron (325 mg tablets)","mean change in hemoglobin concentration","Baylor College of Medicine|Pharmacosmos Therapeutics, Inc.","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-49444","September 15, 2022","October 2024","October 2024","March 31, 2022",,"January 12, 2024","Ben Taub Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05304442"
364,"NCT05515367","A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)",,"Recruiting","No Results Available","Chronic Kidney Diseases|Anemia of Chronic Kidney Disease","Drug: Desidustat","To asses the Proportion of Subjects with treatment emergent adverse events.|To asses the Proportion of Subjects with treatment emergent Serious adverse events.|Mean change in hemoglobin level|Mean change in Lipid profile including Small dense LDL from baseline|Mean change in VEGF|Mean change in serum Hepcidin","Zydus Lifesciences Limited","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","1004","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DESI.22.001","April 20, 2023","May 31, 2024","August 30, 2025","August 25, 2022",,"December 26, 2023","Indira Gandhi Institute of Medical Sciences, Sheikhpura, Bihar, India",,"https://ClinicalTrials.gov/show/NCT05515367"
365,"NCT00495365","A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.",,"Terminated","No Results Available","Anemia|Chronic Renal Insufficiency","Drug: Epoetin alfa","The primary objective was to evaluate the proportion of subjects who maintained hemoglobin levels within 10% of entry levels and/or a range of 11-13 g/dL for the 24-week duration of the study.|The secondary objective was to evaluate safety in subjects with chronic kidney disease throughout the study","Ortho Biotech Products, L.P.","All","18 Years and older   (Adult, Older Adult)","Phase 4","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR005104","June 2003",,"September 2003","July 3, 2007",,"May 19, 2011",,,"https://ClinicalTrials.gov/show/NCT00495365"
366,"NCT00337935","A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.",,"Completed","Has Results","Renal Failure , Chronic|Anemia","Drug: Epoetin Alfa|Other: Standard of care","Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks)|The Number of Patients Achieved a Hemoglobin Response.|Time to Hemoglobin Response","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho Biotech Clinical Affairs, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 2","157","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR012229","July 2006","July 2009","July 2009","June 20, 2006","May 13, 2013","May 13, 2013",,,"https://ClinicalTrials.gov/show/NCT00337935"
367,"NCT00307814","A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)",,"Completed","No Results Available","Anemia|Chronic Renal Insufficiency","Drug: Epoetin Alfa","The primary efficacy variable is hemoglobin maintenance. Also, patients will be assessed for incidence and severity of adverse events and vital signs (blood pressure) during the 16 week study period.|The secondary variable is Quality of Life and Hemoglobin Change over Time","Ortho Biotech Products, L.P.","All","18 Years and older   (Adult, Older Adult)","Phase 2","519","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR005101","January 2002",,"January 2004","March 28, 2006",,"May 19, 2011",,,"https://ClinicalTrials.gov/show/NCT00307814"
368,"NCT00121602","Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease",,"Completed","No Results Available","Anemia|Kidney Disease","Drug: Darbepoetin Alfa","Change in Hb level between the screening/baseline period and the evaluation period|The ratio of weekly dosing requirements between baseline and the evaluation period|Change from baseline Hb over time|Proportion of subjects maintaining mean Hb within target range during evaluation period|Average darbepoetin alfa dose over evaluation period|Change from baseline dose over time","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","446","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20040104","March 2005","October 2005","October 2006","July 21, 2005",,"February 28, 2008",,,"https://ClinicalTrials.gov/show/NCT00121602"
369,"NCT05240677","Endoscopy in CKD With Iron Deficiency Anemia",,"Completed","No Results Available","Chronic Kidney Diseases|Iron-Deficiency Anemia","Procedure: Upper GIT endoscopy","Rate of upper gastrointestinal endoscopic findings In chronic kidney disease patients with iron deficiency anemia","Walid Ahmed Ragab Abdelhamid|Zagazig University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","9145/2-2-2022","May 1, 2021","March 15, 2022","April 15, 2022","February 15, 2022",,"January 5, 2024","Zagazig university, Zagazig, Egypt",,"https://ClinicalTrials.gov/show/NCT05240677"
370,"NCT00004464","Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria",,"Completed","No Results Available","Aplastic Anemia|Paroxysmal Hemoglobinuria, Nocturnal","Drug: cyclophosphamide|Drug: filgrastim",,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 2","69","Other","Interventional","Primary Purpose: Treatment","J9611|96-01-17-02|JHOC-96011702|JHOC-9611|199/13895","February 1996","March 1, 2007","November 11, 2008","October 19, 1999",,"January 18, 2019","Johns Hopkins Oncology Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00004464"
371,"NCT03476330","Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia",,"Active, not recruiting","No Results Available","Fanconi Anemia|Squamous Cell Carcinoma","Drug: Quercetin (dietary supplement)","Reduction of buccal micronuclei","Children's Hospital Medical Center, Cincinnati","All","2 Years and older   (Child, Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018-0073|6353","May 8, 2018","October 2025","October 2026","March 26, 2018",,"November 1, 2023","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03476330"
372,"NCT00001749","Medical Treatment for Diamond Blackfan Anemia",,"Completed","No Results Available","Fanconi's Anemia|Hematologic Disease","Drug: Antithymocyte globulin|Drug: Cyclosporine",,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","25","NIH","Interventional","Primary Purpose: Treatment","980144|98-H-0144","July 1998",,"July 2005","November 4, 1999",,"March 4, 2008","National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001749"
373,"NCT01001598","Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita",,"Terminated","Has Results","Fanconi Anemia|Dyskeratosis Congenita","Drug: danazol","Number of Participants With Toxicity Associated With Danazol Therapy: Virilization, and/or New or Progressive Evidence of Either Hepatic or Renal Toxicity at a Grade II Level Using National Cancer Institute Common Toxicity Criteria (NCI-CTC).|The Optimal Dose and Number of Participants With Hematologic Response Rate in Fanconi Anemia (FA) and Dyskeratosis Congenita (DC) Patients Receiving Danazol Therapy|The Gene Expression Profile of Progenitor Cells in Response to Danazol, Both to Predict Responsiveness and to Screen for Small Molecules That Show a Profile Similar to That of Responsive Patients","Boston Children's Hospital","All","3 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-03-0131","November 2009","May 2014","May 2014","October 26, 2009","February 19, 2019","February 19, 2019","Children's Hospital Boston, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01001598"
374,"NCT00318812","Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure",,"Completed","Has Results","Anemia|Renal Failure","Drug: Heme Iron Polypeptide (Proferrin)|Drug: Iron sucrose (Venofer)","Hemoglobin Concentration at 6 Months|Ferritin|Transferrin Saturation","Ottawa Hospital Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","2005840-01H","May 2007","December 2011","December 2011","April 27, 2006","May 2, 2014","May 10, 2016","The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00318812"
375,"NCT05699109","Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients",,"Completed","No Results Available","Anemia of Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Failure Anemia",,"Percentage of patients reaching the target Hemoglobin in each group.|Analyze the cost-effectiveness of long-acting (DPO) versus short-acting (EPO) erythropoietin-stimulating agents in hemodialysis patients.","Helwan University","All","18 Years to 75 Years   (Adult, Older Adult)",,"127","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Anemia in CKD","January 1, 2021","September 30, 2021","September 30, 2021","January 26, 2023",,"January 26, 2023","the Memorial Souad Kafafi University Hospital, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT05699109"
376,"NCT00899522","Tissue Sample Collection From Patients With Fanconi Anemia",,"Completed","No Results Available","Fanconi Anemia|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Other: biologic sample preservation procedure|Procedure: biopsy","Creation of a Fanconi Anemia Cell Repository using rare solid tumor samples from patients with Fanconi anemia|Study tissue samples by molecular methods, including gene microarrays|Development of cancer cell lines from tissue archived from patients with Fanconi anemia","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","1 Year to 55 Years   (Child, Adult)",,"8","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","IRB00001100|P30CA069533|OHSU-HEM-03022-LX|OHSU-IRB00001100|OSHU-CR00003822|CDR0000445453","August 2005","March 2013","May 2013","May 12, 2009",,"December 4, 2017","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00899522"
377,"NCT00006127","Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia",,"Unknown status","No Results Available","Fanconi's Anemia","Drug: amifostine",,"Dana-Farber Cancer Institute|Office of Rare Diseases (ORD)","All","2 Years and older   (Child, Adult, Older Adult)","Phase 1","21","Other","Interventional","Primary Purpose: Treatment","199/15281|DFCI-9910170|ALZA-99-004-ii","April 2000",,,"August 4, 2000",,"June 24, 2005","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00006127"
378,"NCT05687149","Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia",,"Recruiting","No Results Available","Fanconi Anemia|Inherited Bone Marrow Failure Syndrome",,"Screen Patients with FA|Clinical and Pathological Natural History of Oral Potentially Malignant Lesion|Cohort of Patients with FA","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","8 Years and older   (Child, Adult, Older Adult)",,"200","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","10001109|001109-C","March 23, 2023","December 31, 2035","December 31, 2035","January 18, 2023",,"April 9, 2024","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05687149"
379,"NCT03157804","Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A","FANCOLEN-1","Completed","No Results Available","Fanconi Anemia","Procedure: IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|Biological: Genetically Engineered Hematopoietic Stem/Progenitor Cells|Other: Laboratory Biomarker Analysis|Biological: Filgrastim|Drug: Plerixafor|Procedure: Bone Marrow Aspiration","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Proportion of patients with at least 0.1 copy of the therapeutic vector per nucleated bone marrow or peripheral blood cells two years after infusion.|Proportion of patients with clinical hematological response after the infusion of autologous CD34 + cells transduced with the therapeutic lentiviral vector","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)|Centro de Investigación en Red de Enfermedades Raras (CIBERER)|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Hospital Vall d'Hebron|Universitat Autonoma de Barcelona","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-006100-12","January 7, 2016","April 23, 2019","September 8, 2023","May 17, 2017",,"March 21, 2024","Hospital Vall d'Hebron, Barcelona, Spain|Hospital Infantil del Niño Jesus, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03157804"
380,"NCT00005891","Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia",,"Completed","No Results Available","Fanconi's Anemia","Drug: cyclophosphamide|Procedure: Allogeneic Bone Marrow Transplantation",,"Fairview University Medical Center|Office of Rare Diseases (ORD)","All","0 Years to 54 Years   (Child, Adult)","Not Applicable",,"Other","Interventional","Primary Purpose: Treatment","199/15099|UMN-MT-1982-10|UMN-MT-8210","March 2000",,,"June 5, 2000",,"June 24, 2005","Fairview University Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00005891"
381,"NCT02940860","Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease",,"Completed","Has Results","Iron Deficiency Anaemia|Iron Deficiency Anemia|Chronic Kidney Disease","Drug: Iron isomaltoside/ferric derisomaltose|Drug: Iron sucrose","Change in Hemoglobin (Hb) From Baseline to Week 8|Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions|Composite Cardiovascular Adverse Events (AEs)|Time to First Composite Cardiovascular Safety AE|S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8|Hb Concentration Increase of ≥1 g/dL From Baseline to Week 1, 2, 4, and 8|Time to Change in Hb Concentration ≥1 g/dL|Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8|Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8|S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8|Change in Hb Concentration From Baseline to Week 1, 2, and 4|Change in S-ferritin From Baseline to Weeks 1, 2, 4, and 8|Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8|Change in Concentration of S-iron From Baseline to Week 1, 2, 4, and 8|Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8|Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking|Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car|Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit|Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits|Health Care Resource Use Questionnaire","Pharmacosmos A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","1538","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-Monofer-CKD-04","November 29, 2016","May 29, 2018","May 29, 2018","October 21, 2016","March 6, 2020","October 6, 2020","Pharmacosmos Investigational Site, Huntsville, Alabama, United States|Pharmacosmos Investigational Site, Little Rock, Arkansas, United States|Pharmacosmos Investigational Site, Little Rock, Arkansas, United States|Pharmacosmos Investigational Site, Chula Vista, California, United States|Pharmacosmos Investigational Site, Fresno, California, United States|Pharmacosmos Investigational Site, Glendale, California, United States|Pharmacosmos Investigational Site, Glendale, California, United States|Pharmacosmos Investigational Site, Granada Hills, California, United States|Pharmacosmos Investigational Site, La Mesa, California, United States|Pharmacosmos Investigational Site, Los Angeles, California, United States|Pharmacosmos Investigational Site, Los Angeles, California, United States|Pharmacosmos Investigational Site1, Los Angeles, California, United States|Pharmacosmos Investigational Site2, Los Angeles, California, United States|Pharmacosmos Investigational Site, Los Angeles, California, United States|Pharmacosmos Investigational Site, Lynwood, California, United States|Pharmacosmos Investigational Site, Montebello, California, United States|Pharmacosmos Investigational Site, Northridge, California, United States|Pharmacosmos Investigational Site, Northridge, California, United States|Pharmacosmos Investigational Site, Porterville, California, United States|Pharmacosmos Investigational Site, Rialto, California, United States|Pharmacosmos Investigational Site, Riverside, California, United States|Pharmacosmos Investigational Site, Sacramento, California, United States|Pharmacosmos Investigational Site, San Dimas, California, United States|Pharmacosmos Investigational Site, San Francisco, California, United States|Pharmacosmos Investigational Site, Tarzana, California, United States|Pharmacosmos Investigational Site, Arvada, Colorado, United States|Pharmacosmos Investigational Site, Denver, Colorado, United States|Pharmacosmos Investigational Site, Westminster, Colorado, United States|Pharmacosmos Investigational Site, Middlebury, Connecticut, United States|Pharmacosmos Investigational Site, Plainville, Connecticut, United States|Pharmacosmos Investigational Site, Boynton Beach, Florida, United States|Pharmacosmos Investigational Site, Brandon, Florida, United States|Pharmacosmos Investigational Site, Coral Gables, Florida, United States|Pharmacosmos Investigational Site, Coral Springs, Florida, United States|Pharmacosmos Investigational Site, Doral, Florida, United States|Pharmacosmos Investigational Site, Fort Lauderdale, Florida, United States|Pharmacosmos Investigational Site1, Hialeah, Florida, United States|Pharmacosmos Investigational Site2, Hialeah, Florida, United States|Pharmacosmos Investigational Site3, Hialeah, Florida, United States|Pharmacosmos Investigational Site, Hollywood, Florida, United States|Pharmacosmos Investigational Site, Homestead, Florida, United States|Pharmacosmos Investigational Site, Lake City, Florida, United States|Pharmacosmos Investigational Site1, Lauderdale Lakes, Florida, United States|Pharmacosmos Investigational Site2, Lauderdale Lakes, Florida, United States|Pharmacosmos Investigational Site, Miami Beach, Florida, United States|Pharmacosmos Investigational Site, Miami Lakes, Florida, United States|Pharmacosmos Investigational Site1, Miami, Florida, United States|Pharmacosmos Investigational Site2, Miami, Florida, United States|Pharmacosmos Investigational Site, Miami, Florida, United States|Pharmacosmos Investigational Site, Miami, Florida, United States|Pharmacosmos Investigational Site, Miami, Florida, United States|Pharmacosmos Investigational Site1, Miami, Florida, United States|Pharmacosmos Investigational Site2, Miami, Florida, United States|Pharmacosmos Investigational Site3, Miami, Florida, United States|Pharmacosmos Investigational Site1, Miami, Florida, United States|Pharmacosmos Investigational Site2, Miami, Florida, United States|Pharmacosmos Investigational Site3, Miami, Florida, United States|Pharmacosmos Investigational Site, Miami, Florida, United States|Pharmacosmos Investigational Site1, Miami, Florida, United States|Pharmacosmos Investigational Site2, Miami, Florida, United States|Pharmacosmos Investigational Site, Miami, Florida, United States|Pharmacosmos Investigational Site, Miami, Florida, United States|Pharmacosmos Investigational Site1, Miami, Florida, United States|Pharmacosmos Investigational Site2, Miami, Florida, United States|Pharmacosmos Investigational Site, Miami, Florida, United States|Pharmacosmos Investigational Site, Miami, Florida, United States|Pharmacosmos Investigational Site1, Miami, Florida, United States|Pharmacosmos Investigational Site2, Miami, Florida, United States|Pharmacosmos Investigational Site, Naples, Florida, United States|Pharmacosmos Investigational Site, Ocala, Florida, United States|Pharmacosmos Investigational Site, Palmetto Bay, Florida, United States|Pharmacosmos Investigational Site, Pembroke Pines, Florida, United States|Pharmacosmos Investigational Site, Plantation, Florida, United States|Pharmacosmos Investigational Site, Port Charlotte, Florida, United States|Pharmacosmos Investigational Site, Saint Petersburg, Florida, United States|Pharmacosmos Investigational Site1, Tampa, Florida, United States|Pharmacosmos Investigational Site2, Tampa, Florida, United States|Pharmacosmos Investigational Site, Tampa, Florida, United States|Pharmacosmos Investigational Site, W. Miami, Florida, United States|Pharmacosmos Investigational Site, Atlanta, Georgia, United States|Pharmacosmos Investigational Site, Augusta, Georgia, United States|Pharmacosmos Investigational Site, Macon, Georgia, United States|Pharmacosmos Investigational Site, Chicago, Illinois, United States|Pharmacosmos Investigational Site, Chicago, Illinois, United States|Pharmacosmos Investigational Site, Crystal Lake, Illinois, United States|Pharmacosmos Investigational Site, Hinsdale, Illinois, United States|Pharmacosmos Investigational Site, Fort Wayne, Indiana, United States|Pharmacosmos Investigational Site, Marion, Indiana, United States|Pharmacosmos Investigational Site, Merrillville, Indiana, United States|Pharmacosmos Investigational Site, Michigan City, Indiana, United States|Pharmacosmos Investigational Site, Kansas City, Kansas, United States|Pharmacosmos Investigational Site, Wichita, Kansas, United States|Pharmacosmos Investigational Site, Owensboro, Kentucky, United States|Pharmacosmos Investigational Site, Baton Rouge, Louisiana, United States|Pharmacosmos Investigational Site, Covington, Louisiana, United States|Pharmacosmos Investigational Site, Shreveport, Louisiana, United States|Pharmacosmos Investigational Site, Annapolis, Maryland, United States|Pharmacosmos Investigational Site, Bethesda, Maryland, United States|Pharmacosmos Investigational Site, Rockville, Maryland, United States|Pharmacosmos Investigational Site, Grand Rapids, Michigan, United States|Pharmacosmos Investigational Site, Florissant, Missouri, United States|Pharmacosmos Investigational Site, Albuquerque, New Mexico, United States|Pharmacosmos Investigational Site, Flushing, New York, United States|Pharmacosmos Investigational Site, New York, New York, United States|Pharmacosmos Investigational Site, New York, New York, United States|Pharmacosmos Investigational Site, Asheville, North Carolina, United States|Pharmacosmos Investigational Site, Gastonia, North Carolina, United States|Pharmacosmos Investigational Site, Greenville, North Carolina, United States|Pharmacosmos Investigational Site, Jacksonville, North Carolina, United States|Pharmacosmos Investigational Site, Wilmington, North Carolina, United States|Pharmacosmos Investigational Site, Cincinnati, Ohio, United States|Pharmacosmos Investigational Site, Cincinnati, Ohio, United States|Pharmacosmos Investigational Site, Cleveland, Ohio, United States|Pharmacosmos Investigational Site, Norman, Oklahoma, United States|Pharmacosmos Investigational Site, Tulsa, Oklahoma, United States|Pharmacosmos Investigational Site, Bethlehem, Pennsylvania, United States|Pharmacosmos Investigational Site, Philadelphia, Pennsylvania, United States|Pharmacosmos Investigational Site, Columbia, South Carolina, United States|Pharmacosmos Investigational Site, Greenville, South Carolina, United States|Pharmacosmos Investigational Site, Orangeburg, South Carolina, United States|Pharmacosmos Investigational Site, Jackson, Tennessee, United States|Pharmacosmos Investigational Site, Austin, Texas, United States|Pharmacosmos Investigational Site, Beaumont, Texas, United States|Pharmacosmos Investigational Site, DeSoto, Texas, United States|Pharmacosmos Investigational Site, El Paso, Texas, United States|Pharmacosmos Investigational Site, Fort Worth, Texas, United States|Pharmacosmos Investigational Site, Greenville, Texas, United States|Pharmacosmos Investigational Site1, Houston, Texas, United States|Pharmacosmos Investigational Site2, Houston, Texas, United States|Pharmacosmos Investigational Site, Houston, Texas, United States|Pharmacosmos Investigational Site, Houston, Texas, United States|Pharmacosmos Investigational Site1, Houston, Texas, United States|Pharmacosmos Investigational Site2, Houston, Texas, United States|Pharmacosmos Investigational Site, Lufkin, Texas, United States|Pharmacosmos Investigational Site, McKinney, Texas, United States|Pharmacosmos Investigational Site, Pearland, Texas, United States|Pharmacosmos Investigational Site1, San Antonio, Texas, United States|Pharmacosmos Investigational Site2, San Antonio, Texas, United States|Pharmacosmos Investigational Site, Saint George, Utah, United States|Pharmacosmos Investigational Site, Arlington, Virginia, United States|Pharmacosmos Investigational Site, Fairfax, Virginia, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/60/NCT02940860/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/60/NCT02940860/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02940860"
382,"NCT05356325","FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.",,"Unknown status","No Results Available","Fibroblast Growth Factor 23|Anemia|CKD",,"FGF23 on the induction of cardiovascular damage in anemia with and without CKD","Maimónides Biomedical Research Institute of Córdoba|Fondo de Investigacion Sanitaria","All","18 Years to 85 Years   (Adult, Older Adult)",,"401","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","PI20/1645","October 18, 2021","December 31, 2022","June 2023","May 2, 2022",,"May 2, 2022","Hospital Universitario Reina Sofia, Córdoba, Spain","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/25/NCT05356325/Prot_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/25/NCT05356325/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05356325"
383,"NCT00005896","Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's Anemia",,"Unknown status","No Results Available","Fanconi's Anemia","Drug: filgrastim|Genetic: Autologous stem cells transduced with FACC retroviral vector|Procedure: Autologous Stem Cell Transplantation",,"University of Minnesota|Office of Rare Diseases (ORD)","All","5 Years and older   (Child, Adult, Older Adult)","Phase 1","6","Other","Interventional","Primary Purpose: Treatment","199/15107|UMN-MT-1997-10|UNM-MT-9710","March 2000",,,"June 5, 2000",,"June 24, 2005",,,"https://ClinicalTrials.gov/show/NCT00005896"
384,"NCT00440557","An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease",,"Completed","Has Results","Anemia","Drug: Epoetin alfa 3 times weekly /once weekly|Drug: Epoetin alfa once weekly|Drug: Epoetin alfa once every two weeks","Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22|Participants With an Increase of ≥1 g/dL in Hb Concentration From Baseline by Week 9","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 3","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR010411|EPOAKD3001","September 2006","February 2008","February 2008","February 27, 2007","February 8, 2010","May 7, 2014","Glendale, Arizona, United States|Tempe, Arizona, United States|Chula Vista, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Lynwood, California, United States|Riverside, California, United States|San Diego, California, United States|Visalia, California, United States|Whittier, California, United States|Yuba City, California, United States|Colorado Springs, Colorado, United States|Lakewood, Colorado, United States|Thornton, Colorado, United States|Lauderdale Lakes, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Palm Beach Gardens, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Zephyrhills, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Carrollton, Georgia, United States|Macon, Georgia, United States|Statesboro, Georgia, United States|Chicago, Illinois, United States|Peoria, Illinois, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Methuen, Massachusetts, United States|Plymouth, Massachusetts, United States|Flint, Michigan, United States|Hackensack, New Jersey, United States|Old Bridge, New Jersey, United States|Vineland, New Jersey, United States|Albuquerque, New Mexico, United States|Great Neck, New York, United States|New Hartford, New York, United States|New York, New York, United States|Springfield Gardens, New York, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|Maumee, Ohio, United States|Doylestown, Pennsylvania, United States|Easton, Pennsylvania, United States|Erie, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Wynnewood, Pennsylvania, United States|Bamberg, South Carolina, United States|Orangeburg, South Carolina, United States|Sumter, South Carolina, United States|Dyersburg, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Chesapeake, Virginia, United States|Fairfax, Virginia, United States|Hampton, Virginia, United States|Richmond, Virginia, United States|Tacoma, Washington, United States|Caguas, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00440557"
385,"NCT00312871","Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency",,"Terminated","No Results Available","Anemia|Renal Failure, Chronic Renal Failure","Drug: Epoetin alfa","Rate of progression of chronic renal failure over 36 months as measured by at least 2 glomerular filtration rate assessments.|Need for renal replacement therapy; quality of life; blood pressure control; hospital admissions; mortality; cardiovascular events; nutritional status.","Janssen Cilag S.A.S.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR003181","February 2001",,"June 2003","April 11, 2006",,"May 17, 2011",,,"https://ClinicalTrials.gov/show/NCT00312871"
386,"NCT05951192","A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease","ROQ-IT","Active, not recruiting","No Results Available","Anemia|Renal Insufficiency, Chronic|Renal Anemia","Drug: Daprodustat","Change in hemoglobin from baseline to the effectiveness evaluation period|The number/proportion of subjects with a hemoglobin in target range of 10-11 g/dL from baseline to effectiveness evaluation period|The number/proportion of subjects with a change in hemoglobin under 0.5 g/dL from baseline to effectiveness evaluation period|Number of hemoglobin excursions that are < 8.5 g/dL or ≥ 12 g/dL during the treatment period.|Number of dose adjustments in daprodustat per patient during the treatment period|Number of subjects retained on daprodustat therapy from Day 1 through Day 120|The number/proportion of subjects who receive a refill prescription with the correct prescribed dose with no gap (0 days) in drug supply from the previous prescription|The time (in days) from initial and refill prescription to delivery to patient|Average monthly (percent) compliance with daprodustat daily dosing, per subject report.","USRC Kidney Research|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","161","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","USRC-2023-001","July 1, 2023","November 2023","November 2023","July 18, 2023",,"October 23, 2023","USRC Kidney Research, Lone Tree, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT05951192"
387,"NCT03579875","T Cell Receptor α/β TCD HCT in Patients With Fanconi Anemia",,"Recruiting","No Results Available","Fanconi Anemia|Severe Aplastic Anemia|Myelodysplastic Syndromes","Drug: Total Body Irradiation (TBI) (Plan 1)|Drug: Cyclophosphamide (CY) (Plan 1)|Drug: Fludarabine (FLU)|Drug: Methylprednisolone (MP)|Device: Donor mobilized PBSC infusion|Drug: G-CSF|Drug: Cyclophosphamide (CY) (Plan 2)|Drug: Rituximab|Drug: Busulfan","Grade II-IV acute graft versus host disease (GVHD)|Neutrophil engraftment|Platelet engraftment|Acute graft versus host disease (aGVHD)|Chronic graft versus host disease (cGVHD)|Regimen related toxicity|Bacterial, viral and fungal infections|Opportunistic infections|Overall survival (OS)","Masonic Cancer Center, University of Minnesota","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016LS161|MT2017-17","November 13, 2018","January 1, 2026","January 5, 2029","July 9, 2018",,"November 3, 2023","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03579875"
388,"NCT00869856","Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)","SWEEP","Withdrawn","No Results Available","Anemia|Chronic Renal Insufficiency","Drug: HX575 solution for s.c. administration","Change in hemoglobin level|To document the safety and lack of immunogenicity of HX575. To determine the optimal dosing regimen of HX575 s.c. administration.","Sandoz","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HX575-304","April 2009","August 2009","August 2009","March 26, 2009",,"June 2, 2015","MHAT ""Dr. Tota Venkova"", Gabrovo, Bulgaria|MHAT Pazardzhik, Pazardzhik, Bulgaria|MHAT""Sveti Ivan Rilski"", Sofia, Bulgaria|MHAT ""Sveta Anna"", Varna, Bulgaria|Polyclinique de Bordeaux-Nord, Bordeaux, France|Centre Hospitalier Universitaire Limoges, Hôpital Dupuytren, Limoges Cedex, France|KfH Nierenzentrum, Bad König, Germany|KfH Nierenzentrum, Berlin, Germany|Gemeinschaftspraxis Dr. Spitthöver, Dr. Knee, Dr. Gröschel, Essen, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Gesundheitszentrum Alzey Internistische Gemeinschaftspraxis, Slzrx, Germany|Nierenzentrum Weinheim Kreiskrankenhaus Weinheim, Weinheim, Germany|Spitalul Clinic de Nefrologie Dr. Carol Davila, Bucuresti, Romania|Spitalul Universitar de Urgenta Bucuresti, Bucuresti, Romania|Spitalul Judetean de Urgenta Deva, Deva, Romania|Spitalul Clinic Municipal ""Dr. Gavril Curteanu"", Oradea, Romania|Spitalul Clinic Judetean Timisoara, Timisoara, Romania|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital de Navarra, Pamplona, Spain",,"https://ClinicalTrials.gov/show/NCT00869856"
389,"NCT00701714","Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients",,"Terminated","Has Results","Anemia|Chronic Renal Insufficiency","Drug: HX575 recombinant human erythropoietin alfa|Drug: ERYPO","Change in Hemoglobin Level|Weekly Epoetin Dose|Immunogenicity","Sandoz","All","18 Years and older   (Adult, Older Adult)","Phase 3","337","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2007-22-INJ-17","September 2007","July 2009","January 2010","June 19, 2008","February 5, 2018","February 5, 2018","Diakonissen KH Salzburg, Salzburg, Austria|LKH Steyr, Steyr, Austria|Krankenanstalt der Stadt Wien, Wien, Austria|AKH Wien, Wien, Austria|Sozialmedizinisches Zentrum Ost Donauspital, Wien, Austria|MHAT Pazardijk, Pazardzhik, Bulgaria|MHAT Sveti Ivan Rilski, Sofia, Bulgaria|MHAT Stara Zagora, Stara Zagora, Bulgaria|MHAT ""Sv. Anna"", Varna, Bulgaria|Ambulance vnitrního lékarstvi, Brno, Czechia|Nemocnice Kladno, Kladno, Czechia|Litomyslska nemocnice, a.s., Litomyšl, Czechia|Nemocnice s poliklinikou v Novem Jicine, Novi Jicin, Czechia|Dialcorp, s.r.o., Praha 4 - Michle, Czechia|IKEM, Praha 4, Czechia|FN Motol, Praha 5, Czechia|Nemocnice Prostìjov, Prostìjov, Czechia|Nemocnice Šternberk, Šternberk, Czechia|Nefrologická a interní amb., Žïár n. Sázavou, Czechia|CHU d'Amiens - Hopital Sud, Amiens, France|CHU de Rouen - Hopital de Bois Guillaume, Bois-Guillaume, France|Gesundheitszentrum Alzey, Alzey, Germany|Studienzentrum Hämatologie / Onkologie / Diabetes, Aschaffenburg, Germany|Gemeinschaftspraxis Dr. med. Gert-Peter Dragoun, Dr. med Günther Hevendehl, Aschaffenburg, Germany|Nephrologische Praxis Bad Münder, Bad Münder, Germany|Praxis Dr. Scharla, Bad Reichenhall, Germany|Nephrologisches Zentrum an Stadtkrankenhaus, Bad Wildungen, Germany|Dialyse-Centrum, Bad Windsheim, Germany|KfH Kuratorium f. Dialyse und Nierentransplantation e.V., Bergisch Gladbach, Germany|Schwerpunktpraxis für Diabetologie und Nephrologie, Bernkastel-Kues, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.V., Bischofswerda, Germany|Nephrologische Gemeinschaftspraxis Dr. Rensinghoff & Dr. Becker, Bochum-Wattenscheid, Germany|Dialysepraxis drs. Riedasch/Schreiber, Coesfeld, Germany|Praxis Dr. Kraatz, Demmin, Germany|Gemeinschaftspraxis Dr. Steffen & Dr. Perino, Dinkelsbühl, Germany|Diabetes- und Dialysezentrum Merker, Vogt, Dormagen, Germany|Gemeinschaftspraxis Karlstraße, Düsseldorf, Germany|Dialysepraxis Häger, Schanze, Brause, Düsseldorf, Germany|KfH Kuratorium f. Dialyse und Nierentransplantation e.V., Eberswalde, Germany|Gemeinschaftspraxis Dr. Spitthöver, Dr. Knee, Dr. Gröschel, Essen, Germany|Praxis Dr. Zimmermann, Essen, Germany|Praxis Dr. Lüdemann, Falkensee, Germany|Dialysepraxis, Friedrichroda, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.V., Fürstenzell, Germany|Dialysepraxis Barmbek, Hamburg, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.V., Haßfurt, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.V., Heringen, Germany|Dialysezentrum, Homberg/Efze, Germany|Gemeinschaftspraxis und Dialyse, Hürth, Germany|Dialyseplaxis DR. Rieck, DR. Göbel, DR. Wagner, Krefeld, Germany|Leipziger Institut für Präventivmedizin, Leipzig, Germany|Med Center Leipzig, Leipzig, Germany|GDG Gemeinnützige Dialyse Gesellschaft, Leverkusen, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.V., Ludwigshafen, Germany|Gemeinschaftspraxis Dres. Leistikow, Hafezi und Sandner, Mannheim, Germany|Praxis Dr. Schütterle, Marburg, Germany|Praxis Dr. Vogel-Wagner, Mittweida, Germany|Praxis Dr. Rose, Pohlmeier und Dr. Lammers, Münster, Germany|Dialyse Nettetal, Nettetal, Germany|KfH Kuratorium für dialyse und Nierentransplantation e.V., Nördlingen, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.V., Passau, Germany|Praxis Dipl. med. Kosch, Pirna, Germany|Dialysepraxis Dipl. med. Gierak & Dipl. med. Rettig, Quedlinburg, Germany|Klinik für Nephrologie und Allgemeine Innere Medizin, Solingen, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.V., Straubing, Germany|Gemeinschaftspraxis Dr. Kirchner und Dr. Menge, Sömmerda, Germany|Praxis Dr. med. Mauersberger, Villingen-Schwenningen, Germany|Kamineni Hospitals Ltd., Hyderabaad, India|NIZAM Institute of Medical Sciences, Hyderabaad, India|Bombay Hospital, Indore, India|Monilek Hospital and Research Center, Jaipur, India|Vinaya Hospital & Research Centre, Mangalore, India|Pulse Diagnostix Cardiac and Medical Center, Pune, India|Kerala Institute of Medical Sciences, Trivandrum, India|SP ZOZ Miejski Szpital Zespolony, Czestochowa, Poland|Specjalistyczna Przychodnia Lekarska Medikard, Plock, Poland|Szpital Wojewódzki w Poznaniu, Poznan, Poland|Specjalistyczne Centrum Diagnostyczno-Lecznicze Bamberski Dwor (Solumed SC), Poznan, Poland|NZOZ NEFROLUX Sp. J. Lucjan Sobieraj, Wojciech Kaminski, Siemianowice Slaskie, Poland|Wojewodzki Szpital Specjalistyczny nr. 1 im. Jozefa Gasinskiego, Tychy, Poland|Szpital Praski p.w. Przemienienia Panskiego II Oddzia Chorob Wewnetrznych, Warszawa, Poland|NZOZ Centrum Badan Klinicznych, Wroclaw, Poland|Centrul Medical de Diagnostic si Tratament Ambulator si Medicina Preventiva Bucuresti, Bucuresti, Romania|Institutul National de DiabetNutritie si Boli Metabolice Paulescu, Bucuresti, Romania|Institutul Clinic Fundeni, Bucuresti, Romania|Spitalul Universitar Bucuresti, Bucuresti, Romania|Spitalul Clinic Judetean Cluj, Cluj, Romania|County Hospital Deva, Deva, Romania|Spitalul Clinic CI Parhon Iasi, Iasi, Romania|Dr. Gavril Curteanu Clinical Hospital, Oradea, Romania|County Hospital Tg Mures, Tg Mures, Romania|SC Medicali's SRL, Timisoara, Romania|Emergency Clinical County Hospital, Timisoara, Romania|Spitalul Judetean Timisoara, Timisoara, Romania|Policlinica Dr. Citu, Timisoara, Romania|Municipal medical Institution ""City Hospital #1"", Barnaul, Russian Federation|Municipal Institution ""City Clinical Hospital #40"", Ekaterinburg, Russian Federation|State Healthcare Institution ""Sverdlovsk Regional Clinical Hospital #1"", Ekaterinburg, Russian Federation|State Healthcare Institution ""Kemerova Regional Clinical Hospital"", Kemerovo, Russian Federation|Federal State Institution ""National Medical Surgery center named after NI Pirogov of Federal Agency of Health Care and Social Development"", Moscow, Russian Federation|State Educational Institution of Higher Professional Education ""Moscow State University of Medicine and dentistry of Federal Agency of health Care and Social Development"", City Clinical Hospital #23, Moscow, Russian Federation|Russian University of Peoples Frienship (clinical base: City clinical hospital #53), Moscow, Russian Federation|State Health Care Institution City Clinical Hospital named after SP Botkin, Moscow, Russian Federation|State healthcare Institution ""Nizhegorodsky Regional Clinical Hospital named after NA Semashko"", Nizhniy Novgorod, Russian Federation|State Healthcare Institution ""Reoublic Hospital named after VA Baranov"", Petrozavodsk, Russian Federation|Municipal healthcare Institution ""City Clinical Hospital #2"", Pyatigorsk, Russian Federation|State Healthcare Institution ""Ryazan Regional Cardiological Dispensary"", Ryazan, Russian Federation|State Educational Institution of High Professional Education Saratov State Medical University of Roszdrav, Saratov, Russian Federation|State Educational Institution of Higher Professional Education ""Smolensk State Medical Academy of Federal Agency of Health Care and Social Development"", Smolensk, Russian Federation|State Educational Institution of Higher Professional Education ""St. Petersburg State Medical Academy for Postgraduate studies of Roszdrav"", St. Petersburg, Russian Federation|St. Petersburg State Healthcare Institution ""City Mariinsky Hospital"", St. Petersburg, Russian Federation|State Institution ""St. petersburg Clinical research Institute of Emergency Medical Care named after I.I. Dzhanelidze"", St. petersburg, Russian Federation|St. Petersburg State Healthcare Institution ""City Outpatient Clinic #17"", St. petersburg, Russian Federation|State Educational Institution of Higher Professional Education ""St. Petersburg State Medical Academy named after I.I. Mechnikov of Roszdrav"", St. Petersburg, Russian Federation|State Institute St. Petersburg, St. Petersburg, Russian Federation|State Educational Institution of Higher Professional Education ""St. Petersburg State Medical Institute named after IP Pavlov of Roszdrav"", St. Petersburg, Russian Federation|State Institution Scientific Research Institute of Cardiology of Tomsk Research Center of Siberian Branch of Russian Academy of Medical Sciences, Tomsk, Russian Federation|SibMedCenter LLC, Tomsk, Russian Federation|Municipal Healthcare Institution ""City Clinical Hospital #2"", Yaroslavl, Russian Federation|State Healthcare Institution of Yaroslavl region ""Regional Clinical Hosptal"", Yaroslavl, Russian Federation|SMOLKO s.r.o., Kosice, Slovakia|MEDIKOL s.r.o., Košice, Slovakia|FN Trnava, Trnava, Slovakia",,"https://ClinicalTrials.gov/show/NCT00701714"
390,"NCT01155388","A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease",,"Terminated","Has Results","Iron Deficiency Anemia|Nondialysis-dependent Chronic Kidney Disease","Drug: Ferumoxytol|Drug: Oral Iron","Mean Change In Hemoglobin From Baseline To Week 5|Pharmacokinetics: Area Under The Curve Of Ferumoxytol","AMAG Pharmaceuticals, Inc.","All","6 Months to 17 Years   (Child)","Phase 3","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMAG-FER-CKD-252","October 17, 2011","June 24, 2014","June 24, 2014","July 1, 2010","November 6, 2017","April 28, 2022","AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01155388"
391,"NCT00338468","A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)",,"Terminated","No Results Available","Anemia|Kidney Diseases","Drug: epoetin alfa","Change in physical function score as measured by the Six Minute Walk Test (6MWT) and Short Physical Performance (SPP) Summary Score compared from Baseline to Week 5, Week 9, Week 13, Week 17/ Early Withdrawal and Week 20/Follow-up.|Proportion of patients who achieve the target hemoglobin levels of > 13.0 g/dL and < =14.0 g/dL (independent of transfusion within 1 month of assessment) compared from Baseline to Week 5, Week 9, Week 13, Week 17/ Early Withdrawal and Week 20/Follow-up.","Ortho Biotech Products, L.P.","All","65 Years and older   (Older Adult)","Phase 4","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR004606","November 2003",,"September 2005","June 20, 2006",,"May 19, 2011",,,"https://ClinicalTrials.gov/show/NCT00338468"
392,"NCT01102413","Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia",,"Completed","Has Results","Iron Deficiency Anemia|Chronic Kidney Disease","Drug: Monofer|Drug: Iron Sulphate","Change in Hemoglobin (Hb) Concentration From Baseline to Week 4.|Change in Hemoglobin Concentration From Baseline to Week 8","Pharmacosmos A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","351","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-Monofer-CKD-02","April 2010","June 2014","June 2014","April 13, 2010","December 3, 2015","December 3, 2015","Pharmacosmos, Holbaek, Denmark",,"https://ClinicalTrials.gov/show/NCT01102413"
393,"NCT01599507","Study of FG-4592 in Subjects With Chronic Kidney Disease in China",,"Completed","No Results Available","Anemia in Chronic Kidney Disease","Drug: FG-4592|Drug: Placebo","Maximum change in hemoglobin by Week 9 from baseline|Proportion of subjects achieving a target Hb level ≥11 g/dL by Weeks 5,6,7,8 and 9.|Proportion of subjects with a Hb increase from baseline ≥1.0 g/dL.","FibroGen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FGCL-4592-047","December 2011","January 2013","January 2013","May 16, 2012",,"March 3, 2014","Peking Union Medical College Hospital, Beijing, China|Peking University First Hospital, Beijing, China|Sichuan Provincial People's Hospital, Chengdu, China|West China Hospital, Chengdu, China|First affiliated hospital of Dalian medical university, DaLian, China|First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China|Zhejiang University No 1. Hospital, Hangzhou, China|Chang Zheng Hospital, Shanghai, China|Huashan Hospital, Shanghai, China|Renji Hospital, Shanghai, China|RuiJin Hospital, Shanghai, China|XinHua Hospital, Shanghai, China|Shenzhen People's Hospital, Shenzhen, China",,"https://ClinicalTrials.gov/show/NCT01599507"
394,"NCT05691257","Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia",,"Not yet recruiting","No Results Available","Heart Failure|Chronic Kidney Diseases|Anemia","Drug: Roxadustat|Drug: Recombinant human eythropoietin and/or Iron agents","Change in the hemoglobin from baseline|Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)|Change in Left Ventricular Systolic Function|Change in Left Ventricular End-Diastolic Diameter|Change in Left Ventricular Diastolic Function|Change in Low-density lipoprotein（LDL）|Change in Serum ferritin|Change in Transferrin saturation|Change in Left atrial volume|Change in Left atrial volume index","China-Japan Friendship Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JRen","February 1, 2023","August 1, 2023","December 1, 2023","January 19, 2023",,"January 20, 2023",,,"https://ClinicalTrials.gov/show/NCT05691257"
395,"NCT04543812","PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD",,"Completed","No Results Available","Anemia of Chronic Kidney Disease","Drug: Ferric citrate|Drug: Placebo","The proportion of subjects achieving an increase in Hgb of ≥1.0 g/dL at any time point between baseline and the end of the 16-week Randomized Period.|Hemoglobin (Hgb)|Transferring saturation (TSAT)|Ferritin|Serum Phosphate|Sustained increase in Hgb of ≥0.75 g/dL","Panion & BF Biotech Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","141","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PBB00601","October 14, 2020","October 28, 2022","December 16, 2022","September 10, 2020",,"March 9, 2023","Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan|Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan|Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital, New Taipei City, Taiwan|Division of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan|Division of Nephrology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei county, Taiwan|Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, Taipei, Taiwan|Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04543812"
396,"NCT02968368","Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease","AEGIS-CKD","Completed","Has Results","Renal Insufficiency, Chronic|Iron-Deficiency Anemia","Drug: Ferric maltol|Other: Placebo","Change in Hb Concentration From Baseline to Week 16|Number of Subjects That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 16|Number of Subjects That Achieve a Hb Concentration of ≥11 g/dL at Week 16|Change in Hb Concentration From Baseline to Week 8|Number of Subjects That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 16|Changes in Ferritin From Baseline to Week 16|Number of Participants With (TEAEs)|Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)|Changes in TSAT From Baseline to Week 16|Changes in Iron Parameter From Baseline to Week 16|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","Shield Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","167","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ST10-01-303","December 1, 2016","January 18, 2018","October 10, 2018","November 18, 2016","May 1, 2020","November 2, 2020","Peoria, Arizona, United States|Phoenix, Arizona, United States|Prescott, Arizona, United States|Tucson, Arizona, United States|La Mesa, California, United States|Long Beach, California, United States|Roseville, California, United States|Sacramento, California, United States|Denver, Colorado, United States|Coral Springs, Florida, United States|Edgewater, Florida, United States|Lauderdale Lakes, Florida, United States|Miami, Florida, United States|Macon, Georgia, United States|Shreveport, Louisiana, United States|Pontiac, Michigan, United States|Roseville, Michigan, United States|Las Vegas, Nevada, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Bethlehem, Pennsylvania, United States|Knoxville, Tennessee, United States|Nashville, Tennessee, United States|El Paso, Texas, United States|San Antonio, Texas, United States|Hampton, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT02968368/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02968368"
397,"NCT00563446","Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia",,"Completed","No Results Available","Anemia|Kidney Failure, Chronic|Peritoneal Dialysis, Continuous Ambulatory","Drug: Darbepoetin alfa","Hemoglobin level","Hospital Authority, Hong Kong|Kirin Pharmaceutical (Asia) CO., LTD","All","Child, Adult, Older Adult","Not Applicable","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KWC/EX/05-041|HARECCTR0500029","July 2005",,"May 2006","November 26, 2007",,"June 16, 2011","Princess Margaret Hospital, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT00563446"
398,"NCT04205266","IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding",,"Recruiting","No Results Available","Anemia, Iron Deficiency|Heavy Menstrual Bleeding","Drug: Ferumoxytol|Drug: Ferrous Sulfate","Hemoglobin|Participant satisfaction with treatment|Quality of Life Score","Thomas Jefferson University|AMAG Pharmaceuticals, Inc.","Female","18 Years to 55 Years   (Adult)","Phase 4","76","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19C.864","February 14, 2020","January 2025","January 2025","December 19, 2019",,"November 21, 2023","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04205266"
399,"NCT00922610","A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients",,"Completed","No Results Available","Anemia","Drug: methoxy polyethylene glycol-epoetin beta [Mircera]","Increase in Hb >1.0g/dL from baseline, and Hb conc. >11g/dL without red blood cell transfusion, for dialysis patients;Hb conc >11-12 g/dL for pre-dialysis patients|>=60% responders with target Hb >11g/dL for dialysis patients; Hb conc >11-12g/dL for pre-dialysis patients;incidence of RBC transfusions; no. of patients with dose adjustments","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML21983","February 2009","July 2010","July 2010","June 17, 2009",,"November 2, 2016","Cavite, Philippines|Makati City, Philippines|Manila, Philippines|Marikina, Philippines|Pasig City, Philippines",,"https://ClinicalTrials.gov/show/NCT00922610"
400,"NCT03350347","A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects","MIYABI ND-M","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)|Drug: Darbepoetin alfa","Mean Hb (Hemoglobin) level|Change in hemoglobin level from baseline to the average during the evaluation period|Responder rate: proportion of responders among the subjects|Proportion of subjects who meet each component of the response|Hb level|Change in Hb level|Proportion of subjects whose mean hemoglobin levels are in the target range during the evaluation period|Proportion of subjects whose mean hemoglobin levels are above the target range during the evaluation period|Proportion of subjects whose mean hemoglobin levels are below the target range during the evaluation period|Proportion of subjects whose hemoglobin levels are in the target range|Proportion of subjects whose hemoglobin levels are above the target range|Proportion of subjects whose hemoglobin levels are below the target range|Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week|Number of participants with serious adverse events|Maximum concentration (Cmax) of Molidustat|Area under the concentration-time curve (AUC) of Molidustat|EPO (Erythropoietin) serum concentration of Molidustat","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19350","December 13, 2017","July 5, 2019","November 28, 2019","November 22, 2017",,"January 29, 2021","Kainan Hospital, Yatomi, Aichi, Japan|Seikeikai New Tokyo Heart Clinic, Matsudo, Chiba, Japan|Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan|Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan|National Fukuoka-Higashi Medical Center, Koga, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|St.Mary's Hospital, Kurume, Fukuoka, Japan|Matsunami Health Promotion Clinic, Hashima-gun, Gifu, Japan|Mazda Hospital of Mazda Motor Corporation, Aki-gun, Hiroshima, Japan|Nippon Kokan Fukuyama Hospital, Fukuyama, Hiroshima, Japan|Higashihiroshima Medical Center, Higashihiroshima, Hiroshima, Japan|Teine Keijinkai Clinic, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|National Hospital Organization Kobe Medical Center, Kobe, Hyogo, Japan|Mito Kyodo General Hospital, Mito, Ibaraki, Japan|Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan|KenAiKai medical corporation Akiyama clinic, Takamatsu, Kagawa, Japan|Ikeda Hospital, Kanoya, Kagoshima, Japan|Fujisawa City Hospital, Fujisawa, Kanagawa, Japan|Koukan Clinic, Kawasaki, Kanagawa, Japan|Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan|Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan|Arao Municipal Hospital, Arao, Kumamoto, Japan|JCHO Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan|Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan|Asama Nanroku Komoro Medical Center, Komoro, Nagano, Japan|Niigata Prefectural Shibata Hospital, Shibata, Niigata, Japan|R.I.A.C Naha City Hospital, Naha, Okinawa, Japan|Osaka Pref. Saiseikai Tondabayashi Hospital, Tondabayashi, Osaka, Japan|Kitasato University Medical Center, Kitamoto, Saitama, Japan|Iwata City Hospital, Iwata, Shizuoka, Japan|Toshima Hospital, Itabashi-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|Showa University Koto Toyosu Hospital, Koto-ku, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan|University of Yamanashi Hospital, Chuo, Yamanashi, Japan|Fukui Prefectural Hospital, Fukui, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Asahi University Hospital, Gifu, Japan|National Hospital Organization Kochi National Hospital, Kochi, Japan|Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan|Nara Prefecture General Medical Center, Nara, Japan|Japanese Red Cross Oita Hospital, Oita, Japan|Kitano Hospital, Osaka, Japan|Yodogawa Christian Hospital, Osaka, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka Red Cross Hospital, Osaka, Japan|Nippon Life Hospital, Osaka, Japan|Chibune Clinic, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|Social Corporation Keigakukai Minamiosaka Hospital, Osaka, Japan|Shizuoka Saiseikai General Hospital, Shizuoka, Japan|Suruga Clinic, Shizuoka, Japan|Wakayama Medical University Hospital, Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT03350347"
401,"NCT00642967","A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis",,"Completed","No Results Available","Anemia","Drug: Methoxy Polyethylene Glycol-epoetin Beta","Proportion of patients maintaining average Hb concentration within target range of 10-12g/dL during evaluation period|Mean change in Hb concentration|Mean time spent in Hb range|% patients maintaining Hb concentration within target range; % patients requiring dose adjustments; incidence of RBC transfusions|AEs, lab parameters","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","127","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML21146|2007-005757-28","June 2008","August 2010","August 2010","March 25, 2008",,"September 14, 2021","Aix En Provence, France|Angers, France|Angers, France|Annonay, France|Avignon, France|Bastia, France|Beauvais, France|Besancon, France|Bois-guillaume, France|Bordeaux, France|Boulogne Sur Mer, France|Bourg En Bresse, France|Bourges, France|Brest, France|Caen, France|Chalon Sur Saone, France|Chartres, France|Cherbourg Octeville, France|Cholet, France|Clermont-ferrand, France|Colmar, France|Creil, France|Creteil, France|Dieppe, France|Evreux, France|Greize, France|Harfleur, France|La Garenne-colombes, France|La Tronche, France|Le Havre, France|Le Mans, France|Lille, France|Limoges, France|Lyon, France|Maubeuge, France|Metz Tessy, France|Metz, France|Montlucon, France|Montpellier, France|Montpellier, France|Nancy, France|Nice, France|Nimes, France|Orleans, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Pierre Benite, France|Poitiers, France|Quimper, France|Roubaix, France|Saint Laurent Du Var, France|Saint Lo, France|Saint-malo, France|Saint-michel, France|Salouel, France|Sens, France|St Brieuc, France|St Nazaire, France|Strasbourg, France|Suresnes, France|Thionville, France|Toulouse, France|Tournan-en-brie, France|Valenciennes, France|Vandoeuvre-les-nancy, France|Vannes, France",,"https://ClinicalTrials.gov/show/NCT00642967"
402,"NCT02268994","KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD",,"Completed","Has Results","Anemia of Chronic Kidney Disease","Drug: ferric citrate|Drug: Placebo","Percentage of Subjects Achieving an Increase in Hemoglobin of ≥1.0 g/dL at Any Time Point Between Baseline and the End of the 16-week Randomized Period|Mean Change in Hemoglobin (Hgb) at the End of 16 Weeks Minus Baseline|Mean Change in Transferrin Saturation (TSAT) at the End of 16 Weeks Minus Baseline|Mean Change in Ferritin at the End of 16 Weeks Minus Baseline|Percentage of Subjects Experiencing a Sustained Treatment Effect on Hemoglobin (Hgb)|Mean Change in Serum Phosphate at the End of 16 Weeks Minus Baseline","Keryx Biopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","234","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KRX-0502-306","October 2014","January 2016","January 2016","October 20, 2014","February 22, 2018","March 22, 2018","AKDHC Medical Research Services, LLC, Phoenix, Arizona, United States|Southwest Kidney Institute, Tempe, Arizona, United States|California Renal Research, Glendale, California, United States|Southern California Medical Research Center, La Palma, California, United States|Academic Medical Research Institute, Inc, Los Angeles, California, United States|Apex Research of Riverside, Riverside, California, United States|Capital Nephrology Medical Group, Sacramento, California, United States|La Jolla Clinical Research, Inc, San Diego, California, United States|California Institute of Renal Research, San Diego, California, United States|Denver Nephrology, Denver, Colorado, United States|Creekside Medical Research, DeLand, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Pines Clinical Research, Inc, Pembroke Pines, Florida, United States|Kidney Care Associates, LLC, Augusta, Georgia, United States|Renal Physicians of Georgia, PC, Macon, Georgia, United States|Pacific Renal Research Institute, Meridian, Idaho, United States|Advanced Renal Care, Evergreen Park, Illinois, United States|Kansas Nephrology Research Institute, Wichita, Kansas, United States|Renal Associates of Baton Rouge, Baton Rouge, Louisiana, United States|Western New England Renal & Transplant Associates, Springfield, Massachusetts, United States|Renaissance Renal Research, Detroit, Michigan, United States|Michigan Kidney Consultants, PC, Pontiac, Michigan, United States|Clinical Research Consultants, Kansas City, Missouri, United States|Lincoln Nephrology & Hypertension, Lincoln, Nebraska, United States|Sierra Nevada Nephrology Asoociates, Reno, Nevada, United States|Mountain Kidney & Hypertension Associates, Asheville, North Carolina, United States|Metrolina Nephrology, Charlotte, North Carolina, United States|Research Management, Inc, Austin, Texas, United States|Research Management, Inc., Austin, Texas, United States|TAD Clinical Research, Lufkin, Texas, United States|Kidney & Hypertension Specialists, San Antonio, Texas, United States|Clinical Advancement Center, San Antonio, Texas, United States|San Antonio Kidney Disease Center, San Antonio, Texas, United States|Mendez Center for Clinical Research, Alexandria, Virginia, United States|Nephrology Associates of Northern VA, Inc., Fairfax, Virginia, United States|Peninsula Kidney Associates, Hampton, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02268994"
403,"NCT00132535","Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda",,"Completed","No Results Available","Malaria in Pregnancy|HIV Infections","Drug: sulfadoxine-pyrimethamine intermittent preventive treatment|Drug: chloroquine","maternal peripheral parasitaemia|placental parasitaemia|clinical malaria|maternal and infant Hb|birth weight|congenital parasitaemia|maternal HIV viral load at inclusion and before delivery","London School of Hygiene and Tropical Medicine|DBL -Institute for Health Research and Development|Uganda AIDS Commission","Female","15 Years to 49 Years   (Child, Adult)","Not Applicable","2548","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention","MV-714-624-03-0001","August 2003",,"June 2007","August 22, 2005",,"January 12, 2017","Uganda AIDS Commission, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00132535"
404,"NCT00442793","A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.",,"Completed","No Results Available","Anemia","Drug: Epoetin beta|Drug: methoxy polyethylene glycol-epoetin beta [Mircera]","Hb response rate|Change in Hb concentration between baseline and evaluation period|Hb over time|Time to Hb response|RBC transfusions|AEs, laboratory parameters, vital signs|Serum concentration of Mircera","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","265","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML20680","May 2007","May 2010","May 2010","March 2, 2007",,"November 2, 2016","Beijing, China|Beijing, China|Beijing, China|Chengdu, China|Guangzhou, China|Guangzhou, China|Hangzhou, China|Nanjing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00442793"
405,"NCT00422513","A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.",,"Terminated","Has Results","Anemia","Drug: methoxy polyethylene glycol-epoetin beta|Drug: Epoetin alfa","Time Spent on Anemia Treatment Over Evaluation Period|Change in Hemoglobin (Hb) Concentration From Baseline to the Average Over the Evaluation Period|Number of Participants Assessed for AEs|The Number of Participants With Marked Laboratory Abnormalities Occurring in ≥5% of the Participants","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML20336","March 2007","December 2007","December 2007","January 17, 2007","December 14, 2011","December 14, 2011","Birmingham, Alabama, United States|Rainbow City, Alabama, United States|Hot Springs, Arizona, United States|Fairfield, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Mountain View, California, United States|Riverside, California, United States|San Diego, California, United States|Simi Valley, California, United States|Whittier, California, United States|Lakewood, Colorado, United States|Brandon, Florida, United States|Hudson, Florida, United States|Lauderdale Lakes, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Palm Beach Gardens, Florida, United States|Augusta, Georgia, United States|Gurnee, Illinois, United States|Fort Wayne, Indiana, United States|Detroit, Michigan, United States|Pontiac, Michigan, United States|Sparks, Nevada, United States|New Brunswick, New Jersey, United States|Bronx, New York, United States|Brooklyn Center, New York, United States|Brooklyn, New York, United States|Flushing, New York, United States|Orchard Park, New York, United States|Williamsville, New York, United States|Raleigh, North Carolina, United States|Toledo, Ohio, United States|Tulsa, Oklahoma, United States|Lancaster, Pennsylvania, United States|Lewistown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|West Homestead, Pennsylvania, United States|Columbia, South Carolina, United States|Orangeburg, South Carolina, United States|Corpus Christi, Texas, United States|Houston, Texas, United States|Chesapeake, Virginia, United States|Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00422513"
406,"NCT00255437","Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients",,"Completed","No Results Available","Anemia","Drug: ferumoxytol or oral iron","The mean change in hemoglobin from baseline.|Change in iron indices.","AMAG Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","62745-7","June 2004",,"November 2006","November 21, 2005",,"January 9, 2015","Phoenix, Arizona, United States|Tempe, Arizona, United States|New Haven, Connecticut, United States|Augusta, Georgia, United States|Peoria, Illinois, United States|Bethesda, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Columbus, Mississippi, United States|Broken Bow, Nebraska, United States|Greenville, South Carolina, United States|Charlottesville, Virginia, United States|Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00255437"
407,"NCT00255424","Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients",,"Completed","No Results Available","Anemia","Drug: ferumoxytol or oral iron","The mean change in hemoglobin from baseline.|Change in iron indices.","AMAG Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","62745-6","May 2004",,"August 2006","November 21, 2005",,"January 9, 2015","Encino, California, United States|Riverside, California, United States|Tarzana, California, United States|Ocala, Florida, United States|Shreveport, Louisiana, United States|Shreveport, Louisiana, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|Flushing, New York, United States|Orchard Park, New York, United States|Columbus, Ohio, United States|Hershey, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Chattanooga, Tennessee, United States|Knoxville, Tennessee, United States|Houston, Texas, United States|Fairfax, Virginia, United States|Bluefield, West Virginia, United States|Appleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00255424"
408,"NCT01083888","ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis",,"Completed","No Results Available","Anemia|Hemodialysis|Renal Impairment","Drug: roxadustat","ASP1517 concentrations in plasma|ASP1517 concentrations in dialysate|Plasma EPO level|Safety assessed by Adverse Event, vital signs standard 12-lead ECG or lab tests","Astellas Pharma Inc","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1517-CL-0203","February 15, 2010","June 7, 2010","June 7, 2010","March 10, 2010",,"January 9, 2020","Chubu, Japan",,"https://ClinicalTrials.gov/show/NCT01083888"
409,"NCT02586402","Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis",,"Unknown status","No Results Available","Chronic Renal Failure|Anemia|Dialysis","Drug: pegol-Sihematide|Drug: Epoetin Alfa","Average reticulocytes and hemoglobin change from baseline|Proportion of patients whose Hb within ±1.0 g/dL of baseline during Weeks 12 to 16|Average RBC, hematokrit and reticulocytes change from baseline|Proportion of patients whose Hb levels were maintained within 10 to 12.0g/dL during Weeks 12 to 16|Incidence of adverse events and serious adverse events","Jiangsu Hansoh Pharmaceutical Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-EPOP2c","October 2015","August 2016","August 2016","October 26, 2015",,"October 26, 2015","Changzheng Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02586402"
410,"NCT01940484","An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis",,"Completed","Has Results","Anemia","Drug: Methoxy polyethylene glycol epoetin beta","Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 2 (Month 1)|Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 3 (Month 2)|Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 4 (Month 3)|Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 5 (Month 4)|Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 6 (Month 5)|Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 7 (Month 6)|Mean Hemoglobin Value at Visit 2 (Month 1)|Mean Hemoglobin Value at Visit 3 (Month 2)|Mean Hemoglobin Value at Visit 4 (Month 3)|Mean Hemoglobin Value at Visit 5 (Month 4)|Mean Hemoglobin Value at Visit 6 (Month 5)|Mean Hemoglobin Value at Visit 7 (Month 6)|Mean Methoxy Polyethylene Glycol-Epoetin Beta Dose During the Study|Number of Participants With Dose Adjustments of Methoxy Polyethylene Glycol-Epoetin Beta|Number of Participants Treated According to European Renal Best Practice Guideline (ERBPG) and National Kidney Function (NKF) Kidney Disease Outcomes Quality Initiative (NKF KDOQI) and Mircera Package Insert","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)",,"98","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML22344","August 31, 2009","July 31, 2012","July 31, 2012","September 12, 2013","April 20, 2016","July 5, 2017","Glynnwood Hospital, Benoni, South Africa|Universitas Private Hospital, Bloemfontein, South Africa|GVI Constantiaberg, Cape Town, South Africa|Groote Schuur Hospital; Renal Unit, Cape Town, South Africa|N1City Hospital, Cape Town, South Africa|Dr KB Parag & Raghubir Kidney and Dialysis Centre, Durban, South Africa|St Augustine Hospital / Chelmsford Medical Center; Nephrology, Durban, South Africa|Mayo Clinic, Johannesburg, South Africa|Sunninghill Hospital, Johannesburg, South Africa|Donald Gordon Medical Centre, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT01940484"
411,"NCT01902628","OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis","OPTIMA","Completed","Has Results","Anemia",,"Percentage of Participants With Hemoglobin Levels Within 10.0 - 12.0 g/dL at Months 8-10|Percentage of Participants With Hemoglobin Levels Within the Following Ranges: 11.0 - 12.0 g/dL, 11.0 - 13.0 g/dL, and 10.0 - 13.0 g/dL at Months 8-10|Percentage of Participants With MIRCERA Dose Adjustments|Number of Participants With Serious Adverse Events (AEs) and Non-Serious AEs","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)",,"437","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28261","July 15, 2013","September 4, 2016","September 4, 2016","July 18, 2013","August 7, 2018","August 9, 2019","Uni Hospital of Alexandroupoli; Nephrology Dept., Alexandroupolis, Greece|Laiko General Hospital; Nephrology Div., Athens, Greece|Red Cross Hospital;Nephrology Dpt., Athens, Greece|General Hospital Of Athens G.Gennimatas; Nephrology, Athens, Greece|Ippokrateion Gen. Hospital Of Athens; 2nd University Clinic Of Internal Medicine, Diabetes Center, Athens, Greece|Kyanos Stavros Private Hospital; Nephrologic Clinic, Athens, Greece|General Hospital Of West Attikis; Nephrology, Athens, Greece|University Hospital Attikon ; Pathology Clinic, Athens, Greece|Nikea General Hospital; Nephrologic Clinic, Athens, Greece|General Hospital Of Dramas; Dialysis Center Unit, Drama, Greece|University Hospital Of Heraklion; Nefrologiki Clinic, Heraklion, Greece|Uni Hospital of Ioannina; Nephrology Dept., Ioannina, Greece|General Hospital Of Katerinis; Nephrology Unit, Katerini, Greece|General Hospital of Kilkis; Nephrology, Kilkis, Greece|Univeristy Hospital of Larissa; Nephrology, Larissa, Greece|Agios Andreas General Hospital; Nephrology, Patra, Greece|Olympion Therapeytirion; Nefrology, Patra, Greece|General Hospital Tzanio ; Nephrology, Piraeus, Greece|General Hospital Of Serres; Nephrology, Serres, Greece|AXEPA Pathology Section; A Pathology Clinic, Thessaloniki, Greece|Thermi Private Clinic; Nephrology, Thessaloniki, Greece|Agios Loukas Private Clinic; Nephrology, Thessaloniki, Greece|Thessaliki Nossileytiki; Nephrology, Volos, Greece|General Hospital of Xanthi; Nephrology, Xanthi, Greece",,"https://ClinicalTrials.gov/show/NCT01902628"
412,"NCT00081471","A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis",,"Completed","No Results Available","Anemia","Drug: darbepoetin alfa|Drug: methoxy polyethylene glycol-epoetin beta [Mircera]","Hemoglobin response rate|Hb concentration over time, time to target Hb response, incidence of RBC transfusions. Vital signs, ECG, adverse events, laboratory values\n\n","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","324","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BA16738","June 2004","July 2006","July 2006","April 16, 2004",,"November 2, 2016","Los Angeles, California, United States|Mather, California, United States|Stanford, California, United States|Stamford, Connecticut, United States|Bay Pines, Florida, United States|Ocala, Florida, United States|Shreveport, Louisiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Flushing, New York, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Columbia, South Carolina, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Burlington, Vermont, United States|Salem, Virginia, United States|Morgantown, West Virginia, United States|Clayton, Australia|Liverpool, Australia|Parkville, Australia|Perth, Australia|Antwerpen, Belgium|Leuven, Belgium|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Kamloops, British Columbia, Canada|New Westminster, British Columbia, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|St. John's, Newfoundland and Labrador, Canada|Kitchener, Ontario, Canada|London, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Angers, France|Besancon, France|Chartres, France|Colmar, France|Lille, France|Lyon, France|Nantes, France|Paris, France|Paris, France|Perpignan, France|Salouel, France|Toulouse, France|Vandoeuvre-les-nancy, France|Aschaffenburg, Germany|Berlin, Germany|Bonn, Germany|Dortmund, Germany|Düsseldorf, Germany|Tübingen, Germany|Alexandroupolis, Greece|Athens, Greece|Ioannina, Greece|Piraeus, Greece|Thessaloniki, Greece|Cagliari, Italy|Cuneo, Italy|Genova, Italy|Lecco, Italy|Lodi, Italy|Modena, Italy|Napoli, Italy|Padova, Italy|Pavia, Italy|Prato, Italy|Reggio Calabria, Italy|Roma, Italy|Amersfoort, Netherlands|Heerlen, Netherlands|San Juan, Puerto Rico|Almería, Spain|Barcelona, Spain|Lerida, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Palma de Mallorca, Spain|Valencia, Spain|Boras, Sweden|Umea, Sweden|Birmingham, United Kingdom|Carshalton, United Kingdom|Leicester, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00081471"
413,"NCT00981045","Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function","REPAIR-IDA","Completed","Has Results","Iron Deficiency Anemia|Impaired Renal Function","Drug: Ferric Carboxymaltose (FCM)|Drug: Iron Sucrose (Venofer)","Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.|Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.","American Regent, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","2561","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1VIT09030","August 2009","July 2011","August 2011","September 22, 2009","October 18, 2013","February 20, 2018","Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00981045"
414,"NCT00354341","(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy",,"Completed","Has Results","Anemia","Drug: Epoetin beta","Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15|Left Ventricular End Systolic Volume Index (LVESVI)|Left Ventricular End Diastolic Volume Index (LVEDVI)|Fractional Myocardial Shortening (FS)|Left Ventricular Ejection Fraction (LVEF)|Percentage of Participants With Stable Hb Levels Between 13 to 15 g/dL","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA16620","September 2002","July 2005","July 2005","July 20, 2006","March 31, 2016","March 31, 2016","Linz, Austria|Sao Paulo, Brazil|Jihlava, Czech Republic|Liberec, Czech Republic|Koebenhavn, Denmark|Roskilde, Denmark|Jyvaeskylae, Finland|Heidelberg, Germany|Muenchen, Germany|Alexandroupolis, Greece|Athens, Greece|Ioannina, Greece|Nikea, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Veria, Greece|Budapest, Hungary|Budapest, Hungary|Miskolc, Hungary|Pecs, Hungary|Szombathely, Hungary|Ancona, Italy|Cagliari, Italy|Caserta, Italy|Cinisello Balsamo, Italy|Desio, Italy|Lecco, Italy|Messina, Italy|Milano, Italy|Milano, Italy|Chihuahua, Mexico|Mexico City, Mexico|Monterrey, Mexico|Bialystok, Poland|Katowice, Poland|Radom, Poland|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Singapore, Singapore|Baracaldo, Spain|Barcelona, Spain|Galdakao, Spain|La Coruna, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|Stockholm, Sweden|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Chonburi, Thailand|Belfast, United Kingdom|Cambridge, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Middlesborough, United Kingdom|Salford, United Kingdom|Sheffield, United Kingdom|Wrexham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00354341"
415,"NCT00413101","A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.",,"Completed","No Results Available","Anemia","Drug: epoetin beta [NeoRecormon]","Hb level, BP.|LVMI ejection fraction, ejection fraction.|SAEs, AEs leading to withdrawal, AEs related to NeoRecormon.","Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML20201",,,"March 2008","December 19, 2006",,"May 14, 2009","Novi Sad, Serbia",,"https://ClinicalTrials.gov/show/NCT00413101"
416,"NCT00968617","A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)",,"Terminated","Has Results","Anemia|Chronic Kidney Disease","Drug: MK2578|Drug: Comparator: darbepoetin alfa","Change From Baseline in Hemoglobin Level at Week 4|Number of Participants With Composite Events of Death, Myocardial Infarction and Cerebrovascular Accident, Serious Events of Unstable Angina, Transient Ischemic Attack, Arrythmia and Congestive Heart Failure, Peripheral Thrombo-embolic Events|Number of Participants With Composite Events of Transfusion-related Adverse Experiences|Number of of Participants With Composite Events of Injection Site Reactions|Number of Participants With Hypertension, Seizure, and Pure Red Cell Aplasia|Number of Participants With Confirmed, Treatment Emergent Antibodies to MK2578|Hemoglobin Concentration After Treatment With MK2578|Change From Baseline in Hemoglobin Level|Number of Participants Who Were Responders","Merck Sharp & Dohme LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2578-002|2009_653","November 2009","April 2010","May 2010","August 31, 2009","November 11, 2011","November 1, 2015",,,"https://ClinicalTrials.gov/show/NCT00968617"
417,"NCT00436748","Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease",,"Terminated","Has Results","Anemia|Chronic Kidney Disease|Kidney Disease","Drug: Darbepoetin Alfa|Drug: Placebo","Proportion of Participants Achieving Hemoglobin ≥ 10.0 g/dL|Time to First Hemoglobin Value ≥ 10.0 g/dL|Hemoglobin Concentration Over Time|Weight-adjusted Darbepoetin Alfa Dose at Time of Achieving First Hemoglobin ≥ 10.0 g/dL|Darbepoetin Alfa Weight-Adjusted Dose Over Time|Change From Baseline at Week 13 and Week 25 in Parent-reported Pediatric Quality of Life Inventory (PedsQL) Scores|Change From Baseline at Week 13 and Week 25 in Child Self-reported Pediatric Quality of Life Inventory (PedsQL) Scores|Number of Participants With Treatment-emergent Adverse Events|Hemoglobin Serial Rate of Change (ROC) Over Time|Number of Participants With Hemoglobin > 12.0, > 13.0, and > 14.0 g/dL During the Study|Maximum Increase in Hemoglobin Over Any 2 Week Period|Change From Baseline in Systolic Blood Pressure Over Time|Change From Baseline in Diastolic Blood Pressure Over Time|Number of Participants Who Developed Anti-erythropoiesis Antibodies|Darbepoetin Alfa Serum Concentrations for Participants Less Than 6 Years of Age","Amgen","All","1 Year to 18 Years   (Child, Adult)","Phase 3","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20050256","September 16, 2008","March 3, 2014","March 3, 2014","February 19, 2007","March 31, 2015","November 29, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Stanford, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainesville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Kansas City, Missouri, United States|Research Site, Livingston, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Jurmala, Latvia|Research Site, Vilnius, Lithuania|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Puebla, Mexico|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Szczecin, Poland|Research Site, San Juan, Puerto Rico|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Orenburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Birmingham, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00436748"
418,"NCT00005898","Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia",,"Completed","No Results Available","Fanconi's Anemia","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: filgrastim|Drug: fludarabine|Drug: methylprednisolone",,"University of Minnesota|Office of Rare Diseases (ORD)","All","0 Years to 34 Years   (Child, Adult)","Phase 1|Phase 2","30","Other","Interventional","Primary Purpose: Treatment","199/15109|UMN-MT-1999-05|UMN-MT9905","February 2000",,,"June 5, 2000",,"June 24, 2005","University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00005898"
419,"NCT01121237","MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5","MONITOR-CKD5","Completed","No Results Available","Chronic Kidney Disease|End-stage Renal Disease|Anaemia","Drug: Recombinant human erythropoietin alfa (biosimilar)","Haemoglobin outcomes, including haemoglobin levels in g/dL, change in haemoglobin levels over time (in g/dL and %), number and proportion of patients with haematopoietic response, number and proportion of patients reaching target haemoglobin levels.|Number and proportion of participants with thrombovascular events, hospitalization,and mortality as measures of safety.","Sandoz|Hexal AG","All","18 Years and older   (Adult, Older Adult)",,"2086","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HX575-503","February 2010","November 2014","November 2014","May 12, 2010",,"April 6, 2016","Sandoz Investigational Site, Bregenz, Austria|Sandoz Investigational Site, Eisenstadt, Austria|Sandoz Investigational Site, Feldkirch, Austria|Sandoz Investigational Site, Nenzing, Austria|Sandoz Investigational Site, Vienna, Austria|Sandoz Investigational Site, Ajaccio, France|Sandoz Investigational Site, Dourlers, France|Sandoz Investigational Site, Fourmies Cedex, France|Sandoz Investigational Site, Lille, France|Sandoz Investigational Site, St. Quentin, France|Sandoz Investigational Site, Alsfeld, Germany|Sandoz Investigational Site, Arnstadt, Germany|Sandoz Investigational Site, Bad Neustadt a. d. Saale, Germany|Sandoz Investigational Site, Bassum, Germany|Sandoz Investigational Site, Berlin, Germany|Sandoz Investigational Site, Bochum, Germany|Sandoz Investigational Site, Cloppenburg, Germany|Sandoz Investigational Site, Cochem, Germany|Sandoz Investigational Site, Darmstadt, Germany|Sandoz Investigational Site, Dresden, Germany|Sandoz Investigational Site, Duisburg, Germany|Sandoz Investigational Site, Düsseldorf, Germany|Sandoz Investigational Site, Erftstadt, Germany|Sandoz Investigational Site, Georgsmarienhütte, Germany|Sandoz Investigational Site, Greifswald, Germany|Sandoz Investigational Site, Güstrow, Germany|Sandoz Investigational Site, Herne, Germany|Sandoz Investigational Site, Herzberg, Germany|Sandoz Investigational Site, Hoyerswerda, Germany|Sandoz Investigational Site, Höchstadt, Germany|Sandoz Investigational Site, Kamen, Germany|Sandoz Investigational Site, Kiel, Germany|Sandoz Investigational Site, Magdeburg, Germany|Sandoz Investigational Site, Mettmann, Germany|Sandoz Investigational Site, Munich, Germany|Sandoz Investigational Site, Nürnberg, Germany|Sandoz Investigational Site, Osnabrück, Germany|Sandoz Investigational Site, Pinneberg, Germany|Sandoz Investigational Site, Quedlinburg, Germany|Sandoz Investigational Site, Remagen, Germany|Sandoz Investigational Site, Rendsburg, Germany|Sandoz Investigational Site, Schrobenhausen, Germany|Sandoz Investigational Site, Schwabach, Germany|Sandoz Investigational Site, Seehausen, Germany|Sandoz Investigational Site, Viersen, Germany|Sandoz Investigational Site, Wetzlar, Germany|Sandoz Investigational Site, Wilhelmshaven, Germany|Sandoz Investigational Site, Acireale, Italy|Sandoz Investigational Site, Altamura, Italy|Sandoz Investigational Site, Arenzano, Italy|Sandoz Investigational Site, Arezzo, Italy|Sandoz Investigational Site, Biella, Italy|Sandoz Investigational Site, Catania, Italy|Sandoz Investigational Site, Chivasso, Italy|Sandoz Investigational Site, Cinisello Balsamo, Italy|Sandoz Investigational Site, Cirié, Italy|Sandoz Investigational Site, Cosenza, Italy|Sandoz Investigational Site, Cuneo, Italy|Sandoz Investigational Site, Ivrea, Italy|Sandoz Investigational Site, Montevarchi, Italy|Sandoz Investigational Site, Pavia, Italy|Sandoz Investigational Site, Pontecorvo, Italy|Sandoz Investigational Site, Putignano, Italy|Sandoz Investigational Site, Roma, Italy|Sandoz Investigational Site, Torino, Italy|Sandoz Investigational Site, Bialystok, Poland|Sandoz Investigational Site, Ciechanów, Poland|Sandoz Investigational Site, Gdańsk, Poland|Sandoz Investigational Site, Lublin, Poland|Sandoz Investigational Site, Poznań, Poland|Sandoz Investigational Site, Rzeszów, Poland|Sandoz Investigational Site, Wołomin, Poland|Sandoz Investigational Site, Bistrita, Romania|Sandoz Investigational Site, Braila, Romania|Sandoz Investigational Site, Brasov, Romania|Sandoz Investigational Site, Bucharest, Romania|Sandoz Investigational Site, Miercurea Ciuc, Romania|Sandoz Investigational Site, Odorheiu Secuiesc, Romania|Sandoz Investigational Site, Resita, Romania|Sandoz Investigational Site, Roman, Romania|Sandoz Investigational Site, TG. Jiu, Romania|Sandoz Investigational Site, Maribor, Slovenia|Sandoz Investigational Site, San Pietro, Slovenia|Sandoz Investigational Site, Avila, Spain|Sandoz Investigational Site, León, Spain|Sandoz Investigational Site, Sevilla, Spain|Sandoz Investigational Site, Zamora, Spain|Sandoz Investigational Site, Fribourg, Switzerland|Sandoz Investigational Site, Lausanne, Switzerland|Sandoz Investigational Site, Nyon, Switzerland|Sandoz Investigational Site, Zürich, Switzerland|Sandoz Investigational Site, Cambridge, United Kingdom|Sandoz Investigational Site, Chester, United Kingdom|Sandoz Investigational Site, Norwich, United Kingdom|Sandoz Investigational Site, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01121237"
